2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
&/,1,&$/678'<35272&2/
3URWRFRO7LWOH $5DQGRPL]HG2SHQODEHO 3KDVH6WXG\LQ6XEMHFWV
ZLWK5HODSVHGDQG5HIUDFWRU\0XOWLSOH0\HORPD5HFHLYLQJ&DUILO]RPLELQ&RPELQDWLRQZLWK'H[DPHWKDVRQH&RPSDULQJ2QFHZHHNO\YHUVXV7ZLFHZHHNO\&DUILO]RPLE'RVLQJ
3URWRFRO1XPEHU )RUPHUO\&)=
1DPHRI,QYHVWLJDWLRQDO
3URGXFW&DUILO]RPLEIRU,QMHFWLRQ
,1'1XPEHU ,1'
(XGUD&71XPEHU 
6SRQVRU 2Q\[7KHUDSHXWLFV,QFDQ$PJHQ,QFVXEVLGLDU\ 
2QH$PJHQ&HQWHU'ULYH7KRXVDQG2DNV&$86$
6WXG\0HGLFDO0RQLWRU
0'06
2QH$PJHQ&HQWHU'ULYH06$
7KRXVDQG2DNV&$86$
,QYHVWLJDWRUV 0'
0'
0'
'DWHRI2ULJLQDO3URWRFRO 'HFHPEHU
'DWHRI3URWRFRO
$PHQGPHQW)HEUXDU\
'DWHRI3URWRFRO
$PHQGPHQW0DUFK
'DWHRI3URWRFRO
$PHQGPHQW$SULO
'DWHRI3URWRFRO
$PHQGPHQW$SULO
'DWHRI3URWRFRO
$PHQGPHQW)HEUXDU\
'DWHRI6XSHUVHGLQJ
3URWRFRO$PHQGPHQW0DUFK
&RQILGHQWLDOLW\6WDWHPHQW 7KLVPDWHULDOLVWKHSURSHUW\RI2Q\[7KHUDSHXWLFV,QFDZKR OO\
RZQHGVXEVLGLDU\RI2Q\[3KDUPDFHXWLFDOV,QFDQ$PJHQ,QF
VXEVLGLDU\7KHPDWHULDOLVKL JKO\FRQILGHQWLDODQGLVWREHX VHG
RQO\LQFRQQHFWLRQZLWKPDWWHUVDXWKRUL]HGE\DVHQLRUUHSUHVHQWDWLYHRI2Q\[7KHUDSHXWLFV,QFDQGQRSDUWRILWLV WREH
GLVFORVHGWRDWKLUGSDUW\ZLWKRXWWKHH[SUHVVSULRUZULWWHQ
SHUPLVVLRQRI2Q\[7KHUDSHXWLFV,QF

6XSHUVHGLQJ $PHQGPHQW 0DUFK &21),'(17,$/PPD
PPD
PPD
PPDPPD
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 2 of 165 
Compliance Statement:  This study will be conducted in accordance with 
Protocol  20140355 , the International Conference on Harmonisation 
(ICH), Guideline for Good Clinical Practice (GCP), and the applicable country and regional (local) regulatory requirements.  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 3 of 165 
PROTOCOL ACCEPTANCE PAGE  
 
Issue/Date: 20140355  (Superseding  Protocol Amendment 4.0)/07 March  2017  
 
I have read this protocol for Study 20140355  entitled: A Randomized, Open -label, 
Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving 
Carfilzomib in Combination with Dexamethasone, Comparing Once- weekly versus 
Twice -weekly Carfilzomib Dosing   
 
 
As investigator, I understand and agree to conduct this study as outlined herein.  
   
Investigator Name (print)    
Inves tigator Signature   Date  
Signature on this page assures the sponsor that, to the best of the investigatorâ€™s knowledge, the affiliated 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) operates in accordance with the 
governing regulations,  and that the investigator understands, and agrees to abide by, all governing 
regulatory obligations and the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) and country and regional (local) requirements while cond ucting this clinical 
investigation.  Once signed, the original of this form should be detached from the protocol and returned to 
Onyx or its designee (please retain a copy for your files).  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 4 of 165 
SYNOPSIS  
Name of 
sponsor/company
: Onyx Therapeutics, Inc.  
Name of product:  Carfilzomib for Injection  
Title of study and protocol number 
and phase:  A Randomized, Open -label, Phase 3 Study in Subjects with Relapsed and 
Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once -week ly versus Twice -weekly Carfilzomib 
Dosing / 20140355  
Study objective(s):  Primary Objective  
To compare the progression -free survival  (PFS) of once -weekly carfilzomib 
dosing in combination with dexamethasone to  the PFS of twice -weekly 
carfilzomib dosing in  combination with dexamethasone in subjects with relapsed 
and refractory multiple myeloma who have received prior treatment with a 
proteasome inhibitor  and an IMiD (immunomodulatory agent).   
Secondary Objectives  
To compare the following between treatment groups:  
â€¢ Overall response rate ( ORR) 
â€¢ Overall survival (OS)  
â€¢ Safety and tolerability  
â€¢ Pharmacokinetics (PK) of carfilzomib using sparse sampling  
Exploratory Objectives  
â€¢ Intensive pharmacokinetics (PK) and pharmacodynamics (PDn) of carfilzomib in a subset of su bjects (substudy)  
â€¢ All subscales of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Module (QLQ -C30), and the EORTC 
Quality of Life Multiple Myeloma Module 20 (QLQ -MY20)  
â€¢ European Quality of Life -5 Dimensions (EQ -5D- 5L); a standardized 
measure of health status developed by the European Quality of Life 
(EuroQol) Group  
â€¢ Patient reported convenience and satisfaction with the carfilzomib schedule  
â€¢ Healthcare resource utilization  
Study design:  This is an open -label, multicenter, randomized Phase 3 study comparing 
carfilzomib dosing in combination with dexamethasone administered once -weekly 
to twice -weekly carfilzomib dosing in subjects with relapsed and refractory 
multiple myeloma, previously treated with a proteasome inhi bitor  and an IMiD.  
The primary endpoint is PFS.  The study design is illustrated in the schema below.  
Eligible subjects will be randomized in a 1:1 ratio to receive a regimen consisting 
of either once -weekly or twice -weekly carfilzomib in combination with 
dexamethasone.   
The randomization will be stratified by:  
â€¢ The International Staging System (ISS) at study entry (Stage  1 versus 
Stage  2 or 3) per International Myeloma Working Group  (Greipp  2005).   
See Appendix  H 
â€¢ Refractory to bortezomib treatment (Yes versus No) 
â€¢ Age (<  65 versus â‰¥  65 years)    
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 5 of 165 
Study design 
(contâ€™d):  Study treatment will be administered in 28 -day cycles.  Subjects will receive study 
treatment determined by randomization until disease progression, unacceptable toxicity, withdrawal of consent, or d eath (whichever occurs first).  No crossover 
between the 2  treatment groups will be allowed.  
Following termination of study treatment all subjects will be followed for disease status (if progressive disease [PD] has not been reached), subsequent antimyelom a 
treatment, and survival.  All subjects will be followed for safety at least 30 
additional days after the last study treatment administration.  All treatment -related 
adverse events (AEs) and serious adverse events (SAEs) will be followed until resolution or stabilization.   
Study 20140355 Schema 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
ECOG = Eastern Cooperative Oncology Group; IMiD = immunomodulatory agents; 
IV = intravenous(ly); ORR = overall respon se rate; OS = overall survival;  
PD = progressive disease; PFS = progression-f ree survival; PI = proteasome inhibitor; 
PO = orally . 
Subjects will be assessed for response using central laboratory results  every 
28 days (Â±  4 days).  Subjects are followed for disease status until confirmed PD.  
Long- term follow -up (LTFU) for disease st atus (only in cases where subjects 
discontinued treatment prior to PD) and for survival (after reaching PD) will 
continue after treatment discontinuation or until the subject has withdrawn consent for further participation, is lost to follow -up, has died, or the sponsor makes a 
decision to close the study.  For subjects who discontinued treatment before disease progression occurred (such as for an adverse event, noncompliance, etc.), disease response assessments will be performed using central laboratory results every 28 days  until disease progression.  Follow -up for survival will continue 
approximately every 12 weeks Â±  28 days , or as needed, for all surviving subjects 
until study closure.  For any subject who is lost to follow -up, the study site will 
attemp t to ascertain survival information via public database search.   
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
1XPEHURI
LQYHVWLJDWLRQDOVLWHV$SSUR[LPDWHO\VLWHVZRUOGZLGH
3ODQQHGQXPEHU
RIVXEMHFWV VXEMHFWV
HDFKDUP
6DPSOHVL]H
MXVWLILFDWLRQ WKH
VDPSOHVL]HRIVXEMHFWVLQHDFKDUP 




DWRWDORI3)6HYHQWVIRUWKHILQDO3)6DQDO\VLV
ZLOOSURYLGHSRZHUWRGHWHFW DVLJQLILFDQWG LIIHUHQFHLQ3) 6EHWZHHQWKH
WUHDWPHQWJURXSVZLWKVLGH GRYHUDOO7\SH,HUURURIZ KHQLQWHULP
DQDO\VLVLVSHUIRUPHGDWDSSUR[LPDWHO\LQIRUPDWLRQWLPHL H
HYHQWVXVLQJWKH2Â¶%ULHQ)OHPLQJW\SHDOSKDVSHQGLQJIXQFW LRQ
6WXG\SRSXODWLRQ $GXOWVZLWKUHODSVHGDQGUHIUDFWRU\PXOWLSOHP\HORPDZLOOEHFR QVLGHUHGIRU
HOLJLELOLW\6XEMHFWVPXVWKDYHKDGDWOHDVWEXWQRPRUHWKD QSULRUWKHUDSLHV
IRUPXOWLSOHP\HORPD
7UHDWPHQWUHJLPHQV &DUILO]RPLEDQGGH[DPHWKDVRQHZLOOEHDGPLQLVWHUHGLQGD\F\ FOHVLQRI
WUHDWPHQWUHJLPHQV$OOF\FOH VZLOOVWDUWG D\VÂ“GD\V DIWHUWKHVWDUWRIWKH
SULRUF\FOH
$UP$2QFHZHHNO\ 
x&DUILO]RPLEPJP

R6WXG\'D\&\FOH
x&DUILO]RPLEPJP
R6WXG\'D\VDQG&\FOH
x&DUILO]RPLEPJP
R6WXG\'D\VDQG&\FOHV
x'H[DPHWKDVRQH
RPJLQWUDYHQRXVO\>,9@RURUDOO\>32@6WXG\'D\VDQG 
DOO&\FOHV
RPJ,9RU326WXG\'D\&\FOHVWRRQO\
$UP%7ZLFHZHHNO\
x&DUILO]RPLEPJP
R6WXG\'D\VDQG&\FOH
x&DUILO]RPLEPJP
R6WXG\'D\VDQG&\FOH
x&DUILO]RPLEPJP
R6WXG\'D\VDQG&\FOHV
x'H[DPHWKDVRQH
RPJ,9RU326WXG\'D\VDQGDOO&\FOHV
RPJ,9RU326WXG\'D\&\FOHVWRRQO\
6XEMHFWVHOHFWLRQ $SSUR[LPDWHO\VXEMHFWVZLOOEHUDQGRPL]HGLQWKLVVWXG\6 XEMHFWVZLOOEH
HYDOXDWHGIRUVWXG\HOLJLELOLW\ZLWKLQWKHGD\VSULRUWRUDQ GRPL]DWLRQ

6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
CCICCICCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 7 of 165 
Inclusion criteria:  101. Age â‰¥  18 years  
102. Able to provide written informed consent in accordance with federal, local, 
and institutional guidelines  
103. Relaps ed multiple myeloma  
104. Refractory multiple myeloma , defined as meeting 1 or more of the 
following:  
a.  Nonresponsive to most recent therapy (stable disease or PD while on 
treatment), or  
b. Disease progression within 60  days of discontinuation from most 
recent therapy  
105. At least 2 but no more than 3 prior lines of  therapies for multiple myeloma  
106. Prior exposure to an immunomodulatory agent (IMiD)  
107. Prior exposure to a proteasome inhibitor (PI)  
108. Documented response of at least partial response (PR) to at least  1 prior line 
of therapy  
109. Measurable disease with at least 1 of the following assessed at a central laboratory  within the 21  days prior to randomization:  
a.  Serum M -protein â‰¥  0.5 g/dL  
b. Urine M -protein â‰¥  200 mg/24  hours  
c.  In subjects without measurable serum or urine M -protein, serum free 
light chain (SFLC) â‰¥ 100  mg/L (involved light chain) and an 
abnormal serum kappa lambda ratio  
110. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 
111. Left ventricular ejection fraction (LVEF) â‰¥  40% within the 21  days prior  to 
randomization  
112. Adequate organ and bone marrow function performed at a central laboratory  
within the 21  days prior to randomization , defined by:  
a. Bilirubin <  1.5 times the upper limit of normal (ULN)  
b. Aspartate aminotransferase (AST) and alanine aminotran sferase 
(ALT) <  3 times the ULN  
c. Absolute neutrophil count (ANC) â‰¥  1 x 10
9/L (screening ANC must  
be independent of growth factor support for â‰¥ 7 days ) 
d. Hemoglobin â‰¥  8 g/dL (Use of erythropoietic stimulating factors and 
red blood cell [RBC] transfusion s per institutional guidelines are 
allowed, however the most recent RBC transfusion may not have 
been done within 7  days prior to obtaining  the screening hemoglobin) 
e. Platelet count â‰¥  50,000/mm3 (â‰¥ 30,000/mm3 if myeloma involvement 
in the bone marrow is > 50%.  Subjects must not have received 
platelet transfusions for at least 7 days  prior to obtaining the 
screening platelet count ) 
f. Calculated or measured creatinine clearance (CrCl) of â‰¥ 30 mL/min.  
Calculation must  be based on the Cockcroft and Gault formula:   
[(140 â€“ Age) Ã— Mass (kg) / (72 Ã— Creatinine  mg/dL)]; multiply  result 
by 0.85 if female  
113. Females of childbearing potential (FCBP) must have a confirmed negative 
serum pregnancy test  performed at a central laboratory  within the 21  days 
prior to randomization  and must not be breastfeeding   
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 8 of 165 
Inclusion criteria 
(contâ€™d):  114. Females of childbearing potential must agree to use highly effective 
method(s) of contraception during the study and for 30 days following the 
last study drug administration .  (Refer to  Appendix  K for specific 
contraception requirements)  
115. Male subjects who are sexually active with an FCBP must agree to use 
condoms (unless they have had a vasectomy with medical confirmation of surgical success), during treatment and for an additional 90 days  following 
the last study drug administration  
116. Male subjects must agree to not donate sperm, during treatment and for an additional 90 days following the last study drug administration  
Exclusion criteria:  201. WaldenstrÃ¶m macroglobulinemia  
202. Multiple myeloma of I mmunoglobulin M (IgM) subtype  
203. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)  
204. Plasma cell leukemia (> 2.0 Ã— 10
9/L circulating plasma cells by standard 
differential)  
205. Myelodysplastic syndrome  
206. Second malignancy within the past 5  years except:  
a. Adequately treated basal cell or squamous cell skin cancer  
b. Carcinoma in situ of the cervix  
c. Prostate cancer < Gleason score 6 with stable prostate -specific antigen 
(PSA) over 12  months  
d. Ductal breast carcinoma in situ with  full surgical resection 
(i.e., negative  margins)  
e. Treated medullary or papillary thyroid cancer  
f. Similar condition with an expectation of >  95% five -year disease -free 
survival  
207. History of or current amyloidosis  
208. Cytotoxic chemotherapy  or other antineoplastic therapy, aside from 
immunotherapy or proteasome inhibitors,  within the 28  days prior to 
randomization  
209. Immunotherapy , such as an IMiD or a proteasome inhibitor within the 
21 days prior to randomization  
210. Glucocorticoid therapy exceed ing a cumulative dose of  160 mg of 
dexamethasone or equivalent within 14 days prior to randomization 
211. Radiation therapy:  
a. Focal therapy within the 7  days prior to randomization  
b. Extended field therapy within the 21  days prior to randomization  
212. Prior treatment with either carfilzomib or oprozomib  
213. Known history of allergy to Captisol (a cyclodextrin derivative used to 
solubilize carfilzomib)  
214. Contraindication to dexamethasone or any of the required concomitant 
medications  or supportive treatments  
215. Active congestive heart failure (New Yo rk Heart Association [NYHA] Class 
III or IV, refer to  Appendix  F), symptomatic ischemia, conduction 
abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial  disease, or myocardial infarction 
within 6  months prior to randomization  
216. Active infection requiring systemic treatment  within the  14 days prior to 
randomization  
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 9 of 165 
Exclusion criteria  
(contâ€™d): 217. Pleural effusions requiring thoracentesis within the 14  days pr ior to 
randomization  
218. Ascites requiring paracentesis within the 14  days prior to randomization  
219. Ongoing graft -versus -host disease  
220. Uncontrolled hypertension or diabetes mellitus  
221. Significant neuropathy (â‰¥  Grade 3) within the 14  days prior to 
randomization  
222. Known cirrhosis  
223. Known human immunodeficiency virus (HIV) seropositivity, hepatitis C 
infection, or hepatitis B infection.  Subjects with past hepatitis B virus (HBV) 
infection, defined as having a negative HBsAg test and a positive antibody to hepatitis B c ore antigen (anti HBc) antibody test, are eligible.  Subjects 
positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.  
224. Participation in another interventional study within the 28 days prior  to 
randomization  
225. Major surgery (except kyphoplasty) within the 28 days prior to randomization  
226. Any other clinically significant medical disease or social condition that, in the investigatorâ€™s opinion, may interfere with protocol adherence or a subjectâ€™s ability to give informed consent, be compliant with study 
procedures, or provide accurate information  
Efficacy 
variables:   The primary endpoint is PFS.   
Secondary endpoints are: ORR, overall survival (OS), safety  and tolerability, and 
pharmacokinetics (s parse sampling) (PK).   
Disease assessments according to the International Myeloma Working Group -Uniform Response Criteria (IMWG -URC) will be conducted at baseline 
and then every 28  days (Â± 4  days)  thereafter until progression.  
PK (sparse 
sampling)  For both arms, blood samples will be collected from subjects who consent to the additional testing except for those participating in the intensive PK/PDn substudy for determination of plasma concentrations of carfilzomib on C2D1.   
Intensive PK and PDn Substudy  Intensive pharmacokinetic (PK) and pharmacodynamic (PDn) samples will be obtained as a substudy (approximately n  = 15 evaluable subjects  in each arm) 
from subjects who consent to the additional testing at selected sites.  Pharmacokinetic samples will be collected on Day  15 of Cycle  1 and PDn samples 
will be collected on Days  1, 15, 16, 17, and 22 of Cycle  1.   
Health related Quality of Life (HRQL):  The following patient reported outcomes (PRO) will be collected in the study:  
â€¢ The EORTC 30 -item QLQ -C30 que stionnaire  
â€¢ The EORTC 20 -item QLQ -MY20 module specifically designed to address 
the quality of life for those with multiple myeloma  
â€¢ The EQ -5D-5L and patient reported convenience and satisfaction 
questionnaire  
QLQ -C30, QLQ -MY20 , and EQ -5D-5L questionnaires sh ould be administered 
prior to study treatment on Day  1 of Cycle  1, then every second cycle  (Cycle 1, 3, 
5, etc)  during treatment and every 12 weeks (every 84  days Â± 4 days) until 
progression, or withdrawal of consent during LTFU .  Patient convenience and 
satisfaction questionnaire  will be collected at Day 1  Cycle  2 and end of treatment 
(EOT ) only.  Healthcare resource utilization will be collected for all subjects 
during the study.   Details on hospitalizations (not related to adver se events ) will 
also be co llected.  
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 10 of 165 
Safety variables:   Safety and tolerability will be assessed by incidence and severity of adverse 
events and changes from baseline of all relevant parameters, including laboratory values, physical examination, vital signs , and electrocardiogram ( ECG).  Severity 
of adverse events will be assessed according to the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI -CTCAE), 
Version 4.03.  All subjects will be monitored for adverse events for at least 30 days after the last administration of study treatment.   
Statistical 
methods and 
analyses:  Efficacy analyses will be based on the ITT (Intent -To-Treat) Population, which 
includes all randomized subjects.   
The primary endpoint, PFS, will be calculated from the time of randomi zation 
until PD or death due to any cause, whichever occurs first.  If a subject is 
alive or lost to follow -up without experiencing documented disease 
progression  by the data cutoff date, the PFS data for the subject will be 
censored at the date of last va lid disease and response assessment.  The 
distribution of PFS will be estimated using the Kaplan- Meier method.  The 
inferential comparison between treatment groups will be made using the log-rank test stratified by the randomization stratification factors.   The HR 
and its 95% CI will be estimated using a Cox proportional hazards model stratified by the same randomization stratification factors.    
The following  randomization stratification factors will be included in the model:  
â€¢ The ISS Stage at study entry ( Stage  1 versus Stage  2 or 3)  
â€¢ Refractory to bortezomib treatment (Yes versus No) 
â€¢ Age (<  65 versus â‰¥  65 years)  
Response and disease progression will be determined using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]), 
as well as by local investigators and by an Independent Review Committee 
(IRC).  The prim ary analysis of PFS will be based on ORCA -assessed 
outcomes.  The PFS outcomes assessed by the investigator will serve as a supportive analysis of PFS, as will IRC -assessed outcomes.   
The secondary endpoint ORR is defined as the proportion of subjects 
achieving a best overal l response of PR, very good partial response (VGPR), 
complete response (CR), or stringent complete response (sCR), based on the 
IMWG -URC.   The ORR will be calculated by treatment group , and the 
associated 95% confidence interval [CI] wi ll be estimated using the 
Clopper -Pearson method.  The odds ratio (and its 95% CI) will be estimated using 
the logistic regression model.   
The duration of response (DOR), defined as time in months from the start date of 
the response to the earlier date of  documented PD or death, will be calculated for 
subjects who achieve PR, VGPR, CR or sCR.  The DOR will be censored at date of the last valid assessment for responders who have not experienced PD or death.  
The distribution of the DOR, including the median will be estimated using the 
Kaplan -Meier method based on the subjects who achieve overall response.   
The secondary endpoint of OS will be analyzed using the log- rank test stratified 
by the randomization stratification factors.  The cor responding HRs  will be 
estimated using a stratified Cox proportional hazards model.  The distribution of OS including medians will be summarized using the Kaplan -Meier method.   
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI

6WDWLVWLFDO
PHWKRGVDQG
DQDO\VHVFRQWÂ¶G7KHK\SRWKHVHVIRUWKHSULPDU\HIILFDF\HQGSRLQW 3)6DQGVHFRQGDU\HIILFDF\
HQGSRLQWV 255DQG26ZLOOEHWHVWHGXVLQJDIL[HGVHTXHQFHKLHUDUFKLFDOWHV WLQJ
SURFHGXUHWRFRQWUROWKHIDPLO\ ZLVH7\SH,HUURUUDWHEHORZ VLGHGOHYHO
7KHIDPLO\RIK\SRWKHVHVLVRUGHUHGDVIROORZV 3)6255DQG266WDUWLQJ
ZLWKWKHK\SRWKHVLVRI 3)6LIDQ\K\SRWKHVLVLQWKHVHTXHQFHLVUHMHFWHGDWD
VLGHGVLJQLILFDQFHOHYHORIWKHQWKHVXEVHTXHQWK\SRWK HVLVZLOOEHWHVWHG
LIDQ\K\SRWKHVLVLVDFFHSWHGWKHQWKHVXEVHTXHQWK\SRWKHVHVZ LOOQRWEHWHVWHG
6DIHW\DQDO\VHVZLOOEHEDVHGRQWKH6DIHW\3RSXODWLRQGHILQHG DVDOOUDQGRPL]HG
VXEMHFWVZKRKDYHUHFHLYHGDWOHDVWGRVHRIVWXG\WUHDWPHQW 7KHQXPEHUDQG
SHUFHQWDJHRIVXEMHFWVH[SHULHQFLQJRUPRUH$(VZLOOEHVXPPD UL]HGE\
WUHDWPHQWJURXSUHODWLRQVKLSWRVWXG\WUHDWPHQWDQGVHYHULW\ &KDQJHVIURP
EDVHOLQHDQGVKLIWLQWR[LFLW\JU DGHLQVDIHW\ODERUDWRU\WHVW UHVXOWVDQGYLWDOVLJQV
ZLOOEHVXPPDUL]HGXVLQJGHVFULS WLYHVWDWLVWLFV$GYHUVHHYHQW VDQGVDIHW\
ODERUDWRU\WHVWUHVXOWVZLOOEHJUDGHGIRUVHYHULW\XVLQJWKH1 &,&7&$(
9HUVLRQ
6XEMHFWVÂ¶GHPRJUDSKLFVEDVHOLQHDQGGLVHDVHFKDUDFWHULVWLFVL QDGGLWLRQWRSULRU
DQGFRQFRPLWDQWPHGLFDWLRQVDQGVWXG\WUHDWPHQWH[SRVXUHZLOOE HVXPPDUL]HG
GHVFULSWLYHO\IRUHDFKWUHDWPHQWJURXS
7KHILQDO3)6DQDO\VLVZLOOEHF RQGXFWHGZKHQDSSUR[LPDWHO\ 3)6HYHQWV
KDYHRFFXUUHGRUE\HQG RI\HDUZKLFKHYHULVHDUOLHU$ WRWDORI
3)6HYHQWVZLOOSURYLGHSRZHUWRGHWHFWDVLJQLILFDQWG LIIHUHQFHLQ
3)6EHWZHHQWKHWUHDWPHQWJURXSVZLWKLQWHULPDQDO\VLV 
7KHLQWHULPDQDO\VLVZLOOEHSHUIRUPHGZKHQDSSUR[LPDWHO\
RIWKHWRWDO3)6HYHQWVL HHYHQWVKDYHRFFXUUHG 7KH255DQG
26DQDO\VHVZLOOEHSHUIRUPHGDWWKHVDPHWLPHDVWKHSULPDU\3 )6DQDO\VLV
LQWHULPRUILQDO 

6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 12 of 165 
TABLE OF CONTENTS  
Page 
CLINICAL STUDY PROTOCOL  ...................................................................................1  
PROTOCOL ACCEPTANCE PAGE  ..............................................................................3  
SYNOPSIS  ..........................................................................................................................4  
TABLE OF CONTENTS  ................................................................................................12  
1 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ..................19  
2 BACKGROUND INFORMATI ON ...................................................................23  
2.1 Introduction ................................................................................................23  
2.2 Multiple Myeloma  .....................................................................................23  
2.3 Proteasome Background  ............................................................................24  
2.3.1  Carfilzomib Background (N onclinical)  ......................................24  
2.3.2  Carfilzomib Background (Clinical)  ............................................25  
2.4 Study Rationale  ..........................................................................................27  
2.5 Dose Rationale  ...........................................................................................28  
2.5.1  Rationale for Once- weekly Dosing  .............................................29  
2.5.2  Pharmacokinetics and Pharmacodynamics Dat a for 
Once- weekly Dosing  ...................................................................32  
3 STUDY OBJECTIVES  ........................................................................................35  
3.1 Primary Objective  ......................................................................................35  
3.2 Secondary Objectives .................................................................................35  
3.3 Exploratory Objectives ..............................................................................35  
4 EXPERIMENTAL PLAN ...................................................................................35  
4.1 Study Design  ..............................................................................................35  
4.2 Number of Centers .....................................................................................37  
4.3 Number of Subjects....................................................................................37  
4.4 Estimated Study Duration and Closure ......................................................37  
4.4.1  End of Study ...............................................................................37  
5 SUBJECT ELIGIBILITY  ...................................................................................38  
5.1 Inclusion Criteria  .......................................................................................38  
5.2 Exclusion Criteria  ......................................................................................40  
6 SUBJECT SCRE ENING  .....................................................................................41  
7 SUBJECT RANDOMIZATIO N .........................................................................42  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 13 of 165 
8 STUDY DRUGS  ...................................................................................................43  
8.1 Carfilz omib  ................................................................................................43  
8.1.1  Packaging and Labeling  ..............................................................43  
8.1.2  Storage  ........................................................................................43  
8.2 Dexamethasone  ..........................................................................................43  
8.3 Study Drug Accountability ........................................................................43  
8.4 PRODUCT COMPLAINTS  ......................................................................43  
9 DOSAGE AND TREATMENT  ADMINISTRATION .....................................44  
9.1 Treatment Regimen  ....................................................................................44  
9.2 Intravenous preHydration ..........................................................................45  
9.2.1  Study Treatment Administration .................................................45  
9.2.1.1  Carfilzomib  ...............................................................47  
9.2.1.2  Dexamethasone  .........................................................47  
9.3 Dose Modification RULES ........................................................................47  
9.3.1  Carfilzomib: RULES for Dose Modification  ..............................48  
9.3.1.1  Hematologic Toxicity  ...............................................48  
9.3.1.2  Nonhematologic Toxicity .........................................49  
9.3.2  Dexamethasone: Guidelines for Toxic ities and Dose 
Modification  ................................................................................52  
9.3.3  Conditions not Requiring Dose Reduction .................................54  
9.4 Concomitant Medications and Therapies...................................................54  
9.4.1  Required Concomitant Medications ...........................................54  
9.4.1.1  Gastrointestinal Prophylaxis  .....................................54  
9.4.1.2  Pregnancy and Contraception ...................................55  
9.4.2  Recommended Concomitant Medications ..................................55  
9.4.2.1  Antiviral Prophylaxis  ................................................55  
9.4.2.2  Uric Acid -lowering Agents .......................................55  
9.4.2.3  Mycostatin or Oral Fluconazole ................................55  
9.4.2.4  Antiemetics and Antidiarrheal Agents  ......................55  
9.4.2.5  Thrombophrophylaxis ...............................................55  
Venous thromboembolism has been observed in patients 
receiving carfilzomib.  Thromboprophylaxis 
may be considered on the basis of a benefit- risk 
assessment.  ................................................................55  
9.4.3  Excluded Concomitant Medications and Therapies ...................56  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 14 of 165 
9.4.3.1  Anticancer Agents  .....................................................56  
9.4.3.2  Radiation Therapy  .....................................................56  
9.4.3.3  Myel oid Growth Factors ...........................................56  
9.4.3.4  Corticosteroids ..........................................................56  
9.4.3.5  Plasmapheresis  ..........................................................56  
9.4.3.6  Novel Agents for Non-neoplastic Conditions ...........57  
10 STUDY ASSESSMENTS AND PROCEDURES  ..............................................57  
10.1  Study Specific Procedures .........................................................................57  
10.1.1  Multiple Myeloma History and Prior Lines of Therapy 
Assessment  ..................................................................................57  
10.1.2  Vital Signs  ...................................................................................58  
10.1.3  Complete Physical Examination  .................................................58  
10.1.4  Eastern Cooperative Oncology Group Performance Status ........59  
10.1.5  International Staging System Stage Determination  ....................59  
10.2  Multiple Myeloma Disease Assessments  ...................................................59  
10.3  Multiple Myeloma Response Assessments  ................................................61  
10.3.1  Disease Response and Progression Assessments  ........................61  
10.3.2  Tumor Response Assessment .....................................................61  
10.3.3  Disease Progression  ....................................................................61  
10.4  Laboratory Tests  ........................................................................................62  
10.4.1  Hematology  .................................................................................63  
10.4.2  Serum Chemistry  ........................................................................63  
10.4.3  Coagulation .................................................................................64  
10.4.4  Pregnancy Testing  .......................................................................64  
10.5  Electrocardiogram  ......................................................................................64  
10.6  Echocardiogram .........................................................................................65  
10.7  Patient Reported Outcomes ........................................................................65  
10.8  Healthcare Resource Utilization  ................................................................67  
10.9  Correlative Studies  .....................................................................................67  
10.9.1  Intensive Pharmacokinetics/Pharmacodynamics Substudy  ........67  
10.9.2  Sparse Pharmacokinetic Sampling  ..............................................68  
10.10  Long -term Follow -up .................................................................................68  
10.10.1  Long -term Follow -up Before Disease Progression  .....................69  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 15 of 165 
10.10.2  Long -term Follow -up After Disease Progression 
(For Survival) ..............................................................................69  
11 STUDY DISCONTINUATIO N ..........................................................................69  
11.1  Withdrawal of Subjects from Study Trea tment .........................................69  
11.2  Withdrawal of Subjects from Study ...........................................................70  
11.3  Study Termination  .....................................................................................71  
12 ADVERSE EVENTS AND SERIOUS ADVERSE EVENT S ..........................71  
12.1  Adverse Event Reporting ...........................................................................71  
12.1.1  Adverse Event Terminology .......................................................71  
12.1.2  Severity  .......................................................................................72  
12.1.3  Duration ......................................................................................73  
12.1.4  Causality  .....................................................................................73  
12.2  Adverse Events Reporting Procedures .......................................................74  
12.2.1  General  ........................................................................................74  
12.3  Serious Adverse Event Definition .............................................................75  
12.4  Serious Adverse Event Reporting and Documentation Requirements ......75  
12.5  Pregnancy and Lact ation Exposure Reporting ...........................................76  
12.6  Death Reporting  .........................................................................................77  
13 STATISTICAL CONSIDERATIONS  ...............................................................77  
13.1  Study Endpoints  .........................................................................................78  
13.1.1  Primary Endpoints ......................................................................78  
13.1.2  Secondary Endpoints ..................................................................78  
13.2  Study Populations ......................................................................................78  
13.2.1  Intent- to-Treat Population ...........................................................78  
13.2.2  Safety Analysis Pop ulation  .........................................................78  
13.3  Statistical Methods  .....................................................................................78  
13.3.1  Analysis of the Conduct of the Study .........................................78  
13.3.2  Efficacy Analyses  .......................................................................79  
13.3.2.1  Primary Efficacy Endpoint .......................................79  
13.3.2.2  Secondary Efficacy Endpoints ..................................80  
13.3.2.3  Control of Family- wise Type I Error Rate  ................81  
13.3.3  Safety Analysis  ...........................................................................81  
13.3.3.1  Adverse Events  .........................................................81  
13.3.3.2  Safety Laboratory Values  .........................................82  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 16 of 165 
13.3.3.3  Vital Signs  .................................................................83  
13.3.4  Sparse Pharmacokinetic Analyses  ..............................................83  
13.3.5  Exploratory Analyses ..................................................................84  
13.4  Handling o f Data  ........................................................................................85  
13.4.1  Handling Missing Data in Descriptive Analyses  ........................85  
13.4.2  Handling Missing or Partially Missing Dates  .............................85  
13.4.3  Missing Grade or Relationship of Adverse Event to Study 
Treatments ...................................................................................86  
13.4.4  Unscheduled Visits .....................................................................86  
13.5  Determination of Sample Size  ...................................................................86  
13.6  Independent Review Committee ................................................................86  
13.7  Data Monitoring Committee  ......................................................................87  
13.8  Interim Analysis  .........................................................................................87  
14 REGULATORY OBLIGATIONS  .....................................................................88  
14.1  Informed Consent.......................................................................................88  
14.2  Compliance with Laws and Regulations....................................................89  
14.3  Subject Confidentiality  ..............................................................................90  
15 ADMINISTRATIVE AND L EGAL OBLIGATIONS  .....................................90  
15.1  Protocol Amendments ................................................................................90  
15.2  Study Term ination  .....................................................................................91  
15.3  Study Documentation and Archives ..........................................................91  
15.3.1  Source Documents ......................................................................91  
15.3.2  Archival of Records ....................................................................91  
15.4  Data Collection and Study Monitoring ......................................................91  
15.4.1  Electronic Case Report Forms  ....................................................91  
15.4.2  Study Monitoring ........................................................................92  
15.4.3  Data Quality Assurance  ..............................................................92  
15.5  Publication Policy  ......................................................................................93  
16 REFERENCES  .....................................................................................................94  
APPENDIX A  SCHEDULE OF ASSESSME NTS  ..........................................97  
APPENDIX B  SCHEDULE OF DISEASE ASSESSMENTS  ........................99  
APPENDIX C  SCHEDULE OF STUDY TREATMENT 
ADMINISTRATION .........................................................................................100  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 17 of 165 
APPENDIX D  SCHEDULE OF STUDY AS SESSMENTS FOR THE 
PHARMACOKINETIC SPARSE SAMPLING AND INTENSIVE 
PHARMACOKINETIC & PHARMACODYNAMIC SUB -STUDY  ...........101  
APPENDIX E  ECOG PERFORMANCE STATUS  ......................................103  
APPENDIX F  NEW YORK HEART ASSOCIATION (NYHA) 
CLASSIFICATION ...........................................................................................104  
APPENDIX G  SUMMARY OF INTERNATIONAL MYELOMA 
WORKING GROUP UNIFOR M RESPONSE 
CRITERIA (IMWG -URC)  ...............................................................................105  
APPENDIX H  INTERNATIONAL STAGIN G SYSTEM  ...........................107  
APPENDIX I  NATIONAL CANCER INST ITUTE 
COMMON  TERMINOLOGY CRITERIA FOR  ADVERSE EVENTS 
(NCI -CTCAE) GRADING SCALE ..................................................................108  
PATIENT REPORTED OUTCOMES .................................109 APPENDIX J 
APPENDIX K COUNTRY SPECIFIC PREGNANCY AND 
CONTRACEPTIVE SUPPLE MENT  ..............................................................110  
APPENDIX L  SAMPLE SERIOUS ADVERSE EVENT 
REPORT  FORM  ................................................................................................113  
APPENDIX M  PREGANCY NOTIFICATION FORM  ...............................118  
APPENDIX N  LACTATION NOTIFICATI ON FORM  ..............................119  
APPENDIX O  SUMMARY OF CHANGES F OR PROTOCOL 
AMENDMENT  4 AND FOR SUPERSEDING PROTOCOL 
AMENDMENT  4 ...............................................................................................120  
LIST OF TABLES  
Table 1  Summary of Pharmacokinetic Parameters from CHAMPION 1  .....................32  
Table 2  Pharmacokinetic Parameters Comparison of CHAMPION 1 and PX-171-003 â€“ Part 2 (A1) ................................................................................33
 
Table 3  Carfilzomib Dose Decrements  .........................................................................48  
Table 4  Carfilzomib Dose Modification Rules for Treatment- emergent 
Hematologic  Toxicity  ......................................................................................49  
Table 5  Carfilzomib Dose Modifications for Nonhematologic Toxicity  ......................50  
Table 6  Dose Decrements for Dexamethasone .............................................................52  
Table 7  Treatment Rules for Dexamethasone- related Toxicities  ..................................53  
Table 8  Laboratory Tests:  Hematology  .......................................................................63  
Table 9  Laboratory Tests:  Chemistry Panel  .................................................................64  
Table 10  Study 20140355 Pharmacodynamics Sampling Timepoints  ...........................67  
Table 11  Grading for Adverse Events not Covered in the NCI- CTCAE  ........................72  
Superseding  Amendment  4: 07 March  2017  CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 18 of 165 
Table 12  Stopping Boundaries for Progression -free Survival ........................................88  
LIST OF FIGURES  
Figure  1 Proteasome Percent Activity in Peripheral Blood Mononuclear Cells ............34  
Figure  2 Study 20140355 Schema..................................................................................36  
Figure  3 Arm A and Arm B Carfilzomib with Dexamethasone Regimens  ....................46  
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 19 of 165 
1 LIST OF ABBREVIATION S AND DEFIN ITIONS OF TERMS  
Abbreviation  Definition  
ADL  Activities of daily living  
AE(s)  adverse event(s)  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
ASCO  American Society of Clinical Oncology  
ASCT  autologous stem cell transplantation  
AST  aspartate aminotransferase  
AUC  area under the curve  
AUC 0-last area under the curve from time 0 to last time measurable concentration  
BSA  body surface area  
BUN blood urea nitrogen 
CBR  clinical benefit rate  
CFZ carfilzomib  
CI confidence interval  
Cmax maximum plasma concentration  
C1D1  Cycle  1 Day  1 
C2D1  Cycle  2 Day  1 
CR complete response  
CrCl  creatinine clearance  
CT computed tomography  
CT-L chymotrypsin -like 
D5W  5% Dextrose Injection  
Dex dexamethasone  
DLT(s)  dose-limiting toxicity(ies)  
DMC  Data  Monitoring Committee  
DOR  duration of response  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG PS  Eastern Cooperative Oncology Group Performance Status  
EORTC European Organization for Research and Treatment of Cancer 
eCRF  electronic Case Report Form  
EDC  electronic data capture 
EOT  End of Treatment  
EQ VAS  EQ Visual Analogue scale  
EuroQOL  European Quality of Life  
EQ-5D-5L European Quality of Life -5 Dimensions   
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 20 of 165 
Abbreviation  Definition  
FDA  Food and Drug Administration 
FCBP  females of childbearing potential 
FISH  Fluores cence in situ hybridization  
GCP  Good Clinical Practice  
H2 histamine 2  
HIV human immunodeficiency virus  
HR(s)  hazard ratio(s)  
HRQL  health -related quality of life  
HUS  hemolytic uremic syndrome  
IB Investigatorâ€™s Brochure  
ICF informed consent form 
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IgM immunoglobulin M  
IMiD(s) immunomodulatory agent(s)  
IMWG -URC  International Myeloma Working Group -Uniform Response Criteria  
IND Investigational New Drug  
INR international n ormalized ratio  
IP(s)  investigational product(s)  
IPIM  Investigational Product Instruction Manual  
IRB Institutional Review Board  
IRC Independent Review Committee  
ISRG  Independent Statistical Reporting Group  
IST(s)  investigator -sponsored trial(s)  
ISS International Staging System  
ITT Intent -to-Treat  
IUD intrauterine device  
IV intravenous(ly)  
IVR/IWR  Interactive Voice (IVR) and Web Response (IWR) 
LDH  lactate dehydrogenase  
LFT(s)  liver function test(s)  
LMP2  latent membrane protein 2  
LMP7  latent me mbrane protein 7 
LTFU  Long- term follow -up 
LVEF  left ventricular ejection fraction  
MECL -1 multicatalytic endopeptidase complex -like 1  
MedDRA  Medical Dictionary for Regulatory Activities  
MR minimal response  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 21 of 165 
Abbreviation  Definition  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
MUGA multigated acquisition  
NCI-CTCAE  National Cancer Institute -Common Terminology Criteria for Adverse Events  
NYHA New York Heart Association  
ORCA  Onyx Response Computational Assessment  
ORR  overall response rate  
OS overall survival  
PBMC(s)  peripheral blood mononuclear cell(s) 
PD progressive disease  
PDn pharmacodynamic s 
PET positron emission tomography 
PK pharmacokinetic  
PFS progression- free survival  
PI proteasome inhibitor  
PN peripheral neuropathy  
prn as needed  
PO orally   
POEMS  polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin 
changes  
PR partial response  
PRO(s)  patient reported outcome (s) (psychosocial measures)  
PSA prostate -specific antigen  
PT prothrombin time  
PTT partial thromboplastin tim e 
QLQ -C30 Quality of Life Core Module  
QLQ -MY20  Quality of Life Multiple Myeloma Module 20 
QOL  Quality of Life  
QTc corrected QT -interval  
RBC(s)  red blood cell(s)  
SAE(s) serious adverse event(s)  
SAg surface antigen  
SAP Statistical Analysis Plan  
SBE-CD sulfobutylether -beta-cyclodextrin (Captisol)  
SOC  system organ class  
SWI Sterile Water for Injection  
sCR stringent complete response  
SFLC  serum free light chain  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 22 of 165 
Abbreviation  Definition  
SOPs  Standard Operating Procedures  
SPEP serum protein electrophoresis  
t1/2 terminal ha lf-life  
TEAE(s) treatment -emergent adverse event(s)  
TLS tumor lysis syndrome  
tmax time to maximum plasma concentration  
TTP thrombocytopenic thrombotic purpura  
ULN  upper limit of normal  
UPEP  urine protein electrophoresis  
US United States  
USP Unite d States Pharmacopeia  
VGPR  very good partial response  
WBC(s)  white blood cell(s)  
WOCBP  woman of childbearing potential  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 23 of 165 
2 BACKGROUND INFORMATION 
2.1 INTRODUCTION 
Carfilzomib for Injection received accelerated approval from the United States Food and 
Drug Admi nistration ( US FDA) in July 2012 for the treatment of patients with multiple 
myeloma who have received at least 2 prior therapies, including bortezomib and an 
immunomodulatory agent (IMiD) and have demonstrated disease progression on or 
within 60 days  of completion of the last therapy.  The approval was based on the results 
of the Study PX-171-003 â€“ Part 2 (A1) in 266 subjects with relapsed and refractory multiple myeloma.    
Per the 2012 approved label, carfilzomib is administered intravenously (IV) over 
10 minutes , on 2 consecutive days  each week for 3 weeks ( Days  1, 2, 8, 9, 15, and 16 of a 
28-day cycle).  The recommended Cycle  1 dose is 20 mg/m
2/day with an  increase to 
27 mg/m2 on Cycle  2 Day 1 onwards.   
This study will assess the superiority of a higher dose level of carfilzomib (70 mg/m2) 
given once- weekly ( Days  1, 8, and 15) over 30 minutes in combination with 
dexam ethasone compared to the twice-weekly regimen at 20/27 mg/m2 in combination 
with dexam ethasone .  Subjects will receive the study treatment determined by 
randomization until disease progression, unacceptable toxicity, withdrawal of consent, or mortality (whichever occurs first).  Subjects will be evaluated in long -term follow -up 
(LTFU) for health status and survival.   
2.2 MULTIPLE MYELOMA  
Multip le myeloma, a clonal neoplastic proliferation of plasma cells, is the second most 
common hematologic malignancy and accounts for approximately 72,000 annual deaths 
worldwide ( Ferlay  2010) .  There are an estimated 11,0 00 deaths per year in the US and 
more than 19,000 deaths per year in Europe (American  Cancer  Society  2014; 
Boyle  2005).  Multiple myeloma is characterized by anemia, bon e destruction, 
monoclonal gammopathy, renal failure, hypercalcemia, and increased susceptibility to infections.  The disease is systemic and chemotherapy is indicated for management of 
symptomatic myeloma.   
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 24 of 165 
Historically, multiple myeloma was treated with chemotherapy with the introduction of 
melphalan in the 1960s.  Subsequent treatment paradigms for the next three decades 
relied largely on combination of chemotherapy regimens with corticosteroids, with 
minimal to no incremental improvements in survival.  In the 1990s, the introduction of 
autologous stem cell transplantation (ASCT) after a conditioning regimen that incorporates high doses of melphalan resulted in improvements in survival.  Additional 
improvements in survival followed the advent of the IMiDs, thalidomide (Thalomid) and 
lenalidomide (Revlimid) and the proteasome inhibitor (PI) bortezomib (Velcade) 
(Kumar  2008).  Since then, these 3 agents have been used in combination with 
corticosteroids, and with chemotherapy agents (e.g., alkylating agents) (National 
Comprehensive Cancer Network 2014; Harousseau 2010).   
Despite improvements in progression free survival (PFS) and overall survival (OS), 
patients  who have received several lines of prior therapy experience progressively lower 
rates and durations of response as resistance emerges (Kumar  2004; Durie  2012; 
Kumar  2012) ; and current therapeutic options for patients who have multiply relapsed  
and refractory disease, especially those refractory to both IMiDs and bortezomib, are limited.  A recent retrospectiv e review of 286 patients from treatment centers in the US, 
Europe, and Asia with a median of 4 prior therapies and 3.3 years since initial diagnosis 
of multiple myeloma, revealed that such patients with multiply relapsed multiple 
myeloma can anticipate a median OS of approximately 9 months ( Kumar  2012) .  
2.3 PROTEASOME BACKGROUND 
The proteasome is a multicatalytic proteinase complex that is responsible for degradation 
of a wide variety of protein substrates within normal and m alignant cells.  Intracellular 
proteins targeted for degradation by the proteasome are first ubiquitinated via the ubiquitin conjugation system.  Ubiquitinated proteins are cleaved within the proteasome 
by 1 or more of 3 separate N -terminal threonine prote ase activities: a chymotrypsin -like 
(CT-L) activity, a  trypsin -like activity, and a caspase- like activity . 
2.3.1 
CARFILZOMIB BACKGROUND (NONCLINICAL)  
Carfilzomib (formerly known as P R-171) is a tetrapeptide epoxyketone-based inhibitor of 
the 20S proteasome, prim arily of the CT -L activity , and at higher concentrations, 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 25 of 165 
of multiple 20S proteolytic activities .  Carfilzomib is a synthetic small molecule peptide 
bearing the chemical name (2S) -N-((S)-1- ((S)-4- methyl-1- ((R)-2- methyloxiran -2-yl) 
-1-oxopentan-2- ylcarbamoy l)-2-phenylethyl) -2-((S)-2- (2-morpholinoacetamido) 
-4-phenylbutanamido)-4- methylpentanamide.  The molecular formula is C 40H57N5O7 and 
the molecular weight is 719.91.  Carfilzomib, which is structurally and mechanistically 
different from the dipeptide boronic acid PI bortezomib, showed less off- target activity 
when measured against a broad panel of proteases including metallo-, aspartyl -, and 
serine proteases compared to bortezomib; the latter showed off- target inhibitory activity 
in the nanomolar range agai nst several serine proteases (Arastu -Kapur 2009).  This 
selectivity may be responsible for the reductions in myelosuppression and neuropathy 
observed in clinical and  nonclinical studies comparing carfilzomib with bo rtezomib.  
Carfilzomib primarily inhibits the CT-L activity of both the constitutive proteasome and 
the immunoproteasome ( Kuhn 2007; Demo  2007).   The importance for co -inhibition of 
multiple proteasome active sites for cytotoxicity ( CT-L, trypsin-like, and/or caspase- like) 
has been demonstrated against multiple myeloma cell lines (Britton  2009; Geurink 2013).  
Nonclinical work supported improved tolerability with increased infusion time, possibly because of the reduced maximum concentration (C
max) with a 30 -minute IV infusion 
(Yang  2011).  Correlative clinical pharmacodynamics (PDn) studies have confirmed that 
longer infusion times and higher doses of carfilzomib resulted in increased proteasome 
inhibition ( Papadopoulos 2014; Lee 2012).  Clinical e vidence for carfilzomib dose 
response has been observed in a multivariable modeling analysis comparing 20 mg/m2 
with 27 mg/m2, (Lonial 2011; Squifflet  2011) suggesting th at more effective inhibition of 
proteasome activity may improve efficacy.  An increased infusion time of 30 minutes  
enabled carfilzomib to be administered at a higher dose, with a maximum tolerated dose 
(MTD) of 56  mg/m2 in Study PX -171-007, compared to 27 mg/m2 over a 2 to 10- minute 
infusion as discussed in Section  2.3.2.  
2.3.2 CARFILZOMIB BACKGROUND (CLINICAL)  
As of 1 0 July 2015, approximately 2921 individual subjects have been treated with 
carfilzomib as participan ts in Onyx -sponsored clinical studies, and 89 subjects have been 
enrolled in studies in Japan sponsored by Ono Pharmaceutical Company.  Approximately 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 26 of 165 
3549 subjects have been treated with carfilzomib through the 76 completed or actively 
enrolling investigator-sponsored trials (ISTs) ( Carfilzomib IB ). 
There are five Phase 3 studies in multiple myeloma: PX -171-009 (ASPIRE), PX-171-011 
(FOCUS), 2011-003 (ENDEAVOR), 2012- 005 ( CLARION ), and this study, 20140355 
(A.R.R.O.W.).  Additionally , 137 subjects with solid tumors  have been treat ed with 
carfilzomib.  
These trials have explored various doses of carfilzomib either as monotherapy or in combination with other agents and in the majority of studies conducted to date, 
carfilzomib  has been administered on 2 consecutive days  for 3  weeks in a 28 -day cycle .  
Carfilzomib clinical activity has been demonstrated in these studies along with  an 
acceptable safety profile.  
Higher doses of carfilzomib administered on a tw ice-weekly schedule have been studied.  
PX-171-007, a Phase 1b/2 study, was the first to establish the MTD of single agent 
carfilzomib administered as a 30 -minute infusion in subjects  with relapsed and/or 
refractory multiple myeloma  (Papadopolous 2014 ).  Subjects received carfilzomib 
monotherapy on Days  1, 2, 8, 9, 15, and 16 of a 28- day cycle.  Cycle  1 Day  1 and Day 2 
doses were 20  mg/m
2 followed thereafter by dose escalation to 36, 45, 56, or 70 mg/m2.  
Carfilz omib  was administered later with low -dose dexamethasone (40 mg/week)  at the 
45 mg/m2 and 56 mg/m2 dose levels .  Thirty- three subjects were treated , and there were 
dose- limiting toxicities (DLTs) in 2 subjects dosed at 70  mg/m2 of renal tubular necrosis 
(Grade 3) and proteinuria (Grade 3).  The MTD was determined to be 56 mg/m2. 
In the 56 mg/m2 cohort (n = 24), the most common treatment- related adverse events 
(AEs) of any grade were nausea (54.2 %), dyspnea (50.0%), fatigue (45.8%), pyrexia 
(41.7%), and thrombocytopenia and chills (both 37.5%); a majority were Grade 1 or 2.  At this dose, hematologic AEs of thrombocytopenia (37.5%) and anemia (16.7%) were 
the most common treatment- related AEs of â‰¥ Grade  3.  When carfilzomib at 56 mg/m
2 
was combined with dexamethasone (n = 8), nausea (25%), fatigue (25%), and dyspnea and chills (each 12.5%) occurred less frequently than with carfilzomib alone.  The overall 
response rate (ORR) was 50% in the 56 mg/m
2 cohort where the majority of subjects 
were refractory to IMiDs and bortezomib.  The Phase 2 PX-171-003 â€“ Part  2 (A1) study 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 27 of 165 
with single agent carfilzomib at 20/27  mg/m2 in a similar population had an ORR 
of 22.9% in the Safety population. 
As evidenced by Study PX -171-007, higher doses of carfilzomib on a twice- weekly 
schedule administered over 30 minutes  were well tolerated and efficacious  with an 
acceptable safety profile.  This led the sponsor to investigate whether higher doses of 
carfilzomib could be tolerated and be efficacious on a more convenient weekly dosing 
schedule in the CHAMPION 1 study as discussed in Section 2.5. 
Additional information on the safety and activity of c arfilzomib is described in the 
Carfilzomib IB . 
2.4 STUDY RATIONALE  
Based on the aspiration of improving the convenience of the currently approved carfilzomib dosing regimen and the recognition that higher doses appeared active and 
tolerable when given over a longer infusion time, a Phase 1b/2 Study CHAMPION 1 was 
initiated to evaluate the safety and efficacy of once- weekly carfilzomib with 
dexamethasone in subjects with relapsed myeloma, who had received 1 to 3 prior therapies.  The dose -escalation portion of the study has identified an MTD of 70 mg/m
2 
administered once-weekly over 30 minutes on Days 1, 8, and 15 of a 28- day cycle.  
Preliminary results from the ongoing Phase  2 portion of this multicenter, single -arm 
study suggested that the dose and regimen of 70 mg/m2 once- weekly appeared  to be well 
tolerated, highly active, and able to  offer a more convenient treatment regimen for 
subjects as discussed in Section 2.5. 
The rationale for this study is to compare carfilzomib  administered once weekly  in 
combination with dexamethasone, based on the CHAMPION 1 results, to twice -weekly 
carfilzomib in combination with dexamethasone in subjects with relapsed and refractory 
multiple myeloma, previously treated with a proteasome inhibitor  and an IMiD.  The 
hypothesis is that this regimen will have superior efficacy with an acceptable safety profile and a more convenient dosing regimen when compared with the US approved 
dose and schedule of carfilzomib administered at 20/27 mg/m
2 twice weekly . 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 28 of 165 
The primary endpoint in this study is PFS.  Response rates, especially high -quality 
responses of substantial duration, are important indicators of benefit in relapsed and 
refractory multiple myeloma (Anderson 2008 ).  A number of studies have shown an 
association between deeper responses and improved survival in patients with multiple myeloma (Lonial 2014).  For these reasons, this study was ori ginally designed with 
ORR as the primary endpoint and PFS as a key secondary endpoint.  Although 
ORR remains a meaningful clinical endpoint, recent advances in antimyeloma 
therapy have altered the landscape such that PFS is now considered to be the more 
relevant regulatory endpoint in this setting .  To support regulatory interactions and 
protect the integrity of the the PFS data, the primary endpoint has been amended to 
PFS, with ORR as a key secondary endpoint.  
2.5 DOSE RATIONALE  
Carfilzomib 20/27 mg/m
2 twice -weekly is an  approved monotherapy dose 
and 20/70 mg/m2 once- weekly is the MTD that was determined in the CHAMPION 1 
study described in Section 2.5.1. 
In the proposed study, dexamethasone will be administered pri or to carfilzomib 
administration at 40  mg weekly on Days  1, 8, and 15 in both arms during all Cycles and 
on Day  22 in both arms during Cycle 1 to 9 only.  This dose and schedule of therapeutic 
dexamethasone was part of the once- weekly treatment regimen in Study CHAMPION 1.  
The equivalent weekly doses of dexamethasone in both treatment arms will enable a clear 
interpretation of the studyâ€™s primary comparison between high-dose once- weekly 
carfilzomib and standard- dose twice- weekly carfilzomib.  
Carfilzomib study treatment administration will use a step -up approach in which the first 
dose level for all subjects will be 20  mg/m2 (Cycle  1 Day  1 for the once- weekly regimen 
and Cycle  1 Days  1 and 2 for the twice- weekly regimen) and the dose le vel will then 
increase to 70 mg/m2 or 27 mg/m2 respectively, beginning on Day 8 of Cycle  1. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 29 of 165 
The dose levels of carfilzomib and dexamethasone being evaluated in this study are: 
Arm A: Once -weekly  
â€¢ Carfilzomib  20 mg/m2 
o Study Day 1 (Cycle  1) 
â€¢ Carfilzomib 70  mg/m2  
o Study Days 8 and 15 ( Cycle  1) 
â€¢ Carfilzomib 70  mg/m2 
o Study Days  1, 8, and 15 ( Cycles  2+) 
â€¢ Dexamethasone  
o 40 mg (IV or PO  [orally] ) on Study Days  1, 8, and 15 (a ll Cycles)  
o 40 mg (IV or PO) Study Day 22 (Cycles  1 to 9 only) 
Arm B: Twice -weekly  
â€¢ Carfilzomib 20  mg/m2  
o Study Days  1 and 2 ( Cycle  1) 
â€¢ Carfilzomib 27  mg/m2  
o Study Days  8, 9, 15, and 16 ( Cycle  1) 
â€¢ Carfilzomib 27  mg/m2 
o Study Days  1, 2, 8, 9, 15, and 16 ( Cycles  2+) 
â€¢ Dexamethasone  
o 40 mg (IV or PO) on Study Days  1, 8, and 15 (a ll Cycles)  
o 40 mg (IV or PO) on Study Day  22 (Cycle s 1 to 9 only) 
2.5.1 RATIONALE FOR ONCE -WEEKLY DOSING  
CHAMPION 1, a Phase 1b/2 study in subjects with relapsed multiple myeloma who had 
received 1 to 3 prior therapies  was initiated to investigate higher doses of carfilzomib  
given once- weekly  in combination with  dexamethasone, and preliminary results indicate d 
that these modifications were well tolerated and active.  In the Phase 1b dose- escalation 
portion of the study , all subjects received 20  mg/m2 carfilzomib on Cycle  1 Day  1 and 
then received the cohort- assig ned test dose on Cycle  1 Days 8 and 15.  The initial dose 
level evaluated was 45  mg/m2, with escalation to 56  mg/m2, 70 mg/m2, and 88 mg/m2 in 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 30 of 165 
successive cohorts.  Subjects received 40  mg dexamethasone on Days  1, 8, 15, and 22 of 
Cycles  1 through 8 and on Days  1, 8, and 15, from Cycle  9 onward. 
No DLTs were observed during dose escalation at the dose levels of 45  mg/m2, 
56 mg/m2, or 70 mg/m2.  At the carfilzomib dose level of 88 mg/m2, 2 DLTs were 
observed during Cycle  1: 
â€¢ Dyspnea (Grade 3, Days 9 to 11)  
â€¢ Vomiting (Grade  3, Day  15)  
Per protocol, an expansion cohort of 9 additional subjects  was enrolled at the 70  mg/m2 
dose.  There was 1  DLT in the 70 mg/m2 expansion cohort: Grade 3 dyspnea ( Days  16 to 
18).  The MTD of once-weekly carfilzomib in combination w ith dexamethasone was 
determined to be 70 mg/m2. 
A total of 27 subj ects were enrolled in the Phase 1 portion of the study with a median of 
1 prior therapy.  Fifteen subjects received study treatment at a dose of 70 mg/m2.  
The majority of the 27  subjects ( 85%) received prior bortezomib and 63% of those were 
refractory to bortezomib.  The ORR in the Phase 1 population was 81% with a clinical 
benefit rate (CBR) of 93%.  The once- weekly treatment regimen of 70  mg/m2 showed 
promising activity with an ORR of 93% (95% [confidence interval] CI:  68.1 to  99.8%), 
4 subjects achieved a complete response (CR) and the CBR was 100% (95%  CI:  78.2 
to 100%).  The  median treatment duration was 8.3 months in this cohort ( Berenson  2014).  
All 27 subjects (100%) experienced at least 1 AE.  The most common (â‰¥ 20% of 
subjects) AEs were upper respiratory tract infection, fatigue (each 52%), insomnia (44%), 
diarrhea, nausea, headache (each 41%), anemia, decreased hematocrit (each 37%), 
pyrexia (33%), constipation (30%), back pain, cough, muscle spasms, dyspnea, decreased 
red blood cell count (each 26%), arthralgia, dizziness, and pain in extremity (each 22%).  
Five serious adverse events (SAEs) were reported in the Phase 1 part of this ongoing 
study: 
â€¢ One subject at 45  mg/m2 had 2 SAEs; increased blood creatinine (Grade 3) , and 
hyponatremia (Grade 4).   
â€¢ One subject at 70  mg/m2 had pneumonia (Grade 3).   
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 31 of 165 
â€¢ One subject at 88  mg/m2 had dyspnea (Grade 3).   
â€¢ One subject at 70  mg/m2 had chronic obstructive pulmonary disease (Grade  3).   
All SAEs were determined to be unrelated to carfilzomib and dexamethasone , except for 
the Grade 3 dyspnea event, a DLT in a subject receiving the 88 mg/m2 dose. 
As of 0 1 May  2015, 104 subjects (Phase 1 n = 15, Phase  2 n = 89) have received at least 
1 dose of carfilzomib at the MTD.  The majority of subjects ( 82%) had received prior 
bortezomib.  A total of 48% of subjects were bortezomib- refractory, 28% were 
lenalidomide -refractory, and 16% were refractory to both.  The ORR to  date was 7 7% 
(95% CI:  6 8% to 8 5%) with a CBR of 8 4% (95% CI:  7 5% to 90%).  Median PFS was 
10.6 months (95% CI:  9.0 to 16.1).  Preliminary median carfilzomib treatment duration 
in the ongoing study is 8.3  months (range:  > 1 to 20) for the Phase 1 portion of the 
study and 7.2 months (range:  0.03 to 22.6) for the Phase 2 portion of the study 
(Berenson 2015).  
All 104 subjects experienced at least 1  AE.  The most common AEs (â‰¥ 15% of subjects) 
were fatigue ( 52%), nausea (3 5%), headache, diarrhea (each  31%),  insomnia, upper 
respiratory tract infection  (each 30%), cough (26%), dyspnea (2 5%), anemia (24%), 
thrombocytopenia, pyrexia (each 22 %), peripheral edema (20%), and back pain  (17%).  
A total of 64 subjects ( 62%) experienced at least 1 Grade 3 or higher AE.  The most 
common (â‰¥ 5% of subjects) Grade 3 or higher AEs were fatigue ( 11%), pneumonia (7%), 
thrombocytopenia, hypertension, acute renal failure (each 6%),  dyspnea , anemia,  back 
pain, asthenia, and chronic obstructive pulmonary disease (each 5%) (Carfilzomib IB ). 
The preliminary results from CHAMPION  1 demonstrated that once- weekly carfilzomib 
at 70  mg/m2 administered as a 30 -minute infusion in combination with dexamethasone in 
subjects with relapsed and refractory multiple myeloma had an acceptable safety and 
tolerability profile and promising efficacy.  Eighty-nine subjects were enrolled into the 
Phase 2 portion of the study.   
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 32 of 165 
2.5.2 PHARMACOKINETICS AND PHARMACODYNAMICS DAT A FOR 
ONCE -WEEKLY DOSING  
Pharmacokinetics (PK) and pharmacodynamics ( PDn) results from CHAMPION 1 are 
supportive of the proposal to study the once- weekly 70 mg/m2 regimen as an effective 
alternative regimen for carfilzomib.  
Preliminary PK results from CHAMPION 1 indicated that a once- weekly 30 -minute 
infusion of carfilzomib had a mean terminal half- life similar to the  half-life of â‰¤ 1 hour 
following the approved twice-weekly dosing regimen (20/27 mg/m2 over 2 to10 minutes ). 
In ad dition, the data showed a dose-proportional increase in the mean C max and area under 
the curve (AUC) from 20 to 88 mg/m2, as indicated by the similar dose normalized values 
for C max and AUC (refer to  Table 1).  The AUC following a 70 mg/m2 dose was  
1045 ngâ‹…h/mL, which is higher than the total weekly AUC following the twice- weekly of 
27 mg/m2 dose (758 ng â‹…h/mL, refer to Table 2).  The mean C max following the 70 mg/m2 
dose administered as a 30 -minute infusion is 2640 ng/mL, which is lower than the mean 
Cmax of 4232 ng/mL in Study PX -171-003 â€“ Part  2 (A1), following the IV infusion of 
27 mg/m2 over 2 to 10 minutes  (Carfilzomib IB ). 
Table 1 Summary of P harmacokinetic  Parameters from CHAMPION 1  
Dose  
(mg/m2) n t1/2 (%CV) Cmax 
(%CV)  Cmax/Dos e 
(ng/mL)/  
mg/m2 AUC 0-last 
(%CV)  AUC/Dose  
(h.ng/mL)/m
g/m2 
20 11 0.77 hr 
(37.4%)  703 ng/mL  
(16.0%)  35.0 283 ngâ‹…h/mL  
(17.6%)  14.2 
70 5 0.91 hr 
(24.3%)  2640 ng/mL  
(24.9%)  37.7 1045 ngâ‹…h/mL  
(22.1%)  14.9 
88 5 0.84 hr 
(11.3%)  3172 ng/mL  
(24.9%)  36.0 1247 ngâ‹…h/mL 
(31.3%)  14.2 
AUC 0-last = AUC from time 0 to last time measurable concentration , CV  = coefficient of variation, 
t1/2 = terminal half -life, C max = maximum plasma concentration, AUC = area under the curve. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 33 of 165 
Table 2 Pharmacokinet ic Parameters Comparison of CHAMPION 1 and 
PX-171-003 â€“ Part 2 (A1) 
Study  Cycle/Dose/Days  Infusion 
Duration  Total 
dose/week  
(mg/m2) Total AUC 
per week  
(ngâ‹…hr/mL)  Maximal 
concentration 
(ng/mL)  
PX-171-003 
â€“ Part 2 (A1)  Cycle  1:  20 mg/m2 
Days  1, 2, 8, 9, 15, a nd 
16 2â€“10 minutes  40 566a 3060  
Cycle  2:  27 mg/m2 
Days  1, 2, 8, 9, 15, and 
16  2â€“10 minutes  54 758a 4232  
2012- 002 
(CHAMPION 1)  Cycle  1 Day  1: 20 mg/m2 
Cycle  1 Days 8 and 15: 
70 mg/m2  30 minutes  
70 1045b 2640  
Cycle  2:  70 mg/m2 
Days  1, 8, and 15  30 minutes  
AUC = area under the curve.  
a AUC following a single 20 and 27 mg/m2 dose (2â€“ 10 minutes infusion) is 283 and 379 ngâ‹… hr/mL, 
respectively.  Total AUC per week is calculated by multiplying the single dose AUC by 2 
(e.g., 379 Ã— 2 = 758 ngâ‹…h/mL).   
b Represents total AUC per week starting on Day 8 . 
An exploratory exposure response analysis indicates a statistically significant relationship  
between the 
carfilzomib average AUC during Cycle  1 and response rates (ORR and 
CBR) with higher AUC exposures associated with improved responses in subjects with 
multiple myeloma (TR-1092-171) .  No statistically significant relationships between C max 
and efficacy or safety endpoints were found.   
Prelimina ry PDn data from CHAMPION 1  revealed  that in blood and peripheral blood 
mononuclear cells (PBMCs) the 70 mg/m2 dose level resulted in a greater depth of 
proteasome inhibition, at 1-hour post dose, compared to 1 hour after the Cycle  2 Day  1 
dose i n a twice-weekly schedule of 27 mg/m2 and 56 mg/m2 (as observed in the 
Phase 1b/2 PX-171-007 study).  Chymotrypsin -like subunits (Beta 5 and latent membrane 
protein 7 [ LMP7 ]) were inhibited most strongly, followed by trypsin- like (Beta 2 and 
multicatalytic endopeptidase complex -like 1  [MECL -1]), and caspase- like (Beta 1 and 
latent  membrane protein 2 [LMP2]) subunits, respectively (refer to Figure  1). 
Together, PK and PDn results from CHAMPION 1 support the investigation of 
once- weekly 70  mg/m2 regimen as a potentially  effective alternative regimen for 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc. Clinical Study Protocol No . 20140355
Carfilzomib Page 34of 165
Superseding Amendment 4:07 March 2017 CONFIDENTIALcarfilzomib.  The PK results from this study  indicate that the total AUC per cy cle 
delivered b y the 70 mg/m2dose is expected to be higher compared to those of the 
20/27 mg/m2regimen, consistent with the high ORR observed in the study  
(Berenson 2014) and exploratory exposure response ana lysis for carfilzomib 
(TR-1092-
171).  Pharmacody namics data are consistent with a greater depth of 
proteasome inhibition with 70 mg/m2compared to those at 2 7mg/m2and 56 mg/m2(as 
observed in the Phase 1b/2 PX -171-007 study ).  
Figure 1Proteasome Percent Activity in Peripheral Blood Mononuclear Cells
% Activity or Subunit Occupancy
(Relative to Cycle 1 Day 1 Predose)
C1D1 = Cycle 1 Day 1; CT -L = Chymotrypsin -like; LMP2 = latent membrane 
protein 2; LMP7 = latent membrane protein 7; MECL -1 = multicatalytic 
endopeptidase complex -like1; PBMCs = peripheral blood mononuclear cells.
27mg/m2(n = 3);56mg/m2(n = 5â€“13) and 70mg/m2(n = 4).  Values (relative to 
Cycle1Day 1pre-dose) are presented as mean (Â±SEM).  Chymotrypsin -likeand 
relative active subunit concentration (LMP7, MECL -1, LMP2) w ere assessed from 
PBMCs 1 hour following the carfilzomib dose.  2 7mg/m2and 56 mg/m2samples 
are from the PX -171-007 study, while 70 mg/m2 data samples are preliminary data 
from the 2012 -002study. Chymotrypsin -likeactivity was measured by the 
fluorescent enzymatic Suc -LLVY -AMC assay, while subunit occupancy was 
measured by the ProCISE assay ( Parlati 2009 ).
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 35 of 165 
3 STUDY OBJECTIVES  
3.1 PRIMARY OBJECTIV E 
The primary objective of this study is to compare the PFS  of once- weekly carfilzomib 
dosing in combination with dexamethasone to the PFS of twice -weekly carfilzomib 
dosing in combination with dexamethasone in subjects with relapsed and refractory 
multiple myeloma who have received prior treatment with a proteasome inhibitor and an 
IMiD.  
3.2 SECONDARY OBJECTIVES   
The secondary objectives of the study are to compare the following between treatment 
groups:  
â€¢ ORR 
â€¢ Overall survival (OS) 
â€¢ Safety and tolerability  
â€¢ Pharm acokinetics (PK) of carfilzomib using sparse sampling  
3.3 EXPLORATORY OBJECTIVES  
The exploratory objectives are to evaluate the following between treatment groups:  
â€¢ Intensive pharmacokinetics (PK) and pharmacodynamics (PDn) of carfilzomib in 
a subset of subjects (substudy) 
â€¢ All subscales of the European Organization for Research and Treatment of Cancer 
(EORTC ) Quality of Life Core Module ( QLQ -C30), and the EORTC Quality of 
Life Multiple Myeloma Module 20 ( QLQ -MY20 ) 
â€¢ European Quality of Life-5 Dimensions (EQ-5D- 5L); a standardized measure of 
health status developed by the European Quality of Life  (EuroQol) Group  
â€¢ Patient reported convenience and satisfaction with the carfilzomib dosing 
schedule 
â€¢ Healthcare resource utilization  
4 EXPERIMENTAL PLAN 
4.1 STUDY DESIGN 
This is an open- label, multicenter, Phase  3 study .  The study design is illustrated in 
Figure  2. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 36 of 165 
Figure  2 Study 20140355 Schema  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
 ECOG = Eastern Cooperative Oncology  Group; IMiD = immunomodulatory agents; IV = intravenous(ly); 
ORR = overall response rate; OS = overall survival; PD = progressive disease; PFS = progression -free 
survival; PI = proteasome inhibitor; PO = orally.  
Subjects with relapsed and refractory multi ple myeloma will be screened for eligibility.  
Subjects must have had 2 or 3 prior therapies for multiple myeloma and received  
treatment with a protea some inhibitor and an IMiD.  Eligible subjects  will be randomized 
in a 1:1 ratio to receive a regimen consisting of either once- weekly or twice -weekly 
carfilzomib in combination with dexamethasone.   
Randomization will be stratified by:  
â€¢ International Staging System (ISS) Stage at study entry (Stage  1 versus Stage 2 or 
3) per International Myeloma Working Group (Greipp  2005).  See Appendix H . 
â€¢ Refractory to bortezomib treatment (Yes versus No)  
â€¢ Age (< 65 versus â‰¥ 65 years)  
The primary endpoint is PFS. 
Study treatment will be administered  in 28- day cycles.  Subjects will receive the study 
treatment determined by randomization until disease progression, unacceptable toxicity, 
Long -Term Follow -up for Survival  
Arm B: Twice -weekly Carfilzomib with Dexamethasone   
Carfilzomib 20  mg/m2 Study Days 1 and 2 (Cycle 1)  
Carfilzomib 27  mg/m2 Study  Days 8, 9, 15, and 16 (Cycle 1), Study 
Days  1, 2, 8, 9, 15, and 16 (Cycles 2+)  
Dexamethasone 40 mg (IV or PO) Study Days 1, 8, and 15 (all Cycles)  
Dexamethasone 40 mg (IV or PO)  Study Day 22 (Cycles 1-9 only)  Baseline  Screening  
Randomization 1:1  Eligibility:  
â€¢ Relapsed and 
 refractory  
â€¢ 2-3 prior therapies  
â€¢ ECOG 0 or 1 
â€¢ PI and IMiD 
 exposure  Primary Endpoint  
â€¢ PFS 
Key Secondary Endpoints  
â€¢ ORR 
â€¢ OS 
Follow -up for Disease Status Until 
Confirmed PD  Arm A: Once -weekly Carfilzomib with Dexamethasone   
Carfilzomib 20  mg/m2 Study Day 1 (Cycle 1)  
Carfilzomib 70  mg/m2 Study Days 8 and 15 (Cycle 1), Study Days 1, 8, 
and 15 (Cycles  2+)  
Dexamethasone 40 mg (IV or PO) Study Days 1, 8, and 15 (all Cycles)  
Dexamethasone 40 mg (IV or PO)  Study Day 22 (Cycles 1-9 only)  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 37 of 165 
withdrawal of consent, or death (whichever occurs first).   No crossover between the 
2 treatment groups before progre ssion will be allowed.  
Disease assessments will be conducted at Screening (within 21  days before 
randomization) and then every 28  days Â±  4 days  after Cycle 1 Day 1 , End of Treatment 
(EOT ), and during LTFU every 28  days  Â± 4 days , until PD and/or administration of 
subsequent antimyeloma therapy.  Response will be evaluated using the International 
Myeloma Working Group- Uniform  Response Criteria (IMWG -URC).  
Following termination of study treatment, all subjects will be followed for disease status  
(if PD has not been reached) , subsequent antimyeloma treatment, and survival. 
All subjects will be  followed for AEs  for at least 30 additional days after the last study  
treatment  administration .  All treatment-related AEs and SAEs will be followed until 
resolution or st abilization.    
4.2 NUMBER OF CENTERS  
Approximately 150 sites worldwide will participate.  
4.3 NUMBER OF SUBJECTS  
Approximately 460 subjects (230 subjects  per treatment group) will take part in this 
study. 
4.4 ESTIMATED STUDY DURATION AND CLOSURE  
The total study accrual period is expected to be approximately 15  months.  The interim 
analysis of PFS will occur when approximately 263 PFS events are observed.  If the 
interim analysis crosses the boundary, the trial may stop early for efficacy; 
otherwise s ubjects will be followed for disease and survival status until approximately 
350 PFS events are observed  or by end of year 2018, whichever is earlier. 
4.4.1 END OF STUDY  
Primary Completion : The primary completion date is defined as the date when the 
last subject is assessed or rec eives an intervention for the final collection of data for 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 38 of 165 
the primary endpoint(s), for the purposes of conducting the primary analysis, 
whether the study concluded as planned in the protocol or was terminated early .   
The p rimary completion is anticipated  to occur when approximately 350 PFS events 
occur or end of year 2018, whichever is earlier.  The primary completion date is the 
date when data for the pr imary endpoint are last collected for the purposes  of 
conducting the primary analysis  or the end of year 2018, whichever is earlier.   
If the study concludes prior to the primary completion date originally planned in the protocol (i .e., early termination of the study), then the primary completion will 
be the date when the last subject is assessed or receives an intervention for evaluation in the study (i .e., last subject last visit).  
End of Study:  The end of study date is defined as the date when the last subject 
across all sites is assessed or receives an intervention for evaluation in the study (i.e., 
last subject last visit), following any additional parts in the study (e .g., long- term 
follow -up), as applicable. 
5 SUBJECT ELIGIBILITY  
5.1 INCLUSION CRITERIA 
101. Age â‰¥ 18 years  
102. Able to provide written informed consent in acco rdance with federal, local, 
and institutional guidelines  
103. Relapsed multiple myeloma  
104. Refractory multiple myeloma , defined as meeting 1 or more of the following: 
a. Nonresponsive to most recent therapy ( stable disease or progressive disease 
[PD] while on treatment), or 
b. Disease progression within 60 days of discontinuation from most recent 
therapy  
105. At least 2 , but no more than 3, prior lines of therap y for multiple myeloma  
106. Prior exposure to an IMiD 
107. Prior ex posure to a proteasome inhibitor (PI) 
108. Documented response of at least partial response (PR) to at least 1 prior line of 
therapy  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 39 of 165 
109. Measurable disease, with at least 1 of the following assessed at a central  
laboratory within the 21 days prior to randomization: 
a. Serum M -protein â‰¥ 0.5 g/dL  
b. Urine M -protein â‰¥ 200 mg /24 hours  
c. In subjects without measurable s erum or urine M -protein, serum free light 
chain (SFLC) â‰¥ 100 mg /L (involved light chain) and an abnormal serum 
kappa: lambda ratio  
110. Eastern Cooperative Oncology Group Performance Status (ECOG  PS) of 0 or 1 
111. Left ventricular ejection fraction (LVEF) â‰¥ 40% within the 21 days  prior to 
randomization  
112. Adequate organ and bone marrow function performed  at a central laboratory  
within the 21 days  prior to randomization, defi ned by:  
a. Bilirubin < 1.5 times the upper limit of normal (ULN)  
b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
< 3 times the ULN  
c. Absolute neutrophil count (ANC) â‰¥ 1 Ã— 109/L (screening ANC must be 
independent of growth factor support for â‰¥ 7 days) 
d. Hemoglobin â‰¥ 8 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion s per institutional guidelines are allowed ; however the 
most recent RBC transfusion may not have been done within 7 days prior to obtaining the screening hemoglobin.) 
e. Platelet count â‰¥ 50,000/mm
3 (â‰¥ 30,000/mm3 if myeloma involvement in the 
bone marrow is > 50%.  Subjects must not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count.) 
f. Calculated or measured creatinine clearance (CrCl) of â‰¥  30 mL/min.  
Calculation must be based on the Cockcroft and Gault formula:   
[(140 â€“ Age) Ã— Mass (kg) / (72 Ã— Creatinine  mg/dL)]; multiply result by 0.85 
if female  
113. Females of childbearing potential (FCBP) must have a confirmed negative serum 
pregnancy test performed at a central laboratory , within the 21 days prior to 
randomization, and must not be breastfeeding.  
114. Females of childbearing potential must agree to use highly effective method(s) of 
contraception, during the study and for 30 days following the last study drug 
administration .  (Refer to  Appendix K  for specific contraceptive requirements ). 
115. Male subjects who are sexually active with an FCBP mus t agree to use condoms 
(unless they have had a vasectomy with medical confirmation of surgical 
success) , during treatment and for an additional 90 days following the last study 
drug administration.   
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 40 of 165 
116. Male subjects must agree  to not donate sperm, during treatment and for an 
additiona l 90 days following the last study drug administration.  
5.2 EXCLUSION CRITERIA 
201. WaldenstrÃ¶m macroglobulinemia  
202. Multiple myeloma of Immunoglobulin M ( IgM) subtype 
203. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal 
protein, and skin changes) 
204. Plasma cell leukemia (> 2.0 Ã— 109/L circulating plasma cells by standard 
differential)  
205. Myelodysplastic syndrome  
206. Second malignancy within the past 5 years except:  
a. Adequately treated basal cell or squamous cell skin cancer  
b. Carcinoma in situ of the cervix 
c. Prostate cancer < Gleason score 6 with stable prostate- specific antigen (PSA) 
over 12 months 
d. Ductal breast carcinoma in situ with full surgical resection (i.e., negative 
margins)  
e. Treated medullary or papillary thyroid cancer  
f. Similar condition with an expectation of > 95% five- year disease- free survival  
207. History of or current amyloidosis 
208. Cytotoxic chemotherapy or other antineoplastic therapy, aside from 
immunotherapy or  proteasome inhibitors, within the 28 days prior to 
randomization  
209. Immunotherapy, such as an IMiD , or a proteasome inhibitor, within the 21 days 
prior to randomization  
210. Glucocorticoid therapy exceeding a cumulative dose of 160 mg dexamethasone or 
equivalent, within the 14 days prior to randomization 
211. Radiation therapy:  
a. Focal therapy within the 7  days prior to randomization  
b. Extended field therapy within the 21 days prior to randomization  
212. Prior treatment with either carfilzomib or oprozomib  
213. Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize 
carfilzomib)  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 41 of 165 
214. Contraindicatio n to dexamethasone or any of the required concomitant 
medications  or supportive treatments 
215. Active congestive heart failure (New York Heart Association [NYHA] Class III 
or IV, refer to  Appendix F ), symptomatic ische mia, conduction abnormalities 
uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial  disease, or myocardial infarction within 6 months prior to 
randomization 
216. Active infection requiring systemic treatment within  the 14 days prior to 
randomization 
217. Pleural effusions requiring thoracentesis within the 14 days prior to randomization  
218. Ascites requiring paracentesis within the 14  days prior to randomization  
219. Ongoing graft -versus -host disease  
220. Uncontrolled hypertension or diabetes  mellitus   
221. Significant neuropathy (â‰¥ Grade 3) within the 14 days prior to randomization 
222. Known cirrhosis 
223. Known human immunodeficiency virus (HIV) seropositi vity, hepatitis C 
infection, or hepatitis B infection . Subjects with past hepatitis B virus  infection , 
defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen (anti-HBc) antibody test, are eligible. S ubjects positive for hepatitis 
C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is 
negative for HCV RNA.  
224. Participation in another interventional study within the 28 days  prior to 
randomization  
225. Major surgery (except kyphoplasty) within the 28 days prior to randomization  
227. Any other clinically significant medical disease or social condition  that, in the 
investigatorâ€™s opinion, may interfere with protocol adherence or a subjectâ€™s ability to give informed consent, be compliant with study procedures, or provide accurate 
information.   
6 SUBJECT SCREENING  
A signed and dated informed consent form ( ICF) must  be obtained before any s creening 
procedures or study- specific tests are performed .  Evaluations obtained as part of routine 
medical care prior to signing of the ICF may be used to satisfy the s creening 
requirements, provided that these evaluations were obtained within the required s creening 
period and do not require analysis at a central laboratory. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 42 of 165 
All subjects who provide consent will be assigned a unique study number.  This number 
will be used to identify the subject throughout the clinical stu dy and must be used on all 
study documentation related to that subject. 
The Screening period commences when  the subject or a legally -authorized representative 
signs the ICF. Screening must be completed within the 21 days prior to randomization. 
7 SUBJECT RANDOMIZATION  
The primary investigator will determine the subjectâ€™s eligibility, ensuring that the results 
of the required screening procedures are consistent with all of the eligibilit y criteria 
presented in Section 5.  No eligibility waivers will be permitted.   Randomization will be 
carried out centrally through an interactive voice and web response ( IVR/ IWR) system .  
Please refer to the separate study reference manual.   
Eligible subjects will be randomized in a 1:1 ratio to either:  
â€¢ Arm A:  Once -weekly carfilzomib with dexamethasone regimen  
â€¢ Arm B:  Twice -weekly carfilzomib with dexamethasone regimen  
The randomization will be stratified by the following factors:  
â€¢ International Staging System (ISS) at study entry (Stage  1 versus Stage 2 or 3) 
(Appendix H ) 
â€¢ Refractory to bortezomib treatment (Yes versus No)  
â€¢ Age (< 65 versus â‰¥ 65 years)  
Within each stratum defined by the stratification factors, subjects will be randomized according to a randomly permuted blocked randomization scheme. 
Study treatment will ideally commence on the day of randomization , but at l east within 
5 calen dar days  of randomization.  Initiation of study treatment (Cycle  1 
Day 1) > 5 calendar days after randomization must be approved by the study medical 
monitor. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
678'<'58*6
&$5),/=20,%
3$&.$*,1*$1'/$%(/,1*
&DUILO]RPLELVVXSSOLHGDVDO\ RSKLOL]HGSDUHQWHUDOSURGXFWLQ VLQJOHXVHYLDOVSDFNDJHGLQ
PXOWLYLDOFDUWRQV,QVWLWXWLRQDOSKDUPDFLHVZLOOEHVXSSOLHG ZLWKRSHQVWRFNYLDOVZLWK
IXOOGLVFORVXUHODEHOV$GGLWL RQDOGHWDLOVDUH SURYLGHGLQWKH ,QYHVWLJDWLRQDO3URGXFW
,QVWUXFWLRQ0DQXDO,3,0
6725$*(
6WXG\WUHDWPHQWVVKRXOGEHVWRUH GLQDVHFXUHO\ORFNHGDUHDZLW KDFFHVVOLPLWHGWR
DSSURSULDWHVWXG\SHUVRQQHO&D UILO]RPLEPXVWEHVWRUHGDW Âƒ&W R Âƒ& Âƒ)Ã­ Âƒ)LQD
UHIULJHUDWRU
3OHDVHUHIHUWRWKH,3,0IRU IXUWKHUVWRUDJHLQIRUPDWLRQ
'(;$0(7+$621(
'H[DPHWKDVRQHLVFRPPHUFLDOO\DY DLODEOHDQGZLOOEHREWDLQHGE\ WKHLQYHVWLJDWLRQDO
VLWH6SRQVRUDQGRUGHVLJQHH PD\SURYLGHGH[DPHWKDVRQHLI WKHLQYHVWLJDWLRQDOVLWHLV
XQDEOHWRREWDLQDGHTXDWHVXSSO\' HWDLOVUHJDUGLQJWKHGHVFUL SWLRQVXSSO\DQGVWRUDJH
LQVWUXFWLRQVIRUGH[DPHWKDVRQH DUHIRXQGLQWKHSUHVFULELQJLQI RUPDWLRQ6LWHVDUH
DGYLVHGWRUHIHUWRWKHSUHVFULELQ JLQIRUPDWLRQIRULQIRUPDWLRQ WKDWLVVSHFLILFWRWKHEUDQG
RUIRUPXODWLRQRIWKH GUXJSURGXFWLQXVH
678'<'58*$&&2817$%,/,7<
3OHDVHUHIHUWRWKH,3,0IRU GHWDLOVRQVWXG\GUXJDFFRXQWDELOL W\
352'8&7&203/$,176
$SURGXFWFRPSODLQWLVDQ\ZULWW HQHOHFWURQLFRURUDOFRPPXQLF DWLRQWKDWDOOHJHV
GHILFLHQFLHVUHODWHGWRWKHL GHQWLW\TXDOLW\G XUDELOLW\UHOL DELOLW\VDIHW\
HIIHFWLYHQHVVRUSHUIRUPDQFHRI DGUXJVRUGHYLFHVDIWHUL WLVUHOHDVHGIRU
GLVWULEXWLRQWRPDUNHWRUFOLQLF E\HLWKHU$PJHQ RUE\GLVWULEX WRUVDQGSDUWQHUVIRU
ZKRP$PJHQPDQXIDFWXUHVWKHPDWHULDO
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/C
CICCICCICCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 44 of 165 
This includes any drug(s), device(s) or combination product (s) provisioned and/or 
repackaged /modified by Amgen.  Drug(s) or device(s) includes investigational 
product.   
Any product complaint(s) associated with an investigational product(s) or non-investigational product(s) or device(s) supplied by Amgen are to b e reported 
according to the instructions provided in the IPIM.  
9 DOSAGE AND TREATMENT  ADMINISTRATION 
9.1 TREATMENT REGIMEN  
Carfilzomib and dexamethasone will be administered in 28- day cycles.  All cycles will 
start 28  days (Â±  2 days ) afte r the start of the prior  cycle.  
In the once -weekly carfilzomib arm, intra -cycle doses of carfilzomib and dexamethasone 
may be administered within Â±  2 days of the scheduled dose. However, carfilzomib must 
not be administered within the 5  days following a previous carfilzomib infusion.  Dose 
delays >  2 days are only permitted during the start of a new cycle.  
In the twice-weekly carfilzomib arm, every effort should be made to maintain the Days 1, 
2, 8, 9, 15, and 16, every 28-day schedule.  If this is not possible, then priority should be 
to maintain consecutive dosing days.  For example, if  Day  1 of a new cycle is started 
2 days later than originally scheduled, the entire cycle should shift by 2 days, such that the new Days  1, 2, 8, 9, 15, and 16 of the next cycle are maintained.   Dosing on 
nonconsecutive days should only occur under exceptional circumstances, such as interruptions due to national holidays.  There must always be at least 5 day s between the 
second dose of 1 week and the first dose of the following week ( ie, between Days 2 and 
8, and  Days 9 and 15).  Mid-cycle doses that are missed should not be made up, unless 
these parameters are maintained.  
The reason s for all cycle delays , schedule changes,  missed doses, and dose interruptions 
will b e reported.  
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 45 of 165 
9.2 INTRAVENOUS PRE HYDRATI ON 
Subjects will receive IV  prehydration prior to each carfilzomib infusion during Cycle  1.  
Prehydration will c onsist of 250 to 500 mL normal saline or other appropriate IV fluid.  
Thereafter, carfilzomib prehydration should only be administered if the su bjectâ€™s 
condition and/or risk factors require it.  The total volume of prehydration and the reason 
for pre hydration after Cycle  1 will be re corded . 
9.2.1 STUDY TREATMENT ADMINISTRATION 
Carfilzomib and dexamethasone will be administered in 28- day cycles in regime ns of 
either once -weekly carfilzomib or twice -weekly carfilzomib as described in detail below 
in Figure  3 
.
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No. 20140355  
Carfilzomib  Page 46 of 165 
Figure  3 Arm A and Arm B Carfilzomib with Dexamethasone Regimens 
Arm A: Once -week ly Carfilzomib with Dexamethasone Regimen (28 -day Cycles)  
Week  1 2 3 4 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
CFZ 20a       70       70              
Dex 40       40       40       40c       
Arm B: Twice -weekly C arfilzomib with Dexamethasone Regimen (28 -day Cycles)  
Week  1 2 3 4 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
CFZ 20b 20b      27 27      27 27             
Dex 40       40       40       40c       
CFZ = carfilzomib,  Dex = dexamethasone; PO = oral(ly).  
a Cycle  1 Day 1 carfilzomib dose level will be 20  mg/m2; all other dose levels will be 70  mg/m2. 
b Cycle  1 Days  1 and 2 carfilzomib dose level s will be 20  mg/m2; all other dose levels will be 27  mg/m2. 
c Dexamethasone on Day  22 in both trea tment arms will be administered  only during Cycles  1 to 9 and should be given PO, whenever possible.  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 47 of 165 
9.2.1.1 Carfilzomib  
Carfilzomib will be administered as an IV infusion over approximately 30 minutes  in the 
once- weekly arm and over approximately  10 minutes in the twice -weekly arm . 
Carfilzomib for Injection is supplied as a lyophilized parenteral product in single- use 
vials.  The lyophilized product is reconstituted with Sterile Water for Injection (SWI), 
United States Pharmacopeia (USP), to a fin al carfilzomib concentration of 2 mg /mL.  
Mechanical infusion pumps are recommended, but gravity-dependent infusions are permitted , if the infusion duration can be reliably maintained.  Carfilzomib infusion must 
occur at a facility capable of managing hyper sensitivity reactions .  Subjects will remain at 
the investigational site  under observation for at least 1 hour following each infusion of 
carfilzomib in Cycle  1.  Carfilzomib should be administered via a dedicated IV line , 
whenever possible.  Refer to the IPIM for detailed information regarding equipment and 
flush requirements. 
9.2.1.2 Dexamethasone 
Dexamethasone will be taken PO or administered by IV infusion.  Dexamethasone will be administered at least 30  minutes (but no more than 4 hours) prior to carfilzomib 
infusion on Days 1, 8, and 15 in both treatment arms.  Dexamethasone on Day  22 should 
be taken PO , whenever possible.  Note: Dexamethasone on Day  22 in both treatment 
arms will only be administered during Cycles  1 to 9. 
9.3 DOSE MODIFICATION RULES   
In the event of a possible study treatment-related AE, the clinical investigator should assess, to the best of his/her ability , its relationship to carfilzomib and/or dexamethasone.  
Dose  reduction rules for carfilzomib  are presented in  Table 4 and  Table 5 and are often 
event -specific .   
â€¢ If a subject requires interruption of carfilzomib for more than 28 days, the subject 
should be removed from study treatment.  Exceptions must first be approved by 
the study medical monitor.   
â€¢ If a subject requires carfilzomib dose reduction, the reduced dose level will be 
continued for at least 1 complete cycle.  After that, if the reduced dose level ha s 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 48 of 165 
been well tolerated, the previous dose level may b e resumed at the investigatorâ€™s 
discretion . 
â€¢ If carfilzomib is temporarily held due to an AE , dexamethasone should be 
continued, unless the investigator determines that criteria for interrupting  
dexamethasone have also been  met.  
â€¢ If carfilzomib is permanentl y discontinued due to toxicity, dexamethasone must 
also be discontinued and the subject will be followed for disease progression per 
the guidelines in Section 10.10.1. 
â€¢ If dexamethasone is permanently discontinued due to toxicity, the subject may 
continue to receive study treatment with carfilzomib at the investigatorâ€™s 
discretion. 
9.3.1 CARFILZOMIB: RULES FOR DOSE MODIFICATION  
Dose decrements for  carfilzomib are provided in Tabl e 3. 
Table 3 Carfilzomib Dose Decrements  
Dose  a Carfilzomib Dose Decrements  
First Dose Reduction  
Dose -1 Second Dose Reduction  
Dose -2 Third Dose Reduction 
Dose -3 
70 mg/m2  56 mg/m2  45 mg/m2  36 mg/m2  
27 mg/m2  20 mg/m2  15 mg/m2  11 mg/m2  
a Note: If  dose reduction of carfilzomib is required on C1D1 (Arm A)  or C1 D1 or D2  (Arm B), the 
investigator should  contact  the medical monitor to discuss the situation , before any additional doses of 
carfilzomib are administered.  
The req uirements for carfilzomib dose modification for specific hematologic and 
nonhematologic toxicities are outlined in Sections 9.3.1.1 and 9.3.1.2,  respectively . 
9.3.1.1 Hematologic Toxicity 
Requirements for dose modification of carfilzomib in the events of thrombocytopenia, 
neutropenia, or neutropenic fever are summarized in Table 4. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 49 of 165 
Table 4 Carfilzomib Dose Modif ication Rule s for Treatment -emergent 
Hematologic Toxicity  
Hematologic Toxicity  Required Actiona 
Thrombocytopenia  
â€¢ Platelets â‰¤  10 Ã— 109/L, 
OR  
â€¢ Platelets â‰¤  30 Ã— 109/L 
with evidence of 
bleeding/bruising  1st episode  â€¢ Withhold doses  
â€¢ Resume at the same dose level when  
platelets â‰¥  10 Ã— 109/L and bleeding is 
controlled  
Subsequent episodes  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement when 
platelets â‰¥  10 Ã— 109/L and bleeding is 
controlled  
Neutropenia    
â€¢ ANC <  0.5 Ã— 109/L  1st episode  â€¢ Withhold doses  
â€¢ Resume at the same dose level when 
ANC  â‰¥  0.5 Ã— 109/L 
Subsequent episodes  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement when ANC 
â‰¥ 0.5 Ã— 109/L  
Febrile neutropenia    
â€¢ ANC < 0.5 x 109/L 
and oral temperature 
either:  
o > 38.5Â°C, OR  
o  > 38.0Â°C on 
2 consecutive 
measurements 
over 2 hours  1st and subsequent episodes  â€¢ Withhold doses  
â€¢ Resume at the same dose level when 
ANC returns to baseline grade a nd fever 
resolves  
ANC = absolute neutrophil count; NA = not applicable.  
9.3.1.2 Nonhematologic Toxicity 
Requirements for dose modification of carfilzomib in the event of nonhematologic 
toxicities are summarized in  Table 5. 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 50 of 165 
Table 5 Carfilzomib Dose Modifications for Nonhematologic Toxicity 
Nonhematologic Toxicity  Required Actiona 
Renal Dysfunction  
â€¢ Serum creatinine â‰¥ 2 Ã— 
baseline , OR  
â€¢ CrCl  < 15 mL/min , OR   
â€¢ CrCl decre ases to â‰¤  50% 
of baseline, OR  
â€¢ Requ irement for dialysis  â€¢ Withhold dose s while the cause of renal dysfunction is being 
assessed  
â€¢ If attributable to carfilzomib, resume at 1 dose decrement when CrCl  
has recovered to within 25% of baseline  
â€¢ If not attributable to carfilzomib, resume the same dose  or reduce by 
1 dose decrement, at the investigatorâ€™s discretion , when CrCl has 
recovered to within 25% of baseline  
â€¢ For patients on dialysis receiving carfilzomib, the  dose is to be 
administered after the dialysis procedure  
Hepatic Dysfunction  
â€¢ Mild to mo derate liver 
dysfunction: defined as 
2 consecutive values, at 
least 28 days apart, of:  
(1) Total bilirubmin (> 33% direct) 
> 1 x ULN to 
< 3 x ULN  
OR 
(2) An elevation of AST and/or ALT with normal 
bilirubin  â€¢ 25% dose reduction.  
â€¢ Dose may be re- escalated if liver function tests return to normal 
and drug -induced hepatotoxicity is excluded.  
â€¢ Grade 3 elevation in ALT 
and/or AST (>  5 x ULN)  â€¢ Hold carfilzomib until resolution to baseline.  
â€¢ Monitor any abnormality weekly.  Resume carfilzomib with a 25% dose reduction if drug -induced hepatoxicity is excluded.  
â€¢ Grade 3 elevation in total 
bilirubin  â€¢ Hold carfilzomib until resolution to baseline.  Monitor total bilirubin and direct bilirubin weekly.  
â€¢ Upon resolution of total bilirubin to normal, resume carfilzomib 
dosing with at 25% dose reduction if drug -induced 
hepatotoxicity is excluded.  
â€¢ Drug -induced 
hepatoxicity attributable 
to carfilzomib  â€¢ Discontinue carfilzomib. 
Infection  
â€¢ â‰¥ Grade 3 Infection  â€¢ Withhold doses  
â€¢ Resume at the same dose level, when the infection is controlled  
 
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 51 of 165 
Nonhematologic Toxicity  Required Actiona 
Cardiovascular Dysfunction  
â€¢ Congestive Heart Failure  â€¢ Withhold doses for any subject with symptomatic heart failu re, 
whether or not it is attributed to carfilzomib  
â€¢ Resume at 1 dose decrement, when symptoms have resolved or 
returned to baseline  
â€¢ LVEF <  40%, OR  
â€¢ LVEF <  55%, if decreased 
> 20% from baseline  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when LVEF returns to â‰¥ 40%, or to 
within 15% of baseline, if carfilzomib was held due to a drop to 
< 55% 
â€¢ â‰¥ Grade  2 Pulmonary 
Hypertension â€¢ Withhold doses  
â€¢ Carfilzomib may be resumed at 1 dose decrement  when pulmonary 
hypertension resolves to grade  â‰¤ 1 
Thrombotic Microangiopat hy 
â€¢ Thrombotic thrombocytopenic 
purpura/hemolytic uremic syndrome (TTP/HUS) â€¢ Withhold doses when TTP/HUS is suspected  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, discontinue carfilzomib.  Subjects 
should not be  rechallenged. 
â€¢ Manage symptoms per standard of care including, plasma exchange as clinically indicated  
b 
Venous Thrombosis  
â€¢ â‰¥ Grade 3  â€¢ Hold carfilzomib and adjust anticoagulation regimen.  
â€¢ Resume at full dose once anticoagulation has been optimized per treating investigatorâ€™s discretion. 
Encephalopathy  
â€¢ Posterior reversible encephalopathy syndrome (PRES) â€¢ Withhold doses  
â€¢ Consider  evaluation with neuroradiological imaging for onset of 
visual or neurological symptoms suggestive of PRES  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, discontinue carfilzomib.  Subjects 
should not be rechallenged.  
Other Nonhematologic Toxicity  
â€¢ â‰¥ Grade 3 and attributed to 
carfilzomib  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when toxicity has resolved to Grade â‰¤ 2 
or to baseline  
ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; 
CrCl  = creatinine  clearance; eCRF = electronic Case Report Form; IB = Investigatorâ€™s Brochure; 
IMWG  = International Myeloma Working Group; LFTs = liver function tests; LVEF  = left ventricular 
ejection fraction;  mL = milliliter(s); PRES  = posterior reversible encephalopathy syndrome ; ULN = upper 
limit of normal.  
Note: Carfilzomib dose schedule does not need to be adjusted for baseline renal dysfunction.  
a The maximum allowed dose interruption is 4 weeks , except with approval by the medical monitor.  
b Subjects requiring plasma exc hange must be withdrawn from study treatment.  Every effort should be 
made to assess disease status in accordance with IMWG criteria, before plasma exchange is initiated.  
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 52 of 165 
9.3.2 DEXAMETHASONE: GUIDELINES FOR TOXICITIES  AND DOSE 
MODIFICATION  
Dose decrements for  dexamethasone are provided in Table 6.  
Table 6 Dose Decrements for Dexamethasone  
Nominal Dose  Dexamethasone Dose Decrements  
Dose -1 Dose -2 
40 mg 20 mg 12 mg 
Dexamethasone will be permanently discontinued, if toxicity persists following 2 dose 
level reductions.  At the investigatorâ€™s discretion, dexamethasone may be tapered, prior to 
complete discontinuation, according to institutional practice.  The requirements for dose 
modification due to  dexamethasone- related toxicities are summarized in  Table  7. 
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 53 of 165 
Table 7 Treatment Rules for Dexamethasone- related Toxicities  
Toxicity  Required Action  
Edema  
â‰¥ Grade  3: 
â€¢ Limb edema  
â€¢ Truncal edema  â€¢ Withhold doses and diurese as needed  
â€¢ Resume at 1 dose decrement when Grade â‰¤  1 or baseline  
Gastrointestinal Distress  
Grade 1 or 2:  
â€¢ Dyspepsia, OR  
â€¢ Gastritis, OR  
â€¢ Gastric or duodenal u lcer â€¢ Continue  doses while attempti ng m edical management  
â€¢ If symptoms persist, reduce by 1 dose decrement  
â‰¥ Grade  3: 
â€¢ Dyspepsia, OR  
â€¢ Gastritis, OR  
â€¢ Gastric or  duodenal ulcer â€¢ Withhold d oses 
â€¢ Resume at 1 dose decrement , when symptoms return to baseline  
â€¢ If symptoms recur despite appropriate medical ma nagement , discontinue dexamethasone  
permanently  
â€¢ Acute pancreatitis  â€¢ Discontinue dexamethasone  permanently  
Psychiatric Disorders  
â‰¥ Grade  2: 
â€¢ Confusion , OR   
â€¢ Mood alteration  â€¢ Withhold d oses 
â€¢ Resume  at 1 dose decrement , when symptoms return to baseline  
Other Toxicities  
â€¢ â‰¥ Grade  3 and attributed to dexamethasone  â€¢ Withhold d oses 
â€¢ Resume at 1 dose decrement , when toxicity has resolved to â‰¤  Grade  2 
 
Superseding Amendment  4: 07 March  2017  CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 54 of 165 
9.3.3 CONDITIONS NOT REQUIRING DOSE REDUCTION 
The following conditions are exceptions to the requirements presented above.  
Carfilzomib and dexamethasone do not require dose modification in the following cases: 
â€¢ Grade 3 nausea, vomiting, or diarrhea (unless persisting more than 3 days despite 
appropriate use of antiemetics or antidiarrheal agents)   
â€¢ Grade 3 hyperglycemia  
â€¢ Grade 3 fatigue (unless persisting for >  14 days)  
â€¢ Alopecia  
9.4 CONCOMITANT MEDICATIONS  AND THERAPIES  
A concomitant medication is defined as any prescription or over-the-counter preparation, 
including vitamins and supplements.  For all randomized subjects, all admini stered 
concomitant medications and therapies, from signing of the informed consent until 30 days after the last dose of study treatment, must be recorded in the designated 
electronic case report f orm (eCRF) . 
Concomitant medications required for the study or used prophylactically should be described as such in the designated eCRF.  Concomitant medications prescribed for â€œprnâ€ 
or â€œas neededâ€ use should not be reported, unless actually administered.  
Blood and  blood products are not considered concomitant medications and must be 
recorded on the appropriate eCRF.  
9.4.1 
REQUIRED CONCOMITANT  MEDICATIONS  
Required prophylactic medications should be initiated at least 1 day prior to the first administration of carfilzomib.  
9.4.1.1 Gastrointestinal Prophylaxis 
Lansoprazole or other oral proton-pump inhibitor, dosed according to institutional practice, is required to prevent peptic ulcer disease throughout the duration of treatment 
with dexamethasone.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 55 of 165 
9.4.1.2 Pregnancy and Contraception 
Contraception must continue during study , during  drug dose interruption intervals , and  
until 30 days (females) or 90 days (males) after the last study drug administration.  If 
applicable, refer to the Country Specific Pregnancy and Contraceptive Supplement 
(refer  to Appendix K ). 
If a subject thinks she may be pregnant (e.g., if a menstrual period in an FCBP does not 
occur at the anticipated time), study drug treatment must be interrupted, and a urine or 
serum pregnancy test must be performed locally.  Study drug administ ration may resume 
after documen tation of a nonpregnant state. 
9.4.2 RECOMMENDED CONCOMITANT MEDICATIONS  
9.4.2.1 Antiviral Prophylaxis 
Valacyclovir  (or an equivalent antiviral agent ) is recommended for prophylaxis against 
herpes zoster reactivation.  
9.4.2.2 Uric Acid-lowering Agent s 
Allopurinol or other approved uric acid- lowering agent  are recommended for subjects at 
high risk for tumor lysis syndrome ( TLS) due to high tumor burden.  R efer to the current  
Carfilzomib IB  for safety guidance regarding TLS.  
9.4.2.3 Mycostatin or Oral F luconazole  
Mycostatin or oral fluconazole may be given  to prevent oral thrush throughout the 
duration of treatment with dexamethasone. 
9.4.2.4 Antiemetics and Antidiarrheal Agents  
Antiemetics and antidiarrheal agents are recommended for prophylaxis and/or 
management of treatment -related gastrointestinal symptoms.   
9.4.2.5 Thrombophrophylaxis 
Venous thromboembolism has been observed in patients receiving carfilzomib.  
Thromboprophylaxis may be considered on the basis of a benefit -risk assessment.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 56 of 165 
9.4.3 EXCLUDED CONCOMITANT  MEDICATIONS  AND T HERAPIES  
If an investigator deems that use of an excluded concomitant medication or therapy is 
required but does not believe that withdrawal from study treatment is indicated, he/she 
must contact the study medical monitor to determine if continued study treatment is 
acceptable.  
9.4.3.1 Anticancer Agents  
Therapy with a marketed or investigational anticancer agent that is not required per this 
protocol is prohibited, while subjects remain on study treat ment , and should be avoided 
prior to documentation of disease progression.   
9.4.3.2 Radiation Therapy 
Radiation to large marrow reserves is prohibited;  however, focal palliative radiation is 
allowed with permission from the study medical monitor.  
9.4.3.3 Myeloid Growth  Factors  
Prophylactic use of myeloid growth factors is prohibited, but they may be used for management of neutropenia, in accordance with American Society of Clinical Oncology 
(ASCO) Guidelines (Smith  2006).  
9.4.3.4 Corticosteroids   
Corticosteroids should not be used to treat concurrent medical conditions, unless the dose 
remains less than the equivalent of 4 mg/day of dexamethasone.  Short term use of higher 
doses may be permitted to treat acute exacerbations of concurrent medical conditions, but 
this must be discussed with the study medical monitor as soon as is possible. 
9.4.3.5 Plasmapheresis  
Plasmapheresis is not permitted at any time during the Screening period or while the 
subject is receiving study treatment.  If a subject  who has started s creening procedures 
requires plasmapheresis or is anticipated to require plasmapheresis during or after the Screening period, this subject will be considered ineligible.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 57 of 165 
For s ubjects requiring plasmapheresis while on study treatment, ever y attempt should be 
made to document disease status by IMWG criteria first .  Study treatment must be 
discontinued and the subject will enter LTFU. 
9.4.3.6 Novel Agents  for Non -neoplastic Conditions  
The use of novel agents for non-neoplastic conditions is prohibited throughout the 
duration of treatment and for 30 days following the last dose of study treatment. 
10 STUDY ASSESSMENTS AND PROCEDURES  
All protocol-required tests and observations, along with their chronology, are outlined in the Schedule of Assessments (refer to  Appendix A ).  Protocol- specified  assessments  and 
procedures are summarized below.  
10.1 STUDY SPECIFIC PROCEDURES  
10.1.1 
MULTIPLE MYELOMA HIS TORY AND PRIOR LINES  OF 
THERAPY ASSESSMENT  
When documenting prior therapies for m ultiple myeloma, the following guidelines should 
be used: 
â€¢ A new line of therapy is considered to start when a planned course of therapy is 
modified to include other treatment agents (alone or in combination) as a result 
of lack of adequate response, PD (ev en if the level of progression has not yet 
met IMWG criteria for PD), relapse, or toxicity.   A new therapy is also 
considered to start when a planned period of observation off- therapy is 
interrupted by a need for additional lines of therapy.  
â€¢ An increase i n treatment administration, with the intention of recapturing 
response in a patient with evidence of disease progression on that line of therapy , is considered  to be  a new line of therapy .   
Examples of a line of therapy include:  
â€¢ Induction therapy and ste m cell transplant followed by planned maintenance 
therapy (provided there is no intervening PD) 
â€¢ Induction therapy followed by maintenance therapy (provided there is no 
intervening PD)  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 58 of 165 
If availabl e, historical FISH data should be entered into the e CRF.   The following results 
should be captured: 
o t(4;14) 
o t(6;14) 
o t(11;14) 
o t(14;16) 
o t(14;20) 
o Del 17p 
o Del 13  
o Chromosome 1 abnormalities 
10.1.2 VITAL SIGNS  
Vital signs will include heart rate, blood pressure, respiratory rate, and temperature and 
will be assessed at Screenin g, prior to each administration of carfilzomib , EOT, and as 
needed to assess potential AEs.  Clinically significant abnormal vital signs will be 
reported as AEs.  
10.1.3 COMPLETE PHYSICAL EXAMINATION 
A physical examination will be performed during Screening, prior to dosing on Day 1 of 
each cycle, and at the EOT.  For Cycle  1 Day  1, the screening physical examination may 
be used if performed within 7  days prior to Cycle 1 Day  1.  Physical exam may be 
completed up to 3 days prior to Day 1 of each cycle.   At a minimu m, the physical exam 
should include constitutional, abdominal, cardiovascular, and respiratory assessments.  
Clinically significant abnormal findings identified after the signing of informed consent 
must be reported as AEs and examined more frequently, as c linically indicated.   Note: 
Clinically  significant a bnormal physical examination findings identified prior to the 
signing of informed consent should be reported as part of Medical History, not as AEs. 
BSA  is to be determined by a standard formula, such as the Mosteller Formula 
(Mosteller  1987): body surface area ( BSA ) (mÂ²) = ([Height (cm) Ã— Weight (kg)]/ 
3600 )Â½.  B ody surface area must be recalculated and used for subsequent dose 
determinations , if the  subject experiences a weight change of â‰¥ 20%.   Recalculations of 
BSA must be made using the same technique as used at baseline.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 59 of 165 
10.1.4 EASTERN COOPERATIVE ONCOLOGY GROUP  PERFORMANCE 
STATUS  
Eastern Cooperative Oncology Group Performance Status will be assessed  at Screen ing 
and at the EOT visit.   Eastern Cooperative Oncology Group Performance Status grades 
and descrip tions are tabulated in  Appendix E . 
10.1.5 INTERNATIONAL STAGING S YSTEM  STAGE DETERMINATION  
Beta-2 microglobulin and albumi n will be assessed at the central laboratory during 
Screening to determine ISS Stage (refer to  Appendix B  and Appendix H ).  These results 
must be available, prior to random ization.  
10.2 MULTIPLE MYELOMA DISEASE ASSESSMENTS  
Disease response and progression assessments include (but are not limited to): SPEP,  
urine protein electrophoresis  (UPEP ), immunofixation, SFLC, bone marrow sample 
evaluation, serum calcium, plasmacytoma evalua tion, and skeletal survey.  Multiple 
myeloma assessment should be based on calendar day, regardless of cycle delay.  SPEP, 
UPEP, immunofixation, SFLC, bone  marrow evaluation, and serum calcium will all be 
conducted at the central laboratory.  
The following disease assessments must be performed at Screening:  
â€¢ SPEP, UPEP (24 -hour assessment, no substitute method is acceptable), 
and immunofixation  
â€¢ SFLC  
â€¢ Quantitative immunoglobulins  
â€¢ Beta-2 microglobulin  
Cycle  1 Day  1 before treatment begins (Screening values may be used if obtained within 
7 days prior to Cycle 1 Day 1), and every 28  days (Â± 4  days) thereafter, at EOT , and 
during LTFU if disease progression has not already been documented (every 28 days Â± 4 
days, until PD and/or started a subsequent antimyeloma ther apy):  
â€¢  SPEP, immunofixation 
â€¢ UPEP (24 -hour assessment, no substi tute method is acceptable), 
and immunofixation : post- Cycle  1 Day  1 measurements required only if Cycle 1 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 60 of 165 
Day 1 UPEP â‰¥ 200 mg/24  hours or to confirm a disease response (for very good 
partial res ponse [VGPR] or better) or progression (if applicable) 
â€¢ SFLC : post- Cycle  1 Day 1 measurements required only for SFLC measurable 
disease or to confirm stringent complete response ( sCR) 
â€¢ Quantitative immunoglobulins  
Subjects will be instructed to collect 24 -hour urine samples for assessment of UPEP at 
Screening and as required during the study.  This collection will occur over 2 days and 
will be assessed at the central laboratory.  For further instructions , refer to the Central 
Laboratory Services Manual.   
Radiological disease assessments at baseline are collected after subject eligibility is 
confirmed and may be done after randomization (as long as they are  done before the start 
of treatment ).  Radiological disease assessments that were done per standard of ca re 
within  30 days before Cycle 1 Day  1 can be used as study baseline disease assessments.  
They  include:  
Extramedullary Plasmacytoma Assessment  
â€¢ A plasmacytoma e valuation will be conducted at b aseline, only if a lesion is 
suspected clinically . 
â€¢ If an extramedullary plasmacytoma is detected, evaluation will be repeated during 
treatment to confirm a response of PR or better or to assess for PD based on 
plasmacytoma . 
â€¢ Plasmacytomas are considered measurable if  they have a longest diameter of at 
least 1 cm and the product of cross diameter measurements is at least 1 cm2.  
Plasmacytomas of lesser size are considered unmeasurable.  Bidi mensional 
measurements must be recorded in the designated eCRF.  The same technique 
must be used to evaluate plasmacytomas throughout the duration of study 
participation and may include: palpation, ultrasound, x-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET), or any other technique that is considered to be standard of 
care.  
Skeletal Survey 
â€¢ Skeletal survey  will include lateral radiograph of the skull, anteroposterior and 
lateral views of the spine, and anteroposterior views of the pelvis, ribs, femora, 
and humeri.  The skeletal survey will be conducted at baseline and will be repeated if worsening clinical symptoms suggest PD, or as clinically indicated.  
â€¢ Other radiologic modalities for performing skeletal assessment (eg , low-dose CT 
scan) are acceptable, in accordance with regional standards.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 61 of 165 
10.3 MULTIPLE MYELOMA RESPONSE ASS ESSMENTS  
10.3.1 DISEASE RESPONSE AND P ROGRESSION ASSESSMEN TS 
Determination of disease response must be based on the reported val ues from the central 
laboratory .  Local laboratory results may be used for hypercalcemia (corrected calcium 
based on albumin), but a confirmatory sample should be collected and sent to the central 
laboratory for documentation. 
Investigator-determined responses must be based on results from the central laboratory  
and must be consistent with the IMWG -URC (see definitions in  Appendix G ).  
10.3.2 TUMOR RESPONSE ASSES SMENT  
The following confirmatory assessments are required for all response categories (sCR, 
CR, VGPR, PR, minimal response [MR] and PD; refer to definitions in Appendix  G: 
â€¢ All laboratory -based PD (except bone marrow sample) and all response categories 
require 2 consecutive assessments made at any time before initiation of new 
therapy.  
â€¢ All response categories require that there be no evidence of disease progression, 
including confirmation of no new bone lesions, if radiographic studies were 
performed.  
â€¢ The preferred method of confirming  CR or sCR is a bone marrow biopsy; 
however, a bone marrow aspirate is also acceptable for confirmation of CR. 
â€¢ Extramedullary plasmacytoma evaluation (if present at Screening).  Two 
consecutive radiographic tests are not required to confirm response or 
progression of extramedullary plasmacytoma. 
â€¢ In the case where a patient does not have measurable M -protein by UPEP at 
baseline (i.e., baseli ne UPEP <  200 mg/24  hours), when SPEP is consistent with 
response (i.e., â‰¥ PR), 2 consecutive UPEP measurements must be performed to 
confirm response. 
10.3.3 DISEASE PROGRESSION 
Disease progression will be documented in an eCRF intended to capture PD information 
and will be analyzed as a study endpoint.  Signs  and symptoms related to  disease 
progression (e.g., pathologic fracture in a subject with progressive multiple myeloma) should be reported in the appropriate e CRF as an  AE or as an SAE (if the event in 
question meets the criteria for seriousness).  Verbatim terms such as â€œdisease progression,â€ â€œprogressive disease,â€ etc. should not be reported as AEs or SAEs unless 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 62 of 165 
the investigator considers the progression to be atypical, accelerated, or caused by the 
study drug.  Similarly deaths occurring as a result of disease progression should be 
reported on the eCRF intended to capture death information and should not be reported as 
SAEs.  
Study treatment should not be discontinued on the basis of disease progression, until PD 
has been appropriately confirmed per IMWG -URC .  Disease progression during LTFU 
must also be confirmed by these same criteria.  Co nfirmation of PD will require 
2 consecutive central laboratory evaluations that indicate PD, except in cases where PD is 
based on extramedullary lesions or hypercalcemia that is attributed solely to PD .  These 
assessments should be separated in time by at least 1 calendar day , but no more than 
28 Â± 4 calendar days.  Local laboratory  results may not be used to determine or conf irm 
disease progression, except when PD is based on hypercalcemia.   The assessments 
outlined in Appendix B  are required for PD  determination . 
10.4 LABORATORY TESTS  
Laboratory tests for efficacy and safety during schedu led and unscheduled study visits, 
including screening will be performed at a central laboratory.   Additional safety 
laboratory samples must also be collected and analyzed by local laboratories if  the results 
are necessary to determine the appropriateness o f dose administration.  In rare 
circumstances, when the central laboratory is unable to provide results for tests that are needed to determine eligibility, the study medical monitor may grant permission for local 
laboratory results to be applied to the s creening requirements.  Local labs may also be 
required for management of treatment -emergent adverse events (TEAEs) .  Laboratory 
tests for disease assessment are described in  Section 10.2. 
Safety samples must be obtained within the 1 day prior to carfilzomib administration  and 
the results must be reviewed prior to the start of the carfilzomib infusion s on Days 1, 8, 
and 15 of Cycles 1 to 4.  Beyond Cycle 4, these labs are only required on Days  1 and 15 
of each cycle.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 63 of 165 
10.4.1 HEMATOLOGY  
Hematology assessments  (Table 8) will be performed during Screening, on Days 1, 8, and 
15 for Cycles 1 to 4 and EOT.  Beyond Cycle 4 labs will be performed on Days 1 and 15 
of each cycle.  For Cycle  1 Day  1, hematology assessments from Screening can be used, 
if they were obtained within 3 days  prior to carfilzomib administration .  For subsequent 
visits, hematology assessments may be completed up to 1 day prior to the scheduled dose. 
Table 8 Laboratory Tests:  Hematology  
Hematology Panel  
Hemoglobin 
Hematocrit  
WBC count with complete differential to include: a 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
RBC count  
Platelet count  
RBC = red blood cells; WBC = white blood cells . 
a Absolute counts or percentage will be acceptable.  
10.4.2 SERUM CHEMI STRY 
A serum chemistry panel (Table 9) will be performed during Screening, on Days 1, 8, and 
15 for Cycles 1 to 4 and EOT.  Beyond Cycle 4, labs will be performed on Days 1 and 15 of each cycle.  For Cycle  1 Day  1, serum  chemistry assessments from Screening can be 
used, if performed within 3  days  prior to  carfilzomib administration .  For subsequent 
visits, serum chemistries may be completed up  to 1 day prior to the scheduled carfilzomib 
dose. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 64 of 165 
Table 9 Laboratory Tests:  Chemistry Panel 
Chemistry Panel  
Albumin  Glucose  
Alkaline Phosphatase  LDH  
ALT  Magnesium  
AST  Phosphorus  
Bicarbonate Potassium  
BUN Sodium  
Calcium  Total Bilirubin  
Chloride  Total Protein  
Creatinine  Uric Acid  
ALT= alanine aminotransferase, AST = aspartate aminotransferase, BUN  = blood urea nitrogen, eCRF = 
electronic C ase Report Form; LDH  = lactate dehydrogenase; ULN = upper limit of normal  
10.4.3 COAGULATIO N 
Coagulation tests  will be performed at a central laboratory at Screening and at EOT :  
â€¢ Prothrombin time (PT)  
â€¢ Activated partial thromboplastin time (PTT)  
â€¢ International normalized ratio (INR)  
10.4.4 PREGNANCY TESTING  
For FCBP, a serum pregnancy test that is confir med negative is required for eligibility 
determination and is to be performed at the central laboratory; FCBP is defined in 
Appendix K .  In addition to the pregnancy tests conducted for eligibility, a serum or urine 
pregnancy test must be confirmed negative locally on Day 1 of each cycle and at  EOT .  
A negative pregnancy test result must be available prior to the first dose of study 
treatment.   More frequent pregnancy tests may be conducted if required per local 
regulations or investigational sites . 
10.5 ELECTROCARDIOGRAM  
Twelve- lead electrocardiogram s (ECGs) including corrected QT -interval (QTc; 
representing the corrected duration of ventricular electrical activity) will be performed 
locally .  Electrocardiogram s will be required from  all subjects at  Screening and EOT.  
Additional ECG assessment is only required if c linically indicated.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 65 of 165 
10.6 ECHOCARDIOGRAM  
A 2-D transthoracic echocardiogram ( ECHO) is required to assess LVEF  during 
Screening and will also serve as the baseline E CHO .  If transthoracic ECHO is not 
available, multigated acquisition ( MUGA) will be acceptable for  LVEF evaluation. 
Any subject with a clinically significant cardiac AE should be evaluated by a cardiologist 
and must have a follow- up ECHO, if medically indicated.   
10.7 PATIENT REPORTED OUTCOMES 
Patient reported outcomes (PRO) are based on the following questionnaires 
(refer to Appendix J). 
All questionnaires should be
 collected on Day 1 of Cycle 1, then every second cycle 
(Cycle  1, 3, 5, etc) during treatment.  The q uestionnaires listed below should be 
completed by the subject prior to drug administration during treatment cycles:  
â€¢EORTC QLQ -C30
â€¢EORTC QLQ -MY20
â€¢EQ-5D- 5L
â€¢Patient reported convenience and satisfaction (collected Day  1 Cycle  2 and EOT
only) 
Health -related Q uality of Life (HRQL ) will be assessed by the EORTC 30 -item 
QLQ -C30 questionnaire and by the 20- item QLQ -MY20 module specifically designed to 
address the quality of life for those with multiple myeloma  (Aaronson 1993; Fayers  2001; 
Cocks 2007) .  The primary constructed scales f rom the QLC -C30 are:  
â€¢Global H ealth Status/Quality of Life
â€¢Physical  functioning
â€¢Role f unctioning
â€¢Emotional functioning
â€¢Cognitive functioning
â€¢Social f unctioning
â€¢Nine additional scales can be derived:
â€¢Fatigue
Superseding Amendment  4: 07 March  2017  CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 66 of 165 
â€¢ Nausea and v omiting  
â€¢ Pain  
â€¢ Dyspn ea 
â€¢ Insomnia  
â€¢ Appetite loss  
â€¢ Constipation  
â€¢ Diarrhea  
â€¢ Financial d ifficulties  
The prim ary scales from the QLQ -MY20 include disease symptoms, side effects of 
treatment, body image and future perspectives.  
The EQ-5D- 5L is a standardized measure of health status developed by the EuroQol 
Group in order to provide a simple, generic measure of he alth for clinical and economic 
appraisal (EuroQol Group  1990) .  The EQ -5D-5L version will be used in this study.  The 
EQ-5D-5L consists of a 1- page descriptive system  and a 1 -page EQ Visual Analogue 
scale (EQ V AS).  The descriptive system comprises 5 dimensions (mobility, self -care, 
usual activities, pain/discomfort, and anxiety/depression).  Each dimension is then scored 
on 5 levels: no problems, slight problems, moderate problems, severe problems, and 
extreme problems.  The respondent is asked to indicate his/her health state by ticking (or 
placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.  The EQ VAS records the respondentâ€™s self-rated health on a 20 cm 
vertical, visual analogue scale with  endpoints labelled â€˜the best health you can imagineâ€™ 
and â€˜the worst health you can imagineâ€™.  This information  can be used as a quantitative 
measure of health as judged by the individual respondents. 
Patient reported convenience a nd satisfaction with the carfilzomib dosing schedule will 
be provided as a 1- page questionnaire on the tablet.  Subjects will be instructed to fill out 
the questionnaires to the best of his/her abilities .  The study coordinator will be 
responsible for signing off that the subject has completed the questionnaires. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 67 of 165 
10.8 HEALTHCARE RESOURCE UTILIZATION   
Healthcare resource utilization data related to AEs will be collected for each subject .  
These data may include inpatient care, outpatient care, surgery, and use of  other 
medications and therapeutic procedures related to AEs.  Details on hospitalizations (not 
related to AEs) will also be collected.  
10.9 CORRELATIVE STUDIES  
Samples for correlative studies will be collected only after confirmation of  study 
eligibility .  Intensive PK and PDn will be conducted as a substudy at selected sites.  
Sparse PK samples will be collected at all other sites from subjects who consent to the 
additional testing.   
10.9.1 INTENSIVE PHARMACOKINETICS/ PHARMACODYNAMICS  
SUBSTUDY  
Approximately 15 evaluable subjects in each arm will participate in the intensive PK/PDn 
substudy at select sites.  On both arms, whole blood and PBMCs will be collected from all subjects on Days 1, 15, 16, 17, and 22 of Cycle 1 at the timepoints (summarized in 
Table 10).  Directions for collection, processing, and shipping of PDn blood samples are provided in the Central L aboratory Services  Manual.  The actual time of when the PDn 
sample was collected will be recorded.  
Table 10 Study 20140355 Pharmacodynamics Sampling Timepoints  
 Arm A  
Once -weekly carfilzomib  Arm B  
Twice -weekly carfilzomib  
Cycle  1 Day  1 Predose  Predose  
Cycle  1 Day  15 Predose and 1 hour after the end of 
infusion  Predose and 1 hour after the end of 
infusion 
Cycle  1 Day  16 24 hours  Â± 2 hours after the end of the 
Day 15 infusion  Predose and 1 hour after the end of 
infusion 
Cycle  1 Day  17 48 hours Â± 2 hours after the end of the 
Day 15 infusion  24 hours Â± 2 hours after the end of the 
Day 16 infusion  
Cycle  1 Day  22 168 hours Â±  2 hours after the end of 
the Day 15 infusion  144 hours Â± 2 hours after the end of 
the Day 16 infusion  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 68 of 165 
For both treatment arms, PK samples will be collected from all subjects for determination 
of plasma concentrations of carfi lzomib on treatment Day  15 of Cycle 1 at the following 
time points: 
â€¢ Predose (within 5 minutes  before the start of infusion) 
â€¢ 15 minutes  (Â± 5  minutes ) after the start of infusion for Arm A only  (once- weekly 
carfilzomib)  
â€¢ Immediately prior to (within 2  minutes  before) the end of infusion 
â€¢ 15 minutes  (Â± 5  minutes ) after the end of infusion 
â€¢ 60 minutes  (Â± 5  minutes ) after the end of infusion 
â€¢ 2 hours (Â± 5  minutes ) after the end of infusion  
The actual time of PK sample collection will be recorded.  Samples will be c ollected 
within Â±  5 minute time window s around the nominal time points (except for the time 
point immediately prior to the end of infusion, for which the PK collection needs to occur 
prior to the end of infusion).  Directions for collection, processing, and shipping of PK 
samples are provided in the Central Laboratory Services Manual.  
10.9.2 SPARSE PHARMACOKINET IC SAMPLING  
Sparse PK samples will be collected from subjects who do not participate in the intensive 
PK/PDn substudy and who consent to the additional te sting.  The actual time of the PK 
sample collection will be recorded.  These samples will be assessed at a central 
laboratory.  Directions for collection, processing, and shipping of PK samples are 
provided in the Central Laboratory Services Manual .   
The sparse PK samples will be collected on Cycle 2 Day  1 at the following time points: 
â€¢ Predose (within 5 minutes  before the start of infusion) 
â€¢ 15 minutes  (Â± 5  minutes ) after the start of infusion  for Arm A only  (once- weekly 
carfilzomib)  
â€¢ Immediately prior to (w ithin 2 minutes  before) the end of infusion 
â€¢ 30 minutes  (Â± 5  minutes ) after the end of infusion 
10.10 LONG -TERM FOLLOW -UP 
There are 2 criteria which mark when subjects may enter LTFU.  Subjects may enter into LTFU when discontinuing treatment before disease progression occurs (refer to 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 69 of 165 
Section  10.10.1, below), or, subjects may enter into LTFU when discontinuing due to 
disease progression (outlined in Section 10.10.2).   
10.10.1 LONG -TERM FOLLOW -UP BEFORE DISEASE PR OGRESSION  
For subjects who discontinue treatment before disease progression occurs , disease 
assessment s will be performed (using the central laboratory results) every 
28 days  Â± 4 days until the subject has PD or until withdr awal of consent  (Appendix B ).  
Confirmatory PD results (refer to  Appendix G ) must be obtained prior to the initiation of 
new antimyeloma therapy.  Subject reported outcomes (PROs) including the EORTC 
QLQ -C30 and QLQ-MY20, EQ -5D- 5L and Healthcare Resource Utilization will be 
collected for these subjects who discontinue therapy prior to progression; assessments will be conducted every 12 weeks (every 84  days  Â± 4 days) until progression, or 
withdrawal of consent during LTFU ( Appendix A ).  Long- term follow -up will continue 
until the subject has withdrawn consent for further participation, is lost to follow-up, has 
died, or the sponsor makes a decision to close the study.  For any subject who is lost to 
follow- up, the study site will attempt to ascertain survival information via public database 
search.  
10.10.2 
LONG -TERM FOLLOW -UP AFTER DISEASE PROGRE SSION 
(FOR  SURVIVAL)  
After completion of the EOT visit, subjects  who have discontinued due to disease 
progression will be followed for survival status, queried by telephone contact or other 
method, approximately every 12 weeks Â± 28 days , or as needed until study closure. 
11 STUDY DISCONTINUATIO N 
11.1 WITHDRAWAL OF SUBJECTS FROM STU DY TREATMENT  
Subjects may withdraw from study treatment at any time.  Reasons for discontinuation include , but are not limited to: 
â€¢ Adverse event  
â€¢ Pregnancy  
â€¢ Death  
â€¢ Lost to follow-up 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 70 of 165 
â€¢ Non-compliance with study requirements  
â€¢ Withdrawal of cons ent by subject  
â€¢ Study termination by Sponsor 
â€¢ Investigator decision  
â€¢ Progression of disease 
The primary reason for study treatment discontinuation will be documented in the eCRF .  
Investigators will be instructed to interview subjects to obtain the most accur ate reason 
for study treatment discontinuation , while respecti ng the privacy of the subject. 
If the reason for study treatment discontinuation is the occurrence of an AE, the subject 
will be followed by the investigator until such event(s) resolve s, stabil izes, or, according 
to the investigatorâ€™s judgment, no longer requires  follow-up.   
Study treatment discontinuation due to PD  should be recorded as â€œdisease progression.â€  
All subjects who are withdrawn from study treatment will be encouraged to complete all relevant safety assessments and continue in the LTFU period.  Subjects who discontinue 
study treatment will be followed for survival and disease status (if discontinuation is prior 
to progression) until study closure (refer to Appendix B , footnote d). 
11.2 WITHDRAWAL OF SUBJECTS FROM STUDY 
Reasons for complete withdrawal from study (treatment and all follow -up) before 
documentation of subject death include: 
â€¢ Withdrawal of consent by subject for all study procedures and study participation  
â€¢ Lost to follow-up 
â€¢ Sponsor decision  
The reason for complete withdrawal from the study will be documented in the eCRF. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 71 of 165 
11.3 STUDY TERMINATION 
Sponsor has the right to terminate this study or to terminate a study site from 
participating in the  study at any time.  Reasons for study or site termination may include , 
but are not limited to : 
â€¢ The incidence or severity of AEs in this or other carfilzomib studies indicates a 
potential health hazard to subjects 
â€¢ Subject enrollment is unsatisfactory  
â€¢ Data recording is inaccurate or incomplete 
â€¢ Investigator does not adhere to the protocol or applicable regulatory requirements 
in conducting the study 
â€¢ Investigational site non -compliance with International Conference on 
Harmonisation/G ood C linical Practice (ICH/ GCP)  
12 ADVERSE EVENTS AND SERIOUS ADVERSE EVENT S  
An AE is any untoward medical occurrence in a subject  administered a  study drug  and 
which is not necessarily caused by the study drug .  An AE can therefore be any 
unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporally  associated with the use of a medicinal product, combination product, 
or medical device, whether or not considered related to the product.  In addition to new events, any worsening of a pre- existing c ondition that occurs after the subject signs the 
ICF for participation is considered an AE.  Worsening indicates that the pre- existing 
medical condition or underlying disease has increased in severity, frequency, and/or duration more than would be expected, and/or has an association with a significantly 
worse outcome than expected.  This includes any side effect, injury, toxicity, or 
sensitivity reaction.  All reported AEs will be coded using the current version of Medical 
Dictionary for Regulatory Activities (MedDRA).  
12.1 ADVERSE EVENT REPORT ING  
12.1.1 
ADVERSE EVENT TERMINOLOGY  
When reporting an AE, accurate and standard medical terminology should be used that clearly identifies the event and the affected body system.  Use of non -standard 
terminology and/or abbreviations should be avoided to ensure accurate and complete 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 72 of 165 
reporting of AEs.  Individual signs and symptoms should be reported unless they result in 
a definitive diagnosis of an event or represent a well-recognized syndrome.   
12.1.2 SEVERITY  
Whenever possible, the National Cancer Institute -Common Terminology Criteria for 
Adverse Events ( NCI-CTCAE)  Version  4.03 should be used to describe the event and to  
assess the severity of AEs (NCI 2010 ).  For AEs not adequately addressed in the 
NCI-CTCAE  Version  4.03, the following criteria should be used (see Table 11). 
Table 11 Grading for Adverse Events not Covered in the NCI -CTCAE  
Severity  Description  
GRADE 1 â€“ Mild Asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated  
GRADE 2 â€“ Moderate  Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)  
GRADE 3  â€“ Severe  Medically significant but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self -care ADL  
GRADE 4 â€“ Life-threatening  Life-threatening consequences; urgent intervention indicated  
GRADE 5 â€“ Fatal  Death  
NCI-CTCAE = National Cancer Institute -Common Terminology Criteria for Adverse Events . 
An AE or suspected adverse reaction (ADR)  is considered â€œunexpectedâ€ if it is not listed 
in the current  Carfilzomib IB  or is not listed at the specificity or severity that has been 
observed.  Adverse events or suspected ADRs  that are mentioned in the IB as occurring 
with a class of drugs or as anticipated from the pharmacological properties of the drug, 
but are not specifically mentioned as occurring with particular study drug are considered 
â€œunexpected.â€  For example, an event more specific or more severe than described in the 
IB would be considered â€œunexpected.â€  Any condition, laboratory abnormality, or physical finding with an onset date prior to the subject signing the ICF is considered to be 
pre-existing in nature and part of the subjectâ€™s medical history and should not be 
considered an AE. 
Abnormal laboratory findings should be reported a s AEs if medical intervention or 
corrective action (e.g. , transfusions, initiation of antibiotics or other treatment regimens, 
hydration, study drug placed on hold) is required or the event is deemed clinically 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 73 of 165 
significant by the treating physician.   Where applicable, clinical sequelae (not the 
laboratory abnormality) are to be recorded  as the AE. 
12.1.3 DURATION 
The start and stop date s for all AEs will be recorded.  The start date is the first date that 
the subject was aware of the AE and the end date is the date that the event has changed in 
grade, totally resolved , or returned to baseline.  Any changes in grade should be recorded 
as a separate event.  Terms such as â€œintermittentâ€ or â€œoccasionalâ€ are not appropriate 
descriptions of AEs; each time a full calendar  day elapses without the subject 
experiencing the event should result in the event stop date recorded and a new event reported if the event recurs.   
12.1.4 
CAUSALITY 
A relationship between study drug and an adverse event is considered causal if there is at 
least a reasonable possibility the adverse event was caused by carfilzomib administration, 
i.e., the relationship cannot be ruled out.  The relationship of the AE to the study drug should be assessed by the investigator taking into account the totality of the e vidence and 
in considering the variables listed below. 
The following criteria should be considered and would support a positive assessment of 
causality:   
â€¢ Time to onset plausible: There is a clinically plausible time sequence between the 
AE onset and admini stration of study treatment. 
â€¢ Biologic plausibility: There is a biologically plausible mechanism for the study 
treatment to cause or contribute to the AE .  Biologic plausibility should be 
evaluated but is not required for a positive causality assessment.  F or example, if 
there is lack of an alternative explanation for the adverse event, then a causal relationship may be positive pending a complete causality assessment.  
â€¢ Positive dechallenge or rechallenge: The event improves or diminishes upon 
withdrawal of t he study drug without the initiation of any specific treatment for 
the event (dechallenge) and/or recurs or worsens with rechallenge (when clinically feasible) . 
â€¢ Alternative explanation or confounding factors do not suggest another etiology for 
the AE: The role of concurrent or underlying illness, co- medication, procedures 
or other events need to be evaluated as possible causes of or contributing to the 
adverse event.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 74 of 165 
The following criteria should be considered and would support a non- causal association 
betw een drug administration and the adverse event. 
â€¢ The AE is more likely to be explained by the subjectâ€™s clinical state, underlying 
disease, concomitant medication, study or non- study procedure.  
â€¢ The amount, duration of exposure , or time of last dose prior to the event suggests 
the AE is not reasonably related to administration of study treatment.  
12.2 ADVERSE EVENTS REPORTING PROCEDURES  
12.2.1 GENERAL  
All AEs (e.g. , any new event or worsening in severity or frequency of a pre- existing 
condition or laboratory finding) with an onset date after the subject signs the informed 
consent for participation in the clinical trial must be promptly documented on the AE 
eCRF via the electronic data capture ( EDC ) system .  Details of the event must include 
severity, relationship to study drug(s), duration, action taken, and, for SAEs only, outcome.  Whenever  possible, reporting specific diagnose s is preferr ed when reporting 
AEs in the AE  eCRF rather than reporting individual signs and symptoms. 
All AEs will be collected from the time the s ubject signs informed consent through 
30 days  after receiving the last dose of study drug(s) .  If initiation of new anticancer 
therapy occurs within 30 days  following the last dose of study drug(s), the date of new 
anticancer therapy will be recorded on the appropriate eCRF .  In addition, the 
investigator should report any AEs that may occur after this time period which are 
assessed to have a reasonable possibility of being associated with study drug.  
All AEs that are considered related  to study drug and al l SAEs regardless of relationship 
to study drug must be followed to resolution or stabilization if improvement is not 
expected .  Adverse events which completely resolve and then recur should be recorded as 
new AE s.  For subjects who complete the EOT visit less than 30 days  following the last 
dose of study drug, a follow-up of ongoing AEs should be documented in the subjectâ€™s 
source file.  Adverse events continuing at 30 days  after the last dose of study treatment 
should have a comment in the source file by the investigator that the event has stabilized or is not expected to improve. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 75 of 165 
The investigator is responsible for evaluating all AEs, obtaining supporting source 
documents, and determining that documentation of the event is adequate.  The 
investigator may delegate these duties to subinvestigators and must ensure that these 
subinvestigators are qualified to perform these duties under the supervision of the 
investigator and that they are listed on the FDA Form 1572. 
12.3 SERIOUS ADVERSE EVENT DEFINITION  
An SAE is an AE that meets 1 or more of the following criteria:  
â€¢ Death   
â€¢ Life-threatening experience defined as any adverse experience that places the 
subject, in the view of the Sponsor or investigator, at immediate risk of death at 
the time of occurrence ( i.e., it does not include a reaction that, had it occurred in 
a more severe form, might have caused death ). 
â€¢ Requires in -subject  hospitalization or prolongation of an existing hospitalization 
(except scheduled hospitalizations for a nonacute, unrelated cause such as elective surgery) . 
â€¢ Results in persistent or significant disability/incapacity (i.e. , substantial disruption 
in a subjectâ€™s ability to conduct normal activities of daily living [ADL] ). 
â€¢ Is a congenital anomaly/birth defect in the offspring of an exposed fema le subject 
or offspring of a female partner of a male subject . 
â€¢ Important medical events that may not result in death, be life -threatening, or 
require hospitalization, may be considered a SAE when, based upon appropriate medical judgment, jeopardizes the subject and may require medical or surgical 
intervention to prevent 1 of the outcomes listed in this definition. 
12.4 SERIOUS ADVERSE EVENT REPORTING AND DOCUMENTATION 
REQUIREMENTS  
Amgen Global Patient Safety must be notified of the occurrence of any SAE within 
24 hours of the investigator, designee, or site personnelâ€™s knowledge of the event.  The 
SAE will be reported by completing and submitting the SAE report form through the 
EDC system.  In the event that the EDC system is not available, paper SAE report forms  
may be used to report the SAE to Amgen Global Patient Safety  (Appendix  L).  Please 
refer to the SAE Reporting Guidelines in the study reference manual.   
Follow-up reports must be submitted in a timely fashion as additional information 
becomes available.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 76 of 165 
The investigator is responsible for notifying the Institutional Review Board (IRB) or 
Independent Ethics Committees (IEC), in accordance with local regulations, of all SAEs.  
The Sponsor may request for additional source documentation pertaining to the SAE 
from the investigational site.  If a subject is permanently withdrawn from the study due to an SAE, this information must be included in the initial or follow -up SAE report in the 
eCRF.  
The Sponsor is responsible for notifying the appropriate global health authorities of 
SAEs, when  required, in accordance with applicable laws and regulations. 
Properly anonymized and de-identified documents (e.g., hospital discharge summaries, 
autopsy reports, and/or death certificates), as available will be provided to Amgen Global 
Patient  Safety . 
12.5 PREGNANCY AND LACTATION EXPOSURE REPORTING  
Pregnancy, although not considered an SAE, must be reported to Amgen Global Patient 
Safety within 24 hours of the investigatorâ€™s awareness, if the pregnancy has occurred  
within 30 days of study treatment (for female participants) or within 90 days of study treatment (for female partners of male participant s).  The pregnancy will be reported on a 
Pregnancy Notification Worksheet ( APPENDIX  M).  Amgen Global Patient Safety will 
follow-up with the investigator regarding additional information that may be requested. 
If a subject becomes pregnant while taking an Amgen  drug, the study treatment  will be 
immediately discontinued.  The investigator will discuss the risks and concerns of 
investigational drug exposure to a developing fetus and counsel the subject and/or 
pregnant partner (or ensure that such counseling is provided). 
Pregnancies will be followed through th e outcome of the pregnancy. 
If the outcome of the pregnancy meets a criterion for immediate classification as an SAE  
(e.g., spontaneous abortion, stillbirth, neonatal death, fetal or neonatal congenital 
anomaly), the investigator will report the event as an SAE.  
With authorization of the subject or female partner, newborns should be followed-up at 6 
and 12 months of age .   
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 77 of 165 
If a female subject breastfeeds during treatment with carfilzomib or up to 30  days 
following the last dose of study drug administration,  the investigator will notify Amgen 
Global Patient Safety within 24 hours of learning of her breastfeeding.  The investigator 
will discuss the risks and concerns of breastfeeding while taking an IP.  The subject will 
be required to either discontinue breas tfeeding or study treatment.  The investigator will 
complete a Lactation Notification Worksheet ( APPENDIX  N).  Amgen Gl obal Patient 
Safety will follow -up with the investigator regarding additional information that may be 
requested.  
12.6 DEATH  REPORTING  
All deaths that occur from signing of informed consent until 30 days  after the last dose of 
study drug are to be reported as SAEs (unless due to PD - refer to  Section 12.4).  
Deaths occurring after the EOT visit do not need to be reported as SAEs.  Additional 
details of the event (such as the primary and contributory causes of death) should be reported on the end of study eCRF.  
13 STATISTIC AL CONSIDERATIONS  
This section describes th e statistical considerations of the study design and summarizes 
the statistical analyses that will be conducted to assess the efficacy and safety endpoints 
in the study .  Further details will be provided separately in the Statistical Analysis Plan 
(SAP) .  If, after the study has begun, but prior to the final analysis, important changes are 
made to the primary or key secondary analyses, then the changes will be reflected in the SAP or its amendment where applicable.  The study protocol may be amended as 
appropriate.  Any other changes made to the planned analyses after the protocol and SAP 
have been finalized, along with an explanation as to when and why they occurred, will be described in the c linical study report, in which any post hoc exploratory analyses also 
will be clearly identified .  Any changes made in the analysis plan , after the primary 
inferential c omparisons between treatment groups are performed , will be exploratory in 
nature.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 78 of 165 
13.1 STUDY ENDPOINTS  
13.1.1 PRIMARY ENDPOINTS  
The primary endpoint is PFS, which is defined as the time in months from 
randomization to the earlier of disease progression  or death due to any cause . 
13.1.2 SECONDARY ENDPOINTS  
The secondary endpoints of the study are as follows: 
â€¢ ORR, defined as the proportion of subjects who achieved a confirmed  PR, 
VGPR, CR, or sCR, according to the IMWG- URC. 
â€¢ OS defined as the time in months from randomization to death due to any cause. 
â€¢ Safety and tolerability  
â€¢ Sparse PK  
13.2 STUDY POPULATIONS  
13.2.1 INTENT -TO-TREAT POPULATION  
The Intent -to-Treat (ITT) P opulation consists of all randomized subjects .  It will be the 
basis for the analysis of efficacy endpoints in this study .  Subjects in the analysis based 
on the ITT Population will be included in the treatment group to which they were 
randomized. 
13.2.2 SAFETY ANALYSIS POPULATION  
The Safety Population is defined as all randomized subjects who received at least 1 dose 
of any study drug (i.e., carfilzomib, dexamethasone).  Subjects in the analysis based on the 
Safety Population will be included in the treatment group corresponding to the actual treatment received . 
13.3 STATISTICAL METHODS  
13.3.1 
ANALYSIS OF THE CONDUCT OF THE STUDY  
The number of subjects screened, randomized, and treated will be presented.  The number 
and percentage of subjects excluded from each analysis population will be summar ized 
with reason s for exclusion.  The number of subjects who discontinue study treatment will 
be tabulated, along with the reason for discontinuation.   
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 79 of 165 
Subjectsâ€™ demographics and baseline characteristics, disease characteristics, prior and 
concomitant med ications, and study drug exposure and treatment compliance  will be 
summarized descriptively for each treatment group. 
The number and percentage of subjects with important protocol deviations will be 
summarized by treatment group. 
13.3.2 EFFICACY ANALYSES  
All effi cacy analyses will be based on the ITT Population, which consists of all subjects 
randomized. 
13.3.2.1 Primary Efficacy Endpoint 
The primary efficacy endpoint is PFS.  Progression- free survival will be calculated 
from the time of randomization until disease progres sion or death due to any cause, 
whichever occurs first.  If a subject is alive or lost to follow- up without experiencing 
documented disease progression by the data cutoff date, the PFS data for the subject 
will be censored at the date of last valid disease and response assessment.  Detailed 
PFS data censoring rules will be described in the SAP.  
The distribution of PFS, including median, will be estimated using the 
Kaplan- Meier method.  Progression -free survival rates at selected time points will 
be reported  by treatment group.  The 95% CI for the median and other percentiles 
of PFS will be constructed using the method of Klein and Moeschberger (1997)  with 
log-log transformation.  The 95% CIs for PFS rates were estimated using the 
method by  Kalbfleisch and Pr entice (1980)  with log -log transformation.  The 
inferential comparison between treatment groups will be made using the log -rank 
test stratified by the randomization stratification factors specified in  Section  7.  The 
hazard ratio ( HR) and its 95% CI will be estimated using a Cox proportional 
hazards model stratified by the same randomization stratification factors.  Duration of follow up for PFS will be estimated using the reverse Kaplan -Meier method 
(Schemper  1996; Smith  2006).  
Response and disease progression will be determined using a validated computer 
algorithm (Onyx Response Computational Assessment; [ORCA ]), as well as by local 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
LQYHVWLJDWRUV DQGDQ,QGHSHQGHQW5HYLHZ&RPPLWWHH,5& 7KHSULPDU\DQDO\VLVRI
3)6ZLOOEHEDVHGRQ25&$DVVHVVH GRXWFRPHV7KH3)6RXWFRPHV DVVHVVHGE\WKH
LQYHVWLJDWRUZLOOVHUYHDVDVXSSRUWLYHDQDO\VLVRI3)6DVZLO O,5&DVVHVVHG
RXWFRPHV 
7KHILQDO3)6DQDO\VLVZLOOEHFRQGXFWHGZKHQDSSUR[LPDWHO\ 3)6HYHQWVKDYH
RFFXUUHGRUE\HQGRI\HDUZKL FKHYHULVHDUOLHU$WRWDO RI3)6HYHQWVZLOO
SURYLGHSRZHUWRGHWHFWDVLJQL ILFDQWGLIIHUHQFHLQ3)6EHW ZHHQWKHWUHDWPHQW
JURXSVZLWKLQWHULPDQDO\VLV 7KHLQWHULPDQDO\VLV
ZLOOEHSHUIRUPHGZKHQRIWKHWRWDO3)6HYHQWVLHH YHQWVKDYHRFFXUUHG
6HHDOVR6HFWLRQIRUWKHLQW HULPDQDO\VLVSODQIRU3)6 
6HFRQGDU\(IILFDF\(QGSRLQWV
 2YHUDOO5HVSRQVH5DWH
7KH255ZLOOEHDQDO\]HGDWWKHW LPHRIWKH3)6DQDO\VLVLQWHU LPRUILQDORQO\LI
WKH3)6DQDO\VLVFUR VVHVWKHERXQGDU\7KHLQIHUHQWLDOFRPSDUL VRQRI255EHWZHHQ
WUHDWPHQWJURXSVZLOOEHPDGH XVLQJDORJLVWLFUHJUHVVLRQPRGHO EDVHGWHVWDJDLQVW
WKHQXOOK\SRWKHVLVWKDWWKHR GGVUDWLRLVÂ”DWDVLGHGVLJ QLILFDQFHOHYHORI
7KHUHJUHVVLRQPRGHOZLOOLQFOXGHWKHUDQGRPL]DWLRQVWUDWLILFDW LRQIDFWRUVDV
FRYDULDWHV7KH255Z LOOEHFDOFXODWHGE\W UHDWPHQWJURXSDQG WKHDVVRFLDWHG
&,ZLOOEHHVWLPDWHGXVLQJW KH&ORSSHU3HDU VRQPHWKRG7KH RGGVUDWLRDQG
LWV&,ZLOOEHHVW LPDWHGXVLQJWKHORJL VWLFUHJUHVVLRQPRG HO
7KHSULPDU\DQDO\VLVRI255ZLOO EHEDVHGRQWKH 25&$DVVHVVHG UHVSRQVHV
,QYHVWLJDWRUD VVHVVHGUHVSRQVHVZLOOEH DQDO\]HGDVDVXSSRUWLY HDQDO\VLVRI255DV
ZLOO,5&DVVHVVHGUHVSRQVHV
7KHGXUDWLRQRIUHVSRQVH'25G HILQHGDVWLPHLQ PRQWKVIURP WKHVWDUWGDWHRI
WKHUHVSRQVHWRWKHHDUOLHUGDWHRIGRFXPHQWHGGLVHDVHSURJUHVV LRQRUGHDWKZLOOEH
FDOFXODWHGIRUVXEMHFWVZKRDFKLH YHV&5&59*35RU357KH '25ZLOOEH
FHQVRUHGDWGDWHRIWKHODVWYD OLGDVVHVVPHQWIRUUHVSRQGHUVZK RKDYHQRW
H[SHULHQFHGG LVHDVHSURJUHVVL RQRUGHDWK7KHGLVWULEXWLRQRI '25LQFOXGLQJWKH
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/ CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 81 of 165 
median , will be estimated using the Kaplan- Meier method on the basis of  subjects 
who achieve overall response.  
13.3.2.2.2 Overall Survival 
Overall Survival will be analyzed using the same methods as for PFS.  
Overall Survival data will be right- censored at the earlier of last known alive date or data 
cutoff date for subjects who are still alive.   
The analysis of OS will be co nducted at the time of the PFS analysis (interim or 
final ), only if both PF S and ORR analyses are positive, per hierarchical testing 
procedures.  There will be  no interim analysis for OS.  Additional follow -up for OS 
may be performed.  
13.3.2.3 Control of Family- wise Type I Error Rate  
The null hypotheses for the primary efficacy endpoint, PFS , and secondary efficacy 
endpoints ( ORR and OS) will be tested using a fixed sequence hierarchical testing 
procedure to control the family- wise Type I Error rate below 1 -sided 0.025 level.  The 
family of hypotheses is ordered as follows: 1) PFS, 2) ORR, and 3) OS.  Starting with 
the hypothesis of PFS, if any hypothesis in the sequence is rejected at a 1 -sided 
significance level of 0.025, then the subsequent hypothesis will be test ed; if any 
hypothesis is accepted, then the subsequent hypotheses will not be tested. 
13.3.3 SAFETY ANALYSIS  
Safety analyses will be based on the S afety Population (defined as all randomized 
subjects who have received at least 1 dose of study treatment) . 
13.3.3.1 Adverse Events  
Treatment -emergent adverse events are defined as AEs that start on or after the first day 
study treatment is administered and within 30  days  of the last administration of study 
treatment .  The reported AE term will be coded using MedDRA and will be graded for 
severity using NCI -CTCAE V ersion  4.03.  The causal relationship between the 
occurrence of an AE and each treatment will be assessed by the investigator as related or 
not related.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 82 of 165 
Treatment -emergent adverse events  will be summarized based on the number and 
percentage of subjects experiencing events by treatment group and by MedDRA system 
organ class  (SOC) and preferred term .  In the event that a patient experiences repeated 
episodes of the same AE, the subject will be counted once within each SOC  and similarly 
counted once within each preferred term and the event with the highest severity grade 
and/or strongest causal relationship to each treatment will be used for purposes of 
incidence tabulations. 
Tabular summaries of the following will be provid ed: 
â€¢ All TEAEs  by SOC  
â€¢ All TEAEs in decreasing order of frequency 
â€¢ TEAEs by causal relationship to study drug  
â€¢ TEAEs by maximum severity grade  
â€¢ All SAEs  by SOC  
â€¢ All SAEs in decreasing order of frequency  
â€¢ TEAEs resulting in modification  (i.e., dose reduction or dose interruption) of 
study treatment  
â€¢ TEAEs resulting in discontinuation of study treatment 
â€¢ Deaths within 30 days  of the last administration of study treatment  
â€¢ All AEs, including TEAEs, will be included in individual patient listings.  
13.3.3.2 Safety Laboratory Values  
For hematology, chemistry, and other laboratory values , the baseline values , changes 
from baseline by visit, the minimum, maximum, and last observed values will be 
summarized descriptively . 
For the summary of changes from baseline by visit,  subjects w ithout a base line and/or 
post baseline value will be excluded; values from unscheduled assessments will be 
excluded.  Subjects with missing data for a scheduled assessment  time point will be 
excluded from the summary for that time point.  Laboratory results from samples taken > 30 days  after the last administration of protocol therapy will be excluded from the 
laboratory summaries . 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 83 of 165 
All available laboratory data, including those excluded from summary tabulations, will be 
included in individual patient listin gs. 
Laboratory test results will be grade d using the NCI- CTCAE  (Version 4.03).  Shifts in 
laboratory toxicity grades to outside the normal range will be evaluated for selected  
laboratory parameter s by assessing the maximum increase and/or decrease observed  
during the course of study treatment relative to the baseline toxicity grade.  
The subject incidence of Grade 3 and 4 hematological laboratory abnormalit ies 
(including neutropenia, thrombocytopenia, and anemia) will be provided by treatment 
group. 
The subject incidence of Grade 3 and 4 nonhematological laboratory abnormalit ies 
(including liver function test [LFT], CrCl) will be provided by treatment group.  Similar 
analyses will be done for selected chemistry tests . 
13.3.3.3 Vital Signs  
Vital sign results (systolic and diastolic blood pressure, pulse, respiratory rate,  and 
temperature) will be summarized descriptively for baseline values and changes from 
baseline to the minimum, maximum, and last observed values.   
For the summary of changes from baseline by visit , subjects without a base line and/or 
past-baseline value will be excluded; values from unscheduled assessments will be 
excluded .  Vital sign results  taken > 30 days  after the last administration of protocol 
therapy will be excluded from all  vital sign  summaries . 
13.3.4 SPARSE PHARMACOKINET IC ANALYSES  
A sparse PK sampling strategy will be employed in this study , at a subset of study sites .  
Blood samples will be collected at specified times, processed and stored until analysis .  
Concentrations of carfilzomib will be measured in plasma using a validated assay 
method. 
The population pharmacokinetic analysis will be a cumulative analysis that will include 
population pharmacokinetic data obtained from previous Phase 2 and Phase 3 studies that 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 84 of 165 
used intensive or sparse PK  sampling .  The analysis plan as well as a stand -alone 
pharmacokinetic analysis report will be prepared separately .  The population modeling 
program may be used to fit a nonlinear mixed effects model to estimate PK parameters , 
including clearance and volume of distribution, the inter- and intra- subject variability , 
and the population variability in the parameter estimates.  The PK concentrations 
obtained from subjects who participate in the sparse PK sampling, along with results 
from the intensive PK/PDn substudy and other carfilzomib studies, will be used in the 
development of a structural model.  The best model will be evaluated by goodness-of- fit 
statistics and reduction in the objective function and posterior predictive checks.  Subject characteristics such as age, gender, body weight, BSA, and race will be included in the 
model to identify potential covariates affecting PK of carfilzomib.  
Additional analyses may be performed to evaluate the relationship between the estimated PK parameters and selected safety  or clinical effect endpoints. 
13.3.5 
EXPLORATORY ANALYSES   
Exploratory analyses will be performed for the following endpoints: 
â€¢ PDn and PK endpoints 
o To characterize the PK and PDn of proteasome inhibition in both treatment 
groups in a subset of subjects.  Actua l collection times will be recorded and 
used in the analysis.  For the intensive PK/PDn substudy, individual and 
mean plasma concentration versus time data will be tabulated and plotted by 
dose level.  The PK parameter will be estimated based on noncompart mental 
methods.  The PK parameter estimates for carfilzomib will be summarized, 
including total plasma exposure (AUC, Cmax, time to maximum plasma 
concentration [tmax], total plasma clearance, and t1/2 [as appropriate for data collected]).  Estimates for these parameters will be tabulated and 
summarized (i.e., mean, standard deviation).  These estimates will be 
summarized descriptively by each arm.   
â€¢ Patient -reported outcomes 
o All subscales of the EORTC  QLQ -C30, and the EORTC QLQ- MY20  
o EQ-5D- 5L: a standardized measure of health status developed by the 
EuroQol Group  
o Patient -reported convenience and satisfaction  
â€¢ Healthcare resource utilization  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 85 of 165 
13.4 HANDLING OF DATA  
13.4.1 HANDLING MISSING DATA IN DESCRIPTIVE ANALYSES  
When summarizing categorical variables, subjects with missing data are generally not  
included in calculations of percentages unless otherwise specified .  When needed , the 
category of â€œMissingâ€ is created and the number of subjects  with missing data is  
presented.  
When summarizing continuous variables, subjects with missing data are n ot included in 
calculations.  No imputations are made. 
13.4.2 HANDLING MISSING OR PARTIAL LY MISSING D ATES  
Missing or partially missing dates will not be imputed at data level.  However, 
assumptions for missing or partially missing dates for important variables will be made to 
allow inclusion of appropriate data records in the analyses.  In general, the assumptions 
about the missing or partially missing dates, when needed, are made conservative to 
avoid overestimation of treatment effect and undere stimation of adverse effects.  
If a medication date or  time is missing or partially missing, and it cannot be determined 
whether it was taken prior or  concomitantly, it will be consider ed as a prior, concomitant, 
and a post- treatment medication.  
If the partial AE onset date information does not indicate whether the AE started prior to 
treatment or after the TEAE period, the AE will be  classified as treatment -emergent . 
If the start day of subsequent anticancer therapy is missing, it will be assumed to be the 
first day of the  month. 
If only the day of a death date is missing, the death will be assumed to be on the first day of the month if the last known alive date is earlier.  If the last known alive date is later 
than the first day of the month, then the death date will be assumed to be the last known 
alive date plus 1 day. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
0,66,1**5$'(255(/$7,216+,32)$'9(56((9(1772
678'<75($70(176
1RLPSXWDWLRQRI$(JUDGHVZLOO EHSHUIRUPHG7UHDWPHQWHPHUJH QWDGYHUVHHYHQWVZLWK
PLVVLQJ&7&$(JUDGHZLOORQO\EH VXPPDUL]HGLQWKHDOOJUDGHVF ROXPQ
,IWKHDVVHVVPHQWRIWKHUHODWL RQVKLSRIDQ$(WRVWXG\WUHDWPH QWVLVPLVVLQJWKHQWKH$(
LVDVVXPHGWREHUHODWH GWRWKHVWXG\WUHDWPHQWVLQWKHVDIHW\ DQDO\VLVEXWQRLPSXWDWLRQ
VKRXOGEHGRQHDWWKHGDWDOHYHO
816&+('8/('9,6,76
8QVFKHGXOHGYLVLWPHDVXUHPHQWVRI ODERUDWRU\GDWDDQGYLWDOVLJ QVZLOOEHLQFOXGHGIRU
FRPSXWLQJZRUVWYDOXHVDQGRUJUDGHV
'(7(50,1$7,212)6$03/(6,=(
WKHVDPSOH
VL]HRIVXEMHFWVLQHDFKDUPZDVFDOFXODWHG 





DWRWDORI3)6HYHQWVIRUWKHILQDO3)6DQDO\VLVZLOOSURY LGH
SRZHUWRGHWHFWDVLJQLILFDQWGLIIHUHQFHLQ3)6EHWZHHQWKH WUHDWPHQWJURXSV
ZLWKVLGHGRYHUDOO7\SH,HUURURIZKHQLQWHULPDQDO\ VLVLVSHUIRUPHGDW
DSSUR[LPDWHO\LQIRUPDWLRQW LPHLH3)6HYHQWVXVLQJ WKH
2Â¶%ULHQ)OHPLQJW\SHDOSK DVSHQGLQJIXQFWLRQ 
,1'(3(1'(175(9,(:&200,77((
$Q,5&ZLOOEHFRQYHQHGIRUWKLVVWXG\WRV XSSRUWWKH25&$GHWHUPLQHGUHVX OWV7KH
,5&ZLOOFHQWUDOO\UHYLHZWKHGLVHDVHUHODWHGWHVWVDQGDVVHVVP HQWV0XOWLSOH 
0\HORPD'LVHDVH$VVHVVPHQWV WRHYDOXDWHGLVHDVHSU RJUHVVLRQDQGUHVSRQVHV
ZLWKRXWNQRZOHGJHRIWKHUDQGRPL ]DWLRQDVVLJQPHQWV7KHGHWDLO VRIWKH,5&
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/ CCICCI
CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 87 of 165 
including the roles and responsibilities of the involved parties, will be described in 
the IRC Charter.  
13.7 DATA MONITORING COMM ITTEE  
An independent Data Monitoring Committee (DMC) will be convened for this study and 
will act in an advisory capacity to the sponsor with respect to safeguarding the interests 
of study subjects through periodic safety data reviews , assessments of interim safety and 
efficacy data, and monitoring of the overall conduct of the study.  To enhance the 
integrity of the study, the DMC may also formulate recommendations relating to the 
selection, recruitment, and retention of subjects, their management, improving adherence 
to protocol treatment, and the procedures for data management and quality control.   
An Independent Statistical Reportin g Group (ISRG) will function independently of the 
Sponsor s tudy team , in support of the DMC.  The ISRG will conduct unblinded analyses, 
generate the open and closed reports to be reviewed at the DMC meetings, and serve as 
the liaison between the Sponsor an d the DMC. 
The details of the DMC , including the roles and responsibilities of the involved parties, 
will be described in the DMC Charter .   
The DMC will meet to review safety data on a periodic basis, including after 
approximately 40 subjects have completed â‰¥ 1 cycle and no less frequently than 
approximately every  6 months thereafter.  Unplanned safety review meetings of the DMC 
may be called at any time , if warranted , for an earlier review of safety data.   The DMC 
will also review the interim PFS analysis re sults and recommend whether the study 
should stop early for efficacy.  
13.8 INTERIM ANALYSIS  
Periodic safety review will be conducted by the DMC.  
One interim analysis will be conducted for PFS when  approximately 263 (75% of total 
350) PFS events are observed.  The objective of the interim analysis is to  monitor for 
differences between treatment arms for evidence of a substantial benefit in the 
carfilzomib once- weekly with dexamethasone arm . 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
7RHQVXUHSURSHUFRQWURORIW\S H,HUURUUDWHWKHLQWHULPDQG ILQDODQDO\VLVRI3)6ZLOOEH
DQDO\]HGXQGHUDJURXSVHTXHQWLDO GHVLJQIUDPHZRUNZLWKWKHVWR SSLQJERXQGDULHV
FRQVWUXFWHGXVLQJWKH 2Â¶%ULHQ)OHPLQJW\SH DOSKDVSHQGLQJIXQ FWLRQDSSURDFK 







5(*8/$725<2%/,*$7,216
,1)250('&216(17
1RLQYHVWLJDWRUPD\LQYROYHDKXP DQEHLQJDVDVXEMHFWLQUHVHD UFKXQOHVVWKHLQYHVWLJDWRU
KDVREWDLQHGWKHOHJDOO\HIIHFWLY HLQIRUPHGFRQVHQWRIWKHVXEM HFWRUWKHVXEMHFWÂ¶VOHJDOO\
DXWKRUL]HGUHSUHVHQWDWLYH$ QLQYHVWLJDWRUZLOOVHHNVXFKFRQV HQWRQO\XQGHUFLUFXPVWDQFHV
WKDWSURYLGHWKHSURVSHFWLYHVXEM HFWRUWKHVXEMHFWÂ¶VOHJDOO\D XWKRUL]HGUHSUHVHQWDWLYH
VXIILFLHQWRSSRUWXQLW\WRFRQVLG HUZKHWKHURUQRWWRSDUWLFLSDW HDQGWKDWPLQLPL]HWKH
SRVVLELOLW\RIFRHUFLRQRUXQGXHLQI OXHQFH7KHLQIRUPDWLRQWK DWLVJLYHQWRWKHVXEMHFWRU
WKHUHSUHVHQWDWLYHZLOOEHLQD ODQJXDJHXQGHUVWDQGDEOHWRWKH VXEMHFWDQGRUUHSUHVHQWDWLYH
DVDSSOLFDEOH
7KH6SRQVRURULWVGHVLJQDWHGUHS UHVHQWDWLYHZ LOOSURYLGHWKHL QYHVWLJDWRUZLWKDVDPSOH
,&)/RFDODQGRULQVWLWXWLRQDOUHTXLUHPHQWVPD\UHTXLUHGLVFO RVXUHRIDGGLWLRQDO
LQIRUPDWLRQLQWKH,&)$Q\FKDQJHVWRWKH,&)PXVWEHVXEPLWW HGWRWKHVSRQVRURULWV
GHVLJQDWHGUHSUHVHQWDWLYHIRU DSSURYDOSULRUWRVXEPLVVLRQWR WKH,5%,(&7KH,5%,(&
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/ CCICCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 89 of 165 
will review the ICF for approval.  A copy of the approved form must be submitted to the 
sponsor or its designated representative prior to initiation of the study. 
Before implementing any study procedure, informed consent will be documented in the 
subjectâ€™s case history and by the use of a written ICF approved by the IRB/IEC and 
signed and dated by the subject or the subjectâ€™s legally authorized representative at the 
time of consent.  A copy of the signed informed consent will be given to the subject or 
subjectâ€™s legally authorized representative.  The original signed consent must be 
maintained by the investigator and available for inspection by the Sponsor , its designa ted 
representative, or reg ulatory authority at any time.  
14.2 COMPLIANCE WITH LAWS  AND REGULATIONS  
The study will be conducted in accordance with US FDA and International Conference 
on Harmonisation (ICH) Good Clinical Practice (GCP), the Declaration of Helsinki, any 
applicable local health authority, and IRB or IEC requirements. 
This study must have the approval of a properly constituted IRB/IEC.  Before the 
investigational drug is shipped to the investigator, the investigator or designee will 
provide the Spons or with a copy of the IRB/IEC approval letter stating that the study 
protocol and any subsequent amendments and the ICF have been reviewed and approved. 
The investigator or designee will be responsible for obtaining annual IRB/IEC 
re-approval throughout the duration of the study.  Copies of the investigatorâ€™s annual 
report to the IRB/IEC and copies of the IRB/IEC continuance of approval must be submitted to the Sponsor or designee.  
The investigator is also responsible for notifying their IRB/IEC of any sign ificant AEs 
that are serious and/or unexpected. 
The Sponsor will provide study sites with any Investigational New Drug (IND) safety 
reports, changes to the IB, and any safety updates.  The investigator is responsible for 
immediately notifying their IRB/IEC  of any such updates. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 90 of 165 
14.3 SUBJECT CONFIDENTIAL ITY 
Subject medical information obtained as part of this study is confidential, and must not be 
disclosed to third parties, except as noted below.  The subject may request in writing that 
medical information be giv en to his/her personal physician. 
The investigator/institution will permit direct access to source data and documents by the 
Sponsor, its designee, the US FDA, and other applicable regulatory authorities.  The 
access may consist of study -related monitoring , audits, IRB/IEC reviews, and US 
FDA/regulatory authority inspections. 
Release of research results should preserve the privacy of medical information and must 
be carried out in accordance with US Department of Health and Human Services 
Standards for Privacy of Individually Identifiable Health Information, 45 CFR 164.508 
and, if and to the extent applicable, the principles set out in Directive 95/46/EC of the 
European Parliament and of the Council of 24 October 1995 on the protection of 
individuals with regard to the processing of personal data and on the free movement of 
such data, and national legislation with regard to data privacy. 
15 ADMINISTRATIVE AND LEGAL OBLIGATIONS  
15.1 PROTOCOL AMENDMENTS  
The Sponsor will implement in writing any substantive changes to this protocol as a 
protocol amendment.  The amendment will be submitted to the applicable local 
regulatory health authority and IRB/IEC, together with a revised ICF, if applicable.  
Amendments must be submitted to the applicable local regulatory health auth ority and 
IRB/IEC approval must be received, signed, and dated by the subject or the subjectâ€™s legally authorized representative at the time of consent before the amendment is 
implemented.  The investigator or designee must send a copy of the approval lett er from 
the IRB/IEC, along with the revised ICF, to the Sponsor or designee.  Upon completion of the study, the investigator must provide the IRB/IEC with a summary of the studyâ€™s 
outcome. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 91 of 165 
15.2 STUDY TERMINATION 
The Sponsor reserves the right to terminate the study at any time.  The investigator or 
designee should notify the IRB/IEC in writing of the studyâ€™s completion or early 
termination and send a copy of the notification to  the Sponsor or designee.  
15.3 STUDY DOCUMENTATION AND ARCHIVES  
15.3.1 SOURCE DOCUMENTS  
Source records are original documents, data, and records (e.g., medical records, raw data collection forms, pharmacy dispensing records, recorded data from automated 
instruments, laboratory data) that are relevant to the clinical study.  The investigator will 
prepar e and maintain adequate and accurate source documents.  These documents are 
designed to record all observations and other pertinent data for each subject randomized in this clinical study.  Source records must be adequate to reconstruct all data entered in  
the designated eCRF.   
15.3.2 
ARCHIVAL OF RECORDS  
According to 21 CFR 312.62(c), the investigators will retain records required to be maintained under this part for a period of 2 years following the date a marketing 
application is approved for the drug for the indication for which it is being investigated.  
If no application is to be filed or if the application is not approved for such indication, the 
investigator will retain these records until 2  years after the investigation is discontinued 
and the US FDA or ap plicable regulatory authorities are notified. 
The investigator must retain protocols, amendments, IRB/IEC approvals, copies of the 
Form  FDA 1572 or Canadian Quality Investigator Undertaking, signed and dated consent 
forms, medical records, eCRFs, drug accountability records, all correspondence, and any other documents pertaining to the conduct of the study. 
15.4 DATA COLLECTION AND STUDY MONITORING  
15.4.1 
ELECTRONIC CASE REPO RT FORMS  
As part of the responsibilities assumed by participating in the study, the investigato r 
agrees to maintain adequate case histories for the subjects treated as part of the research 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 92 of 165 
under this protocol.  The investigator agrees to maintain accurate eCRFs and source 
documentation as part of the case histories.  These source documents may include subject 
diaries, laboratory reports, etc. (refer to  Section 15.3.1).  The Sponsor will supply the 
eCRF, which must be completed in English. 
The investigator or designee must enter all results collected during the clinical study into 
eCRFs.  Guidelines for completion of eCRFs will be reviewed with study site personnel 
at the site initiation visits.  Investigators are responsible for approval of the 
entered/corrected data; however, they can authorize listed sub -investig ators to 
sign/approve the data. 
15.4.2 STUDY MONITORING  
The clinical research associate or study monitor, as a representative of the sponsor, has 
the obligation to follow the study closely.  In doing so, the monitor will visit the 
investigator(s) and stud y facility at periodic intervals, in addition to maintaining 
necessary telephone and letter contacts.  The monitor will maintain current personal knowledge of the study through observation, review of study records and source 
documentation, discussion of the conduct of the study with the investigators and study 
site personnel. 
All aspects of the study will be carefully monitored, by the sponsor or its designee, 
for compliance with applicable government regulation with respect to current GCP and 
current SOPs.  
15.4.3 
DATA QUALITY ASSURANCE  
The clinical research associates will visit each study site, at a frequency documented in the monitoring plan, to review eCRFs for completeness and accuracy.  Any discrepancies 
noted between source documents and completed eCRFs wil l be entered as a discrepancy 
in the EDC system by the clinical research associate, which will then be addressed by the 
study site personnel.  Uniform procedures for eCRF correction (queries) will be discussed 
at the investigator meeting, and during the study site initiation visits.  Data from eCRFs 
and other external data sources will be entered into a clinical database as specified in the 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 93 of 165 
data management plan.  Quality control and data validation procedures will be applied to 
ensure the validity and accuracy of the clinical database.  
15.5 PUBLICATION POLICY 
Authorship of any publications resulting from this study will be determined on the basis of the International Committee of Medical Journal Editors [ICMJE]) Recommendations 
for the Conduct of Reporting, Editing, and Publications of Scholarly Work in Medical 
Journals, which states: 
â€¢ Authorship credit should be based on (1) substantial contributions to conception 
and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final 
approval of the version to be published and (4) agreement to be accountable for 
all aspects of the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated and resolved.  
Authors should meet conditions 1, 2, 3, and 4. 
â€¢ When a large, multicenter group has conducted the work, the group should 
identify the individuals who accept direct responsibility for the manuscript.  These individuals should fully meet the criteria for authorship defined above. 
â€¢ Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship. 
â€¢ All persons designated as authors should qualify for authorship, and all those who qualify should be listed. 
â€¢ Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. 
[Additional information on the current guidelines for publications can be found at the 
following location:  http://www.icmje.org/.]  
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) based on this study must be submitted to Amgen for review.  The Clinical Trial Agreement 
among the institution, investigator, and Amgen will detail the procedures for, and timing 
of, Amgenâ€™s review of publications. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 94 of 165 
16 REFERENCES  
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality-of- life instr ument for use in international 
clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365â€“76. 
Amgen/Onyx. Carfilzomib Investigatorâ€™s Brochure, version 16.1. Onyx Therapeutics, 
Inc. (a wholly owned subsidiary of Onyx Pharmaceuticals, Inc., an Amgen Inc. subsidiary); 16 Jan  2016.  
Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231â€“39. 
Arastu -Kapur S, Shenk KD, Kirk CJ, et al. Nonproteasomal targets of proteasome 
inhibitors bortezomib and carfilzomib. Haematologica. 2009:94(s2). 14th Congress of the 
European Hematology Association. Abstract 0939. 
Berenson J, Cartmell A, Bessudo A, et al. Updated results from CHAMPION-1, a phase 
1/2 study investigating weekly carfilzomib with dexamethasone for patients (pts) with 
relapsed or refractory multiple myeloma (RRMM). J Clin Oncol. May 29 â€“June 2, 2015. 
ASCO Annual Meeting 2015. Abstract accepted. 
Berenson J, Klein L, Rifkin R, et al. Results of the dose-escalation portion of a phase 1/2 
study (CHAMPION -1) investigating weekly carfilzomib in combination with 
dexamethasone for patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2014;32(15_suppl). ASCO Annual Meeting 2014. Abstract 8594. 
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 
16(3):481â€“88. 
Britton M, Lucas MM, Downey SL, et al. Selective in hibitor of proteasomeâ€™s 
caspase -like sites sensitizes cells to specific inhibition of chymotrypsin -like sites. Chem 
Biol. 2009; 16(12):1278â€“89. Cancer facts and figures 2014. Atlanta, GA: American Cancer Society; 2014.  
Cocks K, Cohen D, WislÃ¸ff F, et al.; EORTC Quality of Life Group. An international 
field study of the reliability and validity of a disease -specific questionnaire module (the 
QLQ -MY20) in assessing the quality of life of patients with multiple myeloma. Eur J 
Cancer. 2007;43(11):1670â€“78. 
Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR -171, a novel irreversible 
inhibitor of the proteasome. Cancer Res. 2007;67(13):6383â€“91. Durie BG, Moreau P, Sonneveld P, et al. Regional differences in the treatment 
approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol. 2012;30(15_suppl). ASCO Annual Meeting 2012. Abstract 8095.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 95 of 165 
Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. 
International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467âˆ’73. Errata in: Leukemia 2006;20(12):2220 and Leukemia 2007;21(5):1134. 
EuroQol Group. EuroQol- a new facility for the measurement of health -related quality of 
life.  Health Policy. 1990;16(3):199-208. Fayers PM, Aaronson NK, Bjordal K, et al., on behalf of the EORTC Quality of Life 
Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001. 
Ferlay J, Parkin DM, Steliarova- Foucher E. Estimates of cancer incidence and mortality 
in Europe in 2008. Eur J Cancer. 2010;46(4):765â€“81. 
Geurink PP, van der Linen WA, Mirabella AC, et al. Incorporation of non-natural amino 
acids improves cell permeability and potency of specific inhibitors of pr oteasome 
trypsin -like sites. J Med Chem. 2013;56(3):1262â€“1275. 
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple 
myeloma. J  Clin Oncol. 2005;23(15):3412â€“20.  
Harousseau JL, Dreyling M, ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol. 
2010; 21 Suppl 5:v155âˆ’57. 
Kalbfleisch JD and Prentice  RL. The Statistical Analysis of Failure Time Data, 
Hoboken, New Jersey: John Wiley & Sons; 1980. 
Klein, JP and Moeschberger, M L. Survival Analysis: Techniques for Censored and 
Truncated Data, New York: Springer-Verlag; 1997. 
Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, 
irreversible inhibitor of the ubiquitin proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281â€“90. 
Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple 
myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter internatio nal 
myeloma working group study. Leukemia. 2012;26(1):149âˆ’57. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma 
and the impact of novel therapies. Blood. 2008;111(5):2516â€“20. 
Kumar SK, Therneau TM, Gertz MA, et al. Clinical  course of patients with relapsed 
multiple myeloma. Mayo Clin Proc. 2004;79(7):867â€“74. Lee S, Arastu -Kapur S, Kellerman S, et al. Potent inhibition of select proteasome 
subunits by carfilzomib in multiple myeloma and solid tumor patients is associated with  
patient response. Haematologica. 2012;97(s1). 17th Congress of the European 
Hematology Association. Abstract 840. 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 96 of 165 
Lonial, S. and K. C. Anderson. Association of response endpoints with survival outcomes 
in multiple myeloma. Leukemia 2014;28(2):258â€“68. 
Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory 
multiple myeloma. Clin Cancer Res. 2011;17(6):1264â€“77. 
Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987;317(17): 
1098 (letter). 
National Cancer Ins titute. Common Terminology Criteria for Adverse Events v4.0. May 
29, 2009 (v4.03 June 14, 2010). NCI, NIH, DHHS. NIH publication # 09-7473. National Comprehensive Cancer Network (NCCN) Guidelines 2014. Clinical Practice 
Guidelines in Oncology:  Multiple My eloma . Version 2.2014. 
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649âˆ’55. 
Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I Study of 30-Minute Infusion of 
Carfilzomib As Single Agent or in Combination With Low -Dose Dexamethasone in 
Patients With Relapsed and/or Refractory Multiple Myeloma J Clin Oncol. Sep 2014. Epub ahead of print. 
Parlati  F, Lee SJ, Aujay  M, et al. Carfilzomib can induce tumor cell death through 
selective inhibition of the chymotrypsin -like activity of the proteasome . Blood . 
2009;114(16) : 
3439â€“47. Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the 
uniform reporting of clinical trials: report of the International Myeloma Workshop 
Consensus Panel 1. Blood. 2011;117(18):4691â€“95. 
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. 
Control Clin Trials. 1996;17(4):343â€“46. 
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the 
use of white blood cell growth factors: an evidence- based clinical practice guideline. J 
Clin Oncol. 2006;24(19):3187â€“205. 
Squifflet P, Michiels S, Siegel D, et al. Multivariate modelling reveals evidence of a dose 
response relationship in phase 2 studies of single-agent carfilzomib. Blood. 
2011;118(21). ASH Annual Meeting 2011. Abstract 1877.   
Yang J, Wang, Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, 
distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39(10):1873-82 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 97 of 165 
APPENDIX A SCHEDULE OF ASSESSMENTS  
Assessmenta Screeningb Baselinec All Cycles  
LTFU  D1 D2 D8 D9 D15 D16 D22 EOT  
Informed Consent  X           
Demographics  X           
Medical and treatment histo ry X           
Vital signs  X  X Xd X Xd X Xd  X  
Physical examinatione X  X       X  
ECOG Performance Status  X         X  
12 lead ECG with QTc interval X         X  
ECHO/MUGA  X           
Full hematology panelf X  X  X  X   X  
Full serum chemistry pa nelf X  X  X  X   X  
Coagulation  X         X  
QLQ -C30, QLQ -MY20, EQ -5D-5L, and Patient 
Convenience and Satisfactiong   X       X X 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 98 of 165 
APPENDIX A SCHEDULE OF ASSESSME NTS (CONTâ€™D)  
Assessment  Screeningb Baselinec All Cycles  
LTFU  D1 D2 D8 D9 D15 D16 D22 EOT 
AEs and Survival Status    
Concomitant medications    
Pregnancy Test (FCBP)h X  X       X  
Survival            X 
AEs = adverse events; C1D1 = Cycle 1 Day  1; C2D1 = Cycle  2 Day  1; ECHO = echocardiogram; ECG = electrocardiogram; LTFU = long -term follo w-up; EOT = 
End of Treatment; FCBP = females of childbearing potential; MUGA = multigated acquisition; QLQ -C30 = Quality of Life Core Module; QLQ -MY20 = Quality of 
Life Multiple Myeloma Module ; QT C = corrected QT -interval; EQ-5D-5L = European Quality of Li fe-5 Dimensions .   
Details of Assessments are in the protocol body.  
a Refer to Section 9.1 for study treatment related assessment window.  
b Screening samples can be collected within 21  days of randomization.  Refer  to Section 10.1.   
c Baseline samples are collected only after subject eligibility is confirmed.  Refer to Section 10.2.  
d Arm B only (twice -weekly regimen) . 
e The physical examination Screening may be used if within 7  days prior to C1D1.  Refer to Section 10.1.3.  
f Full hematology and serum chemistry samples from Screening may be used for C1D1 if taken within 3 days prior to C1D1.   Refer to Section 10.4.1 and 
Section  10.4.2.   Beyond Cycle  4, labs will be performed on Days  1 and 15 of each cycle in both arms.  
g Questionnaires to be collected on D ay 1 of Cycle  1, then every second cycle (Cycle 1, 3, 5, etc) during treatment and every 12  weeks (every 84  days Â± 4 days) 
until progression, or withdrawal of consent  during LTFU.  Questionnaires should be completed by the subject  prior to drug administrat ion during treatment cycles .  
Patient convenience and satisfaction collected at Cycle  2 and EOT  only.  Refer to Sections 10.7 and 10.10.1 . 
h Urine or serum pregnancy te st must be confirmed negative locally on Day 1 of each Cycle prior to dosing and at EOT .  At Screening, a confirmed negative serum 
pregnancy test that is performed centrally is required.  Refer to Section 10.4.4 .  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 99 of 165 
APPENDIX B SCHEDULE OF DISEASE ASSESSMENTS  
Disease Assessment Screening  
(within 21  days of 
randomization) Baseline  
(predose -C1D1 ) C1D1 Disease  Assessment 
repeated every 28  days (Â± 
4 days) EOTc LTFU 
SPEP/UPEP/immunofixationa,b X  Xb X X Xd 
SFLCa,b X  Xb X X Xd 
Quantitative immunoglobulinsa,b X  Xb X X Xd 
Beta-2 microglobuline X      
Plasmacytoma Evaluation   Xf     
Skeletal Survey  Xf     
Bone Marrow Sampleg       
C1D1 = Cycle  1 Day 1; C2D1 = Cycle 2 Day  1; LTFU = Long -Term Follow -Up; PD = progressive disease; SFLC = serum free light chain;  
SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; EOT  = End of Treatment . 
a C1D1 before treatment begins (Screening values may be used if obtained within 7 days prior to C1D1) and  every 28  days (Â± 4  days) thereafter, at EOT and during 
LTFU if disease progression has not already been documented, (every 28  days Â± 4 days) until PD and/or start of a subsequent antimyeloma therapy.  Refer to 
Section 10.2.  
b Screening values may be used if within 7  days prior to C1D1.  Refer to Section 7 for allowable window between randomization and C1D1.  
c EOT will be upon treatment discontinua tion or early study withdrawal.  Refer to Section 11.   
d For subjects who did not progress during treatment, SPEP, UPEP, SFLC, and quantitative immunoglobulins will continue to be me asured (by the central 
laborat ory) every 4  weeks (every 28  days Â± 4 days) until PD.  All subjects will be followed for survival and disease status (if discontinuation is prior to 
progression) by telephone contact or other method every 12 weeks Â± 28 days for until study closure.  Refer to Sections 10.10.1, 10.10.2  and 11.1. 
e Must be obtained by central laboratory within 21 days prior to randomization.  
f Extramedullary plasmacytoma assessments will be performed if clinically indicated at baseline and repeated during treatment only to confirm a response of PR or 
better, or to confirm PD, or as clinically indicated.  A skeletal survey will be repeated if worseni ng clinical symptoms suggest PD, or as clinically indicated.  
Historical plasmacytoma evaluation and a skeletal survey performed within 30 days prior to C1D1 may be used for baseline asse ssments.  
g Bone marrow samples:  Bone marrow biopsy or bone marrow aspi rate will be obtained to confirm sCR or CR, or as clinically indicated.  The preferred method for 
a confirmation of CR or sCR is bone marrow biopsy.  However, an aspirate slide is acceptable for confirmation of CR (a confir matory bone marrow sample is not 
required). 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 100 of 165 
APPENDIX C SCHEDULE OF STUDY TREATMENT ADMINISTRATION  
 Cycle  1  Cycles  2+  
 D1 D2 D8 D9 D15 D16 D22 D1 D2 D8 D9 D15 D16 D22 
Arm Aa 
Once -weekly Carfilzomib with Dexamethasone Regimen               
Carfilzomib (20  mg/m2) X              
Carfilzomib (70  mg/m2)   X  X   X  X  X   
Dexamethasone 40  mgb  
(Day  22 admi nistration should be given PO, 
Cycles  1âˆ’9)  X  X  X  X X  X  X  X 
IV Hydration (Cycle  1 Only)  X  X  X          
Arm Ba  
Twice -weekly Carfilzomib with Dexamethasone Regimen               
Carfilzomib (20  mg/m2) X X             
Carfilzomib (27  mg/m2)   X X X X  X X X X X X  
Dexamethasone 40  mgb  
(Day  22 administration should be given PO, 
Cycles  1âˆ’9)  X  X  X  X X  X  X  X 
IV Hydration (Cycle  1 Only)  X X X X X X         
D = Day; IV = intravenous(ly); PO = oral(ly).  
a Study treatment will commence on the day of  randomization or at least within 5  calendar days of randomization according to treatment group assignment.  Refer 
to Sections 7 and 9.1 for study treatment related assessment window.  
b Within 4  hours prior to carfilzomib on Days  1, 8, and 15 in both arms.  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 101 of 165 
APPENDIX D SCHEDULE OF STUDY ASSESS MENTS FOR THE 
PHARMACOKINETIC SPARSE SAMPLING AND INTENSIVE 
PHARMACOKINETIC & PHARMACODYNAMIC SUB -STUDY 
INTENSIVE PK/PDn SUBSTUDY 
SAMPLING  
Optional  Cycle  1  
D1 D2 D8 D9 D1
5 D1
6 D1
7 D2
2 
Arm A          
PDn substudy/whole blood/PBMCs  
â€¢ Predose  X    X    
PDn substudy/whole blood/PBMCs  
â€¢ 1 hour after dose or equivalent time on 
non-dosing day       X Xa Xb Xc 
PK plasma samples  
â€¢ Predose (within 5  minutes before the start of 
infusion)  
â€¢ 15 minutes after the start of  infusion 
(Â± 5 minutes)  
â€¢ Immediately prior to (within 2  minutes 
before) the end of infusion  
â€¢ 15 minutes, 60 minutes, and 2  hours after the 
end of inf usion (Â± 5  minutes)      X    
Arm B          
PDn sub -study/whole blood/PMBCs  
â€¢ Predose  X    X X   
PDn sub -study/whole blood/PBMCs  
â€¢ 1 hour after  dose or equivalent time on 
non-dosing day      X X Xd Xe 
PK plasma samples  
â€¢ Predose (within 5  minutes before the s tart of 
infusion)  
â€¢ Immediately prior to (within 2  minutes 
before) the end of infusion  
â€¢ 15 minutes, 60 minutes, and 2  hours after the 
end of infusion (Â± 5  minutes)      X    
D = Day; PBMC(s) = Peripheral blood mononuclear cell(s); PDn = Pharmacodynamics; 
PK = Pharmacokinetics.  
a. 24 hours Â± 2 hours after the end of the Day  15 infusion  
b. 48 hours Â± 2 hours after the end of the Day  15 infusion  
c. 168 hours Â± 2 hours after the end of the Day  15 infusion  
d. 24 hours Â± 2 hours after the end of the Day  16 infusion  
e. 144 hours Â±  2 hours after the end of the Day  16 infusion  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 102 of 165 
SPARSE PK SAMPLING Optional  
(ALL SUBJECTS NOT IN THE ABOVE 
SUBSTUDY)  Cycle  2 
D
1 D
2 D
8 D
9 D1
5 D1
6 D1
7 D2
2 
Arm A  
â€¢ Predose (within 5  minutes before the start of 
infusion)  
â€¢ 15 minutes after the start of infusion  (Â± 
5 minutes)   
â€¢ Immediately prior to (within 2  minutes before) 
the end of infusion 
â€¢ 30 minutes after the end of infusion (Â± 
5 minutes)  X        
Arm B   
â€¢ Predose (within 5  minutes before the start of 
infusion)  
â€¢ Immediately prior to (within 2  minutes before) 
the end of infusion 
â€¢ 30 minutes after the end of infusion (Â± 
5 minutes)  X        
D = Day; PK = Pharmacokinetics.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI 
$33(1',;( (&2*3(5)250$1&(67$786
*UDGH 'HVFULSWLRQ
1RUPDODFWLYLW\IXOO\DFWLYHDEOHWRFDUU\RQDOOSUHGLVHDVH SHUIRUPDQFHZLWKRXW
UHVWULFWLRQ
6\PSWRPVEXWIXOO\DPEXODWRU\UHVWULFWHGLQSK\VLFDOO\VWUHQX RXVEXWDPEXODWRU\
DQGDEOHWRFDUU\RXWZRUNRIDOLJKWRUVHGHQWDU\QDWXUHHJ OLJKWKRXVHZRUN
RIILFHZRUN
$PEXODWRU\DQGFDSDEOHRIDOOVHOIFDUHEXWXQDEOHWRFDUU\RXW DQ\ZRUN
DFWLYLWLHV8SDQGDERXWPRUHWKDQRIZDNLQJKRXUV
&DSDEOHRIRQO\OLPLWHGVHOIFDUHFRQILQHGWREHGRUFKDLUPRU HWKDQRI
ZDNLQJKRXUV
&RPSOHWHO\GLVDEOHG&DQQRWFDU U\RQDQ\VHOIFDUH7RWDOO\F RQILQHGWREHGRU
FKDLU
 'HDG
6RXUFH2NHQ 
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS 0'*URXS&KDLU
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/PPD
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 104 of 165 
APPENDIX F NEW YORK HEART ASSOCIATION (NYHA) 
CLASSIFICATION 
Class I : Patients with no limitation of activities; they suffer no symptoms from ordinary 
activities.  
Class II:  Patients with slight, mild limitation of activity; they are comfortable with rest or with 
mild exertion.  
Class III:   Patients with marked limitation  of activity; they are comfortable only at rest.  
Class IV:   Patients who should be at complete rest, confined to bed or chair; any physical activity 
brings on discomfort and symptoms occur at rest.  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 105 of 165 
APPENDIX G SUMMARY OF INTERNATIONAL MYELOMA WORKING 
GROUP UNIFORM RESPONSE CRI TERIA  (IMWG -URC)  
Summary of I nternational Myeloma Working Group  Uniform Response Criteria  
(IMWG -URC)  
Response  
Subcategorya Multiple Myeloma Response Criteria  
sCRb â€¢ CR as defined below  and 
â€¢ Normal SFLC ratio and  
â€¢ Absence of clonal cells in bone marrow by immunohistochemistry or 
immunofluorescencec 
CRb, h â€¢ Negative immunofixation on the serum and urine and  
â€¢ Disappearance of any soft tissue plasmacytomas and 
â€¢ < 5% plasma cells in bone marrow  
VGPRb â€¢ Serum a nd urine M -protein detectable by immunofixation but not on electrophoresis  
or  
â€¢ â‰¥ 90% reduction in serum M -protein with urine M -protein level<  100 mg/24  hours  
â€¢ If the serum and urine M -protein are not measurable, a decrease of â‰¥  90% in the 
difference between the involved and uninvolved FLC levels required in place of the 
M-protein crit eria. However, documentation of VGPR requires collection and analysis 
of 24 hour urine sample for UPEP and immunofixation and confirmed to be negative.  
â€¢ If present at baseline, a â‰¥  50% reduction in the size of soft tissue plasmacytomas is 
also required.  
PRb â€¢ â‰¥ 50% reduction of serum M -protein and reduction in 24- hour urinary M -protein by 
â‰¥ 90% or to < 200 mg/ 24 h  
â€¢ If the serum and urine M -protein are unmeasurable, a â‰¥  50% decrease in the difference 
between involved and uninvolved FLC levels is required in pl ace of the M -protein 
criteria.  
â€¢ If serum and urine M -protein are not measureable, and serum free light assay is also 
not measureable, â‰¥  50% reduction in plasma cells is required in place of M -protein, 
provided baseline bone marrow cell percentage was â‰¥  30% 
â€¢ If present at baseline, a â‰¥  50% reduction in the size of soft tissue plasmacytomas is 
also required  
MR â€¢ 25%â€“49% reduction in the level of serum M -protein and a 50% â€“89% reduction in 24 
hour urinary M -protein, which still exceeds 200 mg per 24 hours  
â€¢ If the serum and urine M -protein are not measurable, a decrease of 25% â€“49% in the 
difference between involved and uninvolved FLC levels is required in place of the 
M-protein criteria.  
â€¢ If present at baseline, a 25% â€“49% reduction in the size of soft tissue plasmacy tomas  is 
also required  
Stable disease  â€¢ Not meeting criteria for sCR, CR, VGPR, PR, MR, or PD  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 106 of 165 
Summary of International Myeloma Working Group Uniform Response Criteria 
(IMWG -URC) (contâ€™d) 
Response  
Subcategorya Multiple Myeloma Response Criteria  
PDb Any on e or more of the following:  
â€¢ Increase of â‰¥  25% from lowest response value in:  
o Serum M -component and/or (the absolute increase must be â‰¥  0.5 g/dL)  
o Urine M -component and/or (the absolute increase must be â‰¥  200 mg/24  h) 
o Only in patients without measurable ser um and urine M -protein levels; the 
difference between involved and uninvolved FLC levels.  The absolute increase 
must be >10 mg/dL  
o Bone marrow plasma cell percentages  (absolute percentage must be â‰¥  10%)  
â€¢ Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
e, f, g 
â€¢ Development of hypercalcemia (corrected serum calcium >  11.5 mg/dL or 
2.65mmol/L) that can be attributed solely to the plasma cell proliferative disorder  
Source:  Durie 2006; Rajkumar 2011  (modified for protocol purposes ). 
CR = complete response; sCR = stringent complete response; FLC = serum light chain; PD = progressive 
disease; PR  = partial response; SFLC = serum free light chain; VGPR = very good partial response . 
Note: For patients without measurable protein on UPEP at baseline, UPEP will need to be repeated to confirm a 
response of VGPR or better.  
a Patients  with measurable disease in both serum (SPEP) and urine (UPEP) at study entry are required to 
meet response criteria in both UPEP and SPEP in order to qualify for a MR or better.  Conversely, it should 
be noted that criteria for PD only needs to be met, and confirmed, in one parameter.  
b All response categories (CR, sCR, VGPR, PR) require 2 consecutive assessments  made at any time before 
the institution of any new therapy, as well as no known evidence of progressive or new bone lesions if 
radiographic studies were performed.  Radiographic studies are not required to satisfy these response 
requirements.  Bone marrow, plasmacytoma, and skeletal survey assessments are not required to be 
confirmed by repeat testing.  SD requires a duration of â‰¥ 6 weeks.  
c Presence/absence of clonal cells is based upon the Îº/Î» ratio.  An abnormal Îº/Î» ratio by 
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  
An abnormal ratio reflecting presence of an abnormal clone is Îº/Î» of > 4:1 or < 1:2. 
d Determination of PD while on study requires 2 consecutive assessments made at any time before 
classification of PD and/or the institution of new therapy.  Serum M -component increases of â‰¥ 1 g/dL from 
nadir are sufficient to def ine progression if nadir M -component is â‰¥ 5 g/dL.   
e Plasmacytomas: A definite increase in the size is defined as a â‰¥ 50% increase as measured serially by the 
sum of the products of the cross -diameters of the measurable lesion.  A plasmacytoma is considered  
measurable if the longest diameter is at least 1 cm and the product of the cross diameters is at least 1 cm2.  
Plasmacytomas of lesser size will be considered non -measurable.   
f The requirement for bi -directional measurements applies only to plasmacytomas.  
g The plasmacytoma specifications for PD are based on the Sponsorâ€™s interpretation of the IMWG -URC and 
practical considerations for study execution.  
h In patients with sFLC measurable disease only, normal sFLC ratio is required for CR.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 107 of 165 
APPENDIX H INTERNATIONAL STAGIN G SYSTEM  
The International Staging System (ISS) for myeloma was published by the International 
Myeloma Working Group ( Greipp  2005):  
Stage  Criteria  
I Serum beta -2 microglobulin <  3.5 mg/L and serum albumin  â‰¥ 3.5 g/dL  
II Serum beta -2 microglobulin <  3.5 mg/L and serum albumin <  3.5 g/dL  
or 
Serum beta -2 microglobulin 3.5â€“ 5.5 mg/L irrespective of the serum albumin  
III Serum beta -2 microglobulin â‰¥  5.5 mg/L  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 108 of 165 
APPENDIX I NATIONAL CANCER INSTITUTE COMM ON TERMINOLOGY 
CRITERIA FOR ADVERSE  EVENTS (NCI -CTCAE) GRADING SCALE  
 
Common Terminology Criteria for Adverse Events (CTCAE) of the 
National Cancer Institute (NCI), Version 4.03 
 
Published :  28 May 2009 (v4.03: June 14, 2010) 
 
http://ev s.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06 
-14_QuickReference_8.5x11.pdf 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI 
$33(1',;-3$7,(175(3257('287&20(6
6XSHUVHGLQJ $PHQGPHQW 0DUFK &21),'(17,$/CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 110 of 165 
APPENDIX K COUNTRY SPECIFIC PREGNANCY AND 
CONTRACEPTIVE SUPPLE MENT  
A woman of childbearing pote ntial (WOCBP) is defined as:  
Any woman who has experienced menarche and is not postmenopausal or permanently 
sterilized.  Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.  
A postmenopausal woman is defined as:  
â€¢ Age > 55 years with cessation of menses for 12 or more months 
â€¢ Age < 55 years but no spontaneous menses for at least 2 years 
â€¢ Age < 55 years and spontaneous menses within the past 1 year, but currently 
amenorrheic (e.g., spontaneous or secondary to hysterectomy), and with 
postmenopausal gonadotropin levels (luteinizing hormone and 
follicle -stimulating hormone levels > 40 IU/L) or postmenopausal estradiol 
levels ( < 5 ng/dL) or according to the definition of "postmenopausal range" for 
the laboratory involved. 
â€¢ Underwent a bilateral oophorectomy 
Pregnancy Prevention Information 
Female Subjects  
Highly effective methods of birth control are defined as methods that achieve a failure 
rate of less than 1% per year when used consistently and correctly.  
WOCBP must use a highly effective method of birth control during treatment and for an 
additional 30 days after the last dose of protocol-required therapies.  Highly effective 
methods of birth control for female participants or their male partner include : 
â€¢ Combined (estrogen and progestogen) hormonal methods:  pills, vaginal ring, or 
skin patch. 
â€¢ Single hormonal methods (progestogen to stop the release of the egg from the 
ovary): pills, shots/injections, implants (placed under the skin by a healthcare 
provider) 
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormonal- releasing system (IUS)  surgery to tie both fallopian tubes 
(bilateral tubal ligation/occlusion)   
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 111 of 165 
â€¢ Vasectomised partner:  Provided the partner is the sole sexual partner of the 
WOCBP trial participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
â€¢ Sexual abstinence:  Refraining from heterosexual intercourse during the entire 
period of risk associated with the study treatment.  The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical trial and with the preferred and usual lifestyle of the subject.  
Male Subjects  
If the male subjects sole female partner has received medical confirmation that she is 
postmenopausal or she has had a p ermanent sterilization method (hysterectomy, bilateral 
oophorectomy, or bilateral salpingectomy) or the male subject has had a vasectomy with medical confirmation of surgical success, or his sole female partner has had a bilateral 
tubal ligation/occlusion,  additional contraceptive methods are not required during this 
study.  Otherwise, if the male subjectâ€™s female partner could become pregnant, the male 
must:  
â€¢ Practice true sexual abstinence.  (Refraining from heterosexual intercourse during 
treatment and f or an additional 90 days following the last dose of study drug 
administration.  The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the clinical trial and be the preferred and usual 
lifestyle of the subject.)  
Or 
â€¢ Use a condom with spermicide during treatment and for an additional 90 days 
following the last dose of study drug administration.  (Note a condom without 
spermicide is acceptable in countries where spermicide is not commercially 
available.)  
The female partner s hould also consider using an acceptable method of effective 
contraception such as: 
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormonal- releasing system (IUS)  
â€¢ Hormonal birth control method: pill, shots/injections, implants (placed under the 
skin by a healthcare provider), skin patches, or a vaginal ring 
â€¢ Female barrier method: diaphragm, cervical cap, or contraceptive sponge (a 
female condom is not an option because there is a risk of tearing when both 
partners use a condom) 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 112 of 165 
Male subjects  must not donate sperm during treatment and for an additional 90 days 
following the last dose of study drug administration.  
Males with pregnant partners must practice true sexual abstinence or wear a condom 
during vaginal sex to prevent exposure to the embryo/fetus through semen.  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 113 of 165 
APPENDIX L SAMPLE SERIOUS ADVERSE EVENT REPORT FORM  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 114 of 165 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 115 of 165 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 116 of 165 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 117 of 165 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 118 of 165 
APPENDIX  M PREGANCY NOTIFICATION FORM  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 119 of 165 
APPENDIX  N LACTATION NOTIFICATI ON FORM  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 120 of 165 
APPENDIX  O SUMMARY OF CHANGES F OR PROTOCOL 
AMENDMENT  4 AND FOR SUPERSEDING PROTOCOL  AMENDMENT  4 
Protocol Title:   A Randomized, Open- label, Phase 3 Study in Subjects with Relapsed 
and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with 
Dexamethasone, Comparing Once- weekly versus Twice- weekly Carfilzomib Dosing 
 
Amgen Protocol Number 20140355 (formerly CFZ0 14) 
 
Amendment D ate: 07 March  2017 
Rationale: 
In Protocol Amendment 4, t he protocol is amended to: 
â€¢ Switch progression-free survival (PFS) from a key secondary objective/endpoint 
to the primary objective /endpoint and overall response rate (ORR) from the 
primary objective/endpoint to a key secondary objective/endpoint 
Rationale: This study was originally designed with ORR as the primary endpoint 
because response rates, especially high -quality responses of substantial duration, 
are important indicators of benefit in relapsed and refractory multiple myeloma.  
However, recent advances in antimyeloma therapy have altered the landscape such that PFS is now considered to be the more relevant regulatory endpoint in this setting.  To support regulatory interactions and protect the integrity of the 
PFS data, the primary endpoint has been  amended to PFS, with ORR as a key 
secondary endpoint. 
â€¢ Change the purpose and timing of the interim PFS analysis 
Rationale: The purpose and timing of the interim PFS analysis were amended to monitor ef ficacy and allow the possibility of stopping the trial early for effic acy. 
â€¢ Revise statistical language to align with changes in objectives/endpoints and 
purpose and timing of the interim PFS analysis 
â€¢ Update Table 12 (Stopping Boundaries for P rogression -free Survival) 
â€¢ Allow the possibility for long -term follow -up for overall survival 
â€¢ Add Section  4.4.1 (End of Study) 
â€¢ Add Section 8.4 (Product Complaints) 
â€¢ Update Table 5 (Carfilzomib Dose Modifications for Nonhematologic Toxicity)  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 121 of 165 
â€¢ Add Section 9.4.2.5 (Thromboprophylaxis) 
â€¢ Add the following forms in the Appendices 
o Sample Serious Adverse Event Report Form  
o Pregnancy Notification Form  
o Lactation Notification Form 
â€¢ Update Section 2 (Background Information)  
â€¢ Correct an error in the study schema inserted into Protocol Amendment 4 (thereby 
creating a Superseding Amendment 4)  
â€¢ Make minor text clarifications, a dditions, corrections, and edits throughout the 
protocol 
In Superseding Protocol Amendment 4, the protocol is amended to: 
â€¢ Correct an error in the dexamethasone dosing in the study schema inserted into Protocol Amendment 4 
â€¢ Make minor edits throughout the protocol 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 122 of 165 
Table 1.  Summary of Amendment Change s 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: Global, Footer  Replace:  
Amendment 3: 22 April 2016  With:  
Superseding  Amendment  4: 07 March  2017 Administrative change  
Section: Title P age  
 Add: 
Date of Protocol Amendment 4.0: 08 
February  2017 Administrative change  
Section: Title Page   Add:  
Date of Superseding Protocol Amendment 4.0: 
07 March  2017  Administrative change  
Section: Protocol Acceptance 
Page , Issue/Date  Replace:  
20140355 (Protocol Amendment  3.0)/22 April 
2016  With:  
20140355 ( Superseding  Protocol 
Amendment  4.0)/07 March  2017 Administrative change  
Section: Synopsis, Study 
objective(s), Primary Objective Replace:  
To compare the overall response rate (ORR) of 
once -weekly carfi lzomib dosing in combination 
with dexamethasone to the ORR of twice- weekly 
carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with a proteasome inhibitor and an IMiD (immunomodulatory agent) . With:  
To compare the progression -free survival  (PFS) 
of once -weekly carfilzomib dosing in 
combinatio n with dexamethasone to the PFS of 
twice -weekly carfilzomib dosing in combination 
with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with a proteasome inhibitor and an IMiD (immunomodulatory agent) . Primary/secondary objective switch  
Section: Synopsis, Study 
objective(s), Secondary Objectives , Bullet 1  Replace:  
Progres sion-free survival (PFS)  With:  
Overall response rate (ORR)  Primary/secondary objective switch  
Section: Synopsis, Study 
design , Line 5  Replace:  
The primary endpoint is ORR.  With:  
The primary endpoint is PFS. Primary/secondary endpoint switch  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 123 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: Synopsis, Study 
design, Study Schema  Replace:  
Original Study 20140355 S chema below  With:  
Revised Study 20140355 S chema below  Alignment with 
Primary/secondary objective switch  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 124 of 165 
Original Study 20140355 Schema: 
 
ECOG = Eastern Cooperative Oncology Group; IMiD = immunomodulatory agents; IV  = intravenous(ly); ORR = overall response rate; OS = overall survival; PD = disease 
progression; PFS = progression -free survival; PI = proteasome inhibitor; PO = orally . 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 125 of 165 
Revised Study 20140355 Schema: 
 
ECOG = Eastern Cooperative Oncology Group; IMiD = immunomodulatory agents; IV  = intravenous(ly); ORR = overall response rate; OS = overall survival; PD = progressive 
disease ; PFS = progression-free survival; PI = p roteasome inhibitor; PO = orally . 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH 
6HFWLRQ6\QRSVLV6DPSOHVL]H
MXVWLILFDWLRQ5HSODFH :LWK 6WDWLVWLFDOUHYLVLRQWRDOLJQ
ZLWKSULPDU\REMHFWLYHHQGSRLQWFKDQJH
6HFWLRQ6\QRSVLV(IILFDF\YDULDEOHV3DUDJUDSK 5HSODFH
7KHSULPDU\HQGSRLQWLWLVRYHUDOOUHVSRQVHUDWH
255:LWK
7KHSULPDU\HQGSRLQWLV 3)63ULPDU\VHFRQGDU\
HQGSRLQWVZLWFK
6HFWLRQ6\QRSVLV(IILFDF\YDULDEOHV3DUDJUDSK 5HSODFH
6HFRQGDU\HQGSRLQWVDUHSURJUHVVLRQIUHH
VXUYLYDO3)6RYHUDOOVXUYLYDO26VDIHW\DQG
WROHUDELOLW\DQGSKDUPDFRNLQHWLFVVSDUVHVDPSOLQJ3.:LWK
6HFRQGDU\HQGSRLQWVDUH 255RYHUDOOVXUYLYDO
26VDIHW\DQGWROHUDELOLW\DQG
SKDUPDFRNLQHWLFVVSDUVHVDPSOLQJ3.3ULPDU\VHFRQGDU\
HQGSRLQWVZLWFK

6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 127 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: Synopsis, Statistical 
methods and analyses, 
Paragraph 2  Replace:  
The primary en dpoint, ORR, is defined as the 
proportion of subjects achieving a best overall response of partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) based on the IMWG -URC. With:  
The primary endpoi nt, PFS, will be calculated 
from the time of randomization until PD or 
death due to any cause, whichever occurs first.  
If a subject is alive or lost to follow -up without 
experiencing documented disease progression by the data cutoff date, the PFS data for  the 
subject will be censored at the date of last valid 
disease and response assessment.  The distribution of PFS will be estimated using the Kaplan -Meier method.  The inferential 
comparison between treatment groups will be made using the log -rank test str atified by the 
randomization stratification factors.  The HR and its 95% CI will be estimated using a Cox proportional hazards model stratified by the same randomization stratification factors.   Statistical revision to align with primary objective/endpoin t change  
Section: Synopsis, Statistical 
methods and analyses, Paragraph 3  Delete:  
The inferential comparison of ORR between 
treatment groups will be conducted using a 
logistic regression model -based test against the 
null hypothesis that the odds ratio is â‰¤ 1 at a 1 -
sided significance level of 0.025.    Statistical revision to align with primary objective/endpoint change  
Section: Synopsis, Statistical 
methods and analyses, Paragraph 4, Line 1  Replace:  
The randomization stratification factors will be 
includ ed as covariates  in the model:  With:  
The following  randomization stratification factors 
will be included as covariates  in the model:  Statistical revision to align 
with primary objective/endpoint change  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 128 of 165 
Section   Text in Protocol  Amended Text  Rationale  for Change  
Section: Synopsis, Statistical 
methods and analyses , after 
Paragraph 4   Add: 
Response and disease progression will be 
determined using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]), as well as by local investig ators  and by an Independent Review 
Committee (IRC) .  The primary analysis of 
PFS will be based on ORCA -assessed 
outcomes.  The PFS outcomes assessed by the investigator will serve as a supportive analysis of PFS, as will IRC -assessed outcomes.  Statistical revision to align 
with primary objective/endpoint change  
Section: Synopsis, Statistical 
methods and analyses, Paragraph 5  Replace:  
The ORR will be calculated by treatment group and the associated 95% confidence interval [CI] will be estimated using the Cl opper -Pearson 
method.  The odds ratio (and its 95% CI) will be 
estimated using the logistic regression model.   With:  
The secondary endpoint ORR is defined as the proportion of subjects achieving a best overal l 
response of PR , very good partial response 
(VGPR), complete response (CR), or stringent 
complete response (sCR), based on the 
IMWG -URC.   The ORR will be calculated by 
treatment group , and the associated 95% 
confidence interval [CI] will be estimated using 
the Clopper -Pearson method.  The odds ratio 
(and its 95% CI) will be estimated using the 
logistic regression model.   Clarification  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 129 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: Synopsis, Statistical 
methods and analyses, 
Paragraph 6  Delete: 
Response and disease progress ion will be 
determined using a validated computer algorithm 
(Onyx Response Computational Assessment 
[ORCA]) as well as by local investigators.  The 
primary analysis of ORR will be based on the 
ORCA -assessed responses.  Investigator -assessed 
responses will be analyzed as part of a supportive 
ORR analysis, as will IRC -assessed responses, if 
an Independent Review Committee (IRC) is 
convened.    Statistical revision to align with primary objective/endpoint change  
Section: Synopsis, Statistical 
methods and anal yses, 
Paragraph 8  Delete: 
The secondary endpoint s of PFS and  OS will be 
analyzed using the log -rank test stratified by the 
randomization stratification factors.  The 
corresponding hazard ratios ( HRs) will be 
estimated using a stratified Cox proportional hazards model.  The distribution of PFS and  OS 
including medians will be summarized using the 
Kaplan -Meier method.    Statistical revision to align 
with secondary objective/endpoint change  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 130 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: Synopsis, Statistical 
methods and analyses, 
Paragraph 9  Replace:  
The hypotheses for the primary efficacy endpoint, 
ORR, and secondary efficacy endpoints (PFS and 
OS) will be tested using a fixed sequence hierarchical testing procedure to control the  
family -wise Type I error rate below 1 -sided 0.025 
level.  The  family of hypotheses is ordered as 
follows: ORR, PFS, and OS.  Starting with the 
hypothesis of ORR , if any hypothesis in the 
sequence is rejected at a 1 -sided significance 
level of 0.025, then the subsequent hypothesis 
will be tested; if any hypothesis is accepted, then 
the subsequent hypotheses will not be tested.   With:  
The hypotheses for the primary efficacy endpoint, 
PFS, and secondary efficacy endpoints ( ORR 
and OS) will be tested using a fixed sequence 
hierarchical testing procedure to control the family -wise Type I error rate below 1 -sided 0.025 
level.  The  family of hypotheses is ordered as 
follows: PFS, ORR, and OS.  Starting with the 
hypothesis of PFS, if any hypothesis in the 
sequence is rejected at a 1 -sided significance 
level of 0.025, then the subsequent hypothesis will be tested; if any hypothesis is accepted, then 
the subsequent hypotheses will not be tested.   Statistical revision to align 
with primary/secondary objective/endpoin t switch  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH 
6HFWLRQ6\QRSVLV6WDWLVWLFDO
PHWKRGVDQGDQDO\VHV3DUDJUDSK 5HSODFH
7KHWRWDOVWXG\DFFUXDOSHULRGLVH[SHFWHGWREH
DSSUR[LPDWHO\PRQWKV7KHGDWDFXWRIIGDWHIRUWKHSULPDU\DQDO\VLVRI255ZLOOEHDSSUR[LPDWHO\PRQWKVDIWHUWKHODVWSDWLHQWLVUDQGRPL]HG$WWKHWLPHRIWKHILQDODQDO\VLVRI255LQWHULPDQDO\VLVRI3)6DQG26ZLOOEHFRQGXFWHG7KHSULPDU\REMHFWLYHRIWKLVLQWHULPDQDO\VLVLVWRSURYLGHQHFHVVDU\GDWDWRKHOSDVVHVVWKH255UHVXOW7KHUHIRUHDVLGHGHUURUOHYHORIZLOOEHDVVLJQHGIRUWKLVLQWHULPDQDO\VLV$SSUR[LPDWHO\RI3)6HYHQWVDUHH[SHFWHGWREHLQFOXGHGLQWKHLQWHULPDQDO\VLV6XEMHFWVZLOOFRQWLQXHWREHIROORZHGIRUGLVHDVHDQGVXUYLYDOVWDWXVXQWLO3)6HYHQWVDUHREVHUYHGZKLFKLVH[SHFWHGWRRFFXUDSSUR[LPDWHO\PRQWKVDIWHUWKHILUVWSDWLHQWLVUDQGRPL]HG7KHVHGXUDWLRQVDUHHVWLPDWHGEDVHGXSRQWKHDVVXPSWLRQVRIPHGLDQ3)6RIPRQWKVLQWKHRQFHZHHNO\GRVLQJJURXSDQG
PRQWKVLQWKHWZLFHZHHNO\GRVLQJJURXSZLWKDQXQGHUO\LQJKD]DUGUDWLR+5RI7KHILQDODQDO\VLVRI26ZLOORFFXUDWWKHWLPHRIWKHILQDODQDO\VLVRI3)6:LWK
7KHILQDO3)6DQDO\VLVZLOOEHFRQGXFWHGZKHQ
DSSUR[LPDWHO\3)6 HYHQWVKDYHRFFXUUHG
RUE\HQGRI\HDUZKLFKHYHULVHDUOLHU$WRWDORI3)6HYHQWVZLOOSURYLGHSRZHUWRGHWHFWDVLJ QLILFDQWGLIIHUHQFHLQ
3)6EHWZHHQWKHWUHDWPHQWJURXSVZLWK
LQWHULPDQDO\VLV 
7KHLQWHULPDQDO\VLVZLOOEHSHUIRUPHGZKHQDSSUR[LPDWHO\RIWKHWRWDO3)6HYHQWVLHHYHQWVKDYHRFFXUUHG7KH255DQG26DQDO\VHVZLOOEHSHUIRUPHGDWWKHVDPHWLPHDVWKH3)6DQDO\VLV LQWHULPRUILQDO6WDWLVWLFDOUHYLVLRQWRDOLJQ
ZLWKSULPDU\REMHFWLYHHQGSRLQWFKDQJH
6HFWLRQ678'<5$7,21$/( 3DUDJUDSK
/LQH7KHUDWLRQDOHIRUWKLVVWXG\LVWRFRPSDUH
FDUILO]RPLEDGPLQLVWHUHGRQFHZHHNO\LQFRPELQDWLRQZLWKGH[DPHWKDVRQHEDVHGRQWKH&+$03,21UHVXOWVWRWZLFHZHHNO\FDUILO]RPLELQFRPELQDWLRQZLWKGH[DPHWKDVRQHLQVXEMHFWVZLWKUHODSVHGDQGUHIUDFWRU\PXOWLSOHP\HORPDSUHYLRXVO\WUHDWHGZLWKERUWH]RPLEDQGDQ,0L'7KHUDWLRQDOHIRUWKLVVWXG\LVWRFRPSDUH
FDUILO]RPLEDGPLQLVWHUHGRQFHZHHNO\LQFRPELQDWLRQZLWKGH[DPHWKDVRQHEDVHGRQWKH&+$03,21UHVXOWVWRWZLFHZHHNO\FDUILO]RPLELQFRPELQDWLRQZLWKGH[DPHWKDVRQHLQVXEMHFWVZLWKUHODSVHGDQGUHIUDFWRU\PXOWLSOHP\HORPDSUHYLRXVO\WUHDWHGZLWK DSURWHDVRPH
LQKLELWRUDQGDQ,0L'&RUUHFWLRQ
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 132 of 165 
 
Section   Text in Protoco l  Amended Text  Rationale for Change  
Section: 2.4 STUDY 
RATIONALE , Paragraph 3  Replace:  
The primary endpoint in this study is ORR.  
Response rates, especially high -quality responses 
of substantial duration , are important indicators of 
benefit in relapsed  and refractory multiple 
myeloma ( Anderson  2008).  A number of studies 
have shown an association between deeper responses and improved survival in patients with multiple myeloma ( Lonia l 2014) With:  
The primary endpoint in this study is PFS.  
Response rates, especially high -quality responses 
of substantial duration , are important indicators of 
benefit in relapsed and refractory multiple myeloma ( Ande rson 2008).  A number of studies 
have shown an association between deeper responses and improved survival in patients with multiple myeloma ( Lonial  2014
).  For these 
reasons, this study was originally designed with ORR a s the primary endpoint and PFS as 
a key secondary endpoint.  Although ORR remains a meaningful clinical endpoint, recent advances in antimyeloma therapy have altered the landscape such that PFS is now considered to be the more relevant regulatory endpoint in 
this setting.  To support regulatory interactions and protect the integrity of the PFS data, the primary endpoint has been 
amended to PFS, with ORR as a key secondary 
endpoint.  Addition of rationale for primary/secondary endpoint switch  
Section: 3.1 PR IMARY 
OBJECTIVE  Replace:  
The primary objective of this study is to compare the ORR  of once -weekly carfilzomib dosing in 
combination with dexamethasone to the ORR  of 
twice -weekly carfilzomib dosing in combination 
with dexamethasone in subjects with relapsed  and 
refractory multiple myeloma who have received prior treatment with a proteasome inhibitor and an IMiD.  With:  
The primary objective of this study is to compare the PFS of once -weekly carfilzomib dosing in 
combination with dexamethasone to the PFS of 
twice-weekly carfilzomib dosing in combination 
with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with a proteasome inhibitor and an IMiD.  Primary/secondary objective switch  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 133 of 165 
Section   Text in Pro tocol  Amended Text  Rationale for Change  
Section: 3.2 SECONDARY 
OBJECTIVES , Bullet 1  Replace:  
Progression -free survival (PFS)  With:  
ORR Primary/secondary 
objective switch  
Section: 4.1 STUDY DESIGN, Figure 2 Study 20140355  
Schema  Replace:  
Original Study 20140355 S chema below  With:  
Revised Study 20140355 S chema below  Alignment with Primary/secondary objective switch  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 134 of 165 
Original Study 20140355 Schema: 
 
ECOG = Eastern Cooperative Oncology Group; IMiD = immunomodulatory agents; IV  = intravenous(ly); ORR = ov erall response rate; OS = overall survival; PD = disease 
progression; PFS = progression -free survival; PI = proteasome inhibitor; PO = orally . 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 135 of 165 
Revised Study 20140355 Schema: 
 
ECOG = Eastern Cooperative Oncology Group; IMiD = immunomodulatory agents; IV  = intravenous(ly); ORR = overall response rate; OS = overall survival; PD = progressive 
disease ; PFS = progression-free survival; PI = proteasome inhibitor; PO = orally . 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 136 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: STUDY DESIGN,  
Paragraph 4  Replace:  
The primary endpoint is ORR.  With:  
The primary endpoint is PFS.  Primary/secondary 
endpoint switch  
Section: 4.4 ESTIMATED 
STUDY DURATION AND CLOSURE  Replace:  
The total study accrual period is expected to be approximately 15 months.  T he data cut off date 
for the primary analysis of ORR  will be 
approximately 4 months after the last subject is randomized.  Subjects will be followed for disease and survival status until approximately 350 PFS events are observed, which is expected to occur  approximately 25 months after the first 
subject is randomized.  These durations are estimated based upon the assumptions of median PFS of 8.2 months in the once -
weekly dosing arm 
and 6 months in the twice -weekly dosing arm 
with an underlying hazard ratio (HR) of 0.73.  With:  
The total study accrual period is expected to be approximately 15 months.  The interim analysis 
of PFS will occur when approximately 263 
PFS 
events are observed.  If t he interim analysis 
crosses the  boundary, the trial may stop early 
for efficacy; otherwise s ubjects will be followed 
for disease and survival status until approximately 
350 PFS events are observed or by end of year 
2018, whichever is earlier. Statistical revision to align with change in primary objective/endpoint and 
purpos e and timing of the 
interim PFS analysis.  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 137 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: after Section 4.4 
ESTMATED STUDY 
DURATION AND CLOSURE   Add: 
4.4.1  END OF STUDY 
Primary Completion: The primary completion 
date is defined as the date when the last subject is assessed or receives an intervention for the final collection of data for the primary endpoint(s), for the purposes of conducting the primary analysis, whether the study concluded as planned in the protocol or was termi nated 
early.    
The primary completion is anticipated to occur 
when approximately 350 PFS events occur or end of year 2018, whichever is earlier.  The 
primary completion date is the date when data for the p rimary endpoint are last collected for 
the purpose s of conducting the primary 
analysis  or the end of year 2018, whichever is 
earlier.   
If the study concludes prior to the primary completion date originally planned in the protocol (i .e., early termination of the study), 
then the primary completion will be the date 
when the last subject is assessed or receives an intervention for evaluation in the study (i .e., 
last subject last visit).  
End of Study: The end of study date is defined as the date when the last subject across all sites is assessed or receives an  intervention for 
evaluation in the study (i .e., last subject last 
visit), following any additional parts in the study (e .g., long -term follow -up), as applicable.  Addition of section for end 
of study definition  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 138 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: after 8.3 STUDY 
DRUG ACCOUNTABILITY  Add: 
8.4 PRODUCT COMPLAINTS  
A product complaint is any written, electronic 
or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety , effectiveness, or 
performance of a drug(s) or device(s) after it is released for distribution to market or clinic by either Amgen or by distributors and partners for whom Amgen manufactures the material.  
This includes any drug(s), device(s) or combinati on product(s) provisioned and/or 
repackaged /modified by Amgen.  Drug(s) or device(s) includes investigational product.   
Any product complaint(s) associated with an investigational product(s) or non- investigational product(s) or device(s) 
supplied by Amge n are to be reported 
according to the instructions provided in the IPIM.  Addition of instructions for reporting product complaints  
Section: 9.3.1.2 Nonhematologic Toxicity,  
Table 5 Carfilzomib Dose Modifications for Nonhematologic Toxicity  Replace:  
Original Table 5 below  With:  
Revised Table 5  below  Update of guidelines  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 139 of 165 
Original Table 5: 
 
Nonhematologic Toxicity  Required Actiona 
Renal Dysfunction  
â€¢ Serum creatinine â‰¥ 2 Ã— 
baseline, OR  
â€¢ CrCl  < 15 mL/min, OR  
â€¢ CrCl decre ases to â‰¤  50% 
of baseline, OR  
â€¢ Requireme nt for dialysis  â€¢ Withhold doses while the cause of renal dysfunction is being assessed  
â€¢ If attributable to carfilzomib, resume at 1 dose decrement when CrCl 
has recovered to within 25% of baseline  
â€¢ If not attributable to carfilzomib, resume the same dose or reduce by 
1 dose decrement, at the investigatorâ€™s discretion, when CrCl has 
recovered to within 25% of baseline  
â€¢ For patients on dialysis receiving carfilzomib, the  dose is to be 
administered after the dialysis procedure  
Hepatic Dysfunction  
â€¢ â‰¥ Grade 3 Elevations of 
AST,  ALT, or total 
bilirubin  â€¢ Withhold doses.   
â€¢ Resume at 1 dose decrement when the grade has returned to baseline  
Infection  
â€¢ â‰¥ Grade 3 Infection  â€¢ Withhold doses  
â€¢ Resume at the same dose level, when the infection is controlled  
Cardio vascular Dysfunction  
â€¢ Congestive Heart Failure  â€¢ Withhold doses for any subject with symptomatic heart failure, 
whether or not it is attributed to carfilzomib  
â€¢ Resume at 1 dose decrement, when symptoms have resolved or 
returned to baseline  
â€¢ LVEF <  40%, OR  
â€¢ LVE F < 55%, if decreased 
> 20% from baseline  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when LVEF returns to â‰¥  40%, or to 
within 15% of baseline, if carfilzomib was held due to a drop to < 55% 
â€¢ Pulmonary Hypertension  â€¢ Withhold doses and assess the benefit: risk of resuming carfilzomib  
â€¢ If the assessment favors benefit, carfilzomib may be resumed at the 
same dose level or at 1 dose decrement, at the investigatorâ€™s 
discretion  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 140 of 165 
Nonhematologic Toxicity  Required Actiona 
Thrombotic Microangiopathy  
â€¢ Thrombotic 
thrombocytopenic 
purpura/hemolytic uremic syndrome (TTP/HUS) â€¢ Withhold doses when TTP/HUS is suspected  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, the decision to resume or not resume carfilzomib is at the investigatorâ€™s discretion.  The safeness of resuming carfilzomib following TTP/HUS is unknown.  
â€¢ Manage symptoms  per standard of care including, plasma exchange as 
clinically indicated  
b 
Encephalopathy  
â€¢ Posterior reversible 
encephalopathy syndrome 
(PRES) â€¢ Withhold doses and assess the benefit:risk of resuming carfilzomib  
â€¢ Consider evaluation with neuroradiological im aging for onset of 
visual or neurological symptoms suggestive of PRES  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, the decision to resume or not resume carfilzomib is at the investigatorâ€™s discretion.  The safe ness of 
resuming carfilzomib following PRES is unknown.  
Other Nonhematologic Toxicity  
â€¢ â‰¥ Grade 3 and attributed to 
carfilzomib  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when toxicity has resolved to Grade â‰¤ 2 
or to baseline  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 141 of 165 
Revised Table 5:  
 
Nonhemato logic Toxicity  Required Actiona 
Renal Dysfunction  
â€¢ Serum creatinine â‰¥ 2 Ã— 
baseline, OR  
â€¢ CrCl  < 15 mL/min, OR  
â€¢ CrCl decre ases to â‰¤  50% 
of baseline, OR  
â€¢ Requirement for dialysis  â€¢ Withhold doses while the cause of renal dysfunction is being assessed  
â€¢ If attributable to carfilzomib, resume at 1 dose decrement when CrCl 
has recovered to within 25% of baseline  
â€¢ If not attributable to carfilzomib, resume the same dose or reduce by 
1 dose decrement, at the investigatorâ€™s discretion, when CrCl has 
recovered to within 25 % of baseline  
â€¢ For patients on dialysis receiving carfilzomib, the  dose is to be 
administered after the dialysis procedure  
Hepatic Dysfunction  
â€¢ Mild to moderate liver 
dysfunction: defined as 2 consecutive values, at 
least 28 days apart, of:  
(3) Total bilirubmin (> 33% direct) 
> 1 x ULN to 
< 3 x ULN  
OR 
(4) An elevation of AST and/or ALT with normal 
bilirubin  â€¢ 25% dose reduction.  
â€¢ Dose may be re- escalated if liver function tests return to normal 
and drug -induced hepatotoxicity is excluded.  
â€¢ Grade 3 elevation in ALT 
and/or AST (> 5 x ULN)  â€¢ Hold carfilzomib until resolution to baseline.  
â€¢ Monitor any abnormality weekly.  Resume carfilzomib with a 25% dose reduction if drug -induced hepatoxicity is excluded.  
â€¢ Grade 3 elevation in total 
bilirubin  â€¢ Hold carfilzomib until resolution to baseline.  Monitor total bilirubin and direct bilirubin weekly.  
â€¢ Upon resolution of total bilirubin to normal, resume carfilzomib 
dosing with at 25% dose reduction if drug -induced 
hepatotoxicity is excluded.  
â€¢ Drug -induced 
hepatoxicity attributable 
to carfilzomib  â€¢ Discontinue carfilzomib. 
Infection  
â€¢ â‰¥ Grade 3 Infection  â€¢ Withhold doses  
â€¢ Resume at the same dose level, when the infection is controlled  
Cardiovascular Dysfunction  
â€¢ Congestive Heart Failure  â€¢ Withhold doses for any subject with symptomatic heart failure, 
whether or not it is attributed to carfilzomib  
â€¢ Resume at 1 dose decrement, when symptoms have resolved or 
returned to baseline  
â€¢ LVEF <  40%, OR  
â€¢ LVEF <  55%, if decreased 
> 20% from baseline  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when LVEF returns to â‰¥  40%, or to 
within 15% of baseline, if carf ilzomib was held due to a drop to 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 142 of 165 
Nonhemato logic Toxicity  Required Actiona 
< 55% 
â€¢ â‰¥ Grade  2 Pulmonary 
Hypertension â€¢ Withhold doses  
â€¢ Carfilzomib may be resumed at 1 dose decrement when pulmonary 
hypertension resolves to grade â‰¤  1 
Thrombotic Microangiopathy  
â€¢ Thrombotic 
thrombocytopenic 
purpura/hemo lytic uremic 
syndrome (TTP/HUS) â€¢ Withhold doses when TTP/HUS is suspected  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, discontinue carfilzomib.  Subjects 
should not be rechallenged.  
â€¢ Manage symptoms per standard of care including, plasma exchange as clinically indicated  
b 
Venous Thrombosis  
â€¢ â‰¥ Grade 3  â€¢ Hold carfilzomib and adjust anticoagulation regimen.  
â€¢ Resume at full dose once anticoagulation has been optimized per treating investigatorâ€™s discretion. 
Encephalopathy  
â€¢ Posterior reversible encephalopathy syndrome (PRES) â€¢ Withhold doses  
â€¢ Consider  evaluation with neuroradiological imaging for onset of 
visual or neurological symptoms suggestive of PRES  
â€¢ If the diagnosis is excluded, resume at the same dose level  
â€¢ If the diagnosis is confirmed, discontinue carfilzomib.  Subjects 
should not be rechallenged.  
Other Nonhematologic Toxicity  
â€¢ â‰¥ Grade 3 and attributed to 
carfilzomib  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when toxicity has resolved to Grade â‰¤ 2 
or to baseline  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 143 of 165 
 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 9.4.1.2  Pregnancy and 
Contraception , Line 1 Replace:  
Contraception must continue during study drug dose interruption intervals  until 30  days (females) 
or 90 days (males) after the last study drug administration.  With:  
Contraception must continue during study , 
during  drug dose interruption intervals , and until 
30 days (females) or 90 days (males) after the last study drug administration.  Edit 
Section: after Section 9.4.2.4   Add:  
9.4.2.5  Thromboprophylaxis  
Venous thromboembolism has been observed in patients receiving carfilzomib.  Thromboprophyla xis may be considered on 
the basis of a benefit -risk assessment.  Addition of language for thromboprophylaxis  
Section: 12.4 SERIOUS ADVERSE EVENT REPORTING AND DOCUMENTATION REQUIREMENTS, Paragraph  1, Line 2  Replace:  
The SAE will be reported by completing and 
submitting the SAE report form through the EDC system.  In the event that the EDC system is not 
available, paper SAE report forms may be used to 
report the SAE to Amgen Global Patient Safety . With:  
The SAE will be reported by completing and submitting the SAE report form through the EDC 
system.  In the event that the EDC system is not 
available, paper SAE report forms may be used to 
report the SAE to Amgen Global Patient Safety  
(Appendix L).  Administrative addtion  
Section: 12.5 PREGNANCY AND LACTATION EXPOSURE REPORTING, Paragraph 1, Line 4  Replace:  
The pregnancy will be reported on a Pregnancy Notification Worksheet.  With:  
The pregnancy will be reported on a Pregnancy Notification Worksheet (Appendix M) . Administrative addition  
Section: 12.5 PREGNANCY  
AND LACTATION EXPOSURE REPORTING, Paragraph 6, Line 6  Replace:  
The investigator will complete a Lactation Notification Worksheet.  With:  
The investigator will complete a Lactation Notification Worksheet (Appendix N) . Administrative addition  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 144 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.1.1 PRIMARY  
ENDPOINTS  Replace:  
The primary endpoint is ORR, which is defined 
as the proportion of subjects who achieved a confirmed PR, VGPR, CR, or sCR according to the IMWG URC.  With:  
The pr imary endpoint is PFS, which is defined as 
the time in months from randomization to the earlier of disease progression  or death due to 
any cause . Primary/secondary endpoint switch  
Section: 13.1.2 SECONDARY 
ENDPOINTS,  Bullet 1  Replace:  
â€¢ PFS,  defined as the time in months from 
randomization to the earlier of disease 
progression  or death due to any cause. With:  
â€¢ ORR, defined as the proportion of 
subjects who achieved a confirmed PR, VGPR, CR, or sCR, according to 
the IMWG -URC. Primary/secondary 
endpoint switch  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 145 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.3.2.1 Primary 
Efficacy Endpoint,  Paragraphs 
1-2 Replace:  
The primary efficacy endpoint is ORR.  The data 
cutoff date for the analysis of ORR is about 4 months after the last sub ject is randomized 
(approximately 19 month after the first subject was randomized).  The inferential comparison of ORR between treatment groups will be made using a logistic regression model -based test 
against the null hypothe sis that the odds ratio is  
â‰¤ 1 at a 1 -sided significance level of 0.025.  The 
regression model will include the randomization stratification factors as covariates:  
â€¢ ISS stage at study entry (Stage 1 versus 
Stage 2 and 3)  
â€¢ Refractory to bortezomib treatment (Yes 
versus No)  
â€¢ Age (<  65 versus â‰¥ 65 years)  
The ORR will be calculated by treatment group 
and the associated 95% CI will be estimated using 
the Clopper Pearson method.  The odds ratio (and 
its 95% CI) will be estimated using the logistic regression model.  With:  
The primary eff icacy endpoint is PFS.  
Progression -free survival will be calculated 
from the time of randomization until disease progression or death due to any cause, whichever occurs first.  If a subject is alive or lost to follow -up without experiencing 
documented dis ease progression by the data 
cutoff date, the PFS data for the subject will be 
censored at the date of last valid disease and response assessment.  Detailed PFS data censoring rules will be described in the SAP.  
The distribution of PFS, including median, w ill 
be estimated using the Kaplan- Meier method.  
Progression -free survival rates at selected time 
points will be reported by treatment group.  The 95% CI for the median and other percentiles of PFS will be constructed using the method of Klein and Moeschbe rger (1997) 
with log -log transformation.  The 95% CIs for 
PFS rates were estimated using the method by Kalbfleisch and Prentice (1980) with log -log 
transformation.  The inferential comparison between treatment groups will be made using the log -rank test st ratified by the 
randomization stratification factors specified in Section 7.  The hazard ratio ( HR) and its 
95% CI will be estimated using a Cox proportional hazards model stratified by the same randomization stratification factors.  Duration of follow up for PFS will be 
estimated using the reverse Kaplan -Meier 
method (Schemper 1996; Smith 2006).  Statistical revision to align with primary objective/endpoint change  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH 
6HFWLRQ3ULPDU\
(IILFDF\(QGSRLQW 3DUDJUDSK 5HSODFH
5HVSRQVHDQGGLVHDVHSURJUHVVLRQZLOOEH
GHWHUPLQHGXVLQJDYDOLGDWHGFRPSXWHUDOJRULWKP2Q\[5HVSRQVH&RPSXWDWLRQDO$VVHVVPHQW>25&$@DVZHOODVE\ORFDOLQYHVWLJDWRUV7KHSULPDU\DQDO\VLVRI255ZLOOEHEDVHGRQWKH
25&$DVVHVVHGUHVSRQVHV,QYHVWLJDWRUDVVHVVHG
UHVSRQVHVZLOOEHDQDO\]HGDVDVXSSRUWLYHDQDO\VLVRI255DVZLOO,5&DVVHVVHGUHVSRQVHVLIDQ,QGHSHQGHQW5HYLHZ&RPPLWWHH,5&LVFRQYHQHG:LWK
5HVSRQVHDQGGLVHDVHSURJUHVVLRQZLOOEH
GHWHUPLQHGXVLQJDYDOLGDWHGFRPSXWHUDOJRULWKP2Q\[5HVSRQVH&RPSXWDWLRQDO$VVHVVPHQW>25&$@ DVZHOODVE\ORFDOLQYHVWLJDWRUV DQG
E\DQ,QGHSHQGHQW5HYLHZ&RPPLWWHH,5& 
7KHSULPDU\DQDO\VLVRI3)6ZLOOEHEDVHGRQ
25&$DVVHVVHGRXWFRPHV7KH3)6RXWFRPHVDVVHVVHGE\WKHLQYHVWLJDWRUZLOOVHUYHDVDVXSSRUWLYHDQDO\VLVRI3)6DVZLOO,5&DVVHVVHGRXWFRPHV
7KHILQDO3)6DQDO\VLVZLOOEHFRQGXFWHGZKHQ
DSSUR[LPDWHO\3)6 HYHQWVKDYHRFFXUUHG
RUE\HQGRI\HDUZKLFKHYHULVHDUOLHU$WRWDORI3)6HYHQWVZLOOSURYLGHSRZHUWRGHWHFWDVLJ QLILFDQWGLIIHUHQFHLQ
3)6EHWZHHQWKHWUHDWPHQWJURXSVZLWK
LQWHULPDQDO\VLV 
7KHLQWHULPDQDO\VLVZLOOEHSHUIRUPHGZKHQDSSUR[LPDWHO\RIWKHWRWDO3)6HYHQWVLHHYHQWVKDYH RFFXUUHG6HHDOVR
6HFWLRQIRUWKHLQWHULPDQDO\VLVSODQIRU3)66WDWLVWLFDOUHYLVLRQWRDOLJQ
ZLWKSULPDU\REMHFWLYHHQGSRLQWFKDQJH



6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 147 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.3.2.1 Primary 
Effica cy Endpoint,  Paragraph  4 Delete: 
The duration of response (DOR), defined as time 
in months from the start date of the response to 
the earlier date of documented PD or death, will 
be calculated for subjects who achieve sCR, CR, 
VGPR, or PR.  The DOR will be  censored at date 
of the last valid assessment for responders who 
have not experienced PD or death.  The 
distribution of DOR, including the median will be 
estimated using the Kaplan -Meier method based 
on the subjects who achieve overall response.   Statistical revision to align 
with primary objective/endpoint change  
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 148 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.3.2.2.1 
Progression -Free Survival  Replace:  
Progression -Free Survival  
The distribution of PFS, including median, wil l 
be estimated using the Kaplan -Meier method. 
Progression -free survival rates at selected time 
points will be reported by treatment group.  The 
95% CI for the median and other percentiles of PFS will be constructed using the method of Klein and Moeschberger (1997) with log -log 
transformation.  The 95% CIs for PFS rates were estimated using the method by Kalbfleisch and 
Prentice ( 1980) with log -log transformation.  The 
inferential comparison between treatment groups will be made using the log -rank test stratified by 
the randomization stratification factors specified in Sectio n 7
.  The  HR and its 95% CI will be  
estimated using a Cox proportional hazards model 
stratified by the same randomization stratification factors.  Duration of follow -up for PFS will be 
estimated using the reverse Kaplan -Meier method 
(
Schemper  1996; Smith 2006). 
The primary analysis of PFS will be based on ORCA -assessed outcomes.  The PFS outcomes 
assessed by the investigator serve as a supportive analysis of PFS, as will IRC -assessed outcomes, 
if an IRC is convened.  
 With:  
Overall Response Rate 
The ORR will be analyzed at the time of the 
PFS analysis (interim or final ), only if the PFS 
analysis crosses the boundary.  T he inferential 
comparison of ORR between treatment groups 
will be made using a logistic re gression 
model -based test against the null hypothesis 
that the odds ratio is â‰¤ 1 at a 1 -sided 
significance level of 0.025.  The regression model will include the randomization stratification factors as covariates .  The ORR 
will be calculated by treatment g roup and the 
associated 95% CI will be estimated using the Clopper -Pearson method.  The odds ratio (and 
its 95% CI) will be estimated using the logistic regression model.   
The primary analysis of ORR will be based on the ORCA- assessed responses.  Investig ator 
assessed responses will be analyzed as a supporti ve analysis of ORR, as will 
IRC-assessed responses.  
 Statistical revision to align with primary and secondary objective/endpoint switch  
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ
3URJUHVVLRQ)UHH6XUYLYDOFRQWÂ¶G,IDVXEMHFWLVDOLYHRUORVWWRIROORZXSZLWKRXW
H[SHULHQFLQJGRFXPHQWHGGLVHDVHSURJUHVVLRQE\WKHGDWDFXWRIIGDWHWKH3)6GDWDIRUWKHVXEMHFWZLOOEHFHQ VRUHGDWWKHGDWHRIODVW
YDOLGGLVHDVHDQGUHVSRQVHDVVHVVPHQW'HWDLOHG3)6GDWDFHQVRULQJUXOHVZLOOEHGHVFULEHGLQWKH6$3
$WRWDORI3)6HYHQWVZLOOEHQHHGHGIRUWKH
ILQDO3)6DQDO\VLVLQRUGHUWRKDYHSRZHUWRGHWHFWDVLJQLILFDQWGLIIHUHQFHLQ3)6EHWZHHQWKHWZRWUHDWPHQWJURXSV 
8QGHUWKHDVVXPSWLRQVWKDWWKHDFFUXDOZLOO
WDNHDERXWPRQWKVDQGWKHPHGLDQ3)6LVPRQWKVLQWKHWZLFHZHHNO\GRVLQJJURXSDQGPRQWKVLQWKHRQFHZHHNO\GRVLQJJURXS
3)6HYHQWVDUHH[SHFWHGWRRFFXUDSSUR[LPDWHO\PRQWKVDIWHUWKHILUVWVXEMHFWLVUDQGRPL]HG
6HHDOVR6HFWLRQIRUWKHLQWHULPDQDO\VLVSODQ
IRU3)67KHGXUDWLRQRIUHVSRQVH'25GHILQHGDV
WLPHLQPRQWKVIURPWKHVWDUWGDWHRIWKHUHVSRQVHWRWKHHDUOLHU GDWHRIGRFXPHQWHG
GLVHDVHSURJUHVVLRQRUGHDWKZLOOEHFDOFXODWHGIRUVXEMHFWVZKRDFKLHYHV&5&59*35RU357KH'25ZLOOEHFHQVRUHGDWGDWHRIWKHODVWYDOLGDVVHVVPHQW IRUUHVSRQGHUVZKRKDYH
QRWH[SHULHQFHGGLVHDVHS URJUHVVLRQRUGHDWK
7KHGLVWULEXWLRQRI'25LQFOXGLQJWKHPHGLDQZLOOEHHVWLPDWHGXVLQJWKH.DSODQ0HLHUPHWKRGRQ WKHEDVLVRIVXEMHFWV
ZKRDFKLHYHRYHUDOOUHVSRQVH


6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 150 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.3.2.2.2 Overall 
Surviva l, Paragraph 3  Replace:  
Final analysis of OS will occur at the time of final 
PFS analysis.  Under the a ssumptions that the 
accrual will take about 15 months and the median OS is 14 months in the twice weekly dosing group and 17 months in the once -weekly dosing 
group (HR = 0.82), it is estimated that approximately 245 deaths will be observed at the time of t he final PFS analysis (approximately 
25 months after the first subject randomized).  An 
interim analysis of OS will occur at the time of ORR analysis.  The details of OS interim analysis are in Section 13.8 . Add:  
The analysis of OS will be conducted at the  
time of the PFS analysis (interim or final ), only 
if both PFS and ORR analyses are positive , per 
hierarchical testing procedures.  There will be no interim analysis for OS .  Additional 
follow -up for OS may be performed.  Statistical revision to align with primary 
objective/endpoint change and addition of language to allow for possible long-term follow -up for 
OS. 
 
Section: 13.3.2.3 Control of 
Family -wise Type I Error Rate Replace:  
The hypotheses for the primary efficacy endpoint, ORR, and secondary efficacy  endpoints (PFS and 
OS) will be tested using a fixed sequence hierarchical testing procedure to control the family -wise Type I Error rate below 1 -sided 
0.025 level.  The family of hypotheses is ordered as follows: 1) ORR, 2) PFS, and 3) OS.  Starting with the hypothesis of ORR, if any hypothesis in 
the sequence is rejected at a 1 -sided significance 
level of 0.025, then the subsequent hypothesis will be tested; if any hypothesis is accepted, then the subsequent hypotheses will not be tested.  Add:  
The null hypotheses for the primary efficacy 
endpoint, PFS, and secondary efficacy endpoints 
(ORR and OS) will be tested using a fixed 
sequence hierarchical testing procedure to control the family -wise Type I Error rate below 1 -sided 
0.025 level.  The family of hypot heses is ordered 
as follows: 1) PFS, 2) ORR, and 3) OS.  Starting 
with the hypothesis of PFS, if any hypothesis in 
the sequence is rejected at a 1 -sided significance 
level of 0.025, then the subsequent hypothesis will be tested; if any hypothesis is accepted, then the subsequent hypotheses will not be tested . Statistical revision to align with primary and secondary objective/endpoint switch  
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH 
6HFWLRQ
'(7(50,1$7,212)6$03/(6,=(5HSODFH :LWK

WKHVDPSOH
VL]HRIVXEMHFWVLQHDFKDUPZDV
FDOFXODWHG 








DWRWDORI3)6HYHQWVIRUWKH
ILQDO3)6DQDO\VLVZLOOSURYLGHSRZHUWRGHWHFWDVLJQLIL FDQWGLIIHUHQFHLQ 3)6EHWZHHQ
WKHWUHDWPHQWJURXSV ZLWKVLGHGRYHUDOO
7\SH,HUURURIZKHQLQWHULPDQDO\VLVLVSHUIRUPHGDWDSSUR[LPDWHO\LQIRUPDWLRQWLPHLHHYHQWVXVLQJWKH
2Â¶%ULHQ)OHPLQJW\SHDOSKDVSHQGLQJIXQFWLRQ 6WDWLVWLFDOUHYLVLRQWRDOLJQ
ZLWKSULPDU\DQGVHFRQGDU\REMHFWLYHHQGSRLQWVZLWFK



6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI CCI
CCI
CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 152 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.6 INDEPENDENT  
REVIEW COMMITTEE  Replace:  
An IRC may be convened for this study, if 
required to support the ORCA -determ ined results.  With:  
An IRC  will be convened for this study to support 
the ORCA -determined results.   The IRC will 
centrally review the disease- related tests and 
assessments (Section 10.2) to evaluate disease progression and responses without knowledge of th e randomization assignments.  The details 
of the IRC, including the roles and responsibilities of the involved parties, will be described in the IRC Charter . Clarification  
Section: 13.7 DATA 
MONITORING COMMITTEE, Paragraph 4  Replace:  
The DMC will meet to review safety data on a 
periodic basis, including after approximately 40 subjects have completed â‰¥  1 cycle and no less 
frequently than approximately every 6  months 
thereafter.  Unplanned safety review meetings of the DMC may be called at any time,  if warra nted, 
for an earlier review of safety data.  With:  
The DMC will meet to review safety data on a periodic basis, including after approximately 40 subjects have completed â‰¥  1 cycle and no less 
frequently than approximately every 6  months 
thereafter.  Unplanned safety review meetings of the DMC may be called at any time, if warranted, for an earlier review of safety data.   The DMC 
will also review the interim PFS analysis results and recommend whether the study should stop early for efficacy.  Revision to align with 
primary objective/endpoint change  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 153 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 13.8 INTERIM  
ANALYSIS, Paragraphs 2 -3 Replace:  
One interim analysis will be conducted for PFS 
and OS at the time of the analysis of ORR, which is expected to occur approximately 19  months 
after the first subject is randomized.  It  is 
estimated that approximately 262 (75% of total 350) PFS events and 171 OS events will be observed at the interim analysis.  The primary objective of the interim an alysis of PFS and OS is 
to provide necessary data to help assess the results from the analysis of the primary endpoint ORR, and it is intended that all subjects will continue to be followed for disease assessment and survival status until 350 PFS events ar e 
observed, given a positive result of the ORR analysis.  
To ensure proper control of type I error rate, the interim and final analysis of PFS and OS will be analyzed under a group sequential design framework with the stopping boundaries constructed using the alpha -spending function 
approach.  Based on the objective of the interim analysis and the considerations above, a 1 -sided 
error level of 0.0001 is assigned to the interim analysis and the remaining 1 -side error level of 
0.0249 is reserved for the final analysis.  The 
stopping boundaries are calculated using East 5.4 
and presented in  Table 12.  With:  
One interim analysis will be conducted for PFS  
when approximately 263  (75% of total 350) PFS 
events are observed.  The objective of the interim 
analysis is to  monitor for differences between 
treatment arms for evidence of a substantial 
benefit in the carfilzomib once- weekly with 
dexamethasone arm.  
To ensure proper control of type I error rate, the interim and final analysis of PFS will be analyzed under a group  sequential design framework with 
the stopping boundaries constructed using the  
Oâ€™Brien -Fleming type alpha -spending function 
approach.   The stopping boundaries  in an 
example scenario  are calculated using East  6.4 
and presented in  Table 12 .  Actual boundari es 
will be calculated on the basis of observed PFS events up to the data cut -off date for the 
interim analysis.   If the DMC recommends to 
stop the study for efficacy  after reviewing the 
interim analysis results , the sponsor will 
consider stopping the trial  and conclude that 
the carfilzomib once- weekly with 
dexamethasone arm prolongs PFS compared to the carfilzomib twice- weekly with 
dexamethasone arm.  
 Clarification and statistical revision to align with primary objective/endpoint change  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R
&DUILO]RPLE 3DJHRI
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH 
6HFWLRQ,17(5,0
$1$/<6,6 7DEOH5HSODFH
2ULJLQDO7DEOHEHORZ:LWK
5HYLVHG7DEOHEHORZ6WDWLVWLFDOUHYLVLRQWRDOLJQ
ZLWKSULPDU\DQGVHFRQGDU\REMHFWLYHHQGSRLQWVZLWFK
6XSHUVHGLQJ $PHQGPHQW 0DUFK  &21),'(17,$/CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 155 of 165 
 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 16 REFERENCES , 
Reference 19  Move order to after Reference 20   Minor edit 
Section: APPENDIX L 
SUMMARY OF CHANGES  
FOR AMENDMENT 3  Delete Appendix L   Administrative  
Section: afte r APPENDIX K 
COUNTRY -SPECIFIC 
PREGNANCY AND CONTRACEPTIVE SUPPLEMENT   Add:  
APPENDIX L SAMPLE SERIOUS 
ADVERSE EVENT REPORT FORM  (shown 
below)  Addition of Sample Serious 
Adverse Event Report Form  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 156 of 165 
APPENDIX L SAMPLE SERIOUS ADVERSE EVENT REPORT FORM  
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 157 of 165 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 158 of 165 
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 159 of 165 
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 160 of 165 
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx The rapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 161 of 165 
 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: after APPENDIX K 
COUNTRY -SPECIFIC 
PREGNANCY AND 
CONTRACEPTIVE SUPPLEMENT   Add:  
APPENDIX M PREGNANCY 
NOTIFICATION FORM  (shown below)  Addition of Pregnancy 
Notification For m 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 162 of 165 
APPENDIX M  PREGANCY NOTIFICATION FORM  
 
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 163 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: after APPENDIX K 
COUNTRY -SPECIFIC 
PREGNANCY AND 
CONTRACEPTIVE SUPPLEMENT   Add:  
APPENDIX N LACTATION 
NOTIFICATION FORM (shown below)  Addition of Lactation 
Notification Form  
 
 
 
Superseding Amendment  4: 07 March  2017    CONFIDENTIAL  
Onyx Therapeutics, In c. Clinical Study Protocol No . 20140355  
Carfilzomib  Page 164 of 165 
APPENDIX N LACTATION NOTIFIC ATION FORM  
 
 
Superseding Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355  
Carfilzomib  Page 165 of 165 
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: after APPENDIX K 
COUNTRY -SPECIFIC 
PREGNANCY AND 
CONTRACEPTIVE SUPPLEMENT   Add:  
APPENDIX O SUMMARY OF CHANGES 
FOR PROTOCOL AMENDMENT 4  AND 
SUPSERSEDING PROTOCOL AMENDMENT 4  Addition of Summary of Changes for Protocol Amendment 4  and 
Superseding Protocol Amendment 4  
 
 
 
Superseding  Amendment  4: 07 March  2017   CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 119 of 164 
APPENDIX O  SUMMARY OF CHANGES FOR PROTOCOL AMENDMENT 4  
Protocol Title:  A Randomized, Open- label, Phase 3 Study in Subjects with Relapsed 
and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with 
Dexamethasone, Comparing Once- weekly versus Twice- weekly Carfilzomib Dosing  
 
Amgen Protocol Number 20140355 (formerly CFZ0 14) 
 
Amendment Date:  08 February 2017 
Rationale: 
The protocol is amended to: 
â€¢ Switch progression -free survival (PFS) from a key secondary objective/endpoint 
to the primary objective /endpoint and overall response rate (ORR) from the 
primary objective/endpoint to a key secondary objective/endpoint 
Rationale: This study was originally designed with ORR as the primary endpoint 
because response rates, especially high -quality responses of substantial duration, 
are important indicators of benefit in relapsed and refractory multiple myeloma.  
However, recent advances in antimyeloma therapy have altered the landscape such that PFS is now considered to be the more relevant regulatory endpoint in this setting.  To support regulatory interactions and protect the integrity of the 
PFS data, the primary endpoint has been  amended to PFS, with ORR as a key 
secondary endpoint.  
â€¢ Change the purpose and timing of the interim PFS analysis  
Rationale: The purpose and timing of the interim PFS analysis were amended to monitor efficacy and allow the possibility of stopping the trial early for efficacy. 
â€¢ Revise statistical language to align with changes in objectives/endpoints and purpose and timing of the interim PFS analysis 
â€¢ Update  Table 12 ( Stopping Boundaries for Progression- free Survival) 
â€¢ Allow the possibility for long- term follow -up for overall survival 
â€¢ Add Section 4.4.1 (End of Study) 
â€¢ Add Section 8.4 (Product  Complaints)  
â€¢ Update Table 5 (Carfilzomib Dose Modifications for Nonhematologic Toxicity) 
â€¢ Add Section 9.4.2.5 (Thromboprophylaxis) 
â€¢ Add the following forms in the Appendices 
Amendment 4: 08 February  2017  CONFIDENTIAL  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 120 of 164 
o Sample Serious Adverse Event Report Form  
o Pregnancy Notification Form  
o Lactation Notification Form  
â€¢ Updat e Section 2 (Background Information) 
â€¢ Make minor text clarifications, additions, corrections, and edits throughout the 
protocol 
Amendment 4: 08 February  2017  CONFIDENTIAL  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R 
&DUILO]RPLE 3DJHRI 
$PHQGPHQW$SULO   &21),'(17,$/6800$5<2)&+$1*(6
'HOHWLRQVRIWH[WDUHSUHVHQWH GLQVWULNHWKURXJKIRUPDW$GGHG WH[WLVSUHVHQWHGLQEROGIRUPDW
6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH
6HFWLRQ*OREDO 5HSODFH
&)=:LWK
)RUPHUO\&)=$GPLQLVWUDWLYHFKDQJH
6HFWLRQ7LWOH3DJH6SRQVRU 5HSODFH
2Q\[7KHUDSHXWLFV,QF 
(DVW*UDQG$YHQXH6RXWK6DQ)UDQFLVFR&$:LWK
2Q\[7KHUDSHXWLFV,QF DQ$PJHQ,QF
VXEVLGLDU\ 
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV &$86$8SGDWHG6SRQVRUFRQWDFWLQIRUPDWLRQ
6HFWLRQ7LWOH3DJH6WXG\0HGLFDO
0RQLWRU5HSODFH
0'
(DVW*UDQG$YHQXH6RXWK6DQ)UDQFLVFR&$:LWK
0'06
2QH$PJHQ&HQWHU'ULYH06$
7KRXVDQG2DNV&$86$8SGDWHGVWXG\PHGLFDOPRQLWRU
LQIRUPDWLRQ
6HFWLRQ7LWOH3DJH&OLQLFDO6WXG\3URWRFRO$SSURYDO6LJQDWXUH3DJH$ G G  
'DWHRI3URWRFRO$PHQGPHQW$GPLQLVWUDWLYHFKDQJH
6HFWLRQ&RQILGHQWLDOLW\6WDWHPHQW 5HSODFH
2Q\[7KHUDSHXWLFV,QFDZKROO\
RZQHGVXEVLGLDU\RI2Q\[3KDUPDFHXWLFDOV,QF:LWK
2Q\[7KHUDSHXWLFV,QFDZKROO\RZQHG
VXEVLGLDU\RI2Q\[3K DUPDFHXWLFDOV,QF DQ
$PJHQ,QFVXEVLGLDU\ $GPLQLVWUDWLYHFKDQJH
&OLQLFDO6WXG\3URWRFRO$SSURYDO
6LJQDWXUH3DJH5HSODFH
2Q\[7KHUDSHXWLFV,QF
(DVW*UDQG$YHQXH6RXWK6DQ)UDQFLVFR&$:LWK
$PJHQ,QF
2QH$PJHQ&HQWHU'ULYH7KRXVDQG2DNV&$86$3KRQH8SGDWHG6SRQVRUFRQWDFWLQIRUPDWLRQPPD PPD
PPD PPD
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 111 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
Section: Protocol Acceptance Page  Replace:  
Protocol Amendment 2.0  With:  
Protocol Amendment 3.0 Administrative change  
Section: Protocol Acceptance Page  Replace:  
28 April 2015 With:  
22 April 2016 Administrat ive change  
Section: Synopsis, Study Objectives, 
primary objective  Replace:  
To compare the overall response rate (ORR) between once -weekly 
carfilzomib dosing in combination with dexamethasone to twice -weekly carfilzomib dosing 
in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an IMiD (immunomodulatory agent). With:  
To compare the overall response rate (ORR) of once -weekly carfilzomib dosing in 
combination with de xamethasone to the 
ORR of twice -weekly carfilzomib dosing in 
combination with dexamethasone in subjects with relapsed and refractory multiple myeloma who have received prior treatment with a proteasome inhibitor  and an IMiD 
(immunomodulatory agent).  Revise d text for consistency within 
overall protocol  
Section: Synopsis, Study Design, paragraph 1, sentence 1  Replace:  
This is an open- label, multicenter, 
randomized Phase 3 study comparing carfilzomib dosing in combination with dexamethasone administered once-weekly to twice -weekly carfilzomib dosing 
in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an (IMiD).  With:  
This is an open- label, multicenter, 
randomized Phase 3 study comp aring 
carfilzomib dosing in combination with dexamethasone administered once- weekly to 
twice -weekly carfilzomib dosing in subjects 
with relapsed and refractory multiple myeloma, previously treated with a 
proteasome inhibitor and an (IMiD).  Revised text for  consistency within 
overall protocol  
Section: Synopsis, Study Design, paragraph 2, bullet 1  Replace:  
â€¢ The International Staging With:  
â€¢ The International Staging System (ISS) Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 112 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
System (ISS) at study entry 
(Stage  1 versus Stage  2 or 3)  at study entry (Stage  1 versus Stage  2 or 
3) per International Myeloma 
Working Group (Greipp 2005). See 
Appendix H  
Section: Synopsis, Study Design, paragraph 6, sentences 1 and 2  Replace:  
Subjects will be assessed for response using central laborato ry 
results on Day  1 of each cycle.   With:  
Subjects will be assessed for response using central laboratory results every 28  days (Â± 
4 days) . Updated text for disease assessment timepoints to align with other sections in protocol  
Section: Synopsis, Study D esign, 
paragraph 6, sentence 3  Replace:  
For subjects who discontinue treatment before disease progression occurred (such as for an adverse event, noncompliance, etc.), disease response assessments will be performed using central laboratory response every 4  weeks 
until disease progression.  With:  
For subjects who discontinue treatment before disease progression occurred (such as for an adverse event, noncompliance, etc.), disease response assessments will be performed using central laboratory response every 28 days  until disease progression.  Updated text for disease assessment timepoints to align with other sections in protocol  
Section: Synopsis, Study Design, paragraph 6, sentences 1 and 2  Replace:  
Follow -up for survival will 
continue approximately every 3 months, or as needed, for all 
surviving subjects until study closure.  With:  
Follow -up for survival will continue 
approximately every 12 weeks Â±28 days , or 
as needed, for all surviving subjects until study closure.  Updated text for disease assessment timepoi nts to align with other 
sections in protocol  
Section: Synopsis, Number of investigational sites,  4.2 Number of 
Centers  Replace:  
Approximately 120  sites 
worldwide  With:  
Approximately 1 50 sites worldwide  Updated number of sites to include potential New Zeal and and Australian 
sites 
Section: Synopsis, Treatment Regimen, paragraph 1, sentence 2  Replace:  
Carfilzomib and dexamethasone will be administered in 28 -day 
cycles in 1 of 2  treatment With:  
Carfilzomib and dexamethasone will be administered in 28 -day cycles in 1 of 
2 treatment regimens.  All cycles will start Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 113 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
regimens.  All cycles will start 
28 days (Â±  2) after the start of the 
prior cycle.  28 days (Â±  2 days ) after the start of the prior 
cycle.  
Section: Synopsis, Subject Selection, 
sentence 1 , 5. Subject Selection, sentence 
1 Replace:  
Approximately 460  subjects will 
be enrolled in this study.  With:  
Approximately 460  subjects will be 
randomized  in this study.  Administrative change  
Section: Synopsis, Incl usion and 
Exclusion Criteria,  5.1 Inclusion Criteria, 
5.2 Exclusion Criteria  Replace:  
Criteria Numbers 1 ,2 ,3â€¦â€¦  With:  
Criteria Numbers 101, 102, 103â€¦â€¦.  Administrative change  
Section: Synopsis, Inclusion Criteria, 
criterion 104 a, 5.1 Inclusion Criteria, criterion 104 a  Replace:  
a. Nonresponsive to most recent therapy (stable disease only or
 
progressive disease [PD] while on treatment), or  With:  
a. Nonresponsive to most recent therapy (stable disease or progressive disease [PD] while on treatment), or  Admi nistrative change  
Section: Synopsis, Inclusion Criteria, criterion 105,  5.1 Inclusion Criteria, 
criterion 105 Replace:  
105. At least 2 but no more than 3 prior therapies for multiple myeloma  With:  
105. At least 2 , but no more than 3,  prior 
lines of therap y for multiple myeloma  Revised text for clarification  
Section: Synopsis, Inclusion Criteria, criterion 108,  5.1 Inclusion Criteria, 
criterion 108 Replace:  
108. Documented response of at least partial response (PR) to 1 line of prior therapy  With:  
108. Doc umented response of at least partial 
response (PR) to at least 1 prior line of 
therapy  Revised text for clarification  
Section: Synopsis, Inclusion Criteria, criterion 109,  5.1 Inclusion Criteria, 
criterion 109 Replace:  
109. Measureable disease with at least 1 of the following assessed 
within 21 days prior to randomization:  With:  
109. Measurable disease,  with at least 1 of 
the following assessed at a central 
laboratory within the 21 days prior to 
randomization:  Revised text for consistency within overall pr otocol  
Section: Synopsis, Inclusion Criteria, criterion 109 c,  5.1 Inclusion Criteria, Replace:  
c. In subjects without detectable With:  
c. In subjects without measurable  serum or Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 114 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
criterion 109 c  serum or urine M -protein, serum 
free light chain (SFLC) 
â‰¥ 100 mg/L (involved light chain) 
and an abnormal ser um kappa 
lambda ratio  urine M -protein, serum free light chain 
(SFLC) â‰¥ 100  mg/L (involved light chain) 
and an abnormal serum kappa lambda ratio  
Section: Synopsis, Inclusion Cr iteria , 
criterion 112,  5.1 Inclusion Criteria, 
criterion 112 Replace:  
112. Adequate organ and bone marrow function  within the 
21 days prior to randomization 
defined by:  With:  
112. Adequate organ and bone marrow function  performed  at a central laboratory  
within the 21  days prior to randomization 
defined by:  Revised text for consistency within overall protocol  
Section: Synopsis, Inclusion Criteria , 
criterion 112 c,  5.1 Inclusion Criteria, 
criterion 112 c  Replace:  
c. Absolute neutrophil count (ANC) â‰¥ 1000/mm
3 (screening 
ANC should be independent of growth factor support for â‰¥ 1 week)  With:  
c. Absolute neutrophil count (ANC) â‰¥ 1 
Ã— 10
9/L (screening ANC must  be 
independent of growth factor support for â‰¥ 7 days ) Revised  text for consistency within 
overall protocol  
Section: Synopsis, Inclusion Criteria , 
criterion 112 d, 5.1 Inclusion Criteria, criterion 112 d Replace:  
d. Hemoglobin â‰¥ 8.0 g/dL (Use of 
erythropoietic stimulating factors and red blood cell [RBC] transfusion  per institutional 
guidelines is allowed, however the most recent RBC transfusion may not have been done within 7  days 
prior to obtaining screening hemoglobin.)  With:  
d. Hemoglobin â‰¥ 8 g/dL (Use of 
erythropoietic stimulating factors and red blood cell [RBC] transfusion s per 
institutional guidelines are allowed, 
however the most recent RBC transfusion may not have been done within 7 days prior 
to obtaining the screening hemoglobin.)  Administrative change  
Section: Synopsis, Inclusion Criteria,  
criterion 112 e, 5.1 Inclusion Criteria, 
criterion 112 e  Replace:  
e. Platelet count â‰¥ 50,000/mm3 
(â‰¥ 30,000/mm3 if myeloma 
involvement in the bone marrow is 
> 50%.  Subjects should not have With:  
e. Platelet count â‰¥ 50,000 /mm3 
(â‰¥ 30,000/mm3 if myeloma involvement in 
the bone marrow is > 50%.  Subjects must  
not have received platelet transfusions for at Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 115 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
received platelet transfusions for 
at least 1  week prior to obtaining 
the screening platelet count.)  least 7 days  prior to obtaining the screening 
platelet count.)  
Sectio n: Synopsis, Inclusion Criteria, 
criterion 112 f,  5.1 Inclusion Criteria, 
criterion 112 f  Replace:  
f. Calculated or measured 
creatinine clearance (CrCl) of â‰¥ 30 mL/min.  Calculation should 
be based on the Cockcroft and Gault formula:   
[(140 â€“ Age) Ã— Mass (kg) / (72 Ã— 
Creatinine  mg/dL)]; multiply 
result by 0.85 if female  With:  
f. Calculated or measured creatinine 
clearance (CrCl) of â‰¥ 30 mL/min.  
Calculation must  be based on the Cockcroft 
and Gault formula:   
[(140 â€“ Age) Ã— Mass (kg) / (72 Ã— 
Creatinine  mg/d L)]; multiply result by 0.85 
if female  Revised text for clarification  
Synopsis: Synopsis, Inclusion Criteria,  
criterion 113, 5.1 Inclusion Criteria, criterion 113 Replace:  
113. Females of childbearing potential (FCBP) must have a confirmed negative serum pregnancy test within the 21  days 
prior to randomization (performed at a central laboratory)  With:  
113. Females of childbearing potential 
(FCBP) must have a confirmed negative serum pregnancy test performed at a central laboratory, within the 21  days prior  to 
randomization, and must not be 
breastfeeding . Revised text for consistency within overall protocol  
Synopsis: Synopsis, Inclusion Criteria,  
criterion 114,  5.1 Inclusion Criteria, 
criterion 114 Replace:  
14. Females of childbearing potential and male sub jects who 
are sexually active with FCBP must agree to use effective concomitant method(s) of contraception during the study and for 30  days following the last 
study drug treatment administration.  With:  
114. Females of childbearing potential must 
agree to u se highly effective concomitant 
method(s) of contraception during the study and for 30  days following the last study drug 
treatment administration.  (Refer to 
Appendix K for specific contraception requirements.)  Revised to distinguish female and male contraceptive guidance  
Synopsis: Synopsis, Inclusion Criteria,  
criterion 115, 5.1 Inclusion Criteria,  Add:  
115. Male subjects who are sexually active Updated text to align with current carfilzomib core safety language  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 116 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
criterion 115  with a FCBP must agree to use condoms 
(unless they have had a vasectomy with 
medical confirmation of surgical success), during treatment and for an additional 90 days following the last study drug administration. 
Synopsis: Synopsis, Inclusion Criteria,  
criterion 116,  5.1 Inclusion Criteria, 
criterion 116  Add:  
116. Male subjects must agree to not donate sperm during treatment and for an additional 90 days following the last study drug administration. Updated text to align with current carfilzomib core safety language  
Synopsis: Syno psis, Exclusion Criteria , 
criterion 208 , 5.2 Exclusion Criteria , 
criterion 208 Replace:  
08. Cytotoxic chemotherapy within the 28  days prior to 
randomization  With:  
208. Cytotoxic chemotherapy or other 
antineoplastic therapy, aside from 
immunotherapy or prot easome inhibitors , 
within the 28  days prior to randomization Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria , 
criterion 209 , 5.2 Exclusion Criteria , 
criterion 209 Replace:  
09. Immunotherapy within the 
21 days prior to randomization With:  
209. Immunotherapy, such as an IMiD or a 
proteasome inhibitor  within the 21  days 
prior to randomization Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria , 
criterion 210 , 5.2 Exclusion Criteria , 
criterion 210 Replace:  
10. Glucocort icoid therapy within 
the 14  days prior to randomization 
that exceeds a cumulative dose of 160 mg dexamethasone or 
1000  mg prednisone  With:  
210. Glucocorticoid therapy exceeding  a 
cumulative dose of 160 mg dexamethasone or equivalent , within the 14  days pri or to 
randomization  Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria , 
criterion 214, 5.2 Exclusion Criteria , 
criterion 214 Replace:  
14. Contraindication to dexamethasone or any of the required concomitant drugs or With:  
214. Contraindication to dexamethasone or 
any of the required concomitant medications  or supportive treatments  Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 117 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
supportive treatment s, including 
hypersensitivity to antiviral drugs, 
or intolerance to hydration due to pre-existing pulmonary or cardiac 
impairment  
Synopsis: Synopsis, Exclusion Criteria, criterion 215,  5.2 Exclusion Criteria, 
criterion 215 Replace:  
Active congestive heart failure (New York Heart Association [NYHA] Class III or IV, refer to Appendix F ), symptomatic 
ischemia, con duction 
abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial  disease, or 
myocardial infarction within 6 months prior to enrollment  With:  
Active congestive heart failure (New York Heart Associati on [NYHA] Class III or IV, 
refer to Appendix  F), symptomatic ischemia, 
conduction abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial infarction 
within 6  months prior to randomization  Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria, criterion 216, 5.2 Exclusion Criteria, criterion 216 Replace:  
16. Active infection within the 14 days prior to randomization 
requiring systemic antibiotics  With:  
216. Act ive infection requiring systemic 
treatment  within the 14  days prior to 
randomization  Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria, criterion 220,  5.2 Exclusion Criteria, 
criterion 220 Replace:  
20. Uncontrolled hypertension or unco ntrolled diabetes despite 
medication  With:  
220. Uncontrolled hypertension or diabetes  
mellitus  Revised text for clarification  
Synopsis: Synopsis, Exclusion Criteria, criterion 223, 5.2 Exclusion Criteria, criterion 223 Replace:  
23. Known human immunodefic iency virus (HIV) 
seropositivity, hepatitis C infection, or  hepatitis B infection 
(subjects with past hepatitis B With:  
223. Known human immunodeficiency virus (HIV) seropositivity, hepatitis C infec tion, 
or hepatitis B infection. Subjects with past 
hepatitis B virus infection, defined as having a negative HBsAg test and a positive Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 118 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
virus (HBV) infection or resolved 
HBV infection defined as having a 
negative HBsAg test and a 
positive antibody to hepatitis B core antigen [a nti HBc] antibody 
test are eligible; subjects positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.)  antibody to hepatitis B core antigen (anti 
HBc) antibody test, are eligible. Subjects positive for hepatitis C virus (HCV ) 
antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.  
Synopsis: Synopsis, Exclusion Criteria, criterion 226, 5.2 Exclusion Criteria, criterion 226  Delete:  
226. Female subjects who are pregnant or 
lactating  Removed text to avoid duplication with the inclusion criteria  
Section: Synopsis, Efficacy Variable, paragraph 3  Replace:  
Disease assessments according to the International Myeloma Working Group -Uniform 
Response Criteria (IMWG -URC) 
will be conduct ed at baseline and 
then at Cycle  2 Day 1 (C2D1) and 
on Day 1 of every cycle thereafter 
until progression.  With:  
Disease assessments according to the International Myeloma Working Group -
Uniform Response Criteria (IMWG- URC) 
will be conducted at baseline and then every 
28 days (Â± 4 days)  thereafter until 
progression.  Updated text for disease assessment timepoints to align with other sections in protocol  
Section: Synopsis,  Intensive PK and PDn 
Substudy  Replace:  
Intensive pharmacokinetic (PK) and pharmacodynami c (PDn) 
samples will be obtained as a substudy (approximately n  = 15 in 
each arm) from subjects who consent to the additional testing at selected sites.  Pharmacokinetic samples will be collected on 
Day 15 of Cycle  1 and PDn With:  
Intensive pharmacokinetic (PK) and pharmacodynamic (PDn) samples will be obtained as a substudy (approximately n = 15 evaluable subjects  in each arm) from 
subjects who consent to the additional testing at selected  sites.  Pharmacokinetic 
samples will be collected on Day  15 of 
Cycle  1 and PDn samples will be collected Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 119 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
samples will be collected on 
Days 1, 15, 16, 17, and 22 of 
Cycle  1. on Days  1, 15, 16, 17, and 22 of Cycle  1. 
Section: Synopsis, Health related Quality 
of Life (HRQL), paragraph2, sentence 1  Replace:  
All questionnaires should be administered prior to study treatment on Day  1 of Cycle  1, 
then every other cycle during treatment and every 12  weeks 
(every 84  days Â± 4 days) until 
progression, or withdrawal of consent duri ng LTFU.  With:  
QLQ -C30, QLQ -MY20 and EQ -5D-5L 
questionnaires should be administered prior to study treatment on Day  1 of Cycle  1, then 
every second  cycle (Cycle 1, 3, 5, etc) 
during treatment and every 12  weeks (every 
84 days Â± 4 days) until progression, o r 
withdrawal of consent during LTFU.  Revised text for clarification  
Section: Synopsis, Health related Quality of Life (HRQL), paragraph 2, sentence 2   Add:  
Patient convenience and satisfaction questionnaire will be collected at Cycle 2 
and EOT only.  Revis ed text for consistency within 
overall protocol  
Section: Synopsis, Health related Quality of Life (HRQL), paragraph 2, sentence 3  Replace:  
Healthcare resource utilization data related to AEs will be collected for all subjects during the study. With:  
Healt hcare resource utilization will be 
collected for all subjects during the study.  Updated text for collection of healthcare resource utilization as collection will not just be for AE related healthcare resource utilization  
Section: Synopsis, Health related Quality 
of Life (HRQL), paragraph 2, sentence 4   Add:  
Details on hospitalizations (not related to adverse events) will also be collected.  Added text for collection of hospitalizations not related to AEs to align to with later section  
Section: Synopsis, Sa fety variables, 
sentence 3 Replace:  
All subjects will be monitored for adverse events for 30 days after the past administration of study treatment.  With:  
All subjects will be monitored for adverse events for at least  30 days after the past 
administration o f study treatment.  Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 120 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
Section: Synopsis, Statistical methods and 
analyses, paragraph 4, bullet 2  Replace:  
â€¢ Refractory to proteasome inhibitor ([PI] bortezomib) treatment (Yes versus No)  With:  
â€¢ Refractory to bortezomib) treatment (Yes versus No)  Revised text for consistency within overall protocol  
Section: Synopsis, Statistical methods and analyses, paragraph 6, sentence 3  Replace:  
Investigator -assessed responses 
will be analyzed as part of a supportive ORR a nalysis  With:  
Investigator -assessed responses will be 
analyzed as part of a supportive ORR analysis , as will IRC -assessed responses, if 
an Independent Review Committee (IRC) 
is convened . Added text regarding potential use of 
an IRC.  
Section: 1 List of abb reviations and 
definitions of terms   Delete:  
CRO contract research organization  Administrative change  
Section: 1 List of abbreviations and definitions of terms   Add:  
FISH       fluorescence in situ 
hybridization  Administrative change  
Section: 1 List of a bbreviations and 
definitions of terms   Add:  
IPIM        Investigational Product 
Instruction Manual  Administrative change  
Section: 1 List of abbreviations and definitions of terms  Replace:  
IWRS Interactive Web Response 
System  With:  
IVR/ IWR Interactive Voic e (IVR) and  Web 
Response (IWR)  Administrative change  
Section: 2.1 Introduction, paragraph 2  Replace:  
Per the approved label, carfilzomib is administered intravenously (IV) over 2 to 10 minutes, on 2 consecutive  days 
each week for 3  weeks (Days  1, 2, 
8, 9, 15, and 16 of a 28 -
day cycle).  
The recommended Cycle 1 dose is With:  
Per the 2012 approved label, carfilzomib is 
administered intravenously (IV) over 10 minutes, on 2 consecutive  days each 
week for 3  weeks (Days 1, 2, 8, 9, 15, and 
16 of a 28 -day cycle).  The recommended 
Cycle  1 dose is 20  mg/m
2/day with an 
increase to 27  mg/m2 on Cycle  2 Day  1 Updated text to reflect new IB version  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 121 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
20 mg/m2/day with an increase to 
27 mg/m2 on Cycle  2 Day  1 
onwards (Carfilzomib 
Investigatorâ€™s Brochure [IB] Version 15, 26 February  2015).  onwards (Carfilzomib I nvestigatorâ€™s 
Brochure [IB]).   
Section: 2.3.1 Carfilzomib Background (Nonclinical), paragraph 1, sentence 1  Replace:  
Carfilzomib (formerly known as PR-171) is a tetrapeptide 
epoxyketone -
based inhibitor of the 
of the  20S proteasome, primarily 
of the CT -L activity, and at higher 
concentrations, of  multiple 20S 
proteolytic activities.  With:  
Carfilzomib (formerly known as PR- 171) is 
a tetrapeptide epoxyketone -based inhibitor 
0S proteasome, primarily of the CT -L 
activity,  and at higher concentrations, 
of multiple 20S proteolytic activities.  Updated text to reflect new IB version  
Section: 2.3.1 Carfilzomib Background (Nonclinical), paragraph 1, sentences 2 and 3  Add:  
Carfilzomib is a synthetic small molecule peptide beari ng the chemical name (2S) N 
((S) 1 ((S) 4 methyl 1 ((R) 2 methyloxiran -
2-yl) 1 oxopentan 2 ylcarbamoyl) 2-
phenylethyl) 2 ((S) 2 (2 morpholinoacetamido) 4 phenylbutanamido) 4 methylpentanamide.  The molecular formula is C40H57N5O7 and the molecular weight i s 719.91.  Updated text to reflect new IB version  
Section: 2.3.1 Carfilzomib Background (Nonclinical), paragraph 1, sentences 4  Replace:  
This selectivity may be responsible for the reductions in myelosuppression and neuropathy observed in nonclinical studies comparing carfilzomib with bortezomib. With:  
This selectivity may be responsible for the reductions in myelosuppression and neuropathy observed in clinical and 
nonclinical studies comparing carfilzomib with bortezomib.  Updated text to reflect new IB version 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 122 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
Section: 2.3.2 Carfilzomib Background 
(Clinical), paragraph 1  Replace:  
As of 12  January  2015, 
approximately 2949  individual 
subjects have been treated with carfilzomib as participants in Onyx -sponsored clinical studies.  
Approximately 1975  subjects h ave 
been treated with carfilzomib through the 69 completed or 
actively enrolling investigator -
sponsored trials (ISTs) (Carfilzomib IB).  There are five 
Phase  3 studies in multiple 
myeloma:  PX -171-009 
(ASPIRE), PX -171-011 (FOCUS), 
2011 -003 (ENDEAVOR), 2012 -
005 (CLARION), and this study, CFZ014 (A.R.R.O.W.).  In addition, 137  subjects with solid 
tumors have been treated with carfilzomib in completed Onyx -sponsored clinical studies.  With:  
As of 10 July 2015, approximately 
2921 individual subjects have been tr eated 
with carfilzomib as participants in Onyx -
sponsored clinical studies and 89 subjects 
have been enrolled in studies in Japan sponsored by Ono Pharmaceutical 
Company .  Approximately 3549  subjects 
have been treated with carfilzomib through 
the 76 complet ed or actively enrolling 
investigator -sponsored trials (ISTs) 
(Carfilzomib IB).  There are five Phase 3 
studies in multiple myeloma:  PX -171-009 
(ASPIRE), PX -171-011 (FOCUS), 2011 -003 
(ENDEAVOR), 2012 -005 (CLARION), and 
this study, CFZ014 (A.R.R.O.W.).  Additionally , 137  subjects with solid tumors 
have been treated with carfilzomib in completed Onyx- sponsored clinical studies.  Updated date to reflect most recent statistics on study drug.  
Section: 2.3.2 Carfilzomib Background (Clinical), paragraph 5, senten ce 5 Replace:  
The Phase  2 PX -171-003 â€“ 
Part 2 (A1) study with single 
agent carfilzomib at 20/27  mg/m
2 
in a similar population, which is the basis for the current label, had an ORR of  23.7%.  With:  
The Phase  2 PX -171-003 â€“ Part 2 (A1) study 
with single agent  carfilzomib at 
20/27  mg/m
2 in a similar population had an 
ORR of 22.9% in the Safety population . Updated text to reflect new IB version  
Section: 2.4 Study Rationale, paragraph 1, 
sentence 3 Replace:  
Preliminary results from the 
ongoing Phase  2 portion of  this With:  
Preliminary resu lts from the ongoing 
Phase  2 portion of this multicenter, single -Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 123 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
multicenter, single -arm study 
suggested that the dose and 
regimen of 70 mg/m2 once -weekly 
appears to be well tolerated, highly active and could offer a more convenient treatment regimen for subjects as discussed in Section 2.5.  arm study suggested that the dose and 
regimen of 70 mg/m2 once -weekly appear ed 
to be well tolerated, highly active , and able 
to offer a more convenient treatment 
regimen for subjects as discu ssed in 
Section  2.5. 
Section: 2.4 Study Rationale, paragraph 2  Replace:  
The rationale for this study is to compare carfilzomib dosing in combination with dexamethasone administered once-weekly, infused over 30 minutes based on the 
CHAMPION 1 results to 
twice -weekly carfilzomib dosing 
in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an IMiD. The hypothesis is that this regimen will have superior efficacy  with an 
acceptable safety profile and a more convenient dosing regimen when compared with the US approved dose and schedule.  With:  
The rationale for this study is to compare carfilzomib administered once weekly  in 
combination with dexamethasone , based on 
the CHAMPION  1 results , to twice -weekly 
carfilzomib in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an IMiD. The hypothesis is that this regimen will have superior efficacy  with an acceptable safety 
profile and a more convenient dosing regimen when compared with the US approved dose and schedule of carfilzomib 
administered at 20/27 mg/m
2 twice 
weekly . Revised text for consistency within overall protocol  
Section:  2.5 Dose Rationale, paragraph 1 Replace:  
Carfilzomib 20/27  mg/m2 
twice -weekly is the approved 
monotherapy dose 
and 20/70  mg/m2 once -weekly is With:  
Carfilzomib 20/27  mg/m2 twice -weekly i s 
an approved monotherapy dose 
and 20/70  mg/m2 once -weekly is the MTD 
that was determined in the CHAMPION  1 Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 124 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
the MTD that was determined in 
the CHAMPION  1 study 
described in Section 2.5.1.  study described in Section 2.5.1.  
Section:  2.5 Dose Rationale, paragraph 3  Replace:  
Carfilzomib study treatment 
administrati on will use a step -up 
approach in which the first dose level for all subjects will be 20 mg/m
2 (Cycle  1 Day  1 for the 
once -weekly regimen and Cycle  1 
Days  1 and 2 for the twice -weekly 
regimen) and increased to 70 mg/m
2 or 27  mg/m2 
respectively, beginning o n Day  8 
of Cycle  1. With:  
Carfilzomib study treatment administration will use a step -up approach in which the first 
dose level for all subjects will be 20  mg/m
2 
(Cycle  1 Day  1 for the once -weekly regimen 
and Cycle  1 Days  1 and 2 for the 
twice -weekly regime n) and the dose level 
will then increase to 70  mg/m2 or 27  mg/m2 
respectively, beginning on Day  8 of Cycle  1. Administrative change  
Section:  2.5.1 Rationale for Once -weekly  
Dosing, paragraph 1, sentence 1 Replace:  
CHAMPION 1, a Phase  1b/2 
study in subjec ts with relapsed 
multiple myeloma who had received 1 to 3 prior therapies was initiated to investigate higher doses of carfilzomib given once -weekly in combination with 
dexamethasone, and results indicate that these modifications were well tolerated and ac tive. With:  
CHAMPION 1, a Phase  1b/2 study in 
subjects with relapsed multiple myeloma who had received 1 to 3 prior therapies was initiated to investigate higher doses of carfilzomib given once -weekly in 
combination with dexamethasone, and preliminary results indicate d that these 
modifications were well tolerated and active.  Updated text to reflect new IB version statistics  
Section: 2.5.1 Rationale for Once -weekly  
Dosing, paragraphs 8, 9, and 10 Replace:  
As of 07  January  2015, 
104 subjects (Phase 1 n = 15, 
Phase  2 n = 89) have received at 
least 1  dose of carfilzomib at the 
MTD.  The majority of subjects With:  
As of 0 1 May  2015, 104 subjects (Phase 1 
n = 15, Phase  2 n = 89) have received at 
least 1  dose of carfilzomib at the MTD.  The 
majority of subjects (82%) had received 
prior bortezomib.  A total of 48% of subjects Updated text to reflect new IB version statistics  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 125 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
(82%) had received prior 
bortezomib.  A total of 48% of 
subjects were bortezomib -
refractory, 28% were lenalidomide -refractory, and 16% 
were refractory to bo th.  The ORR 
to date was 72% (95% CI:  63% to 81%) with a CBR of 80% (95% CI:  71% to 87%).  Median PFS was 10.6 months (95% CI:  7.2 to not estimable).  Preliminary 
median carfilzomib treatment duration in the ongoing study is 5.3 months (range:  0.03 to 18.8) 
(Berenson  2015).  
All 104 subjects experienced at 
least 1  AE.  The most common 
AEs ( â‰¥ 15% of subjects) were 
fatigue (48%), nausea (32%), insomnia (30%), anemia, headache, diarrhea (each 24%), dyspnea (23%), upper respiratory tract infection (22%), cou gh 
(21%), pyrexia (19%), thrombocytopenia (18%), constipation (16%), back pain, peripheral edema, and dizziness (each 15%).  A total of 57 subjects (55%) experienced at least 1 Grade 3 or higher AE.  The  most 
common ( â‰¥ 5% of subjects) Grade 
3 or higher AEs were fatigue 
(9%), thrombocytopenia, dyspnea, back pain (each 6%), anemia, and were bortezomib -refractory, 28% were 
lenalidomide -refra ctory, and 16% were 
refractory to both.  The ORR to date was 77% (95% CI:  6 8% to 8 5%) with a CBR of 
84% (95% CI:  7 5% to 90%).  Median PFS 
was 10.6 months (95% CI:  9.0 to 16.1).  
Preliminary median carfilzomib treatment duration in the ongoing study is 8.3 months 
(range:  > 1  to 20) for the Phase 1 portion 
of the study and 7.2 months . (range: 0.03  
to 22.6) for the Phase 2 portion of the 
study  (Berenson  2015).  
All 104 subjects experienced at least 1  AE.  
The most common AEs ( â‰¥ 15% of subjects) 
were fatigue  (52%), nausea (3 5%), 
headache, diarrhea ( each  31%), insomnia, 
upper respiratory tract infection ( each  30% ), 
cough (26 %), dyspnea (2 5%), anemia 
(24%), thrombocytopenia, pyrexia ( each 
22%), peripheral edema ( 20%), and back 
pain (17 %).  A total of 64 subjects ( 62%) 
experienced at least 1 Grade 3 or higher AE.  The most common ( â‰¥ 5% of subjects) 
Grade  3 or higher AEs were fatigue ( 11%), 
pneumonia (7%) , thrombocytopenia, 
hypertension, acute renal failure (each 6%), dyspnea, anemia, back pain, asthenia , and 
chronic o bstructive pulmonary disease  
(each 5%)  (Carfilzomib IB). 
The preliminary results from CHAMPION  1 
demonstrated that once -weekly carfilzomib 
at 70 mg/m2 administered as a 30 -minute 
infusion in combination with dexamethasone 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 126 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
acute renal failure (each 5%)  
(Carfilzomib IB).   
The preliminary results from 
CHAMPION 1 demonstrated that 
once -weekly carfilzomib at 
70 mg/m2 administered as a 30 -
minute infu sion in combination 
with dexamethasone in subjects with relapsed and refractory multiple myeloma had an acceptable safety and tolerability profile and promising efficacy.  Ninety subjects are planned for the Phase  2 portion of the study.  in subjects with relapsed and ref ractory 
multiple myeloma had an acceptable safety and tolerability profile and promising efficacy.  Eighty -nine subjects were 
enrolled into  the Phase  2 portion of the 
study.  
Section:  2.5.2 Pharmacokinetic s and 
Pharmacodynamics Data for Once -weekly Dosing, paragraph 2, 
sentence 4 Replace:  
The mean C
max following the 
70 mg/m2 dose administered as a 
30-minute infusion is 2640  ng/mL, 
which is lower than the mean C max 
of 4232 ng/mL in Study 
PX-71-003 â€“ Part 2 (A1) 
following the IV infusion of 27 mg/m
2 over 2 to 10  minutes 
(Carfilzomib IB).  With:  
The mean C max following the 70  mg/m2 dose 
administered as a 30 -minute infusion is 
2640  ng/mL, which is lower than the mean 
Cmax of 4232  ng/mL in 
Study  PX-171-003- Part 2 (A1),  following 
the IV infusion of 27  mg/m2 over 2 to 
10 minutes (Carfilzomib IB).  Administrative change  
Section:  2.5.2 Pharmacokinetics and Pharmacodynamics Data for Once -weekly Dosing, paragraph 3, 
sentence 2 Replace:  
No statistically significant relationships between C
max and 
efficacy and safety endpoints were found.  With:  
No statistically significant relationships between C
max and efficacy or safety 
endpoints were found.  Administrative change  
Section: 3.1 Primary Objective  Replace:  
The primary objec tive of this With:  
The primary objective of this study is to Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 127 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
study is to compare the ORR 
between once -weekly carfilzomib 
dosing in combination with 
dexamethasone to twice -weekly 
carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma who have receiv ed prior treatment with 
bortezomib and an IMiD.  compare the ORR of once -weekly 
carfilzomib dosing in combination with dexamethasone to the ORR of twice -weekly 
carfilzomib dosing in combination with dexamethas one in subjects with relapsed and 
refractory multiple myeloma who have received prior treatment with a proteasome 
inhibitor and an IMiD. 
Section:  4.1 Study Design, paragraph 2,  
sentence 2 Replace:  
Subjects must have had 2 or 3 
prior therapies for multiple myeloma and received treatment with bortezomib and an IMiD. With:  
Subjects must have had 2 or 3 prior therapies 
for multiple myeloma and received treatment with a proteasome inhibitor  and an IMiD. Revi sed text for consistency within 
overall protocol  
Section:  4.1 Study Design, paragraph 3,  
bullet 1  Replace:  
â€¢ International Staging System 
(ISS) Stage at study entry 
(Stage  1 versus Stage  2 or 3)  With:  
â€¢ International Staging System (ISS) Stage 
at study entry  (Stage  1 versus Stage  2 or 
3) per International Myeloma 
Working Group ( Greipp  2005). See 
Appendix  H Revised text for clarification  
Section: 4.1 Study Design, paragraph 5, 
sentence 1 Replace:  
Disease assessments will be conducted at Screening (within 21 days before dosing on Cycle  1 
Day 1) and then on Day  1 of every 
cycle beginning with Cycle 2 and 
each cycle thereafter, End of Treatment (EOT) and during LTFU every 4  weeks (every 
28 days Â±  4 days), until PD and/or With:  
Disease assessments will be conducted at Screening (within 21  days before 
randomization ) and then every 28  days 
Â± 4 days after  Cycle 1 Day 1, End of 
Treatment (EOT) and during LTFU every 28 days Â±  4 days, until PD and/or 
administration of sub sequent antimyeloma 
therapy.  Updated text for disease assessment timepoints to align with other sections in protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 128 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
administration of subsequent 
antimyeloma t herapy.  
Section:  4.2 Number of Centers  Replace:  
Approximately 120  sites 
worldwide will participate.  With:  
Approximately 1 50 sites worldwide will 
participate. Updated number of sites to include 
potential New Zealand and Australian sites 
Section:  5 Subject Eligibility  Replace:  
5 
Approximately 460  subjects will 
be enrolled in this study.  Subjects 
will be evaluated for study 
eligib ility within the 21  days prior 
to randomization.  Subject Selection  With:  
5 
 Subject Eligibility  Removed text to avoid duplication in 
protocol  
Section: 6 Subject Screening, paragraph 1, sentence 2  Replace:  
Evaluations obtained as part of routine medical care that do not require central lab testing and are 
performed during the Screening period may be used as the study -specific protocol required 
evaluations.  With:  
Evaluations obtained as part of routine medical care prior to signing of the ICF 
may be used to satisfy the screen ing 
requirements, provided that these evaluations were obtained within the required screening period and do not require analysis at a central laboratory.  Revised text for clarification  
Section: 6 Subject Screening, paragraph 3  Replace:  
The Screening perio d for a 
particular subject commences at the point at which the subject signs the ICF, and must be completed within the 21  days prior 
to randomization.  With:  
The Screening period commences when  the 
subject or a legally -authorized 
representative  signs the ICF. Screening  
must be completed within the 21 days prior 
to randomization.  Revised text for clarification  
Section: 7 Subject Randomization, title  Replace:  
Subject Enrollment And With:  
Subject Randomization  Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 129 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
Randomization  
Section: 7 Subject Randomization, 
paragraph 1  Replace:  
Eligibility information for each subject must be provided to the study medical monitor or designee and reviewed and approved prior to randomization (refer to separate study reference manual).  
The Randomization will  be carried 
out centrally through an Interactive Web Response System (IWRS). With:  
The primary investigator will determine the subjectâ€™s eligibility, ensuring that the results of the required screening procedures are consistent with all of the eligibility criteria presented in Section 5.  
No eligibility waivers will be permitted. 
Randomization will be carried out centrally 
through an interactive voice and web 
response ( IVR/IWR)  system.  Please refer 
to the separate study reference manual.  Updated text to al ign with the 
administrative processes followed by Amgen  
Section: 7 Subject Randomization, paragraph 5  Replace:  
After Screening, eligibility determination, and randomization, study treatment will ideally commence on the day of randomization but at least wi thin 5 
calendar  days of randomization 
according to treatment group assignment.  Initiation of study treatment (Cycle  1 Day  1) 
delay  > 5 days after randomization 
must be approved by the study medical monitor.  With:  
Study treatment will ideally commence on the day of randomization , but at least within 
5 calendar  days of randomization.  Initiation 
of study treatment (Cycle  1 
Day 1) > 5 calendar  days after 
randomization must be approved by the study medical monitor.  Clarified the timing of initiation of study t reatment 
Section: 8 Study Drugs, title  Replace:  
Study Treatment  With:  
Study Drugs  Revised text for consistency within overall protocol  
Section: 8.1.1 Physical Description   Delete:  
8.1.1 Physical Description  
Carfilzomib is a synthetic small molecule Removed section to avoid duplication of IPIM  
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R 
&DUILO]RPLE 3DJHRI 
$PHQGPHQW$SULO   &21),'(17,$/6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH
SHSWLGHEHDULQJWKHFKHPLFDOQDPH61
66PHWK\O5PHWK\OR[LUDQ
\OR[RSHQWDQ\OFDUEDPR\O 
SKHQ\OHWK\O6
PRUSKROLQRDFHWDPLGRSKHQ\OEXWDQDPLGR
PHWK\OSHQWDQDPLGH7KHPROHFXODU
IRUPXODLV&+12DQGWKHPROHFXODU
ZHLJKWLV,WVS HFLILFDOO\IXQFWLRQVDV
DQLQKLELWRURIWKH&7 /DFWLYLW\RIWKH6
SURWHDVRPHZKLFKOHDGVWRWKHDFFXPXODWLRQ
RISURWHLQVXEVWUDWHVZLWKLQWKHFHOODQG
LQGXFWLRQRIDSRSWRVLV 
6HFWLRQ)RUPXODWLRQ  'HOHWH
)RUPXODWLRQ 
&DUILO]RPLEIRU,QMHFWLR QZLOOEHSURYLGHGDV
DO\RSKLOL]HGSRZGHUZKLFKZKHQ
UHFRQVWLWXWHGFRQWDLQVD PJP/LVRWRQLF
VROXWLRQRIFDUILO]RPLEIUHHEDVHLQ P0
VRGLXPFLWUDWHEXIIHUS+ FRQWDLQLQJ
ZYVXOIREXW\OHWKHU EHWDF\FORGH[WULQ
6%(&'&DSWLVRO 5HPRYHGVHFWLRQWRDYRLGGXSOLFDWLRQ
RI,3,0
6HFWLRQQHZO\UHQXPEHUHG3DFNDJLQJDQG/DEHOLQJVHQWHQFH5HSODFH
$GGLWLRQDOGHWDLOVDUHSURYLGHGLQ
WKHSKDUPDF\PDQXDO:LWK
$GGLWLRQDOGHWDLOVDUHSURYLGHGLQWKH
,QYHVWLJDWLRQDO3URGXFW,QVWUXFWLRQ
0DQXDO,3,0 5HYLVHGWH[WWRFRUUHFWQDPHRI,3,0
6HFWLRQQHZO\UHQXPEHUHG
6WRUDJHSDUDJUDSKVHQWHQFH 'HOHWH
&DUILO]RPLEYLDOVPXVWEHNHSWLQFDUWRQVLQ
RUGHUWRSURWH FWIURPOLJKWXQWLOUHDG\IRU
UHFRQVWLWXWLRQ 5HPRYHGVHQWHQFHWRDYRLG
GXSOLFDWLRQRI,3,0
6HFWLRQQHZO\UHQXPEHUHG  'HOHWH 5HPRYHGSDUDJUDSKWRDYRLGC
CICCI
CCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 131 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
Storage, paragraph 2  Once carfilzomib is reconstituted and 
inspected, the clear solution may be stored in 
a refrigerator  (recommended) controlled 
temperature from 2Â°C to 8Â°C (36Â°F â€“46Â°F) 
for up to 24  hours.  Once reconstituted, 
carfilzomib must be used within 4  hours if 
not refrigerated and within 24  hours if it has 
been stored in a light -tight refrigerator (refer 
to Table 3 ). duplication of IPIM  
Section:  8.1.2 (newly renumbered) 
Storage, Table 3 Stability of Reconstituted Carfilzomib for Injection (60 mg/vial)  Delete:  
Table 3 Removed table to avoid duplication of IPIM  
Section:  8.1.2 (newly renumbered) Storage, paragraph 2   Add:  
Please refer to the IPIM for further storage information.  Added cross reference to IPIM to avoid text duplication  
Section: 8.2 Dexamethasone, paragraph 1, sentence 2 Replace:  
Onyx (and/or designee) may provide dexametha sone, if the 
investigational site is unable to obtain adequate supply.  With:  
Sponsor  (and/or designee) may provide 
dexamethasone, if the investigational site is unable to obtain adequate supply.  Administrative change  
Section: 8.3 Study Drug Accountability  Replace:  
Onyx (or designee), and the investigator must maintain records of each shipment of 
investigational product (IP).  Upon 
receipt of IP, the designated recipient at the investigational site will inspect the shipment, verify the number and condition of the 
vials, and prepare an inventory or With:  
Please refer to the IPIM for details on study drug accountability.  Added cross reference to IPIM to 
avoid text duplication  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 132 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
drug accountability record.  The 
records will document shipment 
dates, method of shipment, batch numbers, product presentation, quantity of vials contained in the shipment, and dispensation to individual subjects u sing the 
subject identification number.   
Responsibility for drug accountability at the study site rests with the investigator; however, the investigator may assign drug accountability duties to an appropriate pharmacist or designee.  Inventory and account ability records must be 
readily available for inspection by the study monitor and are open to inspection at any time by the sponsor/representative and any applicable regulatory authorities.   
The investigator must ensure that the IPs are used in accordance with the protocol.  The investigator will also maintain 
records adequately documenting 
that the subjects were provided the 
treatment specified and reconciling all IPs.  
Remaining supplies will be retained by the pharmacy at the end of the study, and any unused medication will be discarded or 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 133 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
destroyed according to 
institutional Standard Operating 
Procedures (SOPs).  Documentation of destruction of unused study medication will be maintained by the site.  For each subject, the site pharmacy personnel will be required to 
record and document proper per protocol dispensing of carfilzomib and dexamethasone.  
Additional details are provided in the pharmacy manual. 
Section: 9.1 Treatment Regimen, paragraph 1  Replace:  
Carfilzomib and dexamethasone will be administered in 28 -day 
cycles.  All cycles will start 28 days (Â±  2) after the start of the 
prior cycle.  With:  
Carfilzomib and dexamethason e will be 
administered in 28 -day cycles.  All cycles 
will start 28  days (Â±  2 days ) after the start of 
the prior cycle. Revised text for consistency within overall protocol  
Section: 9.1 Treatment Regimen, paragraph 2, sentences 1 and 2  Replace:  
Once -weekly  carfilzomib must 
never be administered within the 5 days following a previous 
carfilzomib infusion.  With:  
In the once -weekly carfilzomib  arm, intra -
cycle doses of  carfilzomib and 
dexamethasone may be administered within Â±  2 days of the scheduled dose. 
How ever, carfilzomib  must not be 
administered within the 5  days following a 
previous carfilzomib infusion.  Dose delays 
> 2 days are only permitted during the 
start of a new cycle.  Revised text for clarification.  
Section: 9.1 Treatment Regimen, 
paragraph 3  Replace:  
In the twice -weekly carfilzomib With:  
In the twice -weekly carfilzomib arm, every Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 134 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
arm, every effort should be made 
to maintain the Days  1, 2, 8, 9, 15, 
and 16, every 28 -day schedule.  If 
this is not possible due to 
extenuating circumstances, then priority should be to maintain consecutive dosing  days.  For 
example, if  Day 1 of a new cycle 
is started 2  days later than 
originally scheduled, the entire cycle should shift by 2 days, such 
that the new Days  1, 2, 8, 9, 15, 
and 16 of the next cycle schedule is maintained.  If a mid -cycle dose 
is missed, t hat dosing day should 
be skipped and not made up.  Dose delays >  2 days are only 
permitted during the start of a new cycle.  effort should be made to maintain the 
Days  1, 2, 8, 9, 15, and 16, every 28 -day 
schedule.  If this is not possible, then priority 
should be to maintain consecutive dosing days.  For example, if  Day 1 of a new 
cycle is started 2  days later than originally 
scheduled, the entire cycle should shift by 2 days, such that the new Days  1, 2, 8, 9, 15, 
and 16 of the next cycle are maintained.   
Dosing on nonconsecutive days should only occur under exceptional circumstances, such as interruptions due to national holidays.  There must always be at least 5 days between the second dose of one week and the first dose of the 
following week (i.e., between Days 2 and 8, and Days 9 and 15).  Mid -cycle doses 
that are missed should not be made up, unless these parameters are maintained.  
Section: 9.1 Treatment Regimen, paragraph 4 Replace:  
The reason for all cycle delays, missed doses, and dose interruptions will be reported.  With:  
The reason s for all cycle delays, schedule 
changes,  missed doses, and dose 
interruptions will be reported.  Revised text for clarification  
Section: 9.2  Intravenous Hydration  Replace:  
9.2 Intravenous Hydration 
Subjects will receive IV prehydration prior to each carfilzomib infusion during Cycle  1.  Prehydration will consist 
of 250 to 500  mL normal saline or 
other appropriate IV fluid.  
Thereafter, carfilz omib With:  
9.2 Intravenous Prehydrati on 
Subjects will receive IV prehydration prior to each carfilzomib infusion during Cycle  1.  
Prehydration will consist of 250 to 500  mL 
normal saline or other appropriate IV fluid.  Thereafter, carfilzomib prehydration should only be administered if the su bjectâ€™s 
condition and/or risk factors require it.  The Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 135 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
prehydration should only be 
administered if the subjectâ€™s 
condition and/or risk factors require hydration.  The total amount of prehydration will be reported and the reason for hydration after Cycle  1 will be 
reported.  total volume of prehydration and the reason 
for pre hydration after Cycle  1 will be 
recorded . 
Section: 9.2.1 Study Treatment Administration, Figure 3, footnote c  Replace:  
C Dexamethasone on Day 22 in 
both treatment arms will be administered only during Cycles  1 
to 9 and should be given PO; dexamethasone will not be administered on Day  22 after 
Cycle  9. With:  
C Dexamethasone on Day 22 in both 
treatment arms will be administ ered only 
during Cycles  1 to 9 and should be given 
PO, whenever possible  Revised text for clarification  
Section: 9.2.1.1 Carfilzomib, paragraph 2, sentence 2 Replace:  
The lyophilized product is reconstituted with Sterile Water for Injection (SWI), United States 
Pharmacopeia (USP), to a final carfilzomib concentration of 2.0 mg/mL prior to administration. With:  
The lyophilized product is reconstituted with Sterile Water for Injection (SWI), United States Pharmacopeia (USP), to a final carfilzomib concentrat ion of 2.0  mg/mL.  Revised text for clarifcation  
Section: 9.2.1.1 Carfilzomib, paragraph 2, sentences 3, 4 and 5   Delete:  
The dose can be calculated using the 
subjectâ€™s actual body surface area (BSA) at 
Baseline; however, dosing adjustments for 
subsequent actual BSA determinations are 
allowed per institutional guidelines.  
Subjects with a BSA >  2.2 m2 will receive a 
dose based upon a 2.2  m2 BSA.  Dose 
adjustments must be made for weight Revised text for clarifi cation 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 136 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
gains/losses of â‰¥ 20% of baseline body 
weight.  
Section: 9.2.1.1 Carfilzomib, paragraph 3,  
sentences 4 and 5 Replace:  
Carfilzomib should be 
administered via a dedicated IV line.  If an existing IV line or permanent infusion device (e.g., porta -cath) is used for carfilzomib 
administration, the li ne must be 
flushed with a minimum of 20  mL 
of 5% Dextrose Injection (D5W), prior to and following carfilzomib infusion.  With:  
Carfilzomib should be administered via a dedicated IV line , whenever possible.  
Refer to the IPIM for detailed information regardi ng equipment and 
flush requirements . Added cross reference to IPIM to avoid text duplication  
Section: 9.2.1.2 Dexamethasone, sentence 2 Replace:  
Dexamethasone will be administered at least 30  minutes 
(but no more than 4  hours) prior to 
carfilzomib infusio n on Days  1, 8, 
and 15 in both arms.  With:  
Dexamethasone will be administered at least 30 minutes (but no more than 4 hours) prior 
to carfilzomib infusion on Days  1, 8, and 15 
in both treatment  arms.  Revised text for clarification  
Section: 9.2.1.2 Dexamethasone, sentence 3 Replace:  
Dexamethasone on Day  22 should 
be taken PO.  With:  
Dexamethasone on Day 22 should be taken 
PO, whenever possible . Revised text for clarification  
Section: 9.2.1.2 Dexamethasone, sentence 4 Replace:  
Note: Dexamethasone on Day  22 
in both treatment arms will only 
be administered during Cycles  1 to 
9; dexamethasone will not be administered on Day  22 after 
Cycle  9. With:  
Note: Dexamethasone on Day  22 in both 
treatment arms will only be administered during Cycles  1 to 9. Revised text for clarification  
Section: 9.3 Dose Modification Rules  Replace:  With:  Clarified procedures for dose 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 137 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
9.3 Dose Modification Guidelines  
In the event of a possible study 
treatment- related AE, the clinical 
investigator should assess to the best of his/her ability its relationship to carfilzomib a nd/or 
dexamethasone.  Dose reduction 
guidelines for carfilzomib include guidelines where the dose of carfilzomib is decreased based on the observed toxicity.  
â€¢ If a subject requires an 
interruption of carfilzomib of more than 4 weeks, the subject 
should be removed from study treatment.  Exceptions to this must be discussed with the study medical monitor.  
â€¢ If the carfilzomib dose is 
reduced, the reduced dose level will be continued for at least 1 complete cycle.  If the reduced dose level is well tolerated for at 
least one complete cycle, the dose level prior to the reduction may be resumed at the investigatorâ€™s 
discretion. 
If carfilzomib is permanently stopped due to toxicity per below dose modification guidelines (Table  5 and Table  6), 
dexamethasone dosing sho uld also 
be stopped and the subject 9.3 Dose Modification Rules  
In the event of a possible study treatment- related AE, the clinical 
investigator should assess, to the best of 
his/her ability, its relationship to carfilzomib and/or dexamethasone.  Dose  reduction 
rules for carfilzomib are presented in 
Tables 4 and 5 and are often event -
specific . 
â€¢ If a subject requires interruption of 
carfilzomib for more than 28 day s, the 
subject should be removed from study treatment.  Exceptions must first be 
approved by  the study medical monitor.  
â€¢ If a subject requires  carfilzomib dose 
reduc tion, the reduced dose level will be 
continued for at least 1 complete cycle.  After that, if the reduced dose level has 
been well tolerated, the previous dose level 
may be resumed at the investigatorâ€™s discretion. 
â€¢ If carfilzomib is temporarily held due 
to an AE, dexamethasone should be continued, unless the investigator determines that criteria for interrupting 
dexamethasone have also been met.  
â€¢ If carfilzomib is permanently 
discontinued  due to toxicity, 
dexamethasone must  also be discontinued  
and the subject will be followed for disease 
progression per the guidelines in Section 
10.10.1 . interruption for a carfilzomib AE.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 138 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
followed for disease progression 
per protocol -specified disease 
response criteria prior to initiating 
new antimyeloma therapies.   
â€¢ If dexamethasone is 
permanently withdrawn due to toxicity, the subject may continue to receive carfilzomib at the 
clinical investigatorâ€™s discretion and must follow protocol required procedures and assessments.  
 â€¢ If dexametha sone is permanently 
discontinued due to toxicity, the subject 
may continue to receive study treatment 
with  carfilzomib at the investigatorâ€™s 
discretion. 
Section: 9.3.1 Carfilzomib: Rules for  
Dose Modification, heading Replace:  
9.3.1 Carfilzomib: Guidelines for Dose Modification  With:  
9.3.1 Carfilzomib: Rules  for Dose 
Modification  Administrative change  
Section: 9.3.1 Carfilzomib: Rules for Dose Modification, paragraph 1  Replace:  
Dose reduct ion levels of 
carfilzomib for toxicity 
management of individual subjects 
are provided in Table 4. With:  
Dose decrements for  carfilzomib are 
provided in Table 3. Revised text for clarification  
Section: 9.3.1 Carfilzomib: Rules for Toxicities and Dose Modif ication, Table 
3, footnote 1   Add:  
Added footnote to dose column.  
a Note: If dose reduction of carfilzomib is 
required on C1D1 (Arm A) or C1D1 or 
D2 (Arm B), the investigator should contact the medical monitor to discuss the situation, before any addition al doses of 
carfilzomib are administered.  Revised text for clarification  
Section: 9.3.1 Carfilzomib: Guidelines for Toxicities and Dose Modification, Replace:  
Treatment guidelines for specific With:  
The requirements for carfilzomib dose Revised text for clarificatio n 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 139 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Chang e 
paragraph 2  hematologic toxicities are outlined 
in Section 9.3 .1.1 and 
nonhematologic toxicities in 
Section 9.3.1.2.  modification  for specific hematologic and 
nonhematologic toxicities are outlined in 
Section s 9.3.1.1 and 9.3.1.2, respectively . 
Section:  9.3.1.1 Hematologic Toxicity, paragraph 1  Replace:  
Guidelines for dose modification in the event of thrombocytopenia and neutropenia are summarized in Table  5. With:  
Requirements  for dose modification of 
carfilzomib in the event s of 
thrombocyt openia, neutropenia , or 
neutropenic fever are summarized in 
Table  4. Revised text for clarification  
Section:  9.3.1.1 Hematologic Toxicity, Table 4, title  Replace:  
Carfilzomib Dosing Guidelines for Treatment- emergent 
Hematologic  Toxicity With:  
Carfilzomib  Dose Modification Rules  for 
Treatment- emergent Hematologic Toxicity Revised text for clarification  
Section:  9.3.1.1 Hematologic Toxicity,  
Table 4  Replace:  
Original Table 5 below  With:  
Revised Table 4 below Revised for clarity and for consistency with c urrent carfilzomib 
safety guidance  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 140 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Original Table 5:  
Hematologic Toxicity  Recommended Actiona 
Thrombocytopenia  
When platelets  
fall to â‰¤ 30 Ã— 109/L If platelets 10 â€“30 Ã— 109/L without  evidence of 
bleeding Continue at same dose.  
If evidence of bleeding or platelets <  10 Ã— 109/L Withhold dose until platelets return to â‰¥ 10 Ã— 109/L and/or 
bleeding is controlled, then resume at same  dose.  
For each subsequent drop to â‰¤ 30 Ã— 109/L If platelets 10 â€“30 Ã— 109/L without  evidence of 
bleeding Continue at same dose.  
If evidence of bleeding or platelets <  10 Ã— 109/L Withhold dose until platelets return to â‰¥ 10 Ã— 109/L and/or 
bleeding is control led, then resume at 1 dose decrement.  
Neutropenia  
When ANC  
falls to â‰¤ 0.75  Ã— 109/L If ANC 0.5 â€“0.75 Ã— 109/L Continue at same dose.  
If ANC <  0.5 Ã— 109/L Withhold dose until ANC returns to â‰¥ 0.5 Ã— 109/L, then 
resume at same dose.  
For each subsequent drop to â‰¤ 0.75 Ã— 109/L If ANC 0.5 â€“0.75 Ã— 109/L Continue at same dose.  
If ANC <  0.5 Ã— 109/L Withhold dose until ANC returns to â‰¥ 0.5 Ã— 109/L, then 
resume at 1 dose decrement.  
Neutropenic fever  1) If < 1000/mm3 and single  temperature > 
38.3Â°C  
OR 
2) temperature > 3 8.0Â°C for more than 1 
hour Withhold dose until ANC returns to baseline grade, then 
resume at same dose.  
ANC = absolute neutrophil count; NA = not applicable.  
a The maximum allowed dose interruption is 4  weeks.  
 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 141 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Revised Table 4: 
Hematologic Toxicity  Required  Action  
Thrombocytopenia  
â€¢ Platelets â‰¤10 Ã—  109/L, OR  
â€¢ Platelets â‰¤30 Ã— 109/L with  evidence of 
bleeding/bruising   1st episode  â€¢ Withhold doses.  
â€¢ Resume at the same dose level when  platelets 
â‰¥ 10 Ã— 109/L and bleeding is controlled.  
Subsequent  episodes  â€¢ Withhold doses. 
â€¢ Resume at 1 dose decrement when platelets 
â‰¥ 10 Ã— 109/L and bleeding is controlled.  
Neutropenia     â€¢  
â€¢ ANC <  0.5 Ã— 109/L  1st episode  â€¢ Withhold doses.  
â€¢ Resume at the same dose level when  ANC  â‰¥ 0.5 Ã— 109/L 
Subsequent episodes  â€¢ Withhold doses. 
â€¢ Resume at 1 dose decrement when ANC  â‰¥ 0.5 Ã— 109/L  
Febrile neutropenia    
â€¢ ANC < 0.5 x 109/L and  oral temperature 
either:  
o > 38.5Â°C, OR  
o  > 38.0Â°C on 2 consecutive 
measurements over 2 hours  
  1st and subsequent episodes  â€¢ Withhold doses.  
â€¢ Resume at the same dose level when  ANC returns to 
baseli ne grade and fever resolves.  
ANC = absolute neutrophil count; NA = not applicable.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 142 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  9.3.1.2 Nonhematologic Toxicity, 
paragraph 1  Replace:  
Guidelines for dose modification in the event of nonhematologic toxicities are summarized in Table   6. With:  
Requireme nts for dose modification of 
carfilzomib  in the event of nonhematologic 
toxicities are summarized in Table 5.  Revised text for clarification  
9.3.1.2 Nonhematologic Toxicity, Table  5, Title  Replace:  
Carfilzomib Dosing Guidelines for Nonhematologic Toxicity  With:  
Carfilzomib Dos e Modifications  for 
Nonhematologic Toxicity  Revised text for clarification  
Section:  9.3.1.2 Nonhematologic Toxicity,  Table 5  Replace:  
Original Table 6 below  With:  
Revised Table 5 below Revised text for clarification  
 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 143 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Original Tabl e 6: 
Nonhematologic Toxicity  Recommended Actiona 
Renal Dysfunction  
Serum creatinine equal to or greater  than 2 Ã— 
Baseline, or CrCl  < 15 mL/min (or CrCl 
decreases to â‰¤ 50% of baseline), or  need for 
dialysis  Withhold dose and continue monitoring renal function (serum creatinine or creatinine clearance).  
If attributable to carfilzomib, resume when renal function has recovered to within 25%  of Baseline; start at 
1 dose level reduction.  
If not attributable to carfilzomib, dosing may be resumed at the discretion of the physician.  
If tolerated, the reduced dose may be escalated to the previous dose at the discretion of the physician.  For 
patie nts on dialysis receiving carfilzomib, the  dose is to be administered after the dialysis procedure.  
â‰¥ Grade 3 Elevation in LFTs (AST,  ALT, or 
total bilirubin)b Withhold dose.  Resume at 1 dose decrement when toxicity has resolved to Baseline.c 
Grade 3 Infection  â€¢ Withhold carfilzomib until infection resolves.  Resume carfilzomib at same dose.  
Congestive heart failure  â€¢ Any subject with symptoms of congestive heart failure, whether or not drug related, must have the dose held 
until resolution or return to Baseline, after  which treatment may continue at a reduced dose, or the subject 
may be permanently discontinued.   
â€¢ If no resolution after 4  weeks, the subject will be withdrawn from all study treatment.  
LVEF Reductions  
For resting LVEF <  40% or reduction of 
LVEF to <  55% if the drop is greater than 
20% from Baseline  Withhold until LVEF returns to >  40% or, if held due to a drop to <  55%, to  within 15% of Baseline.  Resume at 
1 dose decrement.c 
Micro -Angiopathy  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 144 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Nonhematologic Toxicity  Recommended Actiona 
Thrombotic thrombocytopenic 
purpura/hemolytic uremic syndrome (TTP/HUS) If suspected TTP/HUS, withhold carfilzomib.    
Manage symptoms per standard of care including plasma exchange as clinically indicated.    
If the diagnosis of TTP/HUS is excluded, carfilzomib administration may resume if clinically appropriate.  
Any Other Drug -Related Non- Hematologic 
Toxicity â‰¥ Grade 3  For carfilzomib attribution, withhold dose.   
Resume at 1 dose decrement when toxicity has resolved to Grade  2 or less or to Baseline grade.  
If tolerated, the reduced dose may be escalated to the previous dose at the discretion of the physician.  
Additional dose modification guidance for adverse drug reactions are per the Carfilzomib IB . 
Pulmonary Hypertension  Withhold until resolved or returned to baseline.  
Restart at the dose used prior to the event or reduce dose by 1 dose level (i.e.,  27 mg/m2 to 20  mg/m2 for the 
twice weekly schedule or 70  mg/m2 to 56  mg/m2 for the once weekly schedule), at the discretion of the 
physician. 
If tolerated, the reduced dose may be escalated to the previous dose at the discretion of the physician.  
Posterior reversible encephalopathy syndrome (PRES;  with symptoms including headaches, 
altered mental status, seizures, visual loss, and 
hypertension)  If suspected PRES, withhold carfilzomib.    
Consider evaluation with neuroradiological imaging for onset of visual or neu rological symptoms suggestive of 
PRES.   
If the diagnosis of PRES is excluded, carfilzomib administration may resume if clinically appropriate.  
ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; CrCl  = creat inine  clearance; eCRF = electronic Case Report 
Form; IB = Investigatorâ€™s Brochure;  
LFTs = liver function tests; LVEF  = left ventricular ejection fraction;  mL = milliliter(s); ULN = upper limit of normal.  
Note: Carfilzomib dose schedule does not need to be  adjusted for baseline renal dysfunction.  
a The maximum allowed dose interruption is 4  weeks.  
b If AST or ALT is â‰¥ 3 Ã— ULN, the â€œevaluation of treatment -emergent liver abnormalitiesâ€ eCRF should be completed.  
c Dose reduction should be attempted first to manage treatment -emergent toxicities.   
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 145 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Revised Table 5: 
Nonhematologic Toxicity  Required Actiona 
Renal Dysfunction  
â€¢ Serum creatinine â‰¥ 2 Ã— baseline , OR  
â€¢ CrCl  < 15 mL/min , OR   
â€¢ rCl decre ases to â‰¤ 50% of baseline, OR 
â€¢ Requirement  for dialysis  â€¢ Withhold dose s while the cause of renal dysfunction is being assessed. 
â€¢ If attributable to carfilzomib, resume at 1 dose decrement  when CrCl has recovered to within 25% of 
baseline  
â€¢ If not attributable to carfilzomib, resume the same dose or reduce by 1 dose decrement , at the i nvestigatorâ€™s  
discretion , when CrCl has recovered to within 25% of baseline  
â€¢ For patients on dialysis receiving carfilzomib, the  dose is to be administered after the dialysis procedure.  
Hepatic Dysfunction  
â€¢ â‰¥ Grade 3 Elevations of AST,  ALT, or 
total bilirubin  â€¢ Withhold dose s. 
â€¢ Resume at 1 dose decrement when the grade has returned  to baseline.c 
Infection  
â€¢ â‰¥ Grade 3 Infection  â€¢ Withhold doses . 
â€¢  Resume at the same dose level, when the infection is controlled . 
Cardiovascular Dysfunction  
â€¢ Congestive Heart Failure  â€¢ Withhold doses for any subject with symptomatic heart failure, whether or not it is attributed to 
carfilzomib  
â€¢ Resume at 1 dose decrement, when symptoms have resolved or returned to baseline  
â€¢ LVEF <  40%, OR  
â€¢ LVEF <  55%, if decreased > 20% from 
Baseline  
  â€¢ Withhold doses  
â€¢ Resume at 1 dose decrement, when  LVEF returns to â‰¥ 40%, or to within 15% of baseline, if carfilzomib 
was held due to a drop to <55 % 
â€¢ Pulmonary Hypertension  â€¢ Withhold doses and assess the benefit: risk of resuming carfilzomib.  
â€¢ If the assessment favors benefit, carfilzomib may be resumed at the same dose level or at 1 dose 
decrement, at the investigatorâ€™s discretion . 
Thrombotic Microangiopathy  
â€¢ Thrombotic thrombocytopenic 
purpura/hemolytic uremic syndrome â€¢ Withhold doses when TTP/HUS is suspected. 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 146 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Nonhematologic Toxicity  Required Actiona 
(TTP/HUS)  â€¢ If the diagnosis is excluded, resume at the same do se level.  
â€¢ If the diagnosis is confirmed, the decision to resume or not resume carfilzomib is at the investigatorâ€™s 
discretion.  The safeness of resuming carfilzomib following TTP/HUS is unknown.  
â€¢ Manage symptoms per standard of care including, plasma exchan ge as clinically indicatedb.   
Encephalopathy  
â€¢ Posterior reversible encephalopathy 
syndrome (PRES)  â€¢ Withhold doses and assess the benefit:risk of resuming carfilzomib.  
â€¢ Consider evaluation with neuroradiological imaging for onset of visual or neurological symptoms suggestive of PRES.    
â€¢ If the diagnosis is excluded, resume at the same dose level.  
â€¢ If the diagnosis is confirmed, the decision to resume or not resume carfilzomib is at the investigatorâ€™s 
discretion.  The safeness of resuming carfilzomib following PRES is unknown.  
Other Nonhematologic Toxicity  
â€¢ â‰¥ Grade 3 and attributed to 
carfilzomib  â€¢ Withhold doses.   
â€¢ Resume at 1 dose decrement,, when toxicity has resolved to Grade  â‰¤ 2 or to Baseline. 
ALT = alanine aminotransferase; ANC = absolute neutrophil count ; AST = aspartate aminotransferase; CrCl  = creatinine clearance; eCRF = electronic Case Report 
Form; IB = Investigatorâ€™s Brochure;  
LFTs = liver function tests; LVEF  = left ventricular ejection fraction;  mL = milliliter(s); ULN = upper limit of normal.  
Note: Carfilzomib dose schedule does not need to be adjusted for baseline renal dysfunction.  
a The maximum allowed dose interruption is 4  weeks , except with approval by the medical monitor.  
b Subjects requiring plasma exchange must be withdrawn from study treatme nt.  Every effort should be made to assess disease status in accordance with 
IMWG criteria, before plasma exchange is initiated . 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 147 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL   
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 9.3.2 Dexamethasone: 
Guidelines for Toxicities and Do se 
Modification, paragraph 1  Replace:  
Dose reduction levels of dexamethasone for toxicity management of individual subjects are provided in Table 7. With:  
Dose decrements for dexamethasone are 
provided in Table  6.  Revised text for clarification  
Section: 9.3.2 Dexamethasone: 
Guidelines for Toxicities and Dose Modification, paragraph 2  Replace:  
Dexamethasone will be permanently discontinued after 2-dose level reductions in the event 
of additional dexamethasone- related toxicities.  
At the investigatorâ€™s disc retion, 
dexamethasone may be tapered, prior to complete discontinuation, according to institutional practice.  Guidelines for dexamethasone- related toxicities 
are summarized in Table 8 With:  
Dexamethasone will be permanently discontinued , if toxicity persi sts following 
2 dose level reductions.  At the 
investigatorâ€™s discretion, dexamethasone may be tapered, prior to complete discontinuation, according to institutional practice.  The requirements for dose 
modification due to dexamethasone -related 
toxicities are summarized in Table 7 Revised text for clarification  
Section: 9.3.2 Dexamethasone: Guidelines for Toxicities and Dose Modification , Table 7, title  Replace:  
Treatment Guidelines for Dexamethasone- related Toxicities  With:  
Treatment Rules  for Dexamethas one-related 
Toxicities  Revised text to emphasize requirement 
Section:  9.3.2 Dexamethasone: Guidelines for Toxicities and Dose Modification ,, Table 7  Replace:  
Original Table 8 below  With:  
Revised Table 7 below Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 148 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Original Tab le 8: 
Dexamethasone- related Toxicities, All Days and Cycles  
Symptom  Findings  Recommended Action 
Cardiovascular Edema > Grade  3 (anasarca or limiting 
function and unresponsive to therapy) Diuretics as needed, and restart dexamethasone at 1 dose decrement;  if edema persists despite above 
measures, decrease dose by another dose decrement.  
Discontinue dexamethasone permanently if symptoms persist despite second reduction.  
Gastrointestinal 
Toxicity  Dyspepsia, gastric or duodenal ulcer, or 
gastritis Grade  1or 2 (requiring medical 
management)  Continue dexamethasone at same dose and treat with therapeutic doses of histamine  2 (H2) blockers, 
or proton pump inhibitor.  
Consider adding sucralfate or other antiulcer treatment as clinically indicated.  
If symptoms persi st despite above measures, decrease dexamethasone dose by 1 dose level.  
Dyspepsia, gastric or duodenal ulcer, or gastritis â‰¥ Grade  3 (requiring 
hospitalization or surgery)  Withhold dexamethasone until symptoms return to Baseline.  
Restart dexamethasone at 1 dose decrement along with concurrent therapy with H2 blockers, 
sucralfate, or omeprazole.  
If symptoms persist despite above measures, discontinue dexamethasone permanently.  
Acute pancreatitis  Discontinue dexamethasone permanently.  
General Disorders  Limb edema > Grade  3 (> 30% limb 
discrepancy in volume; gross deviation from normal anatomic contour; limiting 
self-care activities of daily living)  Withhold dexamethasone until symptoms return to Baseline.  
Diuretics as needed, and restart dexamethasone at  1 dose decrement; if edema persists despite above 
measures, decrease dose by another dose decrement.  
Discontinue dexamethasone permanently if symptoms persist despite second reduction.  
Psychiatric Disorders  Confusion or mood alteration â‰¥ Grade  2 
(interfe ring with function Â± interfering 
with activities of daily living)  Withhold dexamethasone until symptoms return to Baseline.  
Restart dexamethasone at 1 dose decrement.  
If symptoms persist despite above measures, reduce by another dose decrement.  
Musculoske letal Muscle weakness â‰¥ Grade  2 
(symptomatic and interfering with 
function Â± interfering with activities of daily living)  Decrease dexamethasone by 1 dose decrement.  
If weakness persists, decrease dose by another dose decrement.  
Discontinue dexamethasone permanently if symptoms persist.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 149 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Revised Table 7: 
Toxicity Required  Action  
Edema  
â‰¥ Grade  3: 
â€¢ Limb Edema 
â€¢ Truncal Edema â€¢ Withhold doses and diurese as needed.  
â€¢ Resume at 1 dose decrement when Grade â‰¤ 1 or baseline .  
Gastrointestinal Distress  
Grade 1 or 2:  
â€¢ Dyspeps ia, OR  
â€¢ Gastri tis, OR  
â€¢ Gastric or Duodenal Ulcer  â€¢ Continue doses while attempting medical management.  
â€¢ If symptoms persist, reduce by 1 dose decrement  
â‰¥ Grade  3: 
â€¢ Dyspepsia, OR 
â€¢  Gastritis, OR  
â€¢ Gastric or  Duodenal Ulcer  â€¢ Withhold doses .  
â€¢ Resume at 1 dose decrement, when symptoms return to baseline. 
â€¢ If symptoms recur despite appropriate medical management  discontinue dexamethasone 
permanently.  
â€¢ Acute pancreatitis  â€¢ Discontinue dexamethasone permanently.  
Psychiatric Disorders 
â‰¥ Grade  2: 
â€¢ Confusion, OR   
â€¢ mood alterati on  â€¢ Withhold doses . 
â€¢ Resume  at 1 dose decrement , when symptoms return to baseline. 
Other Toxicities  
â€¢ â‰¥ Grade  3 and attributed to dexamethasone â€¢ Withhold doses .  
â€¢ Resume  at 1 dose decrement, when toxicity has resolved to â‰¤ Grade  2. 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 150 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL   
Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 9.3.3 Conditions not 
Requiring Dose Reduction, paragraph  1 Replace:  
The following conditions are exceptions to the above guidelines.  Carfilzomib and dexamethasone do not need to be held in the following case s: With:  
The following conditions are exceptions to the requirements presented above.  Carfilzomib 
and dexamethasone do not require dose 
modification in the following cases:  Revised text for consistency within overall protocol  
Section: 9.3.3 Conditions not Requiring Dose Reduction, paragraph  1, bullet 1  Replace:  
Grade  3 nausea, vomiting, or diarrhea (unless 
persisting more than 3  days with adequate 
treatment of antiemetics or antidiarrheal agents)  With:  
Grade  3 nausea, vomiting, or diarrhea (unless 
persist ing more than 3  days despite appropriate 
use of antiemetics or antidiarrheal agents)  Revised text for clarification  
Section: 9.3.3 Conditions not  
Requiring Dose Reduction, paragraph  1, bullet 2  Replace:  
â€¢ Grade  3 dexamethasone -related 
hyperglycemia  With:  
â€¢ Grade  3 hyperglycemia  Removed requirement for hyperglycemia to be dexamethasone- related 
Section: 9.4 Concomitant Medications  
and Therapies, heading  Replace:  
Concomitant Medications and Concomitant Therapies  With:  
Concomitant Medications and Therapies  Admini strative change  
Section: 9.4 Concomitant Medications and Therapies, paragraph 1, sentence 2  Replace:  
For all randomized subjects, all administered concomitant medications and therapies, from signing of the informed consent until 30 days 
after the subjectâ€™s last dose of study treatment, must be recorded in the designated electronic Case Report Form (eCRF). With:  
For all randomized subjects, all administered concomitant medications and therapies, from signing of the informed consent until 30 days 
after the l ast dose of study treatment, must be 
recorded in the designated electronic Case Report Form (eCRF).  Administrative change  
Section: 9.4 Concomitant Medications and Therapies, paragraph 2  Replace:  
Concomitant medications required for the study or used proph ylactically should be described as 
such in the designated CRF.  Concomitant medications prescribed for â€œprn (as needed) useâ€ on an â€œas neededâ€ basis should not be reported With:  
Concomitant medications required for the study or used prophylactically should be described as 
such in the designated eCRF.  Concomitant 
medications prescribed for â€œprn â€ or â€œas needed â€ 
use should not be reported, unless actually Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 151 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
unless actually administered.  administered.  
Section: 9.4 Concomitant Medications 
and Therapies, paragraph 3  Replace:  
Blood or blood products are not considered concomitant medications and must be recorded on the appropriate eCRF.  With:  
Blood and blood products are not considered 
concomitant medications and must be recorded on the approp riate eCRF.  Administrative change  
Section:  9.4.1 Required Concomitant Medications  Replace:  
Required prophylactic medications should be initiated at least 24  hours prior to the first 
administration of carfilzomib.  With:  
Required prophylactic medications s hould be 
initiated at least 1 day prior to the first 
administration of carfilzomib.  Revised text for clarification  
Section:  9.4.1.1 (old) Antiviral Prophylaxis   Section moved to section 9.4.2.1 Revised for consistency with the current label  
Section:  9.4.1.1 (newly renumbered) Gastrointestinal Prophylaxis  Replace:  
Lansoprazole, 15  mg PO daily, or other oral 
proton- pump inhibitor according to institutional 
practice to prevent peptic ulcer disease is a required concomitant medication throughout the duration of study treatment with dexamethasone.  With:  
Lansoprazole or other oral proton- pump 
inhibitor , dosed  according to institutional 
practice, is required  to prevent peptic ulcer 
disease throughout the duration of treatment with dexamethasone.  Administrative change  
Section: 9.4.1.2 Pregnancy and Contraception, paragraph 1 Replace:  
Contraception must continue during study drug dose interruption intervals until 30 days after the 
last study drug administration.  With:  
Contraception must continue during study drug  
dose interruption intervals until 30 days 
(females) and 90 days (males)  after the last 
study drug administration.  If applicable, refer to 
the Country Specific Pregnancy and Contraceptive Supplement (refer  to 
Appendix K). Updated text to align with current  
carfilzomib core safety language  
Section: 9.4.1.2 Pregnancy and Contraception, paragraph 2 Replace:  
If the subject thinks she may be pregnant (e.g., if a menstrual period in a FCBP does not occur at With:  
If a subject thinks she may be pregnant (e.g., if a 
menstrual period in a n FCBP does not occur at Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 152 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
the anticipated time), study drug treatment must 
be interrupted, and a serum pregnancy test must 
be performed locally.  Study drug administration may resume after documentation of a nonpregnant state. the an ticipated time), study drug treatment must 
be interrupted, and a urine or serum pregnancy 
test must be performed locally.  Study drug administration may resume after documentation of a nonpregnant state.  
Section 9.4.2 Recommended Concomitant Medications, heading  Replace:  
Optional and Allowed Concomitant Medications  With:  
Recommended  Concomitant Medications Revised text for clarification  
Section 9.4.2 Recommended Concomitant Medications Replace:  
Allopur inol (or other approved uric acid-
lowering agent) in subjects at high risk for tumor lysis syndrome (TLS) due to high tumor burden may be prescribed at the investigatorâ€™s discretion.  Subjects should be well hydrated to reduce the risk of TLS and decline i n renal 
function; refer to the current Carfilzomib IB for safety guidance regarding TLS.  
Mycostatin or oral fluconazole to prevent oral thrush is optional and may be given at the investigatorâ€™s discretion.  
Subjects may receive antiemetics and antidiarrheal  agents as necessary.  Myeloid 
growth factors may be used if neutropenia occurs in accordance with American Society of Clinical Oncology (ASCO) Guidelines (Smith  2006), but should not be given 
prophylactically.  Subjects may receive RBC transfusions, eryth ropoietic stimulating agents, 
or platelet transfusions if clinically indicated in accordance with institutional guidelines.  Subjects may receive bisphosphonates.  
Palliative radiation for pain management is 
permitted with the written approval of the study With:  
9.4.2.1  Antiviral Prophylaxis 
Valacyclovir (or an equivalent antiviral agent ) is 
recommended for prophylaxis against herpes zoster reactivation.  
9.4.2.2 Uric Acid -lowering Agents  
Allopurinol or other approved uric acid -lowering 
agent  are recommended for subjects at high 
risk for tumor lysis syndrome (TLS) due to high tumor burden. Refer to the current Carfilzomib IB for safety guidance regarding TLS.  
9.4.2.3 Mycostatin or Oral Fluconazole  
Mycostatin or oral fluconazole may be given to  
prevent oral thrush throughout the duration of 
treatment with dexamethasone. 
9.4.2.4 Antiemetics and Antidiarrheal Agents 
Antiemetics and antidiarrheal agents  are 
recommended for prophylaxis and/or 
management of treatment -related 
gastrointestinal symptoms . Headings added for ease of use within the protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 153 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
medical monitor.  
Section: 9.4.3 Excluded Concomitant 
Medications and Therapies  Replace:  
The clinical investigator should contact the study medical monitor if concomitant use of excluded medications or therapies is requi red, to 
determine the appropriateness of continued study 
treatment administration.  
Concurrent therapy with a marketed or investigational anticancer therapeutic or radiation to large marrow reserves for either a palliative or therapeutic intent is prohibite d. 
Additionally, no alternative or investigational anticancer therapy (other than that received in the study) is allowed prior to documentation of PD per protocol -specified disease response 
criteria.  Any new anticancer therapies a subject received during the study (from randomization 
to study completion or early discontinuation) must be recorded in the designated eCRF.  
Corticosteroids for nonmalignant conditions (e.g., asthma, inflammatory bowel disease) equivalent to a dexamethasone dose > 4.0 mg/day or p rednisone >  20 mg/day are not 
permitted.  Higher steroid doses given short term for exacerbations of nonmalignant conditions (e.g., asthma flare) are permitted with the approval of the study medical monitor. Subjects requiring the use of excluded concomita nt 
medications or procedures will be withdrawn from study treatment.  
Plasmapheresis is not permitted at any time 
during the Screening period or while the subject With:  
If an investigator deems that use of an excluded concomitant medication or therapy is required, but does not believe tha t 
withdrawal from study treatment is indicated, 
he/she must contact the study medical monitor to determine if continued study treatment is acceptable.  
9.4.3.1 Anticancer Agents  
Therapy with a marketed or investigational anticancer agent that is not require d per this 
protocol is prohibited, while subjects remain on study treatment, and should be avoided prior to documentation of disease progression.   
9.4.3.2 Radiation Therapy  
Radiation to large marrow reserves is prohibited, however, focal palliative radiat ion 
is allowed with permission from the study medical monitor.  
9.4.3.3 Myeloid Growth Factors  
Prophylactic use of myeloid growth factors is prohibited, but they may be used for management of neutropenia, in accordance with American Society of Clinical Onco logy 
(ASCO) Guidelines (Smith  2006 ). 
9.4.3.4 Corticosteroids  
Corticosteroids should not be used to treat 
concurrent medical conditions , unless the dose 
remains less than the equivalent  of 4 mg/day Reorganized section 
and added headings for eas e of use within 
the protocol and to clarify concomitant medications and therapies that were excluded  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 154 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
is receiving study treatment.  If a subject who 
has started screening procedures requires 
plasmapheresis, or is anticipated to require 
plasmapheresis during or after the Screening period, this subject will be considered ineligible and will not be enrolled.  
For subjects requiring plasmapheresis while on study treatment every attempt should be made t o 
document disease status by IMWG criteria first, and then discontinue study treatment and enter LTFU for monitoring survival and PFS.  
Subjects requiring plasmapheresis must have 2 serum samples (for serum protein electrophoresis [SPEP] and immunofixation)  and 
at least one 24 -hour urine sample (urine  protein 
electrophoresis [UPEP] and immunofixation) obtained prior to the procedure.  of dexamethas one.  Short term  use of higher 
doses may be permitted to treat acute 
exacerbations of concurrent medical 
conditions , but this must be discussed with the  
study medical monitor  as soon as is possible.  
9.4.3.5 Plasmapheresis  
Plasmapheresis is not permitted at  any time 
during the Screening period or while the subject 
is receiving study treatment.  If a subject who has started screening procedures requires plasmapheresis, or is anticipated to require plasmapheresis during or after the Screening period, this subj ect will be considered ineligible.  
For subjects requiring plasmapheresis while on study treatment , every attempt should be made 
to document disease status by IMWG criteria first.  Study treatment  must be discontinued 
and the subject will enter LTFU.  
9.4.3. 6 Novel Agents  for Non-neoplastic 
Conditions  
The use of novel agents for non -neoplastic 
conditions is prohibited throughout the duration of treatment and for 30 days following the last dose of study treatment.  
Section: 10.1.1 Multiple Myeloma History and Prior Lines of Therapy Assessment, paragraph 1, sentence 1   Delete:  
Subjects must have confirmed and verifiab le 
diagnosis of multiple myeloma and documented 
relapse after at least 2 but no more than 
3 therapies for multiple myeloma.  Deleted text to remove redundancies  
Section: 10.1.1 Multiple Myeloma History and Prior Lines of Therapy Replace:  
A new therapy is also considered to start when a With:  
A new therapy is also considered to start when a Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 155 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Assessment, paragraph 1, bu llet 1, 
sentence 2 planned period of observation off -therapy is 
interrupted by a need for additional lines of 
therapy for the disease. planned period of observation off -therapy is 
interrupted by a need for additional lines of therapy.  
Section: 10.1.1 Multiple Myeloma History and Prior Lines of Therapy Assessment, paragraph 1, bullet 2  Replace:  
â€¢ An increase in treatm ent administration, with 
the intention of recapturing response in a patient with evidence of disease progression on that line of therapy is considered a new therapy.  With:  
â€¢ An increase in treatment administration, with 
the intention of recapturing response in a 
patient with evidence of disease progression 
on that line of therapy , is considered to be  a 
new line of  therapy.  Revised text for clarification  
Section: 10.1.1 Multiple Myeloma History and Prior Lines of Therapy Assessment, paragraph 2, after bullet 2  Add:  
If available, historical FISH data should be entered into the eCRF. The following results should be captured:  
o t(4;14) 
o t(6;14) 
o t(11;14) 
o t(14;16) 
o t(14;20) 
o Del 17p  
o Del 13 
o Chromosome 1 abnormalities  Updated to clarify that cytogenetic abnormalities fro m 
prior testing should be reported as part of multiple myeloma history  
Section: 10.1.3 Complete Physical Examination  Replace:  
A physical examination will be performed during Screening, prior to dosing on Day  1 of 
each cycle and at the EOT.  For Cycle 1 Da y 1, 
the screening physical examination may be used if within 7  days prior to Cycle  1 Day  1.  Physical 
exam may be completed up to 3 days prior to 
Day 1 of each cycle.  Additional physical With:  
A physical examination will be performed during Screening, prior to dosing on Day  1 of 
each cycle,  and at the EOT.  For Cycle  1 Day  1, 
the screening physical examination may be used if performed within 7  days prior to Cycle  1 
Day 1.  Physical exam may be completed up to 
3 days prior to Day  1 of each cycle.  At a Clarified required components of complete physical examination  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 156 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
examinations may be performed at the discretion 
of the study invest igator to assess potential AEs 
and for the medical management of the subject.  
Abnormal findings that should be recorded as an AE and will include but not limited to:  
â€¢ Examination of cardiovascular and respiratory systems  
â€¢ Abdominal examination  
â€¢ Peripheral n europathy (PN) assessment 
(including the neurologic physical exam)  
â€¢ Height (at Screening only)  
â€¢ Weight 
Body surface area determination should occur on Day 1 of each cycle prior to dosing.  BSA  is 
determined by a standard formula such as the Mosteller Formul a (Mosteller  1987 ):  BSA  (mÂ²) 
= ([Height (cm) Ã— Weight (kg)]/ 3600)Â½.  Abnormal physical examination findings prior to Screening will be captured as medical history.  Abnormal physical examination findings observed after the signing of informed consent will be recorded as AEs.  minimum, the physical exam should  include  
constitutional, abdominal, cardiovascular, and respiratory assessments.  
Clinicall y significant abnormal findings 
identified after the signing of informed consent must be reported as AEs and examined more frequently, as clinically indicated. Note: Clinically significant abnormal physical examination findings identified prior to the sign ing of informed 
consent should be reported as part of Medical History, not as AEs.  
BSA  is to be  determined by a standard formula , 
such as the Mosteller Formula ( Mosteller  1987
):  
BSA  (mÂ²) = ([Height (cm) Ã— We ight (kg)]/ 
3600  )Â½.  BSA must be recalculated and used 
for subsequent dose determina tions, if the 
subject experiences a weight change of â‰¥20%.  
Recalculations of BSA must be made using 
the same technique as used at baseline. 
Section: 10.1.4 Eastern Cooperative 
Oncology Group Performance Status  Replace:  
Eastern Cooperative Oncology Group Performance Status will be assessed during physical examination at Screening prior to randomization to determine eligibility and at the EOT visit.  Eastern Cooperative Oncology Group Performanc e Status grades and 
descriptions are tabulated in Appendix E. With:  
Eastern Cooperative Oncology Group Performance Status will be assessed at Screening and at the EOT visit.  Eastern Cooperative Oncology Group Performance Status grades and descriptions are tabulated in Appendix E. Revised text for clarification  
Section: 10.1.5 International Staging Replace:  With: Revised text for 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 157 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
System Stage Determination  Beta-2 microglobulin and albumin will be 
assessed at the central laboratory during 
Screening to determine ISS Stage at study  entry 
(refer to Appendix  B and Appendix H).  The ISS 
Stage determined within the 21 days prior to 
randomization will be used to stratify the subject.  These results must be evaluated at the central laboratory and available at the time of randomization. Beta-2 microglobulin and albumin will be 
assessed at the central laboratory during Screening, to determine ISS Stage (refer to Appendix B and  Appendix H).  These results 
must be available, prior to randomization.  consistency within 
overall protocol 
Section: 10.1.6 24 -Hour Urine   Delete:  
10.1.6 24 Hour Urine  
Subjects will be instructed to collect 24 -hour 
urine samples for assessment of UPEP at 
Screening, and as required during the study.  
This collection will occur over 2  days and will 
be assessed at the central laboratory.  For further 
instruction, refer to study laboratory manual.  Relocated text for clarity  
Section: 10.2 Multiple Myeloma Disease Assessments, paragraph 2 (old)   Delete:  
Results for disease assessments SPEP, UPEP, 
SFLC, and immunofixation must be available at 
Screening and before randomization and will be 
repeated on Cycle  1 Day  1 (unless  screening 
values are within 7  days of Cycle  1 Day  1).  
Post-Cycle  1 Day  1 UPEP and urine 
immunofixation will be measured:  
â€¢ Only if Cycle  1 Day  1 UPEP 
â‰¥ 200 mg/24  hours  
â€¢ To confirm a disease response (for very good 
partial response [VGPR] or better) or 
progression (if applicable)  Reorganized section for clarification  
Section: 10.2 Multiple Myeloma Replace:  With:  Reorganized section 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 158 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Disease Assessments, paragraph 3  Cycle 1 Day  1 (screening values may be used if 
obtained within 7 days prior to Cycle  1 Day 1), 
Cycle  2 Day  1 and each cycle thereafter, EOT 
and during LTFU (every 4  weeks, until PD 
and/or started a subsequent antimyeloma 
therapy):  
â€¢ SPEP, UPEP (24 -hour assess ment, no 
substitute method is acceptable), and immunofixation  
â€¢ SFLC  
â€¢ Quantitative immunoglobulins  
 Cycle  1 Day  1 before treatment begins  
(screening values may be used if obtained within 
7 days prior to Cycle  1 Day  1), and every 
28 days (Â± 4 days)  there after, at EOT and 
during LTFU if disease progression has not 
already been documented  (every 28 days Â± 
4 days , until PD and/or started a subsequent 
antimyeloma therapy):  
â€¢ SPEP, immunofixation  
â€¢ UPEP (24 -hour assessment, no substitute 
method is acceptable), and  immunofixation : 
post-Cycle  1 Day  1 measurements 
required only if Cycle 1 Day 1 UPEP 
â‰¥ 200 mg/24  hours or to confirm a disease 
response (for very good partial response [VGPR] or better) or progression (if applicable) 
â€¢ SFLC : post -Cycle  1 Day  1 measurements 
required only fo r SFLC measurable 
disease or to confirm stringent complete response (sCR) for clarification  
Section: 10.2 Multiple Myeloma Disease Assessments, paragraph 4   Add:  
Subjects will be instructed to collect 24 -hour 
urine samples for assessme nt of UPEP at 
Screening and as required during the study.  This collection will occur over 2  days and will 
be assessed at the central laboratory.  For further instructions, refer to the Central Laboratory Services Manual.  Reorganized section for clarificat ion 
Section: 10.2 Multiple Myeloma Disease Assessments, paragraph 5  Replace:  
Disease assessments at baseline are collected With:  
Radiological disease as sessments at baseline are Reorganized section for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 159 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
only after subject eligibility is confirmed by the 
study medical monitor and may be done after 
randomization (as long as it is done before the 
start of treatment and no more than 21  days 
before Cycle  1 Day  1 dosing) and include:  
â€¢ A plasmacytoma evaluation will be conducted at baseline only if a lesion is suspected clinically.  Historical assessment  
for extramedullary plasmacytoma evaluation done as part of standard of care may be used as baseline as long as it was performed within 30  days prior to Cycle 1 Day  1 dosing.  Extramedullary Plasmacytoma Assessment  
â€¢ If an extramedullary plasmacytoma is 
detected, evaluation will be repeated during  
treatment only to confirm a response of PR or 
better, or to confirm PD.  
â€¢ Measurable lesions must have a longest 
diameter of at least 1 cm and the product of 
cross diameter is at least 1 cm2.  
Plasmacytomas of lesser size are considered unmeasurable.  Bidim ensional lesion 
measurements must be performed and recorded in the designated eCRF.  The same technique may include: palpation, ultrasound, x-ray, computed tomography (CT) scan, 
magnetic resonance imaging (MRI), positron emission tomography (PET), or other  
standard -of-care method must be employed 
for each measurement  
â€¢ Skeletal survey will include lateral Skeletal Survey  collected after subject eligibility is confirmed 
and may be done after randomization (as long as they are  done before the start of treatment). 
Radiological disease assessments that were 
done per standard of care within 30  days 
before Cycle  1 Day  1 can be used as study 
baseline disease assessments.  They  include:  
â€¢ A plasmacytoma evaluation will be 
conducted at baseline, only if a lesion is suspected clinically.  Extramedullary Plasmacytoma Assessment  
â€¢ If an extramedullary plasmacytoma is 
detected, evaluation will be repeated during treatment, to confirm a response of PR or better or to assess for  PD based on 
plasmacytoma. 
â€¢ Plasmacytomas are considered measurable 
if they have a longest diameter of at least 1 
cm and the product of cross di ameter 
measurements is at least 1 cm
2.  
Plasmacytomas of lesser size are considered 
unmeasurable.  Bidimensional measurements must be recorded in the designated eCRF.  The same technique must be used to 
evaluate plasmacytomas throughout the 
duration of study participation and may 
include: palpation, ultrasound, x -ray, 
computed tomography (CT) scan, magnetic 
resonance imaging (MRI), positron emission tomography (PET), or any other technique 
that is considered to be standard of  care. 
Skeletal Survey  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 160 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
radiograph of the skull, anteroposterior and 
lateral views of the spine, and anteroposterior 
views of the pelvis, ribs, femora, and humeri.  
The skeletal survey will be conducted at baseline and will be repeated if worsening clinical symptoms suggest PD, or as clinically indicated. A historical survey may be used if performed within 30 days prior to 
Cycle  1 Day  1. â€¢ Skeletal survey will include lateral 
radiograph of the skull, anteroposterior and lateral views of the spine, and anteroposterior 
views of the pelvis, ribs, femora, and humeri.  
The skeletal survey will be conducted at baseline and will be repeated if worsening clinical symptoms suggest PD, or as clinically indicated.  
â€¢ Other radiologic modalities for 
performing skeletal assessment (e.g., 
low-dose CT scan) are acceptable, in 
accordance with regional standards.  
Section: 10.3.1 Disease Response and Progression Assessments  Replace:  
Determination of disease response must be based on the reported values from the central laboratory results not on local laboratory results.  Local laboratory results may be used for hypercalcemia (correct ed calcium using 
albumin) but a confirmatory sample should be collected and sent to the central laboratory for documentation.  As with all clinically significant or relevant local laboratory results, hypercalcemia values should be entered into the Case Rep ort Form (CRF).  
Response will be determined by the investigator based on the disease assessments described above and the IMWG -URC (see definitions in 
Appendix G).  Myeloma response will be 
assessed at each cycle prior to the initiation of subsequent cycles . With:  
Determination of disease response must be based on the reported values from the central laboratory.  Local laboratory results may be used for hypercalcemia (corrected calcium based on 
albumin), but a confirmatory sample should be collected and sent  to the central laboratory for 
documentation.  
Investigator -determined responses must be  
based on results from the central laboratory  
and must be consistent with the IMWG -URC 
(see definitions in Appendix G).   Reworded text for clarification  
Section: 10.3.2 Tumor Response Assessment, bullets 1, 2, 3, 4, and 5  Replace:  
â€¢ All laboratory -based PD (except bone With:  
â€¢ All laboratory -based PD (except bone Reworded text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 161 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
marrow sample) and all response categories 
require 2 consecutive assessments made at 
any time before initiation of any new therapy.  
Confirmatory lab samp les should be 
separated by at least 1 calendar day.  
â€¢ All response categories also require no 
evidence of progression including new bone lesions if radiographic studies were performed.  
â€¢ The preferred method for a confirmation of 
CR or sCR is a bone marrow bio psy.  
However, an aspirate slide is acceptable for 
confirmation of CR (a confirmatory bone marrow sample is not required). 
â€¢ Extramedullary plasmacytoma evaluation (if 
present at Screening).  It is not required to 
have 2 consecutive radiographic tests to confirm response or progression of 
extramedullary plasmacytoma.  
â€¢ In the case where a patient does not have measurable M -protein by UPEP at baseline 
(i.e., screening UPEP <  200 mg/24  hours), 
when SPEP is consistent with response (i.e., â‰¥ PR), 2 consecutive UPEP  must be 
performed to confirm response.  marrow sample) and all response categories 
require 2 consecutive assessments made at any time before initiation of new therapy.  
â€¢ All response categories require that there be 
no evidence of disease progression,  including 
confirmation of no new bone lesions , if 
radiographic studies were performed.  
â€¢ The preferred method of  confirm ing CR or 
sCR is a bone marrow biopsy; however, a 
bone marrow aspirate is  also acceptable for 
confirm ation of CR.  
â€¢ Extramedullary plasmacytoma evaluation (if 
present at Screening).  Two consecutive 
radiographic tests are not required to 
confirm response or progression of 
extramedullary plasmacytoma.  
â€¢ In the case where a patient does not have measurable M -protein by UPEP at baseline 
(i.e., baseline UPEP <  200 mg/24  hours), 
when SPEP is consistent with response (i.e., â‰¥ PR), 2 consecutive UPEP measurements 
must be performed to confirm response.  
Section: 10.3.3 Disease Progression, paragraph 1, sentence 2  Replace:  
Signs  and symptoms related to disease 
progression (e.g., pathologic fracture in a subject with progressive multiple myeloma) should be reported in the appropriate CRF as an AE or as an SAE (if the event in question meets the criteria for seriousness).  With:  
Signs and symptoms related to disease 
progression (e.g., pathologic fracture in a subject 
with progressive multiple myeloma) should be reported in the appropriate eCRF as an AE or as 
an SAE (if the event in question meets the criteria for seriousness).  Revise d text for 
consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 162 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section:10.3.3 Disease Progression, 
paragraph 2  Replace:  
Decisions to discontinue subjects due to PD (including PD due to development of hypercalcemia attributed solely to recurrence/progression of multiple m yeloma) 
must be based on central laboratory evaluation, and must also be verified by the medical monitor. Confirmation of PD will require 2 consecutive central laboratory evaluations that indicate PD.  There is no specified time requirement between the 2 central laboratory 
evaluations.  Local laboratory evaluation will not 
be accepted and change of treatment decisions may only be made based on results of central laboratory evaluation.  Progressive disease by non-laboratory based assessment (i.e., 
plasmacyto ma or skeletal lesion) does not 
require confirmatory report.  The assessments outlined in Appendix  B are required for PD.  With:  
Study treatment should not be discontinued 
on the basis of disease progression, until PD 
has been appropriately confirmed per 
IMWG-URC.  Disease progression during 
LTFU must also be  confirmed by these same 
criteria.  Confirmation of PD will require 2 
consecutive central laboratory evaluations that indicate PD , except in cases where PD is based 
on extramedullary lesions or hypercalcemia that is attributed solely to PD.   These 
assessments should be separated in time by at 
least 1 calendar day, but no more than 28 Â± 4 
calendar days.   Local laboratory results may 
not be used to determine or confirm disease progression, except when PD is  based on  
hypercalcemia.   The assessments outlined in 
Appendix B are required for PD  determination . Clarified requirements 
discontinuation of subjects for PD  
Section: 10.4 Laboratory Tests, paragraphs 1 and 2  Replace:  
Laboratory tests for efficacy and saf ety during 
scheduled and unscheduled study visits will be performed at a central laboratory and results recorded in the study database.   Additional 
laboratory samples may be collected and analyzed by local laboratories if immediate results are necessary for management of treatment- emergent adverse events (TEAEs) or 
dosing determination.  Investigator evaluation of disease response should be based solely on the central laboratory results, not on local laboratory. With:  
Laboratory tests for efficacy and safety during scheduled and unscheduled study vis its, 
including screening  will be performed at a 
central laboratory.  Additional safety laboratory 
samples must also be collected and analyzed by 
local laboratories if the results are necessary to 
determine the appropriateness of dose administration.  In rar e circumstances, when 
the central laboratory is unable to provide results for tests that are needed to determine eligibility, the study medical monitor may grant permission for local laboratory results 
to be applied to the screening requirements.  Clarified because at post Cycle 4 there are no Day 8 lab samples required  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 163 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Clinical laboratory samples may be obtained 
anytime within the 24  hours prior to the 
carfilzomib administration and must be reviewed 
prior to the start of carfilzomib infusion on Days  1, 8, and 15 of all cycles.  Local la bs may also be required for 
management of treatment -emergent adverse 
events (TEAEs) .  Laboratory tests for disease 
assessment are described in Section 10.2.  
Safety  samples must be obtained within the 1 
day prior to carfilzomib administration and the 
result s must be  reviewed prior to the start of the 
carfilzomib infusion s on Days  1, 8, and 15 of 
Cycles 1 to 4 . Beyond Cycle  4, these labs are 
only required on Days  1 and 15 of each cycle.  
Section: 10.4.1 Hematology, paragraph  1 Replace:  
Hematology (central laboratory, Table 9) will be performed during Screening, on Days  1, 8, and 
15 for Cycles  1 to 4, and EOT.  Beyond Cycle  4 
labs will be performed on Days  1 and 15 of each 
cycle.  For Cyc le 1 Day  1, full hematology from 
Screening can be used if within 3 days.  For 
subsequent visits, hematology may be completed up to 24  hours prior to scheduled dose.  With:  
Hematology assessments  (Table  8) will be 
performed during Screening, on Days  1, 8, and 
15 for Cycles  1 to 4, and EOT.  Beyond Cycle  4 
labs will be performed on Days  1 and 15 of each 
cycle.  For Cycle  1 Day  1, hematology 
assessments from Screening can be used, if they 
were obtained within 3 days prior to 
carfilzomib administration .  For sub sequent 
visits, hematology assessments may be 
completed up to 1 day prior to the scheduled 
dose.  Revised text for consistency within overall protocol  
Section: 10.4.1 Hematology, Table 8  Replace:  
WBCs with complete manual or automated differential to inclu de:
 a 
Total neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  With:  
WBC count with complete differential to 
include: a 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 164 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
 
RBCs   
RBC count  
Section: 10.4.1 Hematology, Table 8, 
footnote a  Replace:  
a Absolute or percentage will be acceptable.  With:  
a Absolute counts or percentage will be 
acceptable. Revised text for 
consistency within overall protocol  
Section: 10.4.2 Serum Chemistry, paragraph 1  Replace:  
Full serum chemistry panel (central laboratory, Table  10) will be performed during Screening, 
on Days  1, 8, and 15 for Cycles  
1 to 4, and EOT.  
Beyond Cycle  4, labs will be performed on 
Days  1 and 15 of each cycle.  For Cycle 1 Day  1, 
full chemistr y from Screening can be used if 
within 3  days.  For subsequent visits, chemistries 
may be completed up to 24  hours prior to 
scheduled dose. With:  
A serum chemistry panel (Table  9) will be 
performed during Screening, on Days  1, 8, and 
15 for Cycles  1 to 4, and EOT.  Beyond Cycle  4, 
labs will be performed on Days  1 and 15 of each 
cycle.  For Cycle  1 Day  1, serum  chemistry 
assessments from Screening can be used , if 
performed within 3  days prior to carfilzomib 
administration .  For subsequent visits, serum 
chemi stries may be completed up to 1 day prior 
to the scheduled carfilzomib dose.  Revised text for consistency within overall protocol  
Section: 10.4.2 Serum Chemistry, Table 9, Note at bottom of Table   Delete:  
Note:  If AST or ALT is >  3 Ã— ULN, the 
â€œevaluation  of treatment -emergent liver 
abnormalitiesâ€ eCRF should be completed.  Removed reference to this eCRF, which is no longer being utilized 
Section: 10.5 Electrocardiogram, sentence 2 Replace:  
Electrocardiogram will be required in all subjects at Screening an d EOT.  With:  
Electrocardiogram s will be required from  all 
subjects at Screening and EOT.   Administrative change  
Section: 10.6 Echocardiogram, paragraphs 1 and 2  Replace:  
A 2-D transthoracic echocardiogram (ECHO) to 
assess LVEF for eligibility purposes will be conducted on all potential subjects during Screening and will also serve as the baseline ECHO.  If transthoracic ECHO is not available, 
multigated acquisition (MUGA) will be With:  
A 2-D transthoracic echocardiogram (ECHO) is 
required  to assess LVEF  during Screening and 
will also serve as the baseline  ECHO.   If 
transthoracic ECHO is not available, multigated acquisition (MUGA) will be acceptable for Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 165 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
acceptable for screening LVEF evaluation.  
Additionally, any subject with a c linically 
significant cardiac -related AE should be 
evaluated by a cardiologist and have a follow- up 
ECHO if medically indicated.  LVEF evaluation.  
Any subject with a clinically significant cardiac 
AE should be evaluated by a cardiologist and must have a follow- up ECHO, if medically 
indicated.  
Section: 10.7 Patient Reported Outcomes, paragraph 2, sentences 1 and 2 Replace:  
All questionnaires should be collected on Day  1 
of Cycle  1, then every other cycle during 
treatment.  Questionnaires listed below should be 
comp leted by the subject prior to drug 
administration during treatment cycles:  With:  
All questionnaires should be collected on Day  1 
of Cycle  1, then every second  cycle (Cycle 1, 3, 
5, etc)  during treatment.  The questionnaires 
listed below should be completed by the subject 
prior to drug administration during treatment cycles:  Revised text for consistency within overall protocol  
Section: 10.8 Healthcare Resource Utilization  Replace: 
Healthcare resource utilization data related to 
AEs will be collected for all subjects during the 
study on the eCRF.  These data may include inpatient care, outpatient care, surgery, and use of other medications and therapeutic procedures related to AEs. With:  
Healthcare resource utilization data related to AEs will be collected for each subject .  These 
data may include inpatient care, outpatient care, surgery, and use of other medications and therapeutic procedures related to AEs.  Details 
on hospitalizations (not related to AEs) will also be collected.  Added text for collection of  
hospitalizations not related to AEs to align to with previous section  
Section: 10.9 Correlative Studies  Replace:  
Samples for correlative studies will be collected only after Screening laboratories confirm study eligibility for the subject.  Intensive PK  and PDn 
will be conducted as a substudy at selected sites.  The target number of subjects who participate in the intensive PK/PDn substudy is approximately 15 per arm.  Sparse PK samples will only be collected at all other sites from subjects who consent to the additional testing.  With:  
Samples for correlative studies will be collected only after confirmation of study eligibility.  
Intensive PK and PDn will be conducted as a substudy at selected sites.  Sparse PK samples will be collected at all other site s, from subjects 
who consent to the additional testing.  Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 166 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 10.9.1 Intensive 
Pharmacokinetics/Pharmacodynamics Substudy, paragraph 1  Replace:  
Approximately 15 subjects in each arm will participate in the intensive PK/PDn substudy at 
select sites.  On both arms, whole blood and PBMCs will be collected from all subjects on Days  1, 15, 16, 17, and 22 of Cycle  1 at the 
following timepoints summarized in Table  11.  
Directions for collection, processing, and 
shipping of PDn blood samples are provided in the laboratory manual.  The actual time of when the PDn sample was collected will be recorded.  With:  
Approximately 15 evaluable subjects in each 
arm will participate in the intensive PK/PDn substudy at sele ct sites.  On both arms, whole 
blood and PBMCs will be collected from all subjects on Days  1, 15, 16, 17, and 22 of Cycle  1 
at the timepoints (summarized in Table  10).  
Directions for collection, processing, and shipping of PDn blood samples are provided i n 
the Central Laboratory Services  Manual.  The 
actual time of when the PDn sample was collected will be recorded.  Revised text for consistency within overall protocol  
Section: 10.9.1 Intensive Pharmacokinetics/Pharmacodynamics Substudy,  Table 10 Replace:  
Timepoints in days.  With:  
Timepoints in hours. Revised text for consistency within overall protocol  
Section: 10.9.1 Intensive Pharmacokinetics/Pharmacodynamics  
Substudy, paragraph 2, sentence 1 Replace:  
For both arms, PK plasma samples will be collected from all subjects for determination of plasma concentrations of carfilzomib on treatment Day  15 of Cycle  1 at the following 
time points:  With:  
For both treatment  arms, PK samples will be 
collected from all subjects for determination of plasma concentrations  of carfilzomib on 
treatment Day  15 of Cycle  1 at the following 
time points:  Revised text for consistency within overall protocol  
Section: 10.9.1 Intensive Pharmacokinetics/Pharmacodynamics Substudy, paragraph 3  Replace:  
The actual time of PK sample collection will be recorded.  Samples will be collected within Â± 5 minute time window around the nominal 
time points (except for the time point immediately prior to the end of infusion in which the PK collection needs to occur prior to end of infusion).  Collec ting PK samples at times 
other than nominal time points will not qualify 
for protocol deviation.  These samples will be With:  
The actual time of PK sample collection will be recorded.  Samples will be collected within Â± 5 minute time window s around the nominal 
time points (except for the time point immediately prior to the end of infusion , for 
which the PK collect ion needs to occur prior to 
the end of infusion).  Directions for collection, 
processing, and shipping of PK samples are 
provided in the Central Laboratory Services Revised text for clarification  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 167 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
assessed at a central laboratory.  Directions for 
collection, processing, and shipping of PK blood 
samples are provided in the laboratory manual.  Manual.  
Section: 10.9.2 Sparse Pharmacokinetic Sampling, paragraph  1 Replace:  
Sparse PK samples will only be collected at the sites from subjects who do not participate in the intensive PK/PDn substudy and who consent to the additional testing.  The actual time of the PK sample collection will be recorded.  These samples will be assessed at a central laboratory.  Directions for collection, processing, and shipping of PK blood samples are provided in the lab manual. With:  
Sparse PK samples will be collected from subjects who do not participate in the intensive PK/PD n substudy and who consent to the 
additional testing.  The actual time of the PK sample collection will be recorded.  These samples will be assessed at a central laboratory.  Directions for collection, processing, and shipping of PK samples are provided in the 
Central Laboratory Services Manua l. Administrative change  
Section: 10.10.1 Long -term Follow -up 
Before Disease Progression, paragraph  
1, sentences 1 and 2  Replace:  
For subjects who discontinued treatment before disease progression occurred, disease as sessment 
measurements will be performed (using the central laboratory results) every 4  weeks (every 
28 days Â± 4 days) until the subject has PD or 
until withdrawal of consent (Appendix B).  
Effort should be made to obtain confirmatory PD 
results (refer to Appendix G) prior to the 
initiation of new antimyeloma therapy.  With:  
For subjects who discontinue treatment before disease progression occurs, disease assessment s 
will be performed (using the central laboratory results) every 28  days Â± 4 days until the sub ject 
has PD or until withdrawal of consent (Appendix B ).  Confirmatory PD results (refer to 
Appendix G ) must be obtained  prior to the 
initiation of new antimyeloma therapy.   Aligned with previous  
section as there will be no anticancer therapy until PD.  
Section: 10.10.2 Long -term Follow -up 
After Disease Progression (For Survival)  Replace:  
After completion of the EOT visit, subjects who have discontinued due to disease progression will be followed for survival status queried by 
telephone contact or other method approximately 
every 3  months, or as needed until study closure. With:  
After completion of the EOT visit, subjects who have discontinued due to disease progression will be followed for survival status , queried by 
telephone contact or other method , 
approximately every 12 weeks Â±  28 days , or as 
needed until study closure.  Revised text for consistency within overall protocol  
Section: 11.1 Withdrawal of Subjects Replace:  With:  Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 168 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
from Study Treatment, paragraph 1, 
bullet 5  â€¢ Non-compliance  â€¢ Non-compliance  with study requirements  
Section: 11.1 Withdrawal of Subjects 
from Study Treatment, paragraph 1, bullet 7  Replace:  
â€¢ Study terminated by Onyx  With:  
Study terminat ion by Sponsor  Admin istrative change  
Section: 11.1 Withdrawal of Subjects from Study Treatment, paragraph 1, bullet 8  Replace:  
â€¢ Physician decision  With:  
â€¢ Investigator  decision Administrative change  
Section: 11.1 Withdrawal of Subjects from Study Treatment, paragraph 3  Replace : 
If the reason for study treatment discontinuation is the occurrence of an AE, the subject will be followed by the investigator until such event(s) resolve, stabilize, and, according to the investigatorâ€™s judgment, there is no need of further follow -up. With:  
If the reason for study treatment discontinuation is the occurrence of an AE, the subject will be followed by the investigator until such event(s) resolve s, stabilize s, or, according to the 
investigatorâ€™s judgment, no longer requires  
follow -up. Revise d text for 
clarification  
Section: 11.1 Withdrawal of Subjects from Study Treatment, paragraph 4  Replace:  
Study treatment discontinuation due to progression should be recorded as â€œdisease progression.â€ If the disease progression meets any of the serious cr iteria, as outlined in Section 
12.3 then it should also be recorded as a SAE in the AE eCRF.  With:  
Study treatment discontinuation due to PD 
should be recorded as â€œdisease progression.â€  Removed text to avoid duplication  
Section: 11.2 Withdrawal of Subjec ts 
from Study, paragraph 1, bullet 3  Replace:  
â€¢ Onyx  decision With:  
â€¢ Sponsor  decision Administrative change  
Section: 11.3 Study Termination, paragraph 1, sentences 1 and 2  Replace:  
Onyx has the right to terminate this study or to terminate a study site from participating in the 
study at any time. Reasons for study or site termination may include With:  
Sponsor  has the right to terminate this study or 
to terminate a study site from participating in the study at any time. Reasons for study or site termination ma y include , but are not limited to : Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 169 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section 12 Adverse Events and 
Serious Adverse Events  Replace:  
An AE is any untoward medical occurrence in a study subject administered an IP regardless of the causal relationship with treatment.  
An AE, therefore, can be any unfavorable and 
unintended sign (including laboratory finding), symptom, or disease temporally associated with participation in an investigational study, whether or not considered drug-related.  In addition to new events, any increase in the severity or frequency of a pre -existing condition that occurs 
after the subject signs the ICF for participation is considered an AE.  This includes any side effect, injury, toxicity, or sensitivity reaction.  All reported AEs will be coded usin g the current 
version of Medical Dictionary for Regulatory Activities (MedDRA).  With:  
An AE is any untoward medical occurrence in a subject administered a study drug and which is 
not necessarily caused by the study drug . An 
AE can therefore be any unfavora ble and 
unintended sign ( e.g. an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal product, 
combination product, or medical device , 
whether or not considered related to the 
product .   In addition to new events, any 
worsening  of a pre -existing condition that 
occurs after the subject signs the ICF for participation is considered an AE.  Worsening 
indicates that the pre- existing medical 
condition or underlying disease has increased in severity, frequency, and/or duration more than would be expected, and/or has an 
association with a significantly worse outcome 
than expected. This includes any side effect, 
injury, toxicity, or sensitivity reaction.  All reported AEs will be coded using the current version of Medic al Dictionary for Regulatory 
Activities (MedDRA).  Revised text for clarification  
Section: 12.1.2 Severity, paragraph 1  Replace:  
Whenever possible, the National Cancer Institute -Common Terminology Criteria for 
Adverse Events (NCI- CTCAE) Version  4.03 
should be used to describe the event and for 
assessing the severity of AEs (NCI  2010).  With:  
Whenever possible, the National Cancer Institute -Common Terminology Criteria for 
Adverse Events (NCI- CTCAE) Version  4.03 
should be used to describe the event and to  
assess the severity of AEs (NCI  2010).  Administrative change  
Section: 12.1.2 Severity, paragraph 3, sentence 2  Add:  
Where applicable, clinical sequelae (not the Added text to clarify recording of 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 170 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
laboratory abnormality) are to be recorded as 
the AE.  laborato ry 
abnormalities  
Section: 12.1.3 Duration, sentence 1  Replace:  
The start and stop date for all AEs will be 
recorded.  The start date is the first date that the subject was aware of the AE and the end date is the date that the event totally resolved or returned to baseline.  With:  
The start and stop date s for all AEs will be 
recorded.  The start date is the first date that the subject was aware of the AE and the end date is the date that the event has changed in grade,  
totally resolved, or returned to baseli ne. Clarified definition of AE duration for events that change in grade  
Section: 12.1.3 Duration, sentence 2   Add:  
Any changes in grade should be recorded as a separate event.  Clarified definition of AE duration for events that change in grade  
Section: 1 2.1.4 Causality, paragraph 1 Replace:  
A relationship between carfilzomib and an adverse event is considered causal if there is at least a reasonable possibility the adverse event was caused by carfilzomib administration, i.e., the relationship cannot be ruled out.  With:  
A relationship between study drug  and an 
adverse event is considered causal if there is at least a reasonable possibility the adverse event was caused by carfilzomib administration, i.e., the relationship cannot be ruled out. Administrative change  
Section: 12.1.4 Causality, paragraph 4   Delete:  
In the event of a possible drug -related AE, the 
investigator should to the best of his/her ability 
assess its relationship to each of the study drugs: 
carfilzomib and/or dexamethasone.  Removed text th at was 
duplicated  
Section: 12.2.1 General, paragraph 3, sentence 3 Replace:  
For subjects who complete the EOT visit less than 30 days following the last dose of study 
drug, a follow -up of ongoing AEs should be 
attempted by telephone and documented in the subjectâ€™s source file.  With:  
For subjects who complete the EOT visit less than 30 days following the last dose of study 
drug, a follow -up of ongoing AEs should be 
documented in the subjectâ€™s source file.  Revised to clarify that follow up did not necessarily need to be done by telephone  
Section:  12.2.2 Disease Progression   Delete:  Removed text to avoid 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 171 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
12.2.2 Disease Progression  
Disease progression will be documented in an 
eCRF intended to capture PD information and 
will be analyzed as a study endpoint.  Signs and 
symptoms rela ted to disease progression 
(e.g.,  pathologic fracture in a patient with 
progressive multiple myeloma) should be 
reported in the appropriate case report form as 
an AE or as a SAE (if the event in question 
meets the criteria for seriousness).  Verbatim 
terms  such as â€œdisease progression,â€ 
â€œprogressive disease,â€ etc. should not be 
reported as AEs or SAEs unless the investigator 
considers the progression to be atypical, 
accelerated, or caused by the study drug.  
Similarly deaths occurring as a result of disease  
progression should be reported on the eCRF 
intended to capture death information and should 
not be reported as SAEs.  duplication  
Section: 12.3 Serious Adverse Event 
Definition, bullet 2  Replace:  
â€¢ Life-threatening experience defined a s any 
adverse experience that places the subject, in the view of Onyx or investigator, at immediate risk of death at the time of occurrence (i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death).  With:  
â€¢ Life threatening experience defined as any 
adverse experience that places the subject, in 
the view of the Sponsor  or investigator, at 
immediate risk of death at the time of occurrence (i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death). Administrative change  
Section: 12.4 Serious Adverse Event Reporting and Documentation Requirements, paragraph 1  Replace:  
Onyx Drug Safety must be notified of the occurrence of any SAE within 24  hours of the 
investigator , designee, or site personnelâ€™s 
knowledge of the event.  The SAE will be With:  
Amgen  Global Patient  Safety must be notified 
of the occurrence of any SAE within 24 hours of 
the investigator, designee, or site personnelâ€™s 
knowled ge of the event.  The SAE will be Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 172 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
reported by completing and submitting the SAE 
report form through the EDC system.  In the 
event that the EDC system is not available, paper SAE report forms may be used to report the SAE 
to Onyx Drug Safety.  Please refer to the SAE Reporting Guidelines in the study reference manual.  reported by completing and submitting the SAE 
report form through the EDC system.  In the event that the EDC system is not available, paper SAE report forms may be used to report the SAE to Amgen  Global Patient  Safety.  Pl ease refer 
to the SAE Reporting Guidelines in the study reference manual.   
Section: 12.4 Serious Adverse Event Reporting and Documentation Requirements, paragraph 3, sentence 2  Replace:  
Onyx may request for additional source documentation pertaining to the SAE from the investigational site.  With:  
The sponsor  may request for additional source 
documentation pertaining to the SAE from the investigational site.  Administrative change  
Section: 12.4 Serious Adverse Event Reporting and Documentation Requirements, paragraph 4  Replace:  
Onyx is responsible for notifying the appropriate global health authorities of SAEs, when  required, and in accordance with 
applicable laws and regulations.  With:  
The Sponsor  is responsible for notifying the 
appropriate global health authorities of SAEs, 
when  required, in accordance with applicable 
laws and regulations.  Administrative change  
Section: 12.4 Serious Adverse Event Reporting and Documentation Requirements, paragraph 5  Replace:  
Properly anonymized and de-identified 
documents (e.g. hospital discharge summaries, autopsy reports, and/or death certificates), as available will be provided to Onyx Drug Safety.  With:  
Properly anonymized and de -identified 
documents (e.g. hospital discharge summaries, autopsy re ports, and/or death certificates), as 
available will be provided to Amgen  Global 
Patient  Safety.  Administrative change  
Section: 12.5 Pregnancy and Lactation Exposure Reporting, paragraph 1 Replace:  
Pregnancy occurring in a female subject or in a male subj ectâ€™s partner while enrolled in this 
clinical study through 30 days after the last dose 
of any study drug was received, although not considered an SAE, must be reported on a Pregnancy Monitoring Form to Onyx Drug Safety and the contract research organizati on 
(CRO) within 24  hours of the investigator, With:  
Pregnancy, although not considered an SAE, must be reported  to Amgen  Global Patient  
Safety  within 24 hours of the investigatorâ€™s 
awareness, if the pregnancy  has occurred 
within 30 days of study treatment (for female participants) or within 90 days of study treatment (for female partners of male participants).  The pregnancy will be Updated the window for breastfeeding following the last dose of drug administration.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 173 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
designee, or site personnel learning of the 
pregnancy.  reported on a Pregnancy Notification 
Worksheet. Amgen Global Patient Sa fety will 
follow- up with the investigator regarding 
additional information that may be requested. 
Section: 12.5 Pregnancy and Lactation 
Exposure Reporting, paragraph 2, sentence 1 Replace:  
If the subject becomes pregnant while taking an Onyx drug, the study treatment will be immediately discontinued.  With:  
If a subject becomes pregnant while taking an 
Amgen  drug, the study treatment will be 
immediately discontinued.  Admini strative change  
Section: 12.5 Pregnancy and Lactation  
Exposure Reporting, paragraphs 4, 5, and 6 Replace:  
If the outcome of the pregnancy meets a criterion for immediate classification as an SAE (e.g., spontaneous abortion, stillbirth, neonatal death, fetal or neonatal congenital anomaly), the 
investigator will report the SAE via the EDC system. 
Newborns should be followed for a minimum of 
12 weeks.  
The investigator is responsible for notifying the 
Institutional Review Board (IRB) or Independent 
Ethics Com mittees (IEC) in accordance with 
local regulations, of all SAEs.  Onyx may request for additional source documentation pertaining to the SAE from the investigational site.  If a subject is permanently withdrawn from the study due to a SAE, this  information  must be 
included in the initial or follow -up SAE report in 
the eCRF.  With:  
If the outcome of the pregnancy meets a criterion for immediate classification as an SAE (e.g., spontaneous abortion, stillbirth, neonatal death, fetal or neonatal congenital anoma ly), the 
investigator will report the event as an SAE.  
With authorization of the subject or female 
partner, n ewborns should be followed- up at 6 
and 12 months of age . 
If a female subject breastfeeds during treatment 
with carfilzomib or up to 30  days following the 
last dose of study drug administration, the 
investigator will notify Amgen Global Patient 
Safety within 24 hours of learning of her 
breastfeeding.  The investigator will discuss the risks and concerns of breastfeeding while taking an IP.  The subject will be required to either discontinue breastfeeding or study treatment . 
The investigator will complete a Lactation 
Notification Worksheet. Amgen Global 
Patient Safety will follow -up with the 
investigator regarding additional information 
that may be requ ested . Updated text to align 
with current carfilzomib core safety language  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 174 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 12.5 Pregnancy and Lactation 
Exposure Reporting, paragraph 7  Delete:  
The investigator will complete a Pregnancy 
Monitoring Form and report the information 
regarding the p regnancy, outcome, and status of 
the newborn, as appropriate . Updated text to align with current carfilzomib core safety language  
Section: 12.6 Death Reporting  Replace:  
All deaths that occur from signing of informed consent until 30  days after the last do se of study 
drug are to be reported as SAEs (other than due to PD - refer to Section  12.4).  Deaths  occurring 
after the EOT visit do not need to be reported as SAEs.  Additional details of the event (such as the primary and contributory causes of death) should be reported on the death eCRF.  With:  
All deaths that occur from signing of informed consent until 30  days after the last dose of study 
drug are to be reported as SAEs ( unless  due to 
PD - refer to Section 12.4).  Deaths  occurring 
after the EOT visit do  not need to be reported as 
SAEs.  Additional details of the event (such as the primary and contributory causes of death) should be reported on the end of study eCRF.  Administrative change  
Section: 13 Statistical Considerations, sentence 2 Replace:  
Furthe r details of the analyses will be provided 
separately in the Statistical Analysis Plan (SAP).  With:  
Further details will be provided separately in the Statistical Analysis Plan (SAP).  Administrative change  
Section: 13.1.2 Secondary Endpoints, bullet 4   Add: 
â€¢ Sparse PK  Revised text for consistency within overall protocol  
Section: 13.3.2.1 Primary Efficacy Endpoint, paragraph 1, bullet 2 Replace:  
â€¢ Refractory to proteasome inhibitor ([PI] 
bortezomib) treatment (Yes versus No)  With:  
â€¢ Refractory to bortezomib tre atment (Yes 
versus No)  Revised text for 
consistency within overall protocol  
Section: 13.3.2.1 Primary Efficacy Endpoint, paragraph 3, sentence 3 Replace:  
Investigator -assessed responses will be analyzed 
as a supportive analysis of ORR.  With:  
Investigator -assessed responses will be analyzed 
as a supportive analysis of ORR, as will  
IRC- assessed responses,  if an IRC is 
convened . Added text regarding potential use for an IRC 
Section: 13.3.2.2.1 Progression- Free Replace:  With:  Added text regarding 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 175 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Survival, paragraph 2  The primary analy sis of PFS will be based on 
ORCA -assessed outcomes.  The PFS outcomes 
assessed by the investigator will serve as a 
supportive analysis of PFS.  The primary analysis of PFS will be based on 
ORCA -assessed outcomes.  The PFS outcomes 
assessed by the inve stigator serve as a supportive 
analysis of PFS , as will IRC-assessed 
outcomes, if an IRC is convened . potential use for an 
IRC 
Section: 13.3.3.2 Safety Laboratory Values, paragraph 1  Replace:  
For hematology, chemistry, and other labor atory 
values, the baseline values and changes from baseline to the minimum, maximum, and last observed values will be summarized descriptively by visit.  With:  
For hematology, chemistry, and other laboratory values, the baseline values, changes from baselin e by visit,  the minimum, maximum, and 
last observed values will be summarized descriptively. Administrative change  
Section: 13.3.3.2 Safety Laboratory Values, paragraph 4  Replace:  
Laboratory test results will be graded using the NCI-CTCAE (Version 4.03).   Shifts in 
laboratory toxicity grades to outside the normal range will be evaluated for select laboratory parameters by assessing the maximum increase and/or decrease (as clinically relevant) observed during the course of study treatment relative to the baseline toxicity grade.  With:  
Laboratory test results will be graded using the NCI-CTCAE (Version 4.03).  Shifts in 
laboratory toxicity grades to outside the normal range will be evaluated for select ed laboratory 
parameters by assessing the maximum increas e 
and/or decrease observed during the course of study treatment relative to the baseline toxicity grade.  Administrative change  
Section: 13.3.3.2 Safety Laboratory Values, paragraph 5  Replace:  
The subject incidence of Grade 3 and 4 
hematological toxicities  (including neutropenia, 
thrombocytopenia, and anemia) will be provided by treatment group.  Similar analyses will be done for selected chemistry tests.  With:  
The subject incidence of Grade 3 and 4 
hematological laboratory abnormalities 
(including neutrope nia, thrombocytopenia, and 
anemia) will be provided by treatment group . Revised text for consistency within overall protocol  
Section: 13.3.3.2 Safety Laboratory Values, paragraph 6  Replace:  
The subject incidence of Grade 3 and 4 
nonhematological toxicities (including liver function test [LFT], CrCl) will be provided by treatment group.  Similar analyses will be done With:  
The subject incidence of Grade 3 and 4 
nonhematological laboratory abnormalities 
(including liver function  test [LFT], CrCl) will 
be provided by treatment group.  Similar Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 176 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
for selected chemistry tests.  analyses will be done for selected chemistry 
tests.  
13.3.3.3 Vital Signs  Replace:  
Vital sign results (systolic and diastolic blood 
pressu re, pulse, and temperature) will be 
summarized descriptively for baseline values and changes from baseline to the minimum, maximum, and last observed values. With:  
Vital sign results (systolic and diastolic blood pressure, pulse, respiratory rate,  and 
temp erature) will be summarized descriptively 
for baseline values and changes from baseline to the minimum, maximum, and last observed values.  Revised text for consistency within overall protocol  
13.3.4 Sparse Pharmacokinetic Analyses, paragraph 1, sentence 3  Replace:  
Concentrations of carfilzomib will be measured in plasma with a validated assay method.  With:  
Concentrations of carfilzomib will be measured in plasma using  a validated assay method.  Administrative change  
13.3.4 Sparse Pharmacokinetic Analyses, paragraph 2, sentence 1  Replace:  
The population pharmacokinetic analysis will be a cumulative analysis that will include population pharmacokinetic data obtained from previous Phase  2 studies that used intensive 
sampling. With:  
The population pharmacokinet ic analysis will be 
a cumulative analysis that will include population pharmacokinetic data obtained from previous Phase  2 and Phase 3 studies that used 
intensive or sparse PK sampling.  Revised text to provided updated information and consistency 
Section: 13.6 Independent Review 
Committee  Replace:  
No Independent Review Committee (IRC) will be used for this study.  With:  
An IRC may be convened for this study , if 
required to support the ORCA- determined 
results . Updated text to potentially include an IRC if re quired  
Section: 13.7 Data Monitoring Committee, paragraph 1  Replace:  
An independent Data Monitoring Committee (DMC) will be convened for this study and will act in an advisory capacity to the sponsor with respect to safeguarding the interests of study subjects through periodic safety data reviews, 
assessing interim safety and efficacy data, and monitoring the overall conduct of the study.  With:  
An independent Data Monitoring Committee (DMC) will be convened for this study and will act in an advisory capaci ty to the sponsor with 
respect to safeguarding the interests of study subjects through periodic safety data reviews, assessments of interim safety and efficacy data, 
and monitoring of the overall conduct of the Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 177 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
study.  
Section: 13.7 D ata Monitoring 
Committee, paragraph 2  Replace:  
An Independent Statistical Reporting Group 
(ISRG) will function independently of the Onyx study team in support of the DMC.  The ISRG will conduct unblinded analyses, generate the open and closed reports to be  reviewed at the 
DMC meetings, and serve as the liaison between Onyx and the DMC.  With:  
An Independent Statistical Reporting Group (ISRG) will function independently of the Sponsor  study team in support of the DMC.  
The ISRG will conduct unblinded analyses , 
generate the open and closed reports to be reviewed at the DMC meetings, and serve as the liaison between the Sponsor  and the DMC. Administrative change  
Section: 14.1 Informed Consent, paragraph 2, sentence 1  Replace:  
Onyx or its designated representati ve will 
provide the investigator with a sample ICF.  With:  
The Sponsor  or its designated representative 
will provide the investigator with a sample ICF.  Administrative change  
Section: 14.1 Informed Consent, paragraph 3, sentence 3  Replace:  
The original signed consent must be maintained by the investigator and available for inspection by Onyx its designated representative, or regulatory authority at any time.  With:  
The original signed consent must be maintained by the investigator and available for inspection by the Sponsor,  its designated representative, or 
regulatory authority at any time.  Administrative change  
Section: 14.2 Compliance with Laws and Regulations, paragraph 2, sentence 2 Replace:  
Before the investigational drug is shipped to the investigator , the investigator or designee will 
provide Onyx with a copy of the IRB/IEC approval letter stating that the study protocol and any subsequent amendments and the ICF have been reviewed and approved.  With:  
Before the investigational drug is shipped to the investigator, the investigator or designee will 
provide the Sponsor  with a copy of the IRB/IEC 
approval letter stating that the study protocol and 
any subsequent amendments and the ICF have been reviewed and approved.  Administrative change  
Section: 14.2 Co mpliance with Laws 
and Regulations, paragraph 3, sentence 2 Replace:  
Copies of the investigatorâ€™s annual report to the IRB/IEC and copies of the IRB/IEC continuance of approval must be submitted to Onyx or designee.  With:  
Copies of the investigatorâ€™s annua l report to the 
IRB/IEC and copies of the IRB/IEC continuance of approval must be submitted to the Sponsor  or 
designee.  Administrative change  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 178 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 14.2 Compliance with Laws 
and Regulations, paragraph 5, sentence 1 Replace:  
Onyx will provide study site s with any 
Investigational New Drug (IND) safety reports, changes to the IB, and any safety updates.  With:  
The Sponsor  will provide study sites with any 
Investigational New Drug (IND) safety reports, changes to the IB, and any safety updates.  Administrativ e change  
Section: 14.3 Subject Confidentiality, paragraph 2, sentence 1  Replace:  
The investigator/institution will permit direct access to source data and documents by Onyx, its designee, the US FDA, and other applicable regulatory authorities.  With:  
The investigator/institution will permit direct 
access to source data and documents by the 
Sponsor , its designee, the US FDA, and other 
applicable regulatory authorities.  Administrative change  
Section: 15.1 Protocol Amendments, sentence 1 Replace:  
Onyx will i mplement in writing any substantive 
changes to this protocol as a protocol amendment. With:  
The Sponsor  will implement in writing any 
substantive changes to this protocol as a protocol 
amendment. Administrative change  
Section: 15.1 Protocol Amendments, sentence 4  Replace:  
The investigator or designee must send a copy of the approval letter from the IRB/IEC, along with the revised ICF, to Onyx or designee.  With:  
The investigator or designee must send a copy of 
the approval letter from the IRB/IEC, along wit h 
the revised ICF, to the Sponsor  or designee. Administrative change  
Section: 15.2 Study Termination Replace:  
Onyx reserves the right to terminate the study at any time.  The investigator or designee should notify the IRB/IEC in writing of the studyâ€™s completion or early termination and send a copy 
of the notification to Onyx or designee. With:  
The Sponsor  reserves the right to terminate the 
study at any time.  The investigator or designee should notify the IRB/IEC in writing of the studyâ€™s completion or e arly termination and send 
a copy of the notification to the Sponsor  or 
designee.  Administrative change  
Section: 15.3.1 Source Documents, sentence 3 Replace:  
These documents are designed to record all observations and other pertinent data for each subject enrolled in this clinical study.  With:  
These documents are designed to record all observations and other pertinent data for each subject randomized  in this clinical study.  Clarified that source document recorded information for subjects who are randomized.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 179 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
Section: 15.4.1 Electronic Case Report 
Forms, paragraph 1, sentence 4 Replace:  
Onyx will supply the eCRF, which must be completed in English.  With:  
The Sponsor  will supply the eCRF, which must 
be completed in English.  Administrative change  
Section: 15.5 Publication Policy   Add:  
Publication policy statement  Added publication policy for consistency with Amgen template  
Section: References   Add:  
Amgen/Onyx. Carfilzomib Investigatorâ€™s Brochure, version 16. 1. Onyx Therapeutics, Inc. (a wholly owned subsidiar y of Onyx 
Pharmaceuticals, Inc., an Amgen Inc. subsidiary); 16  Jan 2016.  Administrative change  
Section: Appendix A Schedule of Assessments, footnote g, sentence 1  Replace:  
Questionnaires to be collected on Day  1 of 
Cycle  1, then every other cycle during t reatment 
and every 12  weeks (every 84  days Â± 4 days) 
until progression, or withdrawal of consent   
during LTFU. With:  
Questionnaires to be collected on Day  1 of 
Cycle  1, then every second  cycle (Cycle 1, 3, 5, 
etc) during treatment and every 12  weeks (every  
84 days Â± 4 days) until progression, or 
withdrawal of consent  during LTFU.  Revised text for consistency within overall protocol  
Section: Appendix B Schedule of Disease Assessments, footnote a  Replace:  
C1D1 (Screening values may be used if obtained within 7 days prior to C1D1).  C2D1 and each 
cycle thereafter, EOT and during LTFU every 4 weeks, (every 28  days Â± 4 days) until PD 
and/or start of a subsequent antimyeloma therapy.  Refer to Section 10.2.  With:  
C1D1 before treatment begins  (Screening 
values may be used if obtained within 7 days 
prior to C1D1) and every 28  days (Â± 4  days)  
thereafter, at EOT and during LTFU if disease 
progression has not already been 
documented, (every 28  days Â± 4 days) until PD 
and/or start of a subsequent antimyeloma 
therapy.  Refer to Section 10.2.  Revised text for consistency within overall protocol  
Section: Appendix B Schedule of Disease Assessments, footnote d, sentence 2 Replace:  
All subjects will be followed for survival and 
disease status (if discontinuation is prior to With:  
All subjects will be followed for survival and 
disease status (if discontinuation is prior to Revised text for consistency within overall protocol  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 180 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
progression) by telephone contact or other 
method every 3 months (Â±  1 week) for until 
study closure.  progression) by telephone contact or other 
method every  12 weeks Â±  28 days  for until study 
closure.  
Section: Appendix B Schedule of 
Disease Assessments, footnote g, sentence 1 Replace:  
Bone marrow samples:  Bone marrow biopsy or aspirate slides will be obta ined to confirm sCR 
or CR, or as clinically indicated.  With:  
Bone marrow samples:  Bone marrow biopsy or bone marrow  aspirate will be obtained to 
confirm sCR or CR, or as clinically indicated.  Revised text for consistency within overall protocol  
Section: Appendix D Schedule of 
Study Assessments for the Pharmacokinetic Sparse Sampling and Intensive Pharmacokinetic & Pharmacokinetic Pharmacodynamic Sub-Study   Add:  
a 24 hours Â± 2 hours after the end of the 
Day 15 infusion  
b 48 hours Â± 2 hours  after the end of the  
Day 15 infusion  
c 168 hours Â± 2 hours  after the end of the 
Day 15 infusion  
d 24 hours Â± 2 hours  after the end of the 
Day 16 infusion  
e 144 hours Â± 2 hours  after the end of the 
Day 16 infusion  Added text to clarify timing of PD sampling  
Section: Appendix G  Summ ary of 
International Myeloma Working Group Uniform Response Criteria (IMWG -URC), sCR, bullet 3  Replace:  
Absence of clonal cells in bone marrow
c by 
immunohistochemistry or immunofluorescencec With:  
Absence of clonal cells in bone marrow by immunohistochemis try or immunofluorescence
c Administrative change  
Section: Appendix G  Summary of 
International Myeloma Working Group Uniform Response Criteria (IMWG -URC), CR Replace:  
CR
b Add:  
CRb, h Added footnote h to clarify that for patients with sFLC measurable diseas e only, normal 
sFLC ratio is also required for CR in addition to the CR 
criteria listed in the 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 181 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
table.  
Section: Appendix G  Summary of 
International Myeloma Working 
Group Uniform Response Criteria (IMWG -URC), CR, bullet 3  Replace:  
â€¢ < 5% plasma cells in bone marrow
c With:  
â€¢ < 5% plasma cells in bone marrow  Footnote c is not applicable to this criterion. 
Section: Appendix G  Summary of 
International Myeloma Working Group Uniform Response Criteria (IMWG -URC), Stable disease  Replace:  
â€¢ Not meeting criteria for CR, VG PR, PR, or 
PD With:  
Not meeting criteria for sCR, CR, VGPR, PR, 
MR,  or PD  Added sCR and MR for completeness. 
Section: Appendix G  Summary of 
International Myeloma Working Group Uniform Response Criteria (IMWG -URC), footnote  Replace:  
Note: Patients with me asurable disease in both 
serum (SPEP) and urine (UPEP) at study entry are required to meet response criteria in both UPEP and SPEP in order to qualify for a MR or better.  Conversely, it should be noted criteria for PD only needs to be met, and confirmed, in 1 
parameter.  For patients without measurable protein on UPEP at baseline, UPEP will need to be repeated to confirm a response.  With:  
Note: For patients without measurable protein on 
UPEP at baseline, UPEP will need to be repeated to confirm a response  of VGPR or better . Removed the sentences â€˜ Patients 
with measurable disease in both serum (SPEP) and urine (UPEP) at study entry are required to meet response criteria in both UPEP and SPEP in order to qualify for a MR or better.   
Conversely, it should be noted criteria for 
PD only needs to be met, and confirmed, in 1 parameter.  â€˜ since 
they are redundant to footnote a. 
Added â€˜of VGPR or better â€™ to clarify UPEP 
will need to be repeated to confirm 
VGPR or better (not 
2Q\[7KHUDSHXWLFV,QF &OLQLFDO6WXG\3URWRFRO1R 
&DUILO]RPLE 3DJHRI 
$PHQGPHQW$SULO  &21),'(17,$/6HFWLRQ 7H[WLQ3URWRFRO $PHQGHG7H[W 5DWLRQDOHIRU&KDQJH
QHHGHGIRU35RU05
ZKHQ83(3LVQRW
PHDVXUDEOHDWEDVHOLQH
6HFWLRQ$SSHQGL[*6XPPDU\RI,QWHUQDWLRQDO0\HORPD:RUNLQJ*URXS8QLIRUP5HVSRQVH&ULWHULD,0:*85&IRRWQRWHJ5HSODFH
7KHSODVPDF\WRPDVSHFL ILFDWLRQVIRU3'DUH
EDVHGRQ2Q\[Â¶V LQWHUSUHWDWLRQRIWKH
,0:*85&DQGSUDFWLFDOFRQVLGHUDWLRQVIRUVWXG\H[HFXWLRQ:LWK
7KHSODVPDF\WRPDVSHFL ILFDWLRQVIRU3'DUH
EDVHGRQ WKH6SRQVRUÂ¶V LQWHUSUHWDWLRQRIWKH
,0:*85&DQGSUDFWLFDOFRQVLGHUDWLRQVIRUVWXG\H[HFXWLRQ$GPLQLVWUDWLYHFKDQJH
6HFWLRQ$SSHQGL[*6XPPDU\RI
,QWHUQDWLRQDO0\HORPD:RUNLQJ*URXS8QLIRUP5HVSRQVH&ULWHULD,0:*85&IRRWQRWHK$GG
,QSDWLHQWVZLWKV)/&PHDVXUDEOHGLVHDVH
RQO\QRUPDOV)/&UDWLRLVUHTXLUHGIRU&57RFODULI\WKDWIRU
SDWLHQWVZLWKV)/&PHDVXUDEOHGLVHDVHRQO\QRUPDOV)/&UDWLRLVDOVRUHTXLUHGIRU&5LQDGGLWLRQWRWKH&5FULWHULDOLVWHGLQWKHWDEOH
6HFWLRQ$SSHQGL[-3DWLHQW
5HSRUWHG2XWFRPHVSDUDJUDSKVHQWHQFH5HYLVHGWH[WIRU
FODULILFDWLRQ
6HFWLRQ$SSHQGL[.&RXQWU\6SHFLILF3UHJQDQF\$QG&RQWUDFHSWLYH6XSSOHPHQWSUHJQDQF\SUHYHQWLRQ
LQIRUPDWLRQIHPDOHVXEMHFWVSDUDJUDSK5HSODFH
:2&%3PXVWXVHDKLJKO\HIIHFWLYHPHWKRGRI
ELUWKFRQWUROGXULQJWUHDWPHQWDQGIRUDQDGGLWLRQDOGD\VDIWHUWKH ODVWGRVHRISURWRFRO
UHTXLUHGWKHUDSLHV+LJKO\HIIHFWLYHPHWKRGVRIELUWKFRQWUROLQFOXGH
x&RPELQHGHVWURJHQDQGSURJHVWRJHQ:LWK
:2&%3PXVWXVHDKLJKO\HIIHFWLYHPHWKRGRI
ELUWKFRQWUROGXULQJWUHDWPHQWDQGIRUDQDGGLWLRQDOGD\VDIWHUWKH ODVWGRVHRISURWRFRO
UHTXLUHGWKHUDSLHV+LJKO\HIIHFWLYHPHWKRGVRIELUWKFRQWURO IRUIHPDOHSDUWLFLSDQWVRUWKHLU
PDOHSDUWQHU LQFOXGH8SGDWHGWH[WWRDOLJQ
ZLWKFXUUHQWFDUILO]RPLEFRUHVDIHW\ODQJXDJHCCI
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 183 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
containing) hormonal contrace ption 
associated with inhibition of ovulation  
o Oral 
o Intravaginal  
o Transdermal  
â€¢ Progestogen -only hormonal contraception 
associated with inhibition of ovulation  
o Oral 
o Injectable  
o Implantable  
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormonal -releasing system 
(IUS)  
â€¢ Bilateral tubal occlusion  â€¢ Combined (estrogen and progestogen) 
hormonal methods :  pills, vaginal ring, or 
skin patch. 
â€¢ Single  hormonal methods  (progestogen to 
stop the release of the egg from the ovary) : 
pills, shots/injections,  implant s (placed 
under the skin by a healthcare provider) 
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormonal -releasing system 
(IUS) surgery to tie both fallopian tubes 
(bilateral tubal ligation/ occlusion )  
 
Sectio n: Appendix K Country Specific 
Pregnancy And Contraceptive 
Supplement, Male Subjects, paragraph  1 Replace:  
Male subjects whose partner is a WOCBP potential must use an acceptable method of effective birth control during treatment and for an additional 30  days after the last dose of 
protocol -required therapies.  
â€¢ Acceptable methods of birth control for 
male subjects include:  
â€¢ The female partner uses a:  
o Hormonal birth control method  
â€’ Oral 
â€’ Injectable  
â€’ Transdermal  
â€’ Implantable  
â€’ Intravaginal  
o Intrauterine device (IUD)  With:  
If the male subjects  sole female partner  has 
received medical confirmation that she is postmenopausal or she has had a permanent sterilization method (hyster ectomy, bilateral 
oophorectomy, or bilateral salpingectomy) or the male subject has had a vasectomy with medical confirmation of surgical success, or his sole female partner has had a bilateral tubal ligation/occlusion, additional 
contraceptive methods are  not required 
during this study.  Otherwise, if the male 
subjectâ€™s female partner could become 
pregnant, the male must:   
â€¢ Practice true sexual abstinence. (Refraining 
from heterosexual intercourse during 
treatment and for an additional 90 days Updated the window for breastfeeding following the last dose 
of drug administration.  
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 184 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
o Intrauterine hormonal -releasing system 
(IUS)  
o The female partner has had a bilateral 
tubal occlusion  
â€¢ The male subject has had a vasectomy and 
has received a medical assessment of the 
surgical success.  
â€¢ Two barrier methods:  One by each partner and at least o ne of the barrier methods must 
include spermicide 
o Male must use a condom  
o Female partner may use a diaphragm, 
cervical cap, or contraceptive sponge.  
(Note: The female condom cannot be 
used with a male condom).  
â€¢ Sexual abstinence:  Refraining from 
heterosex ual intercourse during the entire 
period of risk associated with the study treatment.  The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.  
Unacce ptable birth control methods for female 
and male subjects during treatment with protocol -required therapies include:  
â€¢ Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post -ovulation methods)  
â€¢ Withdrawal (coitus interruptus)  
â€¢ Spermicides only  
â€¢ Lactational amenorrhoea method (LAM)  
Female condom and male condom should not be following the  last dose of study drug 
administration . The reliability of sexual 
abstinence needs to be evaluated in relation to 
the duration of the clinical trial and be the preferred and usual lifestyle of the subject.)  
Or 
â€¢ Use a condom with spermicide during treatment  and for an additional 90 days 
following the last dose of study drug administration.  (Note a condom without spermicide is acceptable in countries where spermicide is not commercially available.)  
The female partner should also consider using an acceptable method of effective 
contraception such as:  
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormonal -releasing system (IUS)  
â€¢ Hormonal birth control method: pill, shots/injections, implants (placed under the skin by a healthcare provider), skin patches, or a vaginal ring 
â€¢ Female  barrier method:  diaphragm, cervical 
cap, or contraceptive sponge  (a female 
condom  is not an option because there is a  
risk of tearing when both partners use a 
condom)  
â€¢ Male subjects  must not donate sperm 
during treatment and for an additional 90  days 
following the last dose  of study drug 
administration. 
Onyx Therapeutics, Inc.  Clinical Study Protocol No . 20140355 
Carfilzomib  Page 185 of 185 
Amendment 3: 22 April 2016  CONFIDENTIAL  Section   Text in Protocol  Amended Text  Rationale for Change  
used together  Males with pregnant partners must practice 
true sexual abstinence or wear a condom 
during vaginal sex  to prevent exposure to the 
embryo/fetus through semen.  
Section: Appendix L Summary of 
Changes   Add:  
Updated Appendix L to include current summary of changes.  Administrative change  
 
Onyx Therapeutics, Inc. Clinical Study Protocol No. CFZ014  
Carfilzomib for Injection Page 110 of 126 
CONFIDENTIAL APPENDIX  L SUMMARY OF CHANGES  
Study CFZ014 was amended to include the following:   
ï‚· Adverse events of pulmonary hypertension and TTP/HUS were added to the dose 
modif
ication guide
lines to be consistent with the guidance provided in the updated 
Investigator Brochure version 15, dated 26February 2015. 
ï‚· Updated PK tim epoints for intensive and sparse PK sampling as carfilzomib will be 
administered as an IV infusion over 30 minutes in the once-weekly arm and over 
10 minutes in the twice-weekly arm.  There is a mid-infusion PK timepoint (15 min 
after the
 start of infusion) that is only applicable for the carfilzomib once weekly arm, 
where carfilzomib is administered over 30 min.  The protocol has been amended to 
state that thi
s PK timepoint, 15 min after the start of infusion, is only required for the 
carfilzomib once weekly arm. 
ï‚· Updated cli nical information for carfilzomib to be consistent with IB Version 15.0. 
ï‚· Updated text in the safety section of the protocol to accurately reflect Drug Safety 
re
quirements and how and to whom information is provided. 
ï‚· Updated Medical Monitor information.  
In addition, administrative updates have been made to enhance document clarity.  
Changes made to this protocol are listed in the table below.   
 
 Onyx Therapeutics , Inc. Clinical Study Protocol No . CFZ014
Carfilzomib for Injection Page 109of 115
CONFIDENTIALAPPENDIX L SUMMARY OF CHANGES
Amendment 1.0:  
Study  CFZ014 was am ended to include the fo llowing: 
ï‚·Clarifiedthat consent is required fro m subjects if addit ional blood sam ples will  be 
collected for PK (sparse sampling) and for the intensive PK and PDn substudy .
ï‚·Clarified that dexam ethasone shoul d be administr ated orally on Day 22in 
Cycles 1âˆ’9.  
ï‚·Clarified that dexamethasone will not be administered on Day 22after Cycle 9.
ï‚·Clarified that events occurring prior to consent should be captured as medical history  
inform ation.
ï‚·Clarified the timing of safet y labs after Cycle4.
ï‚·Clarified the timing of pat ient reported outcom e questionnaires.
In addit ion, administrative updates have been made to enhance document clarity.  Changes 
made to this protocol are listed in the table below.  
Amendment 1.1:
Two addit ional administrative update swere made to correct errors found i n 
Protocol CFZ 014 Amendment 1.0:
ï‚·The header on pages 100 -109, Appendix F, of protocol CFZ014 read 
â€œProtocol 2011âˆ’ 003, Am endment 3â€ instead of reading as â€œClinical Study  Protocol  
No. CFZ014â€.
ï‚·Two hy perlinks in the footnote of Appendix A read â€œ Error! Reference source not 
foundâ€ instead of linking to Sections 10.4.1 (Hematology) and 10.4.2 (Serum 
Chemistry ), respectively.